0000950170-24-12340210-Q ASSEMBLY BIOSCIENCES, INC. 20241107202411071624081624091624090 0000950170-24-123402 10-Q 53 20240930 20241107 20241107 ASSEMBLY BIOSCIENCES, INC. 0001426800 2834 000000000 DE 1231 10-Q 34 001-35005 241436216 TWO TOWER PLACE 7TH FLOOR SOUTH SAN FRANCISCO CA 94080 (833) 409-4583 TWO TOWER PLACE 7TH FLOOR SOUTH SAN FRANCISCO CA 94080 VENTRUS BIOSCIENCES INC 20080211 10-Q 1 asmb-20240930.htm 10-Q 10-Q --12-310001426800falseQ3.1429.0588.0833.0833.0833http://fasb.org/us-gaap/2024#CashEquivalentsMemberhttp://fasb.org/us-gaap/2024#CashEquivalentsMemberhttp://fasb.org/us-gaap/2024#CashEquivalentsMemberhttp://fasb.org/us-gaap/2024#CashEquivalentsMemberhttp://fasb.org/us-gaap/2024#CashEquivalentsMemberhttp://fasb.org/us-gaap/2024#CashEquivalentsMemberhttp://fasb.org/us-gaap/2024#CashEquivalentsMember0001426800us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001426800asmb:USAndForeignCommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001426800us-gaap:RetainedEarningsMember2022-12-310001426800asmb:TwoThousandAndTwentyAtTheMarketOfferingsMember2020-08-3100014268002023-01-012023-09-300001426800us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001426800us-gaap:RetainedEarningsMember2024-09-300001426800srt:MaximumMember2023-09-3000014268002024-07-012024-09-300001426800us-gaap:AdditionalPaidInCapitalMember2024-09-300001426800us-gaap:AdditionalPaidInCapitalMember2023-09-300001426800us-gaap:FairValueMeasurementsRecurringMember2024-09-300001426800us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001426800asmb:TwoThousandAndTwentyAtTheMarketOfferingsMember2024-07-012024-09-300001426800srt:MaximumMember2023-07-012023-09-300001426800asmb:USAndForeignCommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001426800us-gaap:AdditionalPaidInCapitalMember2024-06-300001426800us-gaap:CommonStockMember2023-06-300001426800us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001426800us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-3000014268002024-09-300001426800us-gaap:CorporateDebtSecuritiesMember2024-09-300001426800asmb:GileadSciencesIncorporatedMembersrt:MaximumMemberasmb:OptionLicenseAndCollaborationAgreementMember2023-10-012023-10-3100014268002022-12-310001426800asmb:SecuritiesPurchaseAgreementMember2024-06-012024-06-300001426800us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001426800us-gaap:FairValueInputsLevel3Memberasmb:USAndForeignCommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001426800srt:MinimumMember2024-01-012024-01-310001426800us-gaap:WarrantMembersrt:MaximumMemberasmb:SecuritiesPurchaseAgreementMember2024-06-012024-06-300001426800us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001426800us-gaap:CommonStockMember2023-09-300001426800us-gaap:RetainedEarningsMember2023-01-012023-09-3000014268002024-11-010001426800us-gaap:FairValueInputsLevel2Memberasmb:USAndForeignCommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001426800asmb:ArbutusBiopharmaAgreementMember2023-07-012023-09-300001426800us-gaap:AdditionalPaidInCapitalMember2022-12-310001426800us-gaap:CommonStockMember2023-12-310001426800us-gaap:CommonStockMember2022-12-310001426800us-gaap:CommonStockMemberasmb:GileadSciencesIncorporatedMemberus-gaap:PrivatePlacementMemberasmb:SecuritiesPurchaseAgreementMember2024-06-012024-06-300001426800asmb:GileadSciencesIncorporatedMembersrt:MinimumMemberasmb:OptionLicenseAndCollaborationAgreementMember2023-10-012023-10-310001426800us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-300001426800us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-300001426800us-gaap:GeneralAndAdministrativeExpenseMember2024-07-012024-09-300001426800us-gaap:FairValueInputsLevel1Memberasmb:USAndForeignCommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001426800us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001426800us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001426800us-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001426800us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001426800us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001426800us-gaap:RetainedEarningsMember2023-07-012023-09-300001426800us-gaap:RetainedEarningsMember2024-06-300001426800us-gaap:CommonStockMember2023-07-012023-09-300001426800us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001426800srt:MinimumMember2024-01-012024-09-300001426800us-gaap:FairValueInputsLevel3Memberasmb:USAndForeignCommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001426800us-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001426800srt:MaximumMember2024-01-012024-09-300001426800us-gaap:CommonStockMemberasmb:GileadSciencesIncorporatedMemberasmb:EquityAgreementsMember2023-10-012023-10-310001426800us-gaap:FairValueInputsLevel2Memberasmb:USAndForeignCommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-3100014268002023-07-012023-09-300001426800us-gaap:CommonStockMemberasmb:GileadSciencesIncorporatedMemberasmb:EquityAgreementsMember2024-09-300001426800asmb:SecuritiesPurchaseAgreementMember2024-06-300001426800asmb:SecuritiesPurchaseAgreementMemberasmb:CommonStockAndWarrantMember2024-06-012024-06-300001426800us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300001426800us-gaap:RetainedEarningsMember2023-06-300001426800asmb:GileadSciencesIncorporatedMemberus-gaap:PrivatePlacementMemberasmb:SecuritiesPurchaseAgreementMemberasmb:CommonStockAndWarrantMember2024-06-300001426800us-gaap:RetainedEarningsMember2024-01-012024-09-300001426800us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001426800us-gaap:AdditionalPaidInCapitalMember2023-12-310001426800us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001426800us-gaap:AdditionalPaidInCapitalMember2023-06-300001426800asmb:GileadSciencesIncorporatedMemberasmb:SeventhYearOfCollaborationMember2023-10-310001426800us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001426800us-gaap:RetainedEarningsMember2024-07-012024-09-300001426800us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001426800us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001426800us-gaap:USTreasurySecuritiesMember2024-09-3000014268002023-09-300001426800us-gaap:CommercialPaperMember2024-09-300001426800asmb:OptionLicenseAndCollaborationAgreementMemberasmb:GileadSciencesIncorporatedMember2024-07-012024-09-300001426800us-gaap:CommonStockMemberasmb:GileadSciencesIncorporatedMemberasmb:EquityAgreementsMember2024-06-300001426800srt:MinimumMember2023-01-012023-09-300001426800us-gaap:AdditionalPaidInCapitalMember2024-01-012024-09-300001426800us-gaap:CommonStockMember2024-07-012024-09-3000014268002024-02-082024-02-080001426800us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001426800us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001426800us-gaap:WarrantMemberasmb:GileadSciencesIncorporatedMembersrt:MaximumMemberus-gaap:PrivatePlacementMemberasmb:SecuritiesPurchaseAgreementMember2024-06-012024-06-3000014268002024-01-012024-09-300001426800us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-09-300001426800us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001426800asmb:TwoThousandAndTwentyAtTheMarketOfferingsMember2023-07-012023-09-300001426800asmb:GileadSciencesIncorporatedMemberasmb:OptionLicenseAndCollaborationAgreementMember2023-10-012023-10-310001426800us-gaap:RetainedEarningsMember2023-09-300001426800us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300001426800us-gaap:CorporateDebtSecuritiesMember2023-12-310001426800asmb:CommonStockSubjectToPurchaseUnderEmployeeStockPurchaseProgramMember2024-01-012024-09-300001426800us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001426800us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001426800us-gaap:CommonStockMember2024-06-300001426800us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001426800asmb:ArbutusBiopharmaAgreementMember2024-01-012024-09-3000014268002023-06-300001426800asmb:GileadSciencesIncorporatedMemberasmb:RegulatoryAndCommercialMilestonesMembersrt:MaximumMemberasmb:OptionLicenseAndCollaborationAgreementMember2023-10-012023-10-3100014268002024-01-012024-01-310001426800us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001426800us-gaap:WarrantMember2024-01-012024-09-300001426800us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001426800srt:MinimumMember2023-07-012023-09-300001426800srt:MaximumMember2023-01-012023-09-300001426800us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001426800srt:MaximumMember2024-07-012024-09-300001426800us-gaap:MoneyMarketFundsMember2024-09-300001426800asmb:GileadSciencesIncorporatedMemberasmb:OptionLicenseAndCollaborationAgreementMember2024-09-3000014268002023-12-310001426800us-gaap:WarrantMember2023-01-012023-09-300001426800us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001426800asmb:GileadSciencesIncorporatedMemberasmb:OptionLicenseAndCollaborationAgreementMember2024-07-012024-09-300001426800asmb:TwoThousandAndTwentyAtTheMarketOfferingsMember2024-01-012024-09-300001426800us-gaap:RetainedEarningsMember2023-12-310001426800us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001426800us-gaap:FairValueMeasurementsRecurringMember2023-12-310001426800us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001426800us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001426800us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001426800us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300001426800us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300001426800us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001426800us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001426800asmb:CommonStockAndWarrantMemberasmb:SecuritiesPurchaseAgreementMember2024-06-3000014268002024-02-092024-02-090001426800asmb:GileadSciencesIncorporatedMemberus-gaap:PrivatePlacementMemberasmb:SecuritiesPurchaseAgreementMemberasmb:CommonStockAndWarrantMember2024-06-012024-06-300001426800us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001426800us-gaap:CommonStockMemberasmb:SecuritiesPurchaseAgreementMember2024-06-012024-06-300001426800us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001426800us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001426800us-gaap:MoneyMarketFundsMember2023-12-310001426800asmb:TwoThousandAndTwentyAtTheMarketOfferingsMember2023-01-012023-09-300001426800us-gaap:CommercialPaperMember2023-12-310001426800us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001426800srt:MinimumMember2023-09-300001426800us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001426800asmb:CommonStockSubjectToPurchaseUnderEmployeeStockPurchaseProgramMember2023-01-012023-09-300001426800us-gaap:CommonStockMemberasmb:GileadSciencesIncorporatedMemberasmb:EquityAgreementsMembersrt:MaximumMember2023-10-012023-10-310001426800srt:MinimumMember2024-07-012024-09-300001426800asmb:ArbutusBiopharmaAgreementMember2024-07-012024-09-300001426800us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001426800asmb:GileadSciencesIncorporatedMemberasmb:OptionLicenseAndCollaborationAgreementMember2024-01-012024-09-300001426800us-gaap:CommonStockMember2024-09-300001426800us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001426800us-gaap:FairValueInputsLevel1Memberasmb:USAndForeignCommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001426800us-gaap:CommonStockMember2023-01-012023-09-300001426800us-gaap:CommonStockMember2024-01-012024-09-300001426800asmb:OptionLicenseAndCollaborationAgreementMemberasmb:GileadSciencesIncorporatedMember2024-01-012024-09-300001426800asmb:GileadSciencesIncorporatedMemberasmb:OptionLicenseAndCollaborationAgreementMember2023-10-012023-10-310001426800srt:MaximumMember2024-01-012024-01-31asmb:Timepointxbrli:purexbrli:sharesasmb:Programasmb:Segmentasmb:Productiso4217:USDiso4217:USDxbrli:shares Â Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Â FORM 10-Q Â Â Â â˜’ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the quarterly period ended September 30, 2024 Â OR Â â˜ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the transition period from _____to_____. Â Commission file number: 001-35005 Â ASSEMBLY BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Â Delaware 20-8729264 (State or other jurisdiction of (I.R.S. Employer Identification No.) incorporation or organization) Â Â Two Tower Place, 7th Floor South San Francisco, California 94080 (Address of principal executive offices) (zip code) Â (833) 509-4583 (Registrantâ€™s telephone number, including area code) Â Securities registered pursuant to Section 12(b) of the Act: Â Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 ASMB The Nasdaq Global Select Market Â Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes â˜’ No â˜ Â Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes â˜’ No â˜ Â Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting companyâ€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act. Â Large accelerated filer â˜ Â Accelerated filer â˜ Non-accelerated filer â˜’ Â Smaller reporting company â˜’ Emerging growth company â˜ Â Â Â Â If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜ Â Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes â˜ No â˜’ Â As of November 1, 2024, there were 6,356,286 shares of the registrantâ€™s common stock outstanding. Â Â Â Â Index Â Â Â PageNumber Â Â Â PART I: FINANCIAL INFORMATION 2 Â Â Â Item 1. Financial Statements 2 Â Â Â Â Condensed Consolidated Balance Sheets at September 30, 2024 (unaudited) and December 31, 2023 2 Â Â Â Â Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2024 and 2023 (unaudited) 3 Â Â Â Â Condensed Consolidated Statements of Changes in Stockholdersâ€™ Equity for the Three and Nine Months Ended September 30, 2024 and 2023 (unaudited) 4 Â Â Â Â Condensed Consolidated Statements of Cash Flows for the

Nine Months Ended September 30, 2024 and 2023 (unaudited) 6 Â Â Â Â Notes to the Condensed Consolidated Financial Statements (unaudited) 7 Â Â Â Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations 15 Â Â Â Item 3. Quantitative and Qualitative Disclosures About Market Risk 26 Â Â Â Item 4. Controls and Procedures 26 Â Â Â PART II: OTHER INFORMATION 27 Â Â Â Item 1. Legal Proceedings 27 Â Â Â Item 1A. Risk Factors 27 Â Â Â Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 41 Â Â Â Item 3. Defaults Upon Senior Securities 41 Â Â Â Item 4. Mine Safety Disclosures 41 Â Â Â Item 5. Other Information 41 Â Â Â Item 6. Exhibits 42 Â Â SIGNATURES 43 Â Â Â References to Assembly Biosciences, Inc. Throughout this Quarterly Report on Form 10-Q, the â€œCompany,â€ â€œAssembly,â€ â€œwe,â€ â€œus,â€ and â€œour,â€ except where the context requires otherwise, refer to Assembly Biosciences, Inc. and its consolidated subsidiaries, and â€œboard of directorsâ€ refers to the board of directors of Assembly Biosciences, Inc. Forward-Looking Statements This Quarterly Report on Form 10-Q contains â€œforward-looking statementsâ€ that are subject to certain risks and uncertainties, including, without limitation, those set forth in Part I, Item 1A of our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on March 28, 2024 (2023 Annual Report) and Part II, Item 1A of this Quarterly Report on Form 10-Q under the heading â€œRisk Factors,â€ that could cause actual results to materially differ. Such risks and uncertainties include, among other things: â€¢our ability to maintain financial resources necessary to continue our research activities, clinical studies and other business operations; â€¢our ability to realize the potential benefits of our collaboration with Gilead Sciences, Inc. (Gilead), including all financial aspects of the collaboration and equity investments; â€¢our ability to initiate and complete clinical studies involving our therapeutic product candidates, including studies contemplated by our collaboration with Gilead, in the currently anticipated timeframes or at all; â€¢safety and efficacy data from clinical or nonclinical studies may not warrant further development of our product candidates; â€¢clinical and nonclinical data presented at conferences may not differentiate our product candidates from other companiesâ€™ candidates; and â€¢results of nonclinical studies may not be representative of disease behavior in a clinical setting and may not be predictive of the outcomes of clinical studies. You are urged to consider statements that include the words may, will, would, could, should, might, believes, hopes, estimates, projects, potential, expects, plans, anticipates, intends, continues, forecast, designed, goal or the negative of those words or other comparable words to be uncertain and forward-looking. In particular, forward-looking statements include, but are not limited to, statements regarding the timing of commencement of future clinical studies involving our therapeutic product candidates; and our ability to successfully complete, and receive favorable results in, clinical studies for our product candidates. We intend such forward-looking statements to be covered by the safe harbor provisions contained in Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. 1 Â PART I - FINANCIAL INFORMATION Item 1. Financial Statements ASSEMBLY BIOSCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands except for share amounts and par value) Â Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Â Â (Unaudited) Â Â Â Â ASSETS Â Â Â Â Â Â Current assets Â Â Â Â Â Â Cash and cash equivalents Â $ 28,452 Â Â $ 19,841 Â Marketable securities Â Â 66,502 Â Â Â 110,406 Â Accounts receivable from collaboration Â Â â€” Â Â Â 43 Â Prepaid expenses and other current assets Â Â 3,259 Â Â Â 3,497 Â Total current assets Â Â 98,213 Â Â Â 133,787 Â Â Â Â Â Â Property and equipment, net Â Â 316 Â Â Â 385 Â Operating lease right-of-use (ROU) assets Â Â 1,421 Â Â Â 2,339 Â Other assets Â Â 312 Â Â Â 312 Â Total assets Â $ 100,262 Â Â $ 136,823 Â Â Â Â Â Â Â LIABILITIES AND STOCKHOLDERS' EQUITY Â Â Â Â Â Â Current liabilities Â Â Â Â Â Â Accounts payable Â $ 1,335 Â Â $ 461 Â Accrued research and development expenses Â Â 1,586 Â Â Â 885 Â Other accrued expenses Â Â 4,765 Â Â Â 5,744 Â Deferred revenue from a related party - short-term Â Â 32,620 Â Â Â 30,915 Â Operating lease liabilities - short-term Â Â 1,329 Â Â Â 1,220 Â Total current liabilities Â Â 41,635 Â Â Â 39,225 Â Â Â Â Â Â Deferred revenue from a related party - long-term Â Â 32,511 Â Â Â 55,379 Â Operating lease liabilities - long-term Â Â 113 Â Â Â 1,122 Â Total liabilities Â Â 74,259 Â Â Â 95,726 Â Â Â Â Â Â Â Commitments and contingencies Â Â Â Â Â Â Â Â Â Â Â Stockholders' equity Â Â Â Â Â Â Preferred stock, $0.001Â par value; 5,000,000Â shares authorized; noÂ shares issued or outstanding Â Â â€” Â Â Â â€” Â Common stock, $0.001Â par value; 150,000,000Â shares authorized as of September 30, 2024 and December 31, 2023; 6,354,414Â and 5,482,752Â shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively Â Â 6 Â Â Â 5 Â Additional paid-in capital Â Â 841,743 Â Â Â 826,921 Â Accumulated other comprehensive loss Â Â (156) Â Â (81) Accumulated deficit Â Â (815,590) Â Â (785,748) Total stockholders' equity Â Â 26,003 Â Â Â 41,097 Â Total liabilities and stockholders' equity Â $ 100,262 Â Â $ 136,823 Â Â See Accompanying Notes to Condensed Consolidated Financial Statements 2 Â ASSEMBLY BIOSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (In thousands except for share and per share amounts) (Unaudited) Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Collaboration revenue from a related party Â $ 6,845 Â Â Â $ â€” Â Â $ 21,163 Â Â $ â€” Â Â Â Â Â Â Â Â Â Â Â Â Operating expenses Â Â Â Â Â Â Â Â Â Â Â Â Research and development Â Â 13,515 Â Â Â 10,824 Â Â Â 41,653 Â Â Â 37,894 Â General and administrative Â Â 4,286 Â Â Â 4,224 Â Â Â 13,398 Â Â Â 14,201 Â Total operating expenses Â Â 17,801 Â Â Â 15,048 Â Â Â 55,051 Â Â Â 52,095 Â Loss from operations Â Â (10,956) Â Â (15,048) Â Â (33,888) Â Â (52,095) Â Â Â Â Â Â Â Â Â Â Â Â Other income Â Â Â Â Â Â Â Â Â Â Â Â Interest and other income, net Â Â 1,343 Â Â Â 628 Â Â Â 4,452 Â Â Â 1,829 Â Total other income Â Â 1,343 Â Â Â 628 Â Â Â 4,452 Â Â Â 1,829 Â Loss before income taxes Â Â (9,613) Â Â (14,420) Â Â (29,436) Â Â (50,266) Â Â Â Â Â Â Â Â Â Â Â Â Income tax expense Â Â â€” Â Â Â â€” Â Â Â 406 Â Â Â â€” Â Net loss Â $ (9,613) Â $ (14,420) Â $ (29,842) Â $ (50,266) Â Â Â Â Â Â Â Â Â Â Â Â Other comprehensive loss Â Â Â Â Â Â Â Â Â Â Â Â Unrealized gain (loss) on marketable securities Â Â 137 Â Â Â 50 Â Â Â (75) Â Â 528 Â Comprehensive loss Â $ (9,476) Â $ (14,370) Â $ (29,917) Â $ (49,738) Â Â Â Â Â Â Â Â Â Â Â Â Net loss per share, basic and diluted Â $ (1.51) Â $ (3.29) Â $ (5.12) Â $ (11.61) Weighted average common shares outstanding, basic and diluted Â Â 6,351,431 Â Â Â 4,380,444 Â Â Â 5,827,750 Â Â Â 4,329,260 Â Â See Accompanying Notes to Condensed Consolidated Financial Statements 3 Â ASSEMBLY BIOSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERSâ€™ EQUITY (In thousands except for share amounts) (Unaudited) Â Â Â For the Three Month Period Â Â Â Common Stock Â Â Additional Â Â AccumulatedOther Â Â Â Â Â Total Â Â Â Shares Â Â Amount Â Â Paid-inCapital Â Â ComprehensiveLoss Â Â AccumulatedDeficit Â Â Stockholders'Equity Â Balance as of June 30, 2024 Â Â 6,345,561 Â Â $ 6 Â Â $ 840,946 Â Â $ (293) Â $ (805,977) Â $ 34,682 Â Issuance of common stock for settlement of restricted stock units (RSUs) Â Â 8,853 Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Unrealized gain on marketable debt securities Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 137 Â Â Â â€” Â Â Â 137 Â Stock-based compensation Â Â â€” Â Â Â â€” Â Â Â 797 Â Â Â â€” Â Â Â 797 Â Net loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (9,613) Â Â (9,613) Balance as of September 30, 2024 Â Â 6,354,414 Â Â $ 6 Â Â $ 841,743 Â Â $ (156) Â $ (815,590) Â $ 26,003 Â Â Â Â Â Common Stock Â Â Additional Â Â AccumulatedOther Â Â Â Â Â Total Â Â Â Shares Â Â Amount Â Â Paid-inCapital Â Â ComprehensiveLoss Â Â AccumulatedDeficit Â Â Stockholders'Equity Â Balance as of June 30, 2023 Â Â 4,370,863 Â Â $ 4 Â Â $ 815,636 Â Â $ (325) Â $ (760,366) Â $ 54,949 Â Issuance of common stock for settlement of RSUs Â Â 13,622 Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Unrealized gain on marketable debt securities Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 50 Â Â Â â€” Â Â Â 50 Â Stock-based compensation Â Â â€” Â Â Â â€” Â Â Â 1,135 Â Â Â â€” Â Â Â 1,135 Â Net loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (14,420) Â Â (14,420) Balance as of September 30, 2023 Â Â 4,384,485 Â Â $ 4 Â Â $ 816,771 Â Â $ (275) Â $ (774,786) Â $ 41,714 Â Â 4 Â Â Â For the Nine Month Period Â Â Â Common Stock Â Â Additional Â Â AccumulatedOther Â Â Â Â Â Total Â Â Â Shares Â Â Amount Â Â Paid-inCapital Â Â ComprehensiveLoss Â Â AccumulatedDeficit Â Â Stockholders'Equity Â Balance as of December 31, 2023 Â Â 5,482,752 Â Â $ 5 Â Â $ 826,921 Â Â $ (81) Â $ (785,748) Â $ 41,097 Â Issuance of common stock and warrants in a registered direct offering and a private placement, net of issuance costs Â Â 814,000 Â Â Â 1 Â Â Â 12,394 Â Â Â â€” Â Â Â â€” Â Â Â 12,395 Â Issuance of common stock under Employee Stock Purchase Plan (ESPP) Â Â 7,252 Â Â Â â€” Â Â Â 55 Â Â Â â€” Â Â Â â€” Â Â Â 55 Â Issuance of common stock for settlement of RSUs Â Â 49,996 Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Issuance of common stock upon exercise of stock options Â Â 414 Â Â Â â€” Â Â Â 4 Â Â Â â€” Â Â Â â€” Â Â Â 4 Â Unrealized loss on marketable debt securities Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (75) Â Â Â â€” Â Â Â (75) Stock-based compensation Â Â â€” Â Â Â â€” Â Â Â 2,369 Â Â Â â€” Â Â Â â€” Â Â Â 2,369 Â Net loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (29,842) Â Â (29,842) Balance as of September 30, 2024 Â Â 6,354,414 Â Â $ 6 Â Â $ 841,743 Â Â $ (156) Â $ (815,590) Â $ 26,003 Â Â Â Â Â Common Stock Â Â Additional Â Â AccumulatedOther Â Â Â Â Â Total Â Â Â Shares Â Â Amount Â Â Paid-inCapital Â Â ComprehensiveLoss Â Â AccumulatedDeficit Â Â Stockholders'Equity Â Balance as of December 31, 2022 Â Â 4,074,552 Â Â $ 4 Â Â $ 807,983 Â Â $ (803) Â $ (724,520) Â $ 82,664 Â Issuance of common stock under at-the-market (ATM) equity offering program, net of issuance costs Â Â 261,170 Â Â Â â€” Â Â Â 4,546 Â Â Â â€” Â Â Â â€” Â Â Â 4,546 Â Issuance of common stock under ESPP Â Â 7,533 Â Â Â â€” Â Â Â 80 Â Â Â â€” Â Â Â â€” Â Â Â 80 Â Issuance of common stock for settlement of RSUs Â Â 41,230 Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Unrealized gain on marketable debt securities Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 528 Â Â Â â€” Â Â Â 528 Â Stock-based compensation Â Â â€” Â Â Â â€” Â Â Â 4,162 Â Â Â â€” Â Â Â â€” Â Â Â 4,162 Â Net loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (50,266) Â Â (50,266) Balance as of September 30, 2023 Â Â 4,384,485 Â Â $ 4 Â Â $ 816,771 Â Â $ (275) Â $ (774,786) Â $ 41,714 Â Â See Accompanying Notes to Condensed Consolidated Financial Statements 5 Â ASSEMBLY BIOSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) (Unaudited) Â Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Cash flows from operating activities Â Â Â Â Â Â Net loss Â $ (29,842) Â $ (50,266) Adjustments to reconcile net loss to net cash used in operating activities: Â Â Â Â Â Â Depreciation and amortization Â Â 97 Â Â Â 366 Â Stock-based compensation Â Â 2,369 Â Â Â 4,160 Â Net accretion of investments in marketable debt securities Â Â (3,065) Â Â (534) Non-cash rent expense Â Â 1,064 Â Â Â 2,525 Â Changes in operating assets and liabilities: Â Â Â Â Â Â Accounts receivable from collaboration Â Â 43 Â Â Â 944 Â Prepaid expenses and other current assets Â Â 238 Â Â Â 951 Â Other assets Â Â â€” Â Â Â 337 Â Accounts payable Â Â 874 Â Â Â (1,735) Accrued research and development expenses Â Â 701 Â Â Â (1,503) Other accrued expenses Â Â (979) Â Â (3,429) Deferred revenue from a related party Â Â (21,163) Â Â â€” Â Â Operating lease liabilities Â Â (1,047) Â Â (2,720) Net cash used in operating activities Â Â (50,710) Â Â (50,904) Â Â Â Â Â Â Â Cash flows from investing activities Â Â Â Â Â Â Proceeds from maturities of marketable securities Â Â 96,500 Â Â Â 46,315 Â Purchases of marketable securities Â Â (49,605) Â Â (25,615) Purchases of property and equipment Â Â (28) Â Â (184) Net cash provided by investing activities Â Â 46,867 Â Â Â 20,516 Â Â Â Â Â Â Â Cash flows from financing activities Â Â Â Â Â Â Proceeds from the issuance of common stock and warrants in a registered direct offering and a private placement, net of issuance costs Â Â 12,395 Â Â Â â€” Â Proceeds from the issuance of common stock under ATM equity offering program, net of issuance costs Â Â â€” Â Â Â 4,546 Â Proceeds from the issuance of common stock under ESPP Â Â 55 Â Â Â 80 Â Proceeds from the exercise of stock options Â Â 4 Â Â Â â€” Â Net cash provided by financing activities Â Â 12,454 Â Â Â 4,626 Â Â Â Â Â Â Net increase (decrease) in cash and cash equivalents Â Â 8,611 Â Â Â (25,762) Cash and cash equivalents at the beginning of the period Â Â 19,841 Â Â Â 52,418 Â Cash and cash equivalents at the end of the period Â $ 28,452 Â Â $ 26,656 Â Â See Accompanying Notes to Condensed Consolidated Financial Statements 6 Â ASSEMBLY BIOSCIENCES, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) Note 1 - Nature of BusinessOverviewAssembly Biosciences, Inc. (together with its subsidiaries, Assembly or the Company), incorporated in Delaware in October 2005, is a biotechnology company developing innovative therapeutics. The Company's pipeline includes two clinical-stage helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes, an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, a clinical-stage capsid assembly modulator candidate designed to disrupt the replication cycle of hepatitis B virus (HBV) and research programs focused on a non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses and a small molecule interferon-Î± (IFN-Î±) receptor (IFNAR) agonist targeting HBV and HDV. The Company operates in one segment and is headquartered in South San Francisco, California.LiquidityThe Company has not derived any revenue from product sales to date and currently has no approved products. Once a product has been developed, it will need to be approved for sale by the U.S. Food and Drug Administration (FDA) or an applicable foreign regulatory agency. Since inception, the Companyâ€™s operations have been financed through the sale of equity securities, the proceeds from the exercise of warrants and stock options, the issuance of debt, and upfront payments related to collaboration agreements. The Company has incurred losses from operations since inception and expects to continue to incur substantial losses for the next several years as it continues its product development efforts. Management believes the Company currently has sufficient funds to meet its operating requirements for at least the next twelve months following the date these unaudited condensed consolidated financial statements are issued. The Company intends to obtain any additional funding it requires through strategic relationships, public or private equity or debt financings, grants or other arrangements. The Company cannot assure such funding will be available on reasonable terms, if at all. Market volatility, inflation or other factors could also adversely impact the Companyâ€™s ability to access capital when and as needed.If the Company is unable to secure additional sources of funding or generate enough revenue from its collaborations, it may be necessary to significantly reduce the current rate of spending through reductions in staff and delaying, scaling back, or stopping certain research and development programs, including more costly clinical trials. Note 2 - Summary of Significant Accounting PoliciesBasis of PresentationThe accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial information and pursuant to the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the SEC. In managementâ€™s opinion, the unaudited condensed consolidated financial statements have been prepared on the same basis as the annual audited consolidated financial statements and include normal recurring adjustments necessary for the fair presentation of the Companyâ€™s financial position and its results of operations and comprehensive loss and its cash flows for the periods presented. These statements do not include all disclosures required by U.S. GAAP and should be read in conjunction with the Companyâ€™s audited consolidated financial statements and accompanying notes for the fiscal year ended December 31, 2023, which are contained in the 2023 Annual Report. The results for the three and nine months ended September 30, 2024 are not necessarily indicative of results to be expected for the entire year ending December 31, 2024 or future operating periods.Use of EstimatesThe preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and 7 Â disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.Significant estimates inherent in the preparation of the accompanying unaudited condensed consolidated financial statements include estimates for revenue recognition and costs incurred but not yet invoiced for research and development accruals.The Companyâ€™s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible these external factors could have an effect on the Companyâ€™s estimates and could cause actual results to differ materially from those estimates and assumptions.Other Risks and UncertaintiesU.S. and global financial markets have experienced volatility and disruption due to macroeconomic and geopolitical events such as rising inflation, changes in interest rates to combat inflation, the war between Russia and Ukraine, the Israel-Hamas war and the Israel-Hezbollah war in Lebanon. The Company cannot predict at this time to what extent, if at all, it and its employees, contract research organizations, vendors and/or collaborators could potentially be negatively impacted by these events.Reverse Stock SplitIn September 2023, the Company received a letter from the Listing Qualifications Department of the Nasdaq Stock Market notifying the Company, as the bid price for its common stock had closed below $1.00 per share for the last 30 consecutive business days, it was not in compliance with Nasdaq Listing Rule 5450(a)(1), which is the minimum bid price requirement for continued listing on the Nasdaq Global Select Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided a 180-calendar day period, or until March 25, 2024, to regain compliance with the minimum bid price requirement. The continued listing standard would be met once the closing bid price of the Companyâ€™s common stock was at least $1.00 per share for a minimum of ten consecutive business days during the 180-calendar day period. In January 2024, the Company's stockholders approved a reverse stock split of its common stock at a range of ratios between 1-for-7 to 1-for-17, and the Company's board of directors approved the implementation of the reverse stock split at a ratio of 1-for-12 (the Reverse Stock Split). The Reverse Stock Split was effective as of February 9, 2024 and the Company regained compliance with the minimum bid price requirement in February 2024. As of the effective time of the Reverse Stock Split, every 12 issued and outstanding shares of the Companyâ€™s common stock was automatically reclassified into one issued and outstanding share of the Companyâ€™s common stock. This reduced the number of shares outstanding from 65.8 million shares to 5.5 million shares. The Reverse Stock Split did not affect the number of authorized shares of common stock or the par value of the

common stock. No fractional shares of common stock were issued in connection with the Reverse Stock Split and all fractional shares were rounded down to the nearest whole share with respect to outstanding shares of common stock. Any holders of common stock who would have otherwise received a fractional share of common stock pursuant to the Reverse Stock Split, received cash in lieu of the fractional share. All prior period share and per share amounts of the Company's common stock presented have been retroactively adjusted to reflect the 1-for-12 Reverse Stock Split, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital.Net Loss per ShareBasic net loss per share of common stock excludes dilution and is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share of common stock reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity unless inclusion of such shares would be anti-dilutive. Diluted net loss per share is the same as basic net loss per share, since the effects of potentially dilutive securities are antidilutive given the net loss for each period presented. 8 Â A reconciliation of the numerators and the denominators of the basic and diluted net loss per common share computations is as follows (in thousands, except for share and per share amounts): Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Numerator: Â Â Â Â Â Â Â Â Â Â Â Â Net loss Â $ (9,613) Â $ (14,420) Â $ (29,842) Â $ (50,266) Denominator: Â Â Â Â Â Â Â Â Â Â Â Â Weighted average common shares outstanding - basic and diluted Â Â 6,351,431 Â Â Â 4,380,444 Â Â Â 5,827,750 Â Â Â 4,329,260 Â Net loss per share - basic and diluted Â $ (1.51) Â $ (3.29) Â $ (5.12) Â $ (11.61) Securities excluded from the computation of diluted net loss per share because including them would have been antidilutive are as follows: Â Â September 30, Â Â Â 2024 Â Â 2023 Â Warrants to purchase common stock Â Â 814,000 Â Â Â â€” Â Options to purchase common stock Â Â 937,268 Â Â Â 828,789 Â Common stock subject to purchase under ESPP Â Â 7,513 Â Â Â 6,711 Â Unvested RSUs Â Â 69,217 Â Â Â 90,740 Â Total Â Â 1,827,998 Â Â Â 926,240 Â Â Note 3 â€“ Related PartyIn October 2023, the Company entered into an Option, License and Collaboration Agreement (the Gilead Collaboration Agreement), and a Common Stock Purchase Agreement and an Investor Rights Agreement (collectively, the Gilead Equity Agreements) under which it received aggregate gross proceeds of $100.0 million from Gilead Sciences, Inc. (Gilead). During the three and nine months ended September 30, 2024, the Company recognized $6.8 million and $21.2 million of collaboration revenue under the Gilead Collaboration Agreement, respectively (see Note 8).Pursuant to the Investor Rights Agreement, Gilead designated two directors to the Companyâ€™s board of directors, who were appointed in December 2023 and February 2024. In June 2024, the Company entered into a Securities Purchase Agreement with Gilead for the issuance and sale of 179,500 shares of the Companyâ€™s common stock and a warrant to purchase up to 179,500 shares of the Companyâ€™s common stock in a private placement (see Note 6). The common stock and warrant were sold at a combined offering price of $15.46, for aggregate gross proceeds to the Company of approximately $2.8 million. Also in June 2024, the Gilead Equity Agreements were amended to extend deadlines relating to the Companyâ€™s efforts to complete an equity financing and its ability to require Gilead to purchase additional shares of the Companyâ€™s common stock by three months. The extended deadlines lapsed in October 2024. The amendments also explicitly include the shares of the Company's common stock and warrant sold to Gilead in June 2024 in the definition of registrable securities. The amendments to the Gilead Equity Agreements did not have an impact to the Company's condensed consolidated financial statements.As of September 30, 2024, Gilead held approximately 19.9% of the Companyâ€™s outstanding voting common stock. Under the Gilead Equity Agreements, Gilead may elect to purchase additional shares to increase its holdings up to a maximum of 29.9% of the Companyâ€™s then-outstanding voting common stock. The purchase price per share for additional shares purchased by Gilead under the Gilead Common Stock Purchase Agreement will be equal to the lesser of (1) a 35% premium to the 30 trading day volume weighted average price immediately prior to the date of purchase or (2) a 35% premium to the 30 trading day volume weighted average price immediately prior to delivery by Gilead of notice of the anticipated closing date. 9 Â Note 4 â€“ Fair Value Measurements and Investments in Marketable SecuritiesThe carrying amounts of cash equivalents and marketable securities approximate their fair value based upon quoted market prices. Certain of the Companyâ€™s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as cash, accounts receivable, accounts payable and accrued expenses.The Company uses the following three-level hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs to value its financial instruments:Level 1: Observable inputs such as unadjusted quoted prices in active markets for identical instruments.Level 2: Quoted prices for similar instruments that are directly or indirectly observable in the marketplace.Level 3: Significant unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.Investments in marketable securities consisted of the following (in thousands): Â Â September 30, 2024 Â Â AmortizedCost Â Â GrossUnrealizedGain Â Â GrossUnrealizedLoss Â Â Fair Value Â Cash equivalents Â Â Â Â Â Â Â Â Â Â Â Â Money market fund Â $ 27,840 Â Â $ â€” Â Â $ â€” Â Â $ 27,840 Â Total cash equivalents Â Â 27,840 Â Â Â Â â€” Â Â Â â€” Â Â Â 27,840 Â Short-term marketable securities Â Â Â Â Â Â Â Â Â Â Â Â U.S. and foreign corporate debt securities Â Â 16,468 Â Â Â 42 Â Â Â â€” Â Â Â 16,510 Â U.S. treasury securities Â Â 47,298 Â Â Â 64 Â Â Â â€” Â Â Â 47,362 Â U.S. and foreign commercial paper Â Â 2,619 Â Â Â 11 Â Â Â â€” Â Â Â 2,630 Â Total short-term marketable securities Â Â 66,385 Â Â Â 117 Â Â Â â€” Â Â Â 66,502 Â Total cash equivalents and marketable securities Â $ 94,225 Â Â $ 117 Â Â $ â€” Â Â $ 94,342 Â Â Â Â December 31, 2023 Â Â Â AmortizedCost Â Â GrossUnrealizedGain Â Â GrossUnrealizedLoss Â Â Fair Value Â Cash equivalents Â Â Â Â Â Â Â Â Â Â Â Â Money market fund Â $ 18,982 Â Â $ â€” Â Â $ â€” Â Â $ 18,982 Â Total cash equivalents Â Â 18,982 Â Â Â Â â€” Â Â Â â€” Â Â Â 18,982 Â Short-term marketable securities Â Â Â Â Â Â Â Â Â Â Â Â U.S. and foreign corporate debt securities Â Â 17,595 Â Â Â 41 Â Â Â (3) Â Â 17,633 Â U.S. treasury securities Â Â 76,891 Â Â Â 127 Â Â Â â€” Â Â Â 77,018 Â U.S. and foreign commercial paper Â Â 15,728 Â Â Â 27 Â Â Â â€” Â Â Â 15,755 Â Total short-term marketable securities Â Â 110,214 Â Â Â 195 Â Â Â (3) Â Â 110,406 Â Total cash equivalents and marketable securities Â $ 129,196 Â Â $ 195 Â Â $ (3) Â $ 129,388 Â Â There were no realized gains and losses for the three and nine months ended September 30, 2024 and 2023. As of September 30, 2024, there were no investments in an unrealized loss position. The Company did not recognize any credit losses related to its investments and all unrealized gains and losses on available-for-sale securities are recorded in accumulated other comprehensive loss on the condensed consolidated balance sheets as of September 30, 2024 and December 31, 2023. Accrued interest receivable was $0.4 million and $0.3 million as of September 30, 2024 and December 31, 2023, respectively, and was recorded in prepaid expenses and other current assets on the condensed consolidated balance sheets. The Company did not write off any accrued interest receivable during the three and nine months ended September 30, 2024 and 2023. 10 Â The following tables present the fair value of the Companyâ€™s financial assets measured at fair value on a recurring basis (in thousands):Â Â Â September 30, 2024 Â Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Â Fair Value Â Cash equivalents Â Â Â Â Â Â Â Â Â Â Â Â Money market fund Â $ 27,840 Â Â $ â€” Â Â $ â€” Â Â $ 27,840 Â Total cash equivalents Â Â 27,840 Â Â Â Â â€” Â Â Â â€” Â Â Â 27,840 Â Short-term marketable securities Â Â Â Â Â Â Â Â Â Â Â Â U.S. and foreign corporate debt securities Â Â â€” Â Â Â Â 16,510 Â Â Â â€” Â Â Â 16,510 Â U.S. treasury securities Â Â â€” Â Â Â 47,362 Â Â Â â€” Â Â Â 47,362 Â U.S. and foreign commercial paper Â Â â€” Â Â Â 2,630 Â Â Â â€” Â Â Â 2,630 Â Total short-term marketable securities Â Â â€” Â Â Â 66,502 Â Â Â â€” Â Â Â 66,502 Â Total assets measured at fair value Â $ 27,840 Â Â $ 66,502 Â Â $ â€” Â Â $ 94,342 Â Â Â Â December 31, 2023 Â Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Â Fair Value Â Cash equivalents Â Â Â Â Â Â Â Â Â Â Â Â Money market fund Â $ 18,982 Â Â $ â€” Â Â $ â€” Â Â $ 18,982 Â Total cash equivalents Â Â 18,982 Â Â Â Â â€” Â Â Â â€” Â Â Â 18,982 Â Short-term marketable securities Â Â Â Â Â Â Â Â Â Â Â Â U.S. and foreign corporate debt securities Â Â â€” Â Â Â 17,633 Â Â Â â€” Â Â Â 17,633 Â U.S. treasury securities Â Â â€” Â Â Â 77,018 Â Â Â â€” Â Â Â 77,018 Â U.S. and foreign commercial paper Â Â â€” Â Â Â 15,755 Â Â Â â€” Â Â Â 15,755 Â Total short-term marketable securities Â Â â€” Â Â Â 110,406 Â Â Â â€” Â Â Â 110,406 Â Total assets measured at fair value Â $ 18,982 Â Â $ 110,406 Â Â $ â€” Â Â $ 129,388 Â Â The Company estimates the fair value of its investments in marketable securities by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data, and other observable inputs.There were no transfers between Level 1, Level 2 or Level 3 investments during the periods presented. Note 5 â€“ Other Accrued ExpensesOther accrued expenses consist of the following (in thousands): Â Â September 30,2024 Â Â December 31,2023 Â Accrued expenses: Â Â Â Â Â Â Accrued compensation Â $ 4,124 Â Â $ 5,484 Â Accrued professional fees and other Â Â 641 Â Â Â 260 Â Total accrued expenses Â $ 4,765 Â Â $ 5,744 Â Â Note 6 â€“ Sale of Common Stock and WarrantsIn June 2024, the Company entered into a Securities Purchase Agreement with an investor for the issuance and sale of 634,500 shares of the Company's common stock and a warrant to purchase up to 634,500 shares of the Company's common stock in a registered direct offering, pursuant to its shelf registration statement on Form S-3 on file with the SEC. The common stock and warrant were sold at a combined offering price of $15.46 for aggregate gross proceeds to the Company of approximately $9.8 million. The Company also entered into a Securities Purchase Agreement with Gilead for the issuance and sale of 179,500 shares of the Company's common stock and a warrant to purchase up to 179,500 shares of the Company's common stock in a private placement. The common stock and warrant were sold at a combined offering price of $15.46 for aggregate gross proceeds to the Company of approximately $2.8 million. The sale of common stock to Gilead maintains Gilead's ownership of approximately 19.9% of the Company's outstanding 11 Â voting common stock as of the date of closing pursuant to the terms of Gilead's existing Investor Rights Agreement with the Company entered into in October 2023 and amended in June 2024 (see Note 3). The warrants sold to both parties have an exercise price equal to $17.00 per share, became immediately exercisable on the date of issuance and expire on June 18, 2029. Neither party may exercise any portion of the warrants to the extent it would beneficially own more than the limits defined in the warrant agreements. The exercise price and number of shares of common stock issuable upon the exercise of the warrants are subject to adjustment in the event of any stock dividends and distributions, stock splits, stock combinations or stock reclassifications, as described in the respective warrant agreements. Under certain circumstances, the warrants may be exercised on a â€œcashlessâ€ basis. The warrants were classified as a component of permanent stockholdersâ€™ equity within additional paid-in-capital and were recorded at the issuance date. The warrants are equity classified because they are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, permit the holders to receive a fixed number of common shares upon exercise, are indexed to the Companyâ€™s common stock and meet the equity classification criteria. In addition, such warrants do not provide any guarantee of value or return. There were no warrants exercised during the three and nine months ended September 30, 2024.In August 2020, the Company entered into a sales agreement under which the Company may offer and sell shares of its common stock having an aggregate offering price of up to $100.0 million through â€œat-the-marketâ€ offerings (2020 ATM), pursuant to its shelf registration statement on Form S-3 on file with the SEC. During the three months ended September 30, 2024 and 2023 and during the nine months ended September 30, 2024, the Company did not sell any shares of common stock under the 2020 ATM. During the nine months ended September 30, 2023, the Company sold 261,170 shares of common stock under the 2020 ATM, for which the Company received net proceeds of $4.5 million, after deducting commissions, fees and expenses. Note 7 â€“ Stock-Based CompensationThe following table summarizes the components of total stock-based compensation expense included in the condensed consolidated statements of operations and comprehensive loss (in thousands): Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Research and development Â $ 395 Â Â $ 512 Â Â $ 1,152 Â Â $ 1,747 Â General and administrative Â Â 402 Â Â Â 623 Â Â Â 1,217 Â Â Â 2,413 Â Total stock-based compensation expense Â $ 797 Â Â $ 1,135 Â Â $ 2,369 Â Â $ 4,160 Â Â As of September 30, 2024, there was $2.9 million of total unrecognized stock-based compensation related to outstanding equity awards, which is expected to be recognized over a weighted average remaining amortization period of 1.6 years.The fair value of stock options granted during the periods indicated was estimated using the Black-Scholes option pricing model, based on the following assumptions: Â Â Three Months Ended September 30, Â Nine Months Ended September 30, Â Â 2024 Â 2023 Â 2024 Â 2023 Exercise price Â $13.24 Â $11.76 Â $12.90Â - $15.06 Â $10.68Â - $18.36 Expected volatility Â 80.8% - 86.2% Â 77.5% - 83.1% Â 79.1% - 86.9% Â 77.5% - 83.1% Risk-free rate Â 4.39% - 4.40% Â 4.23% - 4.24% Â 4.16% - 4.57% Â 3.59% - 4.24% Expected term (years) Â 5.5Â - 7.0 Â 5.5Â - 7.0 Â 5.5Â - 7.5 Â 5.5Â - 7.5 Expected dividend yield Â 0% Â 0% Â 0% Â 0% Â Note 8 - Collaboration AgreementsGilead AgreementIn October 2023, the Company entered into the Gilead Collaboration Agreement and the Gilead Equity Agreements under which it received total proceeds of $100.0 million. Under the Gilead Collaboration Agreement, Gilead exclusively licensed to the Company its HPI program and NNPI program, while retaining opt-in rights to these programs and has an option to take an exclusive license, on a program-by-program basis, to all of the Companyâ€™s 12 Â other current and future pipeline programs. During the 12-year collaboration term (subject to payment of certain extension fees) and for a specified period thereafter, Gilead may exercise its opt-in rights, on a program-by-program basis, at one of two timepointsâ€”completion of a certain Phase 1 study or completion of a certain Phase 2 study for the first product within the programâ€”upon payment of an opt-in fee ranging from $45.0 million to $125.0 million per program depending on the type of program and when the option is exercised. If Gilead exercises its opt-in right to any current or future program under the collaboration, the Company is eligible to receive up to $330.0 million in potential regulatory and commercial milestones on that program, in addition to royalties ranging from the high single-digits to high teens, depending on the clinical stage of the program at the time of the opt-in. Following Gileadâ€™s exercise of its option for each of the Companyâ€™s programs, the Company may opt in to cover 40% of the research and development costs in the United States and share 40% of the profits and operating loss in the United States for products within the program in lieu of receiving milestones and royalties for that program in the United States, unless the Company later opts out of the cost/profit share for the program. Prior to Gileadâ€™s potential exercise of its opt-in, the Company will be primarily responsible for all discovery, research and development on its programs and the two Gilead-contributed programs. Following Gileadâ€™s opt-in, Gilead will control the further discovery, research, development, and commercialization on any optioned programs. During the term, Gilead will continue to support the collaboration through extension fees of $75.0 million in each of the third, fifth and seventh years of the collaboration.The Gilead Collaboration Agreement is subject to termination by either party for the other partyâ€™s uncured, material breach or insolvency. Subject to certain limitations, the Company and Gilead both have certain termination for convenience rights, upon sufficient prior written notice, with respect to programs that one party in-licenses from the other (subject to Gileadâ€™s option rights), and with respect to Gilead, for programs it has option rights to (subject to certain time limitations with respect to existing Company programs). Gilead also has a right to terminate the collaborative activities under the Gilead Collaboration Agreement at certain specified points during the collaboration term. Other customary termination rights are further provided in the Gilead Collaboration Agreement.The Company concluded Gilead is a customer and accordingly, the Gilead Collaboration Agreement is within the scope of the revenue from contracts with customers guidance. The Company identified a single combined performance obligation for the discovery, research and development services during the collaboration term (the R&D Services). As of September 30, 2024, the total transaction price of the Gilead Collaboration Agreement was determined to be $90.7 million. The Company will reevaluate the transaction price in each reporting period as uncertain events are resolved or other changes in circumstances occur.The transaction price is reflected as collaboration revenue when realized in the Companyâ€™s condensed consolidated statements of operations. The Company will recognize revenue over time using a cost-based input method over the initial non-cancellable term of three years since this method best reflects the transfer of services to Gilead. In applying a cost-based input method of revenue recognition, the Company uses actual costs incurred relative to estimated total costs to fulfill each performance obligation. The Company recognized collaboration revenue of $6.8 million and $21.2 million during the three and nine months ended September 30, 2024. The transaction price for future collaborative activities was recorded as deferred revenue on the condensed consolidated balance sheet as of September 30, 2024, of which $32.6 million was short-term and $32.5 million was long-term. The reimbursable expenses incurred by the Company during the three months ended September 30, 2024 were insignificant. During the nine months ended September 30, 2024, the Company incurred $0.3 million in reimbursable expenses due to Gilead. The following table presents changes in the Companyâ€™s contract liabilities (in thousands): Â Â Balance atBeginningof Period Â Â Additions Â Â Deductions Â Â Balance atEnd ofPeriod Â Nine Months Ended September 30, 2024 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Contract liabilities: Â Â Â Â Â Â Â Â Â Â Â Â Deferred revenue Â $ 86,294 Â Â $ â€” Â Â $ (21,163) Â $ 65,131 Â Â Â Â Â Â Â Â Â Â Â Â Â Â 13 Â Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Collaboration revenue recognized in the period from Â Â Â Â Â Â Â Â Â Â Â Â Amounts included in deferred revenue at the beginning of the period Â $ 6,845 Â Â $ â€” Â Â $ 21,163 Â Â $ â€” Â Performance obligations satisfied in previous period Â $ â€” Â Â $ â€” Â Â $ â€” Â Â $ â€” Â Arbutus Biopharma AgreementIn

August 2020, the Company and Arbutus Biopharma Corporation (Arbutus Biopharma) entered into a Clinical Trial Collaboration Agreement (the Arbutus Biopharma Agreement) to conduct a randomized, multi-center, open-label Phase 2 clinical trial to explore the safety, pharmacokinetics and antiviral activity of the triple combination of vebicorvir (VBR), AB-729 and a nucleos(t)ide analog reverse transcriptase inhibitor (NrtI) compared to the double combinations of VBR with a NrtI and AB-729 with a NrtI. Under the Arbutus Biopharma Agreement, Assembly and Arbutus Biopharma shared responsibility for the costs of the trial equally, excluding manufacturing supply which were the burden of each company to supply their respective drugs, VBR and AB-729. Assembly was responsible for conducting this clinical trial with Arbutus Biopharma reimbursing Assembly its share of expenses. In February 2023, Assembly and Arbutus Biopharma terminated the Phase 2 clinical trial early, at the end of the 48-week on-treatment period.Reimbursements and cost-sharing portions from Arbutus Biopharma are reflected as a reduction of research and development expense when realized in the Companyâ€™s condensed consolidated statements of operations. During the three and nine months ended September 30, 2024, the Company recognized research and development expenses of $0.3 million for net amounts refundable to Arbutus Biopharma after the final reconciliation of clinical trial costs. Amounts refundable to Arbutus Biopharma are recorded as accrued research and development expenses on the condensed consolidated balance sheet as of September 30, 2024. During the three and nine months ended September 30, 2023, the Company recognized a reduction of research and development expenses of $0.1 million and $1.2 million, respectively, under the Arbutus Biopharma Agreement. Note 9 - Milestones and Research AgreementsHBV Research Agreement with Indiana UniversitySince September 2013, the Company was party to an exclusive License Agreement dated September 3, 2013 with Indiana University Research and Technology Corporation (IURTC) from whom it licensed aspects of the Companyâ€™s HBV program held by IURTC. The license agreement required the Company to make milestone payments based upon the successful accomplishment of clinical and regulatory milestones. The aggregate amount of all performance milestone payments under the IURTC license agreement, if all milestones through development were met, was $0.8 million, with a portion having been paid. The Company was obligated to pay IURTC royalty payments based on net sales of the licensed technology as well as a portion of any sublicensing revenue Assembly received. The Company was also required to pay diligence maintenance fees each year to the extent that the royalty, sublicensing, and milestone payments to IURTC were less than such fees for that year. Following its decision to discontinue further development or partnering for ABI-H3733, the Company terminated the IURTC license agreement effective April 2024. There were no fees paid to IURTC during the three months ended September 30, 2024 or 2023. The Company paid IURTC $0.1 million in diligence maintenance fees during both the nine months ended September 30, 2024 and 2023. 14 Â Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations The condensed consolidated financial statements and this Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2023 and the related Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the U.S. Securities and Exchange Commission on March 28, 2024 (2023 Annual Report). In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those expressed or implied in any forward-looking statements as a result of various factors, including those set forth under â€œPart I. Item 1A. Risk Factorsâ€ in our 2023 Annual Report and â€œPart II. Item 1A. Risk Factorsâ€ in this report. Overview We are a biotechnology company developing innovative therapeutics targeting serious viral diseases with the potential to improve the lives of patients worldwide. Our pipeline includes two clinical-stage helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes, an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, a clinical-stage capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) and research programs focused on a non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses and a small molecule interferon-Î± (IFN-Î±) receptor (IFNAR) agonist targeting HBV and HDV. Our Clinical Programs and CTA-Enabling Programs To date, in 2024, we initiated the Phase 1a portion of a Phase 1a/b study of ABI-5366 (5366), a long-acting HPI for recurrent genital herpes and announced interim results from the Phase 1a portion of the study in the third quarter of 2024. In 2024, we also initiated the Phase 1b portion of the Phase 1a/b study of 5366 and initiated a Phase 1b study of ABI-4334 (4334), a highly potent, next-generation CAM for chronic HBV infection. By the end of 2024, we expect to initiate a Phase 1a study of ABI-6250 (6250), an orally bioavailable HDV entry inhibitor; and the Phase 1a portion of a Phase 1a/b study of ABI-1179 (1179), a long-acting HPI for recurrent genital herpes contributed by Gilead Sciences, Inc. (Gilead) through the Gilead Collaboration (as defined below). We also expect to announce interim results from the Phase 1b study of 4334 by the end of 2024. Recurrent Genital Herpes/HSV-1 and HSV-2 Genital herpes can be caused by either herpes simplex virus type 1 (HSV-1) or herpes simplex virus type 2 (HSV-2). HSV-1 and HSV-2 are acquired by oral or genital contact either during symptomatic or asymptomatic reactivation of the virus. Both viruses replicate in neurons, where they can remain latent for the rest of the patientâ€™s life and periodically reactivate, with the virus spreading and replicating in epithelial tissues. Initial infection can be asymptomatic or can be marked by symptoms, including painful skin lesions, swelling of lymph nodes and urinary problems that can persist for two to three weeks. Genital herpes recurrence is common and can cause painful genital lesions that can lead to increased transmission and debilitate patients, and symptoms may become more serious with additional episodes. Additional complications include increased risk of HIV infection, as 30% of incident HIV infections acquired through sexual transmission is attributable to HSV-2 infection. In addition, people with recurrent genital herpes often experience associated psychosocial impacts, including anxiety, concerns about transmission, depression and social stigma. Immunocompromised patients may experience more severe and prolonged symptoms due to increased recurrence rates. While genital herpes can be caused by either HSV-1 or HSV-2, recurrences are more likely to be experienced by patients infected by HSV-2. HPIs are antiviral agents in development for recurrent genital herpes, with a clinically-validated mechanism of action. HPIs inhibit the HSV helicase-primase complex, which is a unique viral enzyme complex without a human homolog, consisting of helicase, primase and cofactor subunits. These subunits have functions that are essential for viral DNA replication and are conserved across HSV-1 and HSV-2. Unlike nucleoside analogs, these compounds do not require phosphorylation by the HSV thymidine kinase (TK) and ongoing viral replication to become active drugs. As a result, HPIs are active immediately upon reactivation of latent HSV-1 and HSV-2. Furthermore, HPIs are active against TK-deficient HSV-1 and HSV-2, which is a major mechanism of resistance to nucleoside analogs. Most people with initial symptomatic genital herpes who are infected with HSV-2 have three or more recurrences per year, including over four million people in the United States and France, Germany, Italy and Spain (collectively, the EU4) and the United Kingdom (UK). Currently, there are three antiviral drugs (all nucleoside analogs) that have been approved in the United States and the EU4/UK for the treatment of genital herpes. However, no new drugs have been 15 Â approved in these regions to treat genital herpes for more than 25 years. In addition to the approved nucleoside analogs, agents such as local anesthetics or analgesics may be used to alleviate local symptoms of minor pain and discomfort. Nucleoside analogs can be administered as episodic therapy as individual outbreaks arise or daily as chronic suppressive therapy for those with high post-exposure recurrences. However, these agents are only partially effective at controlling the infection or reducing transmission risk. With current nucleoside analog therapies, only one out of three recurrent genital herpes patients with six or more recurrences per year are able to make it through a year of treatment without a recurrence. There are still high titer (greater than 104 HSV-2 DNA copies/mL) shedding episodes under this current standard of care for recurrent genital herpes, which can lead to recurrent episodes and transmission of genital herpes. Based on the limitations of current therapies, we see a path to advancing the treatment paradigm for patients suffering from recurrent genital herpes. To reach that goal, we discovered and are developing a novel, potent, long-acting HPI for recurrent genital herpes, 5366, which demonstrated low nanomolar potency in vitro against both HSV-1 and HSV-2 clinical isolates and a favorable nonclinical safety profile in Good Laboratory Practice (GLP) toxicology studies, with high safety margins and minimal potential for off-target effects. During the first quarter of 2024, we filed a Clinical Trial Application (CTA) to support initiation of Phase 1a/b clinical studies, which was approved in April 2024, and we dosed our first participant in the Phase 1a portion of this study during the second quarter of 2024. In September 2024, we announced positive interim data for the Phase 1a portion of the 5366 study. Interim results exceeded our objectives for this Phase 1a study and support 5366's progression into Phase 1b. Across the Part A (Phase 1a) cohorts evaluated as of the September 23, 2024 data cutoff date, 5366 had a mean half-life of approximately 20 days when dosed orally, supporting once-weekly oral dosing, the target profile for 5366, as well as showing the potential for once-monthly oral dosing. 5366 doses within the range tested are projected, with weekly or monthly dosing, to maintain the target plasma concentrations for antiviral activity established by pharmacokinetic (PK) modeling. We plan to explore both once-weekly and once-monthly oral dosing regimens in the Part B (Phase 1b) portion of the study. In these cohorts as of the September 23, 2024 data cutoff date, 5366 has been well-tolerated with a favorable safety profile observed with exposure of up to 70 days. Treatment-emergent adverse events (AEs) were all mild to moderate in intensity and all were considered not related to study treatment by the study investigators; there have been no serious AEs in any dose arm. There were no treatment-related Grade 3 or 4 laboratory abnormalities and no protocol-defined stopping criteria were met. There were no clinically significant electrocardiogram abnormalities or patterns of AEs or laboratory abnormalities noted. We initiated the Phase 1b portion of the 5366 study during the third quarter of 2024, and we expect interim data to be available during the first half of 2025. In addition to 5366, we are also advancing 1179, a structurally-differentiated HPI with single digit nanomolar potency against HSV-1 and HSV-2 and a nonclinical PK and safety profile to date that is supportive of a potential long-acting treatment by once-weekly oral administration. GLP toxicology studies have been completed. We submitted the CTA for a Phase 1a/b study of 1179 in September 2024, which was approved in October 2024, and the Phase 1a portion of the clinical study is expected to begin by the end of 2024. We acquired rights to 1179, Gileadâ€™s HPI program, as part of the Gilead Collaboration in October 2023. In July 2024, we highlighted nonclinical data for both 5366 and 1179 at the International Herpesvirus Workshop through poster presentations for each, as well as an oral presentation for 1179. HBV and HDV The World Health Organization (WHO) estimates that 254 million people worldwide are chronically infected with HBV as of 2022, and 1.2 million new infections occur each year. HBV is a leading global cause of chronic liver disease and liver transplants, and the WHO estimates that 1.1 million people died in 2022 from HBV, mostly due to cirrhosis and hepatocellular carcinoma. As of 2022, of the 254 million people living with chronic HBV infection, only approximately 33 million, or 13%, were aware of their infection, and only approximately 7 million, or 3%, of those diagnosed received treatment. HBV is a highly prevalent disease that infects almost three times the number of people infected with hepatitis C virus and HIV infections combined, according to the WHO. The current standard of care for chronic HBV infection, nucleos(t)ide analog reverse transcriptase inhibitors (NrtIs), are taken life-long and reduce, but do not eliminate, the virus and result in very low cure rates. No new mechanisms 16 Â of action (MOA) have been approved for the treatment of chronic HBV infection in over 25 years. The focus of our HBV program is to improve outcomes and increase the number of patients diagnosed and treated through the development of finite and curative therapies targeting an orthogonal MOA. HDV is a â€œsatellite virusâ€ of HBV because it can only infect people (1) who are already infected with HBV or (2) at the same time as a person is infected with HBV. HDV affects a subset of approximately 12 to 72 million HBV infected people. These individuals infected with HDV, which comprise an estimated 4.5% of hepatitis B surface antigen (HBsAg) positive individuals, experience a substantially increased disease burden, as they account for 18% of cirrhosis and 20% of hepatocellular carcinoma associated with HBV. HDV is considered the most severe form of hepatitis, as 70% of individuals infected with HDV progress to cirrhosis within ten years. While HDV is less prevalent in the United States, it is a significant and serious health problem with inadequate treatment in many parts of Europe, Africa, the Middle East, East Asia and parts of South America. HDV may be significantly underdiagnosed, because there were no HDV-targeted therapies approved until very recently, and the first therapy approved is only approved in the European Union (EU). HDV is known to accelerate disease progression and increase the incidence of liver cirrhosis and liver cancer, which results in higher morbidity and mortality rates than HBV alone. The current standard of care treatment for HDV is off-label pegylated IFN-Î± injected weekly or, in some regions, a large, complex molecule that requires daily injections. There are no approved HDV treatments in the United States, and there is only one approved HDV treatment in the EU. We believe a safe and effective oral small molecule entry inhibitor would be a significant innovation for patients living with HDV, which face a significant and immediate disease burden. HDV Entry Inhibitor Program HDV is a small RNA virus that encodes just two viral proteins and relies on host enzymes as well as the HBsAg from HBV to replicate, which limits the number of HDV-specific antiviral targets. Similar to HBV, HDV utilizes HBsAg to enter hepatocytes by binding the cellular transmembrane protein sodium taurocholate co-transporting peptide (NTCP). NTCP is highly expressed on human hepatocytes, where it serves as one of several proteins involved in the transport of bile acids. The binding of specific small or large molecules to NTCP has been shown to effectively inhibit the interaction of HBsAg with NTCP, which prevents HBV and HDV from infecting hepatocytes. The inhibition of HBV and HDV infection by molecules that bind NTCP has been demonstrated in vitro, in animal models and clinically. Notably, bulevirtide, a peptide blocker of NTCP, is the only approved therapy for HDV (approved in the EU). 6250 uses the same clinically validated MOA as bulevirtide. The binding of NTCP-targeted HBV/HDV entry inhibitors to NTCP has also been shown to inhibit the transport of certain bile acids into cells, which results in plasma elevations of bile acids; this effect has been well tolerated clinically and may serve as a biomarker of pharmacologically active concentrations of drug in the plasma. We believe a safe and effective oral small molecule entry inhibitor would be a significant innovation for patients living with HDV and could significantly improve treatment uptake and diagnosis rates, especially when compared with currently available injectable products. In September 2023, we nominated 6250, a novel, orally bioavailable small molecule designed to inhibit entry of HBV and HDV by targeting NTCP. In nonclinical studies, 6250 demonstrated low nanomolar potency against all tested HBV/HDV genotypes, favorable selectivity for NTCP versus other bile acid transporters, good oral bioavailability and a PK profile in nonclinical species projected to support once-daily oral dosing. In GLP toxicology studies, 6250 demonstrated a favorable nonclinical safety profile with wide safety margins. At the European Association for the Study of the Liver's International Liver CongressTM in June 2024 and the International HBV Meeting in September 2024, we presented nonclinical profiling of 6250. In addition, 6250 was featured in an oral presentation at the Science of HBV Cure Meeting 2024. We expect to initiate a Phase 1a clinical study of 6250 by the end of 2024. Capsid Assembly Modulator Program HBV is a DNA virus that infects hepatocytes and establishes a reservoir of covalently closed circular DNA (cccDNA), a unique viral DNA moiety that resides in the nucleus of HBV-infected hepatocytes and is associated with viral persistence and chronic infection. No currently approved oral therapies target cccDNA activity directly, which makes molecules that can modulate cccDNA generation or disrupt its function highly sought after in the HBV field. As a result, we have worked to discover and develop compounds targeting the core protein, a viral protein involved in numerous aspects of the HBV replication cycle, including the generation of HBV cccDNA. 17 Â A benchmark for therapeutic agents aiming to decrease cccDNA levels is the use of several key viral antigens as surrogate biomarkers of active cccDNA. The same biomarkers can be used in both primary human hepatocytes and infected individuals. On this basis, our next-generation CAM, 4334, has shown nonclinical proof of principle. In a variety of cell culture models, 4334 has demonstrated the ability to reduce production of HBV DNA levels as well as the surrogate markers for cccDNA establishment: HBV e antigen (HBeAg), HBV core-related antigen (HBcrAg) and HBV pre-genomic RNA (pgRNA). As a next-generation CAM, 4334 has been optimized to potently disrupt viral replication (MOA #1) and prevent the establishment and replenishment of new cccDNA (MOA #2). In contrast, while active against MOA #1, first-generation CAMs have not demonstrated adequate potency to sufficiently block cccDNA formation (MOA #2). Further, the current standard of care, NrtIs, impacts the viral life cycle after establishment of cccDNA and can only inhibit production of new viral particles, and it does so incompletely. The chemical scaffold of 4334 is novel and distinct from all our prior CAM candidates. We believe that 4334 has a best-in-class nonclinical profile, with single-digit nanomolar potency against MOA #1 and MOA #2, pan-genotypic activity, an improved resistance profile and a favorable safety profile. Through mechanistic studies presented at multiple conferences, we have demonstrated that 4334 promotes the formation of empty capsids by acceleration of capsid assembly, prevents the formation of cccDNA by disrupting incoming capsids, and prematurely disrupts capsids containing duplex linear DNA, the precursor for integrated HBV DNA. A Phase 1a study demonstrated that 4334 was well tolerated when administered orally as single or multiple doses. In addition, the PK data support 4334 as a once daily oral therapy and predicts best in class activity against both MOA #1 and MOA #2. During the second quarter of 2024, we dosed our first participant in a Phase 1b clinical study of 4334. Interim clinical results from this study are expected by the end of 2024. Research Programs Transplant-Associated Herpesviruses In August 2022, in connection with our announcement of our HPI program, we also introduced our NNPI research program, targeting transplant-associated herpesviruses. In a transplant setting, when people are experiencing immunosuppression, they are at high risk of uncontrolled viral replication and severe disease brought on by one or more herpesviruses, including cytomegalovirus (CMV), HSV-1, HSV-2 and varicella zoster virus (VZV). Each of these herpesviruses are highly prevalent, as approximately (1) 60% of people receiving transplants are CMV-positive; (2) 60% of people receiving transplants are HSV-positive; and (3) 80% of people receiving transplants are VZV-positive. These viruses establish lifelong latent infections and frequently reactivate in people receiving transplants due to the use of immunosuppressive drugs following the transplant. These uncontrolled viral infections increase the risk of severe disease and serious complications, including organ rejection, graft loss and death, and impacted approximately 95,000 people receiving transplants in 2021 in the United States and Europe. While there are approved antivirals that are administered in a transplant

setting, currently approved antivirals are not broad spectrum and pose the risk of potentially serious side effects and drug-drug interactions. As a result of these limitations, we identified an opportunity to develop a potent oral pan-herpes NNPI for these transplant-associated herpesvirus infections, which could greatly advance treatment. Our research team has discovered multiple chemical series of potent, broad-spectrum herpesvirus NNPIs. In addition, Gilead exclusively licensed us its NNPI program, and we believe the combined effort will accelerate candidate nomination and enhance our chance of clinical success. IFNAR Agonist In July 2022, we introduced our research program advancing a novel, small molecule IFNAR agonist designed to selectively activate the IFN-Î± pathway within the liver and offer the convenience of oral dosing. IFN-Î± is a subcutaneous injectable immune modulatory therapy approved for HBV that has demonstrated functional cure in some HBV infected people, but its poor tolerability profile significantly limits its use. Substantial side effects include flu-like symptoms, cytopenias, serious depression and psychiatric effects. In addition, multiple contraindications limit its use, and it requires weekly injections that result in systemic exposure for up to a year. By focusing exposure on the liver, our investigational IFNAR agonist program aims to engage IFN-Î±â€™s validated antiviral and immune modulatory mechanisms, retaining the efficacy of IFN-Î± while reducing systemic exposure to improve tolerability. Lead optimization of multiple IFNAR agonists is in progress. 18 Â Gilead Collaboration On October 15, 2023, we entered into an Option, License and Collaboration agreement (the Gilead Collaboration Agreement) with Gilead pursuant to which Gilead (1) exclusively licensed to us its HPI program and its NNPI program, while retaining opt-in rights to these programs and (2) has an option to take an exclusive license, on a program-by-program basis, to all of our other current and future pipeline programs. During the 12-year collaboration term (subject to payment of certain extension fees) and for a specified period thereafter, Gilead may exercise its opt-in rights, on a program-by-program basis, at one of two timepointsâ€”completion of a certain Phase 1 study or completion of a certain Phase 2 study for the first product within the programâ€”upon payment of an opt-in fee ranging from $45.0 million to $125.0 million per program depending on the type of program and when the option is exercised. Pursuant to the Gilead Collaboration Agreement, Gilead made an $84.8 million upfront cash payment to us. If Gilead exercises its opt-in right to any current or future program under the collaboration, we are eligible to receive up to $330.0 million in potential regulatory and commercial milestones on that program, in addition to royalties ranging from the high single-digits to high teens, depending on the clinical stage of the program at the time of the opt-in. Following Gileadâ€™s exercise of its option for each of our programs, we may opt in to cover 40% of the research and development costs in the United States and share 40% of the profits and operating loss in the United States for products within the program in lieu of receiving milestones and royalties for that program in the United States, unless we later opt out of the cost/profit share for the program. Prior to Gileadâ€™s potential exercise of its opt-in, we will be primarily responsible for all discovery, research and development on both our programs and the two Gilead-contributed programs. Following Gileadâ€™s opt-in, Gilead will control the further discovery, research, development, and commercialization on any optioned programs. During the term, Gilead will continue to support the collaboration through extension fees of $75.0 million in each of the third, fifth and seventh years of the collaboration. The Gilead Collaboration Agreement is subject to termination by either party for the other partyâ€™s uncured, material breach or insolvency. Subject to certain limitations, we and Gilead both have certain termination for convenience rights, upon sufficient prior written notice, with respect to programs that one party in-licenses from the other (subject to Gileadâ€™s option rights), and with respect to Gilead, for programs it has option rights to (subject to certain time limitations with respect to existing Company programs). Gilead also has a right to terminate the collaborative activities under the Gilead Collaboration Agreement at certain specified points during the collaboration term. Other customary termination rights are further provided in the Gilead Collaboration Agreement. We and Gilead also entered into a Common Stock Purchase Agreement and an Investor Rights Agreement (together, the Gilead Equity Agreements), which were both amended in June 2024 in connection with a financing transaction (the 2024 Financing Transaction). Pursuant to the Gilead Equity Agreements, Gilead made an upfront equity investment of $15.2 million by purchasing from us 1,089,472 shares of our common stock at a purchase price of $13.92 per share. Gilead may elect to purchase additional shares of common stock from us in an amount that results in Gilead owning 29.9% of our then-outstanding voting common stock. The purchase price per share for additional shares purchased by Gilead will be equal to the lesser of (1) a 35% premium to the 30 trading day volume weighted average price immediately prior to the date of purchase or (2) a 35% premium to the 30 trading day volume weighted average price immediately prior to delivery by Gilead of notice of the anticipated closing date. The Gilead Equity Agreements also include a three-year standstill provision and a two-year lockup provision, each with customary exceptions, and provide Gilead with certain other stock purchase rights and registration rights, as well as the right to designate two directors (or, alternatively, board observers at Gileadâ€™s election) to our board of directors. In December 2023, Gilead designated Tomas Cihlar, Ph.D. to serve on our board of directors, and in March 2024, Gilead designated Robert D. Cook II to serve on our board of directors. As a part of the 2024 Financing Transaction, we and Gilead entered into a Securities Purchase Agreement for the issuance and sale, in a private placement, of 179,500 shares of our common stock and a warrant to purchase up to 179,500 shares of our common stock. The common stock and warrant were sold to Gilead pursuant to the terms of the Investor Rights Agreement. The warrant sold to Gilead has an exercise price equal to $17.00 per share, became immediately exercisable on the date of issuance and will expire on June 18, 2029. Neither Gilead nor its affiliates may exercise any portion of the warrant to the extent that Gilead would own more than 19.9% of the number of our shares of common stock outstanding immediately after giving effect to such exercise. Operations We currently have corporate and administrative offices and research laboratory space in South San Francisco, California. 19 Â Since our inception, we have had no revenue from product sales and have funded our operations principally through debt financings prior to our initial public offering in 2010 and through equity financings and collaborations since then. Our operations to date have been primarily limited to organizing and staffing our company, licensing our product candidates, discovering and developing our product candidates, maintaining and improving our patent portfolio and raising capital. We have generated significant losses to date, and we expect to continue to generate losses as we develop our product candidates. As of September 30, 2024, we had an accumulated deficit of $815.6 million. Because we do not generate revenue from any of our product candidates, our losses will continue as we further develop and seek regulatory approval for, and commercialize, our product candidates. Additionally, we expect our research and development expenses to increase over the next few years due to the Gilead Collaboration Agreement. As a result, our operating losses are likely to be substantial over the next several years as we continue the development of our product candidates and thereafter if none are approved or successfully launched. We are unable to predict the extent of any future losses or when we will become profitable, if at all. Critical Accounting Estimates Our managementâ€™s discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP). The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. We evaluate our estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. Our critical accounting policies and significant estimates are detailed in our 2023 Annual Report. Our critical accounting policies and significant estimates have not changed from those previously disclosed in our 2023 Annual Report. Results of Operations Comparison of the Three Months Ended September 30, 2024 and 2023 Collaboration Revenue The following table summarizes the period-over-period changes in our collaboration revenue (in thousands, except for percentages): Â Â Three Months Ended September 30, Â Â $ Change Â Â % Change Â Â Â 2024 Â Â 2023 Â Â 2024 vs. 2023 Â Â 2024 vs. 2023 Â Collaboration revenue from a related party Â $ 6,845 Â Â $ â€” Â Â $ 6,845 Â Â Â 100 % Collaboration revenue for the three months ended September 30, 2024 includes the recognition of $6.8 million under the Gilead Collaboration Agreement entered into in October 2023. There was no revenue for the three months ended September 30, 2023. 20 Â Research and Development Expenses Research and development expenses consist primarily of employee-related expenses, fees paid to contract research organizations and contract manufacturing organizations, lab supplies and other third-party expenses that support our research and discovery, nonclinical and clinical activities. External costs represent a significant portion of our research and development expenses, which we track on a program-by-program basis following the nomination of a development candidate. We use our employee and infrastructure resources, as well as certain third-party costs, across multiple research and development programs, and we do not specifically allocate these costs to our programs. The following table summarizes the period-over-period changes in our research and development expenses (in thousands, except for percentages): Â Â Three Months Ended September 30, Â Â $ Change Â Â % Change Â Â Â 2024 Â Â 2023 Â Â 2024 vs. 2023 Â Â 2024 vs. 2023 Â External expenses: Â Â Â Â Â Â Â Â Â Â Â Â Research and discovery Â $ 2,251 Â Â $ 2,404 Â Â $ (153) Â Â (6 %) 5366 Â Â 1,797 Â Â Â 1,116 Â Â Â 681 Â Â Â 61 % 6250 Â Â 1,298 Â Â Â â€” Â Â Â 1,298 Â Â Â 100 % 4334 Â Â 842 Â Â Â 184 Â Â Â 658 Â Â Â 358 % 1179 Â Â 654 Â Â Â â€” Â Â Â 654 Â Â Â 100 % ABI-H3733 (3733) Â Â â€” Â Â Â 437 Â Â Â (437) Â Â (100 %) Vebicorvir (VBR) Â Â (67) (1) Â 118 Â Â Â (185) Â Â (157 %) Total external expenses Â Â 6,775 Â Â Â 4,259 Â Â Â 2,516 Â Â Â 59 % Employee and contractor-related expenses Â Â 6,072 Â Â Â 4,725 Â Â Â 1,347 Â Â Â 29 % Facility and other expenses Â Â 668 Â Â Â 1,840 Â Â Â (1,172) Â Â (64 %) Total research and development expenses Â $ 13,515 Â Â $ 10,824 Â Â $ 2,691 Â Â Â 25 % (1) Reflects net amounts refundable to us after the final reconciliation of costs of the clinical trial conducted pursuant to the Clinical Trial Collaboration Agreement with Arbutus Biopharma Corporation (the Arbutus Biopharma Agreement), which was terminated in February 2023. Research and development expenses were $13.5 million for the three months ended September 30, 2024 compared to $10.8 million for the same period in 2023. The $2.7 million increase in research and development expenses was primarily driven by increases in external expenses from the advancement and expansion of our pipeline, most notably from the nomination of our HDV entry inhibitor, 6250, partially offset by savings from the discontinuation of 3733 and VBR. We also experienced a $1.3 million increase in employee and contractor-related expenses due to higher headcount and increased travel costs. This increase was largely offset by a $1.2 million decrease in facility and other expenses, reflecting cost savings in rent and related expenses from our corporate headquarters sublease, which commenced in November 2023. General and Administrative Expenses General and administrative expenses consist primarily of salaries, consulting fees and other related costs, professional fees for legal services, accounting and tax services, insurance and travel expenses, as well as stock-based compensation expense associated with equity awards to our employees and directors. The following table summarizes the period-over-period changes in our general and administrative expenses (in thousands, except for percentages): Â Â Three Months Ended September 30, Â Â $ Change Â Â % Change Â Â Â 2024 Â Â 2023 Â Â 2024 vs. 2023 Â Â 2024 vs. 2023 Â General and administrative expenses Â $ 4,286 Â Â $ 4,224 Â Â $ 62 Â Â Â 1 % General and administrative expenses were $4.3 million for the three months ended September 30, 2024 compared to $4.2 million for the same period in 2023. Overall, general and administrative expenses remained consistent as increases in our professional fees for legal and tax services were substantially offset by decreases in stock-based compensation expense due to the lower grant date fair value of our awards vesting during the period. 21 Â Interest and Other Income, Net Interest income consists of interest earned on our cash and cash equivalents and available-for-sale securities. The following table summarizes the period-over-period changes in our interest and other income, net (in thousands, except for percentages): Â Â Three Months Ended September 30, Â Â $ Change Â Â % Change Â Â Â 2024 Â Â 2023 Â Â 2024 vs. 2023 Â Â 2024 vs. 2023 Â Interest and other income, net Â $ 1,343 Â Â $ 628 Â Â $ 715 Â Â Â 114 % Interest and other income, net was $1.3 million for the three months ended September 30, 2024, compared to $0.6 million for the same period in 2023. The $0.7 million increase was primarily due to more interest income earned on marketable securities resulting from a larger portfolio balance after the receipt of $100.0 million upon entering into the Gilead Collaboration in October 2023 and $12.6 million upon entering into the 2024 Financing Transaction in June 2024. Comparison of the Nine Months Ended September 30, 2024 and 2023 Collaboration Revenue The following table summarizes the period-over-period changes in our collaboration revenue (in thousands, except for percentages): Â Â Nine Months Ended September 30, Â Â $ Change Â Â % Change Â Â Â 2024 Â Â 2023 Â Â 2024 vs. 2023 Â Â 2024 vs. 2023 Â Collaboration revenue from a related party Â $ 21,163 Â Â $ â€” Â Â $ 21,163 Â Â Â 100 % Collaboration revenue for the nine months ended September 30, 2024 includes the recognition of $21.2 million under the Gilead Collaboration Agreement entered into in October 2023. There was no revenue for the nine months ended September 30, 2023. Research and Development Expenses The following table summarizes the period-over-period changes in our research and development expenses (in thousands, except for percentages): Â Â Nine Months Ended September 30, Â Â $ Change Â Â % Change Â Â Â 2024 Â Â 2023 Â Â 2024 vs. 2023 Â Â 2024 vs. 2023 Â External expenses: Â Â Â Â Â Â Â Â Â Â Â Â Research and discovery Â $ 6,753 Â Â $ 7,828 Â Â $ (1,075) Â Â (14 %) 6250 Â Â 5,361 Â Â Â â€” Â Â Â 5,361 Â Â Â 100 % 5366 Â Â 3,933 Â Â Â 1,654 Â Â Â 2,279 Â Â Â 138 % 1179 Â Â 3,531 Â Â Â â€” Â Â Â 3,531 Â Â Â 100 % 4334 Â Â 1,939 Â Â Â 1,923 Â Â Â 16 Â Â Â 1 % 3733 Â Â Â â€” Â Â Â 2,945 Â Â Â (2,945) Â Â (100 %) VBR Â Â (67) (1) Â 1,463 Â Â Â (1,530) Â Â (105 %) ABI-H2158 Â Â Â â€” Â Â Â 121 Â Â Â (121) Â Â (100 %) Total external expenses Â Â 21,450 Â Â Â 15,934 Â Â Â 5,516 Â Â Â 35 % Employee and contractor-related expenses Â Â 18,081 Â Â Â 17,730 Â Â Â 351 Â Â Â 2 % Facility and other expenses Â Â 2,122 Â Â Â 4,230 Â Â Â (2,108) Â Â (50 %) Total research and development expenses Â $ 41,653 Â Â $ 37,894 Â Â $ 3,759 Â Â Â 10 % (1) Reflects net amounts refundable to us after the final reconciliation of costs of the clinical trial conducted pursuant to the Arbutus Biopharma Agreement, which was terminated in February 2023. Research and development expenses were $41.7 million for the nine months ended September 30, 2024 compared to $37.9 million for the same period in 2023. The $3.8 million increase in research and development expenses was primarily driven by increases in external expenses from the advancement and expansion of our pipeline, most notably from the nomination of our HDV entry inhibitor, 6250, and acquiring the rights to 1179, Gilead's HPI program, in 22 Â October 2023. The overall increase in external expenses was partially offset by decreases from our discontinuation of 3733 and VBR. We also experienced a decrease of $2.1 million in facility and other expenses primarily due to cost savings in rent and related expenses attributable to our corporate headquarters sublease, which commenced in November 2023. General and Administrative Expenses The following table summarizes the period-over-period changes in our general and administrative expenses (in thousands, except for percentages): Â Â Nine Months Ended September 30, Â Â $ Change Â Â % Change Â Â Â 2024 Â Â 2023 Â Â 2024 vs. 2023 Â Â 2024 vs. 2023 Â General and administrative expenses Â $ 13,398 Â Â $ 14,201 Â Â $ (803) Â Â (6 %) General and administrative expenses were $13.4 million for the nine months ended September 30, 2024 compared to $14.2 million for the same period in 2023. The $0.8 million decrease in general and administrative expenses was primarily due to a decrease in stock-based compensation expense because of the lower grant date fair value of our awards vesting during the period. Interest and Other Income, Net Interest income consists of interest earned on our cash and cash equivalents and available-for-sale securities. The following table summarizes the period-over-period changes in our interest and other income, net (in thousands, except for percentages): Â Â Nine Months Ended September 30, Â Â $ Change Â Â % Change Â Â Â 2024 Â Â 2023 Â Â 2024 vs. 2023 Â Â 2024 vs. 2023 Â Interest and other income, net Â $ 4,452 Â Â $ 1,829 Â Â $ 2,623 Â Â Â 143 % Interest and other income, net was $4.5 million for the nine months ended September 30, 2024, compared to $1.8 million for the same period in 2023. The $2.6 million increase was primarily due to more interest income earned on marketable securities resulting from a larger portfolio balance after the receipt of $100.0 million upon entering into the Gilead Collaboration in October 2023 and $12.6 million upon entering into the 2024 Financing Transaction in June 2024. Income Tax Expense The following table summarizes the period-over-period changes in our income tax expense (in thousands, except for percentages): Â Â Nine Months Ended September 30, Â Â $ Change Â Â % Change Â Â Â 2024 Â Â 2023 Â Â 2024 vs. 2023 Â Â 2024 vs. 2023 Â Income tax expense Â $ 406 Â Â $ â€” Â Â $ 406 Â Â Â 100 % Income tax expense was $0.4 million for the nine months ended September 30, 2024 due to the estimated taxable income from the upfront payments received under the Gilead Collaboration in 2023. There was no income tax expense recognized during the nine months ended September 30, 2023. Liquidity and Capital Resources Sources of Liquidity As a result of our significant research and development expenditures and the lack of any FDA-approved products to generate product sales revenue, we have not been profitable and have generated operating losses since we were incorporated in October 2005. We have funded our operations through September 30, 2024 principally through equity financings, raising an aggregate of $631.2 million in net proceeds, and strategic collaborations, raising an aggregate of $185.7 million through upfront payments. 23 Â Cash Flows for the Nine Months Ended September 30, 2024 and 2023 The following table summarizes our cash flow activities (in thousands): Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Operating activities Â $ (50,710) Â $ (50,904) Investing activities Â Â 46,867 Â Â Â 20,516 Â Financing activities Â Â 12,454 Â Â Â 4,626 Â Net increase (decrease) in cash and cash equivalents Â $ 8,611 Â Â $ (25,762) Operating Activities Net cash used in operating activities for the nine months ended September 30, 2024 was $50.7 million, compared to $50.9 million for the same period in 2023. The change was primarily attributable to cost savings in rent and related expenses attributable to our corporate headquarters sublease, which commenced in November 2023, and the timing of vendor invoicing and payments. Investing Activities Net cash provided by investing activities for the nine months ended September 30, 2024 was $46.9 million compared to $20.5 million for the same period in 2023. The change was due to an increase in net proceeds from maturities of our marketable securities. Financing Activities Net cash provided by financing activities for the nine months ended September 30, 2024 was $12.5 million compared to $4.6 million for the same period in 2023.

The change was due to the increase in proceeds from the registered direct offering and private placement in June 2024 compared to the shares sold of our common stock under the 2020 ATM in the nine months ended September 30, 2023. Funding Requirements We expect our future operating expenses to gradually increase over the coming years as we continue to advance our candidates into the clinic. We expect our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements into 2026. However, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to secure additional sources of funding when needed or on attractive terms, we could be forced to reduce staff and delay, scale back or stop certain research and development programs or future commercialization efforts. We monitor our cash needs and the status of the capital markets on a continuous basis. From time to time, we opportunistically raise capital and have done so numerous times since our initial public offering by issuing equity securities, most recently in June 2024. We expect to continue to raise capital when and as needed and at the time and in the manner most advantageous to us. Our future capital requirements will depend on many factors, including: â€¢our ability to raise capital despite macroeconomic and geopolitical events impacting financial markets, such as rising inflation and market volatility; â€¢our ability to realize future potential benefits pursuant to the Gilead Collaboration and maintain the collaboration; â€¢the scope, progress, results and costs of our ongoing drug discovery, nonclinical development, laboratory testing and clinical studies of our product candidates and any additional clinical studies we may conduct in the future; â€¢our ability to manufacture, and to contract with third parties to manufacture, adequate supplies of our product candidates for our clinical studies and any eventual commercialization; â€¢the costs, timing and outcome of regulatory review of our product candidates; and 24 Â â€¢the costs of preparing, filing and prosecuting patent applications in the United States and abroad, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims. Identifying potential product candidates and conducting nonclinical testing and clinical studies is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will likely be derived from sales of medicines that we do not expect to be commercially available for years, if at all. Accordingly, we will need to continue to rely on additional financings to achieve our business objectives. Adequate additional financings may not be available to us on acceptable terms, or at all. Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through additional collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to reduce staff, delay, scale back or discontinue our product development and clinical studies or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. 25 Â Item 3. Quantitative and Qualitative Disclosures About Market Risk Not applicable. Item 4. Controls and Procedures Evaluation of Disclosure Controls and Procedures We maintain a system of disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act, that is designed to provide reasonable assurance that information that is required to be disclosed in our reports filed pursuant to the Exchange Act, is accumulated and communicated to management in a timely manner. At the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and President, who serves as our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Exchange Act Rules 13a-15(b) and 15d-15(b) as of the end of the period covered by this report. Based upon that evaluation, our Chief Executive Officer and President concluded that our disclosure controls and procedures as of the end of the period covered by this report were effective at the reasonable assurance level. Changes in Internal Control over Financial Reporting There were no changes in our internal control over financial reporting in the quarter ended September 30, 2024 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. 26 Â PART II â€“ OTHER INFORMATION Item 1. Legal Proceedings We are not a party to any material legal proceedings. In the future, we may from time to time become involved in litigation relating to claims arising from our ordinary course of business. Item 1A. Risk Factors You should carefully consider the following risk factors, together with all other information in this report, including our condensed consolidated financial statements and notes thereto, and in our other filings with the SEC. If any of the following risks, or other risks not presently known to us or that we currently believe to not be material, develop into actual events, then our business, financial condition, results of operations or prospects could be materially adversely affected. If that happens, the market price of our common stock could decline, and stockholders may lose all or part of their investment. Risks Related to Our Business We have no approved products and depend on the future success of the product candidates in our research and development pipeline. We cannot be certain that we or our collaborators will be able to obtain regulatory approval for, or successfully commercialize, product candidates from our current pipeline or any other product candidates that we may subsequently identify, license or otherwise acquire. We and our collaborators are not permitted to market or promote any products in the United States, Europe, China or other countries before we receive regulatory approval from the FDA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for our current product candidates. We have not submitted a new drug application (NDA) to the FDA or comparable applications to other regulatory authorities and do not expect to be in a position to do so in the near future. All our product candidates are in clinical development or in varying stages of nonclinical development. Data supporting our clinical development programs are derived from nonclinical data that support our early stage clinical programs, which will determine whether pivotal studies are appropriate. These pivotal studies are necessary to support regulatory approval, and it may be years before these larger, pivotal studies are completed, if ever. In addition to our current product pipeline, we may identify, license or otherwise acquire rights to other technologies or product candidates. Any such transactions would involve numerous risks, and we may be unsuccessful in entering into any such transactions or developing any such technologies or product candidates. For these reasons, our drug discovery and development may not be successful, and we may be unable to continue clinical development of our product candidates and may not generate product approvals or product revenue, any of which could have a material adverse impact on our business, results of operations and financial condition. We are not currently profitable and might never become profitable, and we will need additional financing to complete the development of any product candidates and fund our activities into the future. We do not have any approved products, and we have a history of losses. We expect to continue to incur substantial operating and capital expenditures to advance our current product candidates through clinical development, continue research and discovery efforts to identify potential additional product candidates and seek regulatory approvals for our current and future product candidates. All operations and capital expenditures will be funded from cash on hand, securities offerings, debt financings and payments we may receive from out-licenses, collaborations or other strategic arrangements. Adverse geopolitical and macroeconomic developments, such as the recent and potential future disruptions in access to bank deposits and lending commitments due to bank failures, ongoing military conflicts, related sanctions, actual and anticipated changes in interest rates, economic inflation and the responses by central banking authorities to control such inflation, could affect our ability to access capital as and when needed. There is no assurance that we will be successful in raising any necessary additional capital on terms that are acceptable to us, or at all. If we are unable to develop and commercialize any product candidates and generate sufficient revenue or raise capital, we could be forced to reduce staff, delay, scale back or discontinue product development and clinical studies, sacrifice attractive business opportunities, cease operations entirely and sell, or otherwise transfer, all or substantially all of our remaining assets, which would likely have a material adverse impact on our business, results 27 Â of operations, financial condition and share price. In addition, if we are unable to generate sufficient revenue or raise capital, we may conclude there is a substantial doubt about our ability to continue as a going concern, and future reports from our independent registered public accounting firm may also contain statements expressing substantial doubt about our ability to continue as a going concern. We expect our collaboration with Gilead to be a critical part of the development, manufacture and commercialization of our product candidates. If this collaboration is unsuccessful, our business could be adversely affected. In October 2023, we entered into the Gilead Collaboration Agreement with Gilead, whereby Gilead exclusively licensed to us its HPI program and NNPI program, while retaining opt-in rights to these programs, and has an option to take an exclusive license, on a program-by-program basis, to all of our other current and future pipeline programs during the collaboration term. In connection with the entry into the Gilead Collaboration Agreement, we and Gilead also entered into a common stock purchase agreement and an investor rights agreement, which were both amended in June 2024. Also in June 2024, we and Gilead subsequently entered into a securities purchase agreement and warrant agreement. Our agreements and relationship with Gilead pose a number of risks, including, but not limited to, the following: â€¢Conflicts may arise between us and Gilead, such as conflicts regarding the indications to pursue or concerning the clinical data supporting an opt-in decision, the commercial potential of any optioned investigational products, the interpretation of financial provisions or the ownership of intellectual property developed during the collaboration. Any such conflicts could slow or prevent the development or commercialization of our investigational products. â€¢If the collaboration with Gilead does not result in the successful development and commercialization of products or if Gilead terminates the Gilead Collaboration Agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, development of our investigational products could be delayed and we may need additional resources to develop our investigational products. â€¢We will be heavily dependent on Gilead for further development and commercialization of the investigational products from the programs that it opts into. â€¢We may not be successful in this collaboration due to various other factors, including our ability to demonstrate proof of concept in one or more clinical studies so that Gilead will exercise its option to these programs. In addition, even if we demonstrate clinical proof of concept of a candidate, Gilead may choose not to exercise its option. â€¢Gilead has the right to designate (and has designated) two directors for appointment to our board of directors pursuant to the terms of the investor rights agreement and owns approximately 19.9% of our outstanding common stock. Gilead also has the right to acquire additional shares from us, and in the open market, up to an amount resulting in Gilead owning a total of 35% of our outstanding common stock. As a result, Gilead may be able to exert significant influence over us. â€¢Gilead could independently develop, or develop with third parties, products that compete directly or indirectly with our investigational products if Gilead believes that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours. â€¢Because Gilead has an option to all our current, and future, pipeline programs during the collaboration term, it may be difficult for us to enter into new collaborations. Nonclinical and clinical studies required for our product candidates are expensive and time-consuming and may fail to demonstrate the level of safety and efficacy necessary for product approval. Before we or any commercial partners can obtain FDA approval (or other foreign approvals) necessary to sell any of our product candidates, we must show that each potential product is safe and effective. To meet these requirements, we must conduct extensive nonclinical and sufficient, well-controlled clinical studies. 28 Â The results of nonclinical studies may not be representative of disease behavior in a clinical setting and may not be predictive of the outcomes of our clinical studies. In addition, the results of early clinical studies of product candidates may not be predictive of the results of later-stage clinical studies. Conducting nonclinical and clinical studies is a lengthy, time consuming and expensive process. The length of time varies substantially according to the type, complexity, novelty, and intended use of the product candidate, and often can be several years or more. In addition, failure or delays can occur at any time during the nonclinical and clinical study process, resulting in additional operating expenses or harm to our business. The commencement and rate of completion of clinical studies might be delayed by many factors, including, for example: â€¢delays in reaching agreement with regulatory authorities on study design; â€¢delays in reaching agreement on acceptable terms with prospective contract research organizations (CROs) and clinical study sites; â€¢failure to demonstrate efficacy or the emergence of unforeseen safety issues; â€¢insufficient quantities of qualified materials under current good manufacturing practice (cGMP) for use in clinical studies due to manufacturing challenges, delays or interruptions in the supply chain; â€¢slower than expected rates of participant recruitment or failure to recruit a sufficient number of eligible participants, which may be due to a number of reasons, including the size of the participant population, the proximity of participants to clinical sites, the eligibility criteria for the study, the design of the clinical study, and other potential drug candidates being studied; â€¢delays in participants completing participation in a study or return for post-treatment follow-up for any reason, including, product side effects or disease progression; â€¢modification of clinical study protocols; â€¢delays, suspension, or termination of clinical studies by the institutional review board or ethics committee responsible for overseeing the study at a particular study site; and â€¢government or other regulatory agency delays or clinical holds requiring suspension or termination of our clinical studies due to safety, tolerability or other issues related to our product candidates. The failure of nonclinical and clinical studies to demonstrate safety and effectiveness of a product candidate for the desired indications, whether conducted by us or by a CRO, would harm the development of that product candidate and potentially other product candidates. This failure could cause us to abandon a product candidate and could delay development of other product candidates. Any delay in, or failure of, our nonclinical studies or clinical studies could delay, or preclude, the filing of our NDAs and comparable applications with the FDA and foreign regulatory agencies, as applicable, and materially harm our business, prospects, financial condition and results of operations. We rely on CROs to conduct some of our nonclinical and clinical studies due to our lack of suitable facilities and resources. In addition, parts of our business are reliant on CROs, vendors, suppliers and other service providers in locations outside of the United States, including China. We do not have sufficient facilities or resources to conduct all our anticipated nonclinical and clinical studies internally. As a result, we contract with CROs to conduct a significant portion of the nonclinical and clinical studies required for regulatory approval for our product candidates. Our reliance on CROs reduces our control over these activities but does not relieve us of our responsibilities. For example, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards, including, in the case of clinical studies, good clinical practices, even if the study is conducted by a CRO. In the event CROs fail to perform their duties in such a fashion or we are unable to retain or continue with CROs on acceptable terms, we may be unable to complete our clinical studies and may fail to obtain regulatory approval for our product candidates. 29 Â In addition, these CROs may also have relationships with other entities, some of which may be our competitors. CRO personnel are not our employees, and except for remedies available to us under our agreements with such third parties, we cannot control whether they devote sufficient time and resources to our clinical and nonclinical studies. If these CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our research, nonclinical or clinical studies may be extended, delayed or terminated and we may not be able to obtain, or may be delayed in obtaining, regulatory approvals for our product candidates, any of which could materially harm our business, prospects, financial condition and results of operations. Furthermore, we are exposed to a number of risks related to our CROs, vendors, suppliers and other service providers that are located outside of the United States, many of which may be beyond our control. These risks include: â€¢business interruptions resulting from geopolitical actions such as the war between Russia and Ukraine, the Israel-Hamas war, the Israel-Hezbollah war, as well as tariffs, other wars, acts of terrorism, natural disasters or outbreaks of disease; â€¢different regulatory requirements for drug approvals or increased scrutiny on CROs located in foreign countries, including China; â€¢different standards of care in various countries that could complicate the evaluation of our product candidates; â€¢different U.S. and foreign drug import and export rules; â€¢different reimbursement systems and different competitive drugs indicated to treat the indication for which our product candidates are being developed; â€¢reduced protection for intellectual property rights in certain countries; â€¢unexpected changes in tariffs, trade barriers and regulatory requirements; â€¢compliance with the United States Foreign Corrupt Practices Act (the FCPA) and other anti-corruption and anti-bribery laws; â€¢compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; â€¢foreign taxes, including withholding of payroll taxes; and â€¢foreign currency fluctuations and compliance with foreign currency exchange rules, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country. Top-line, preliminary or interim data may not accurately reflect the final results of a particular study. We may publicly disclose top-line, preliminary or interim data based on analysis of then-available efficacy, tolerability, PK and safety data, and the results and related findings and conclusions are subject to change following a more comprehensive data review related to the particular study. We also make assumptions, estimates, calculations and conclusions as part of our data analyses, and we may not have received or had the opportunity to fully and carefully evaluate all data prior to release. As a result, the top-line, preliminary or interim results that we report may differ from final results of the same studies or different conclusions or considerations may qualify such results once additional data have been

received and fully evaluated. Top-line, preliminary or interim data also remain subject to audit and verification procedures that may result in the final data differing materially from previously published top-line, preliminary or interim data. As a result, top-line, preliminary or interim data should be viewed with caution until the final data are available. In addition to top-line, preliminary or interim results, the information that we may publicly disclose regarding a particular nonclinical or clinical study is based on extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure. In addition, any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular drug, drug candidate or our business. If the top-line, 30 Â preliminary or interim data that we report differ from final results, or if others, including regulatory authorities, disagree with, or do not accept, the data or conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed or delayed, which could harm our business, financial condition, operating results or prospects. We rely on third parties to formulate and manufacture our product candidates and products that we study in combination with our product candidates. Our use of third parties may increase the risk that we will not have sufficient quantities of our product candidates or other products on time or at an acceptable cost. We rely on third-party manufacturers to supply the quantities of our investigational product candidates used in our clinical and nonclinical studies. If any product candidate we develop or acquire in the future receives FDA or other regulatory approval, we expect to continue our reliance on one or more third-party contractors to manufacture our products. If, for any reason, we are unable to rely on any third-party sources we have identified to manufacture our product candidates, we would need to identify and contract with additional or replacement third-party manufacturers to manufacture drug substance and drug product for nonclinical, clinical and commercial purposes. We may be unsuccessful in identifying additional or replacement third-party manufacturers, or in negotiating acceptable terms with any that we do identify. If we are unable to establish and maintain manufacturing capacity, the development and sales of our products and our financial performance may be materially and adversely affected. We are exposed to the following risks with respect to the manufacture of our product candidates: â€¢We will need to identify manufacturers for commercial supply on acceptable terms, which we may be unable to do because the number of potential manufacturers is limited, and the FDA must evaluate and approve any new or replacement contractor. â€¢Any third-party manufacturers with whom we contract might be unable to formulate and manufacture our product candidates in the volume and quality required to meet our nonclinical, clinical and, if approved, commercial needs in a timely manner. â€¢Any third-party manufacturers with whom we contract might not perform as agreed or might not remain in the contract manufacturing business for the time required to supply our products. â€¢One or more of any third-party manufacturers with whom we contract could be foreign, which increases the risk of shipping delays and adds the risk of import restrictions. â€¢We do not have complete control over, and cannot ensure, any third-party manufacturersâ€™ compliance with cGMP and other government regulations and corresponding foreign requirements, including periodic FDA and state regulatory inspections. â€¢We may be required to obtain intellectual property rights from third parties to manufacture our product candidates, and if any third-party manufacturer makes improvements in the manufacturing process for our product candidates, we may not own, or may have to share, the intellectual property rights to the innovation. â€¢We may be required to share our trade secrets and know-how with third parties, increasing risk of misappropriation or disclosure of our intellectual property by or to third parties. â€¢When contracting with third-party manufacturers, we might compete with other companies for access to these manufacturersâ€™ facilities and might be subject to manufacturing delays if the manufacturers give other clients higher priority than we are given. Each of these risks could delay our development efforts, nonclinical studies and clinical studies or the approval, if any, of our product candidates by the FDA or applicable non-U.S. regulatory authorities and the commercialization of our product candidates. This could result in higher costs or deprive us of potential product revenues and materially harm our business, financial condition and results of operations. 31 Â If we lose key management personnel and cannot recruit and retain similarly qualified replacements, our business may materially suffer. We are highly dependent on the services of our executive officers. Our employment agreements with our executive officers do not ensure their retention. We do not currently maintain, nor do we intend to obtain in the future, â€œkey personâ€ life insurance that would compensate us in the event of the death or disability of any of the members of our management team. Our executive officers are critical to our success, and unanticipated loss of any of these key employees could have a material adverse impact on our business, financial condition and results of operations. Our collaboration partners might delay, prevent or undermine the success of our product candidates. Our operating and financial strategy for the development, nonclinical and clinical testing, manufacture and commercialization of drug candidates heavily depends on collaborating with corporations, academic institutions, licensors, licensees, and other parties. However, there can be no assurance that we will successfully establish or maintain these collaborations. If a collaboration is terminated, replacement collaborators might not be available on attractive terms, or at all. The activities of any collaborator, including Gilead, will not be within our control and might not be within our power to influence. There can be no assurance that any collaborator will perform its obligations to our satisfaction or at all, that we will derive any revenue or profits from these collaborations, or that any collaborator will not compete with us. If any collaboration, including the Gilead Collaboration, is unsuccessful, we might require substantially greater capital to undertake development and marketing of our proposed products and might not be able to develop and market these products effectively, if at all. In addition, if Gilead does not opt-in to a program, it might lead to significant delays in introducing proposed products into certain markets and/or reduced sales of proposed products in such markets. We may not be successful in establishing and maintaining collaborations, which could adversely affect our ability to develop certain of our product candidates. Developing pharmaceutical products, conducting clinical studies, obtaining regulatory approval and commercializing those products are expensive and lengthy undertakings that require significant resources and expertise. We may seek to enter into collaborations, including licensing or partnering arrangements, with other companies to support the development and commercialization of any or multiple of our programs that Gilead declines to opt into or to obtain financing or share costs on these programs. If we are unable to enter into such collaborations on acceptable terms, if at all, we may be unable to advance certain of our product candidates through further nonclinical or clinical development. We expect to face competition in seeking appropriate partners. Moreover, collaboration arrangements are complex and time consuming to negotiate, document and implement and they may require substantial resources to maintain. We may not be successful in our efforts to establish and implement collaborations or other alternative arrangements for the development of our product candidates that Gilead declines to opt into. If we are unable to reach agreement on favorable terms with a suitable collaboration partner for any of our product candidates that Gilead declines to opt into, we may need to limit the number of our product candidates to advance through further nonclinical or clinical development. Failure to achieve such successful collaborations would limit our options for support of the development and commercialization of our programs and for financing and would likely have a material adverse impact on our business, results of operations, financial condition and share price. We rely on data provided by third parties that has not been independently verified and could prove to be false, misleading, or incomplete. We rely on third-party vendors, scientists, investigators and collaborators to provide us with significant data and other information related to our projects, nonclinical studies and clinical studies, and our business. If these third parties provide inaccurate, misleading, or incomplete data, our business, prospects, and results of operations could be materially and adversely affected. 32 Â Significant disruptions of information technology systems or breaches of data security, including cybersecurity incidents, could materially and adversely affect our business, results of operations and financial condition. We collect and maintain information in digital form and are increasingly dependent on information technology systems and infrastructure to operate our business. In the ordinary course of our business, we collect, store and transmit large amounts of confidential information, including intellectual property, proprietary business information and personal information. It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such confidential information. We have outsourced elements of our information technology infrastructure and, as a result, a number of third-party vendors may or could have access to our confidential information. Our internal information technology systems and infrastructure, and those of our current and any future collaborators, contractors and consultants and other third parties on which we rely, are vulnerable to damage from computer viruses, malware, natural disasters, system outages, terrorism, war, telecommunication and electrical failures, cyberattacks, cybersecurity incidents or cyber intrusions over the Internet, attachments to emails, persons inside our organization, or persons with access to systems inside our organization. The risk of a cybersecurity incident or security breach or disruption, particularly through cyberattacks or cyber intrusion, has escalated as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. In addition, the prevalent use of mobile devices that access confidential information increases the risk of data security breaches, which could lead to the loss of confidential information or other intellectual property. The costs to us to mitigate network security problems, bugs, viruses, worms, malicious software programs, system outages and security vulnerabilities or incidents could be significant, and our efforts to address these problems may not be successful. If unsuccessful, these problems could cause interruptions, delays, cessation of service and other harm to our business and our competitive position, including material disruption of our product development programs. For example, any loss of clinical study data from completed or ongoing or planned clinical studies could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. If a computer security breach affects our systems or results in the unauthorized release of personally identifiable information, our reputation could be materially damaged. In addition, such a breach may require notification to governmental agencies, the media or individuals pursuant to various federal, state and non-U.S. privacy and security laws, if applicable, including the Health Insurance Portability and Accountability Act of 1996 (HIPAA), as amended by the Health Information Technology for Clinical Health Act of 2009, and its implementing rules and regulations, as well as regulations promulgated by the Federal Trade Commission, state breach notification law and the European Union (EU) General Data Protection Regulation (EU GDPR). We would also be exposed to a risk of loss or litigation and potential liability, which could materially adversely affect our business, results of operations and financial condition. Research, development and commercialization goals may not be achieved in the timeframes that we publicly estimate, which could have an adverse impact on our business and could cause our stock price to decline. We set goals and make public statements regarding our expectations on timing of certain accomplishments, developments and milestones under our research and development programs. The actual timing of these events can vary significantly due to a number of factors, including, the amount of time, effort and resources committed to our programs by us and any collaborators and the uncertainties inherent in the clinical development and regulatory approval process. As a result, there can be no assurance that we or any collaborators will initiate or complete clinical development activities, make regulatory submissions or receive regulatory approvals as planned or that we or any collaborators will be able to adhere to our current schedule for the achievement of key milestones under any of our programs. If we or any collaborators fail to achieve one or more of the milestones as planned, or Gilead does not opt-in to any of our programs, our business could be materially and adversely affected, and the price of our common stock could decline. Developments by competitors might render our product candidates or technologies obsolete or non-competitive. The pharmaceutical and biotechnology industries are intensely competitive. In addition, the clinical and commercial landscapes for recurrent genital herpes, HDV, HBV and transplant-related herpesviruses are rapidly changing; we expect new data from commercial and clinical-stage products to continue to emerge. We compete with organizations, some with significantly more resources, who are developing competitive product candidates. If our competitors develop effective treatments for recurrent genital herpes, HDV, HBV and transplant-related herpesviruses or any other 33 Â indication or field we might pursue, and successfully commercialize those treatments, our business and prospects could be materially harmed. Other companies with products using the same or similar mechanisms of action as ours may produce negative clinical data, which would adversely affect public and clinical communitiesâ€™ perceptions of our product candidates, and may negatively impact regulatory approval of, or demand for, our potential products. Negative data from clinical studies using a competitorâ€™s product candidates with the same or similar mechanisms of action (MOA) as ours could adversely impact the perception of the therapeutic use of our product candidates and our ability to enroll individuals in clinical studies. The clinical and commercial success of our potential products will depend in part on the public and clinical communitiesâ€™ acceptance of novel classes of product candidates. Moreover, our success depends upon physicians prescribing, and their patients being willing to receive, treatments that involve the use of our product candidates we may develop in lieu of, or in addition to, existing treatments with which they are already familiar and for which more clinical data may be available. Adverse events in our nonclinical or clinical studies or those of our competitors or of academic researchers utilizing the same MOA as our product candidates, even if not ultimately attributable to our product candidates, and any resulting publicity could result in increased governmental regulation, unfavorable public perception, potential regulatory delays in the testing or approval of our product candidates, stricter labeling requirements for our product candidates that are approved, if any, and a decrease in demand for any such products. Our ability to use our net operating loss and credit carryforwards and certain other tax attributes may be limited. We have net operating loss carryforwards due to prior period losses generated before January 1, 2024, which if not utilized, will begin to expire in 2027 for net operating loss carryforwards prior to 2018. If we are unable to generate sufficient taxable income to utilize our net operating loss carryforwards, pre-2018 carryforwards could expire unused and be unavailable to offset future income tax liabilities. Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the Code), a corporation that undergoes an â€œownership changeâ€ (generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period) is subject to annual limitations on its ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes (such as research tax credits) to offset its post-change income or taxes. We have experienced ownership changes in the past, and recent and future equity issuances may result in additional ownership change. Accordingly, some of our net operating losses or credits could expire unutilized, and our ability to utilize our net operating losses or credits to offset U.S. federal taxable income could be limited, which would result in increased future tax liability to us. We may also be subject to similar limitations at the state level. Risks Related to Our Regulatory and Legal Environment We are and will be subject to extensive and costly government regulation, and the failure to comply with these regulations may have a material adverse effect on our operations and business. Our product candidates are subject to extensive and rigorous domestic government regulation, including regulation by the FDA, the Centers for Medicare and Medicaid Services, other divisions of the U.S. Department of Health and Human Services, the U.S. Department of Justice, state and local governments, and their respective foreign equivalents. Both before and after approval of any product, we and our collaborators, suppliers, contract manufacturers and clinical investigators are subject to extensive regulation by governmental authorities in the United States and other countries, covering, among other things, testing, manufacturing, quality control, clinical studies, post-marketing studies, labeling, advertising, promotion, distribution, import and export, governmental pricing, price reporting and rebate requirements. Failure to comply with applicable requirements could result in one or more of the following actions: warning or untitled letters; unanticipated expenditures; delays in approval or refusal to approve a product candidate; voluntary or mandatory product recall; product seizure; interruption of manufacturing or clinical studies; operating or marketing restrictions; injunctions; criminal prosecution and civil or criminal penalties, including fines and other monetary penalties; exclusion from federal health care programs such as Medicare and Medicaid; adverse publicity; and disruptions to our business. If we or our collaborators obtain regulatory approval for a particular product, the approval might limit the intended medical uses for the product, limit our ability to promote, sell, and distribute the product, require that we conduct 34 Â costly post-marketing surveillance, and/or require that we conduct ongoing post-marketing studies. Once obtained, any approvals might be withdrawn, including, for example, if there is a later discovery of previously unknown problems with the product, such as a previously unknown safety issue. If we, our collaborators, our contractors or our contract manufacturers fail to comply with applicable regulatory requirements at any stage during the regulatory process, such noncompliance could result in delays in the approval of applications or supplements to approved applications, refusal by a regulatory authority (including the FDA) to review pending market approval applications or supplements to approved applications, untitled letters or warning letters, fines, import and export restrictions, product recalls or seizures, injunctions, total or partial suspension of production, civil penalties, withdrawals of previously approved marketing applications, recommendations by the FDA or other regulatory authorities against governmental contracts, and/or criminal prosecutions. The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we or our collaborators are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed. We, or any current or future collaborators, cannot assure you that we will receive the approvals necessary to commercialize for sale any of our product candidates, or any product candidate we acquire or develop in the future. We will need FDA approval to commercialize our product candidates in the United States and approvals from applicable regulatory authorities in foreign jurisdictions to commercialize our product candidates in those jurisdictions. To obtain FDA approval of any product candidate, we must submit to the FDA an NDA demonstrating that the product candidate is safe and effective for its intended use. This requires significant research, nonclinical studies, and clinical studies. Satisfaction of the FDAâ€™s regulatory requirements typically takes many years, depends upon the type, complexity and novelty of the product candidate and requires substantial resources for research, development and testing. We cannot predict whether our research and clinical approaches will result in drugs that the FDA considers safe and effective for their indicated uses. The FDA has substantial discretion in the approval process and might require us to conduct additional nonclinical and

clinical testing, perform post-marketing studies or otherwise limit or impose conditions on any approval we obtain. The approval process might also be delayed by changes in government regulation, future legislation or administrative action or changes in FDA policy that occur prior to or during our regulatory review. Delays in obtaining regulatory approvals might: delay commercialization of, and our ability to derive product revenues from, our product candidates; impose costly procedures on us; and diminish any competitive advantages that we might otherwise enjoy. Even if we comply with all FDA requests, the FDA might ultimately reject one or more of our NDAs. We cannot be sure that we will ever obtain regulatory approval and commercialize any of our current or future product candidates. In foreign jurisdictions, we are subject to regulatory approval processes and risks similar to those associated with the FDA described above. We cannot assure you that we will receive the approvals necessary to commercialize our product candidates for sale outside the United States. We and our collaborators may be subject, directly or indirectly, to applicable U.S. federal and state anti-kickback, false claims laws, physician payment transparency laws, fraud and abuse laws or similar healthcare and security laws and regulations, and health information privacy and security laws, which could expose us or them to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings. Healthcare providers, physicians and others play a primary role in the recommendation and prescription of any products for which we obtain regulatory approval. If we obtain FDA approval for any of our drug candidates and begin commercializing those drugs in the United States, our operations may be subject to various federal and state fraud and abuse laws, including the federal Anti-Kickback Statute, the federal False Claims Act, and physician payment sunshine laws and regulations. Additionally, we are subject to state and non-U.S. equivalents of each of the healthcare laws described above, among others, some of which may be broader in scope and may apply regardless of the payor. These laws may impact, among other things, our proposed sales, marketing and education programs. In addition, we may be subject to patient privacy regulation by both the federal government and the states and foreign jurisdictions in which we conduct our business. If we fail to comply with any applicable federal, state or foreign legal requirement, we could be subject to penalties. Regulators globally are imposing greater monetary fines for privacy violations. The EU GDPR applies to any company established in the EU as well as to those outside the EU if they collect and use personal data in connection with the offering of goods or services to individuals in the EU or the monitoring of their behavior. The EU GDPR enhances data protection obligations for processors and controllers of personal data, including, for example, expanded disclosures about how personal information is to be used, limitations on retention of information, mandatory data 35 Â breach notification requirements and onerous new obligations on services providers. Noncompliance with the EU GDPR may result in monetary penalties of up to â¬20 million or 4% of worldwide revenue, whichever is higher. The EU GDPR may increase our responsibility and liability in relation to personal data that we process and we may be required to put in place additional mechanisms to ensure compliance with the EU GDPR, including as implemented by individual countries. Compliance with the EU GDPR and other changes in laws or regulations associated with the enhanced protection of certain types of personal data, such as healthcare data or other sensitive information, could greatly increase our cost of developing our products or even prevent us from offering certain products in jurisdictions that we may operate in. The California Consumer Privacy Act (CCPA) also created new individual privacy rights for California consumers (as defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households. The CCPA requires covered companies to provide certain disclosures to consumers about its data collection, use and sharing practices, and to provide affected California residents with ways to opt-out of certain sales or transfers of personal information. While there is currently an exception for protected health information that is subject to HIPAA and clinical study regulations, as currently written, the CCPA may impact our business activities. The uncertainty surrounding the implementation of the CCPA exemplifies the vulnerability of our business to the evolving regulatory environment related to personal data and protected health information. Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. Violations of these laws may be punishable by criminal and/or civil sanctions, including penalties, fines and/or exclusion or suspension from federal and state healthcare programs such as Medicare and Medicaid and debarment from contracting with the U.S. government. In addition, private individuals have the ability to bring actions on behalf of the U.S. government under the federal False Claims Act as well as under the false claims laws of several states. If any of the physicians or other providers or entities with whom we expect to do business with are found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs, which may also adversely affect our business. We face the risk of product liability claims and might not be able to obtain insurance. Our business exposes us to the risk of product liability claims that are inherent in drug development. If the use of one or more of our product candidates or approved drugs, if any, harms people, we might be subject to costly and damaging product liability claims brought against us by clinical study participants, consumers, health care providers, pharmaceutical companies or others selling our products. Our inability to obtain sufficient product liability/clinical study insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of pharmaceutical products we develop. We cannot predict all of the possible harms or side effects that might result and, therefore, the amount of insurance coverage we maintain might not be adequate to cover all liabilities we might incur. If we are unable to obtain insurance at an acceptable cost or otherwise protect against potential product liability claims, we will be exposed to significant liabilities, which might materially and adversely affect our business and financial position. If we are sued for any injury allegedly caused by our products, our liability could exceed our total assets and our ability to pay. Any successful product liability claims brought against us would decrease our cash and may adversely affect our business, stock price and financial condition. We might be exposed to liability claims associated with the use of hazardous materials and chemicals. Our research, development and manufacturing activities and/or those of our third-party contractors might involve the controlled use of hazardous materials and chemicals. Although we will strive to have our safety procedures, and those of our contractors, comply with federal, state and local laws and regulations for using, storing, handling and disposing of these materials, we cannot completely eliminate the risk of accidental injury or contamination from these materials. In the event of such an accident, we could be held liable for any resulting damages, and any liability could materially and adversely affect our business, financial condition and results of operations. In addition, the federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of hazardous or radioactive materials and waste products might require us to incur substantial compliance costs that could materially and adversely affect our business, financial condition and results of operations. 36 Â Our employees, independent contractors, consultants, collaborators and CROs may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could result in significant liability for us and harm our reputation. We are exposed to the risk of fraud or other misconduct, including failure to: â€¢comply with applicable regulations of, and provide accurate information to, the FDA or comparable foreign regulatory authorities; â€¢comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities; â€¢comply with the FCPA, the U.K. Bribery Act 2010, the PRC Criminal Law, the PRC Anti-unfair Competition Law and other anti-bribery and trade laws; â€¢report financial information and data accurately; or â€¢disclose unauthorized activities. Misconduct could also involve the improper use or misrepresentation of information obtained during clinical studies, creating fraudulent data in our nonclinical studies or clinical studies or illegal misappropriation of product materials, which could result in regulatory sanctions, delays in clinical studies, or serious harm to our reputation. It is not always possible to identify and deter misconduct. The precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could harm our business, results of operations, financial condition and cash flows, including through the imposition of significant fines or other sanctions. Risks Related to Our Intellectual Property Our business depends on protecting our intellectual property. If we, our licensors and our collaborators do not obtain protection for our respective intellectual property rights, our competitors might be able to take advantage of our research and development efforts to develop competing drugs. Our success, competitive position and future revenues, if any, depend in part on our ability and the abilities of our licensors to obtain and maintain patent protection for our products, methods, processes and other technologies, to preserve our trade secrets, to prevent third parties from infringing on our proprietary rights and to operate without infringing the proprietary rights of third parties. We rely upon a combination of patents, trade secret protection and contractual arrangements to protect the intellectual property related to our technologies. We will only be able to protect our products and proprietary information and technology by preventing unauthorized use by third parties to the extent that our patents, trade secrets, and contractual positions allow us to do so. We cannot be certain that we will secure any rights to any issued patents with claims that cover any of our proprietary product candidates and technologies. The patent prosecution process is expensive and time-consuming, and we may be unable to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. We could fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection or before our competitors secure patents covering such discoveries. The patent process also is subject to numerous risks and uncertainties, and there can be no assurance that we will be successful in protecting our products by obtaining and defending patents. Composition-of-matter patents relating to the active pharmaceutical ingredient are generally considered to be the strongest form of intellectual property protection for pharmaceutical products. Such patents provide protection not limited to any one method of use. Method-of-use patents protect the use of a product for the specified method(s) and do not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. Formulation patents protect the formulation of a product and do not prevent a competitor from making and marketing a product that has an identical active pharmaceutical ingredient to 37 Â our product if the product is formulated differently than the patented formulation. We rely on a combination of these and other types of patents to protect our product candidates, and there can be no assurance that our intellectual property will create and sustain the competitive position of our product candidates. Biotechnology and pharmaceutical product patents involve highly complex legal and scientific questions. Any patent applications that we own or license may fail to result in issued patents. In addition, the U.S. Patent and Trademark Office (USPTO) and patent offices in other jurisdictions often require that patent applications concerning pharmaceutical and/or biotechnology-related inventions are limited or narrowed substantially to cover only the specific innovations exemplified in the patent application, thereby limiting the scope of protection against competitive challenges. As a result, even if we or our licensors obtain patents, the patents might be substantially narrower than anticipated. If patents successfully issue from our applications, third parties may challenge their validity or enforceability, which may result in such patents being narrowed, invalidated, or held unenforceable. Even if our patents and patent applications are not challenged by third parties, those patents and patent applications may not prevent others from designing around our claims and may not otherwise adequately protect our product candidates. Patent and other intellectual property protection is crucial to the success of our business and prospects, and there is a substantial risk that such protections, if obtained, will prove inadequate. The legal systems of certain countries, including China, do not always favor the enforcement of patents, trade secrets, and other intellectual property rights, particularly those relating to pharmaceutical and biotechnology products, which could make it difficult for us to stop infringement of our patents, misappropriation of our trade secrets, or marketing of competing products in violation of our proprietary rights. Beyond the protection afforded by patents, we seek to rely on trade secret protection and confidentiality agreements to protect proprietary know-how, information, or technology that is not covered by our patents. Although our agreements require all of our employees to assign their inventions to us, and we require all of our employees, consultants, advisors, collaborators, contractors and any third parties who have access to our trade secrets, proprietary know-how and other confidential information and technology to enter into appropriate confidentiality agreements, we cannot be certain that our trade secrets, proprietary know-how and other confidential information and technology will not be subject to unauthorized disclosure or that our competitors will not otherwise gain access to or independently develop substantially equivalent trade secrets, proprietary know-how and other information and technology. If we are unable to prevent unauthorized disclosure of our intellectual property related to our product candidates and technology to third parties, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business and operations. We may incur substantial costs as a result of litigation or other proceedings relating to our patents and other intellectual property rights. We may in the future be involved in legal or administrative proceedings involving our intellectual property, including infringement of our intellectual property by third parties. These lawsuits or proceedings likely would be expensive, consume time and resources and divert the attention of managerial and scientific personnel, even if we were successful in stopping the infringement of such patents. There is a risk that these proceedings will decide that such patents or other intellectual property rights are not valid and that we do not have the right to stop the other party from using our inventions. There is also the risk that, even if the validity of such patents is upheld, the court or administrative agency will refuse to stop the other party on the ground that such other partyâ€™s activities do not infringe our rights to such patents. If we were not successful in defending our intellectual property, our competitors could develop and market products based on our discoveries, which may reduce demand for our products. We may infringe the intellectual property rights of others, which may prevent or delay our product development efforts and stop us from commercializing or increase the costs of commercializing our product candidates. Our success will depend in part on our ability to operate without infringing the proprietary rights of third parties. Our competitors may have filed, and may in the future file, patent applications covering products and technologies similar to ours. Any such patent application may have priority over our patent applications, which could further require us to obtain rights from third parties to issued patents covering such products and technologies. We cannot guarantee that the manufacture, use or marketing of any product candidates that we develop will not infringe third-party patents. 38 Â If a patent infringement suit were brought against us, we may be forced to stop or delay developing, manufacturing, or selling potential products that are claimed to infringe a third partyâ€™s intellectual property, unless that third party grants us rights to use its intellectual property. In such cases, we may be required to obtain licenses to patents or proprietary rights of others to continue development, manufacture or sale of our products. If we are unable to obtain a license or develop or obtain non-infringing technology, or if we fail to defend an infringement action successfully, or if we are found to have infringed a valid patent, we may incur substantial costs and monetary damages, encounter significant delays in bringing our product candidates to market and be precluded from manufacturing or selling our product candidates, any of which could harm our business significantly. The cost of maintaining our patent protection globally is high and requires continuous review and compliance. We may not be able to effectively maintain our intellectual property position throughout the major markets of the world. The USPTO and foreign patent authorities require maintenance fees, payments and continued compliance with a number of procedural and documentary requirements. Noncompliance may result in abandonment or lapse of patents or patent applications and a partial or complete loss of patent rights in the relevant jurisdiction. Such a loss could reduce royalty payments for lack of patent coverage from our collaboration partners or may result in competition, either of which could have a material adverse effect on our business. We have made, and will continue to make, certain strategic decisions in balancing the costs and the potential protections afforded by the patent laws of certain countries. As a result, we may not be able to prevent third parties from practicing our inventions in all countries, or from selling or importing products made using our inventions in and into the United States or other countries. Third parties may use our technologies in territories in which we have not obtained patent protection to develop their own products and may infringe our patents in territories which provide inadequate enforcement mechanisms. Such third-party products may compete with our product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. Such competition could materially and adversely affect our business and financial condition. Intellectual property rights do not address all potential threats to any competitive advantage we may have. The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and intellectual property rights may not adequately protect our business or permit us to maintain our competitive advantage. The following examples are illustrative: â€¢Others may be able to make compounds that are the same as, or similar to, our current or future product candidates but that are not covered by the claims of the patents that we own or have exclusively licensed. â€¢We or any of our licensors or strategic partners might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own or have exclusively licensed. â€¢We or any of our licensors or strategic partners might not have been the first to file patent applications covering certain of our inventions. â€¢Others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights. â€¢The prosecution of our pending patent applications may not result in granted patents. â€¢Granted patents that we own or have exclusively licensed may not provide us with any competitive advantages, or may be held invalid or unenforceable, because of legal challenges by our competitors. â€¢Patent protection on our product candidates may expire before we are able to develop and commercialize the product, or before we are able to recover our investment in the product. â€¢Our competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from patent infringement claims for such activities, as well as in countries in which we do not have

patent rights and may then use the information learned from such activities to develop competitive products for sale in markets where we intend to market our product candidates. 39 Â Risks Related to Our Common Stock The price of our common stock might fluctuate significantly, and you could lose all or part of your investment. The price of our common stock fluctuates widely. Continued volatility in the market price of our common stock might prevent a stockholder from being able to sell shares of our common stock at or above the price paid for such shares. The trading price of our common stock may continue to be volatile and subject to wide price fluctuations in response to various factors, many of which are beyond our control, such as the progress, results and timing of our clinical and nonclinical studies and other studies involving our product candidates, the success or failure of our product candidates, the receipt or loss of required regulatory approvals for our product candidates, the availability of capital or the other risks discussed in this â€œRisk Factorsâ€ section. Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholdersâ€™ ability to bring a claim in a judicial forum they find favorable for disputes with us or our directors, officers or other employees. Our amended and restated bylaws provide that, with certain limited exceptions, unless we consent to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the sole and exclusive forum for (1) any derivative action or proceeding brought on our behalf; (2) any action asserting a claim of breach of fiduciary duty owed by any of our current or former directors, officers or other employees to us or to our stockholders; (3) any action asserting a claim arising pursuant to the Delaware General Corporation Law, or our certificate of incorporation or bylaws (as each may be amended from time to time); or (4) any action asserting a claim governed by the internal affairs doctrine. Alternatively, if such court does not have jurisdiction, the Superior Court of Delaware, or, if such other court does not have jurisdiction, the United States District Court for the District of Delaware, will be the sole and exclusive forum for such actions and proceedings. The choice of forum provision may limit a stockholderâ€™s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage such lawsuits against us and our directors, officers, and other employees. Alternatively, if a court were to find the choice of forum provision contained in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could have a material adverse impact on our business. The choice of forum provision in our amended and restated bylaws will not preclude or contract the scope of exclusive federal or concurrent jurisdiction for actions brought under the federal securities laws, including the Exchange Act or the Securities Act, or the respective rules and regulations promulgated thereunder. 40 Â Item 2. Unregistered Sales of Equity Securities and Use of Proceeds None. Item 3. Defaults upon Senior Securities None. Item 4. Mine Safety Disclosures Not applicable. Item 5. Other Information None. 41 Â Item 6. Exhibits (a) Exhibits. The following exhibits are filed or furnished, as applicable, as part of this quarterly report on Form 10-Q: Â ExhibitNumber Description of Document FiledHerewith Incorporatedby Referencefrom Date Number Â Â Â Â Â Â Â Â Â Â Â Â Â 31.1 Â Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Â X Â Â Â Â Â Â Â Â Â Â Â Â Â Â 32.1* Â Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Â X Â Â Â Â Â Â Â Â Â Â Â Â Â Â 101.SCH Â Inline XBRL Taxonomy Extension Schema Document. Â X Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 101.CAL Â Inline XBRL Taxonomy Extension Calculation Linkbase Document. Â X Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 101.LAB Â Inline XBRL Taxonomy Extension Label Linkbase Document. Â X Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 101.PRE Â Inline XBRL Taxonomy Extension Presentation Linkbase Document. Â X Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 101.DEF Â Inline XBRL Taxonomy Extension Definition Linkbase Document. Â X Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 104 Â Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101). Â X Â Â Â Â Â Â * The certification attached as Exhibit 32.1 that accompanies this Quarterly Report on Form 10-Q is to be deemed furnished and shall not be deemed â€œfiledâ€ with the SEC and is not to be incorporated by reference into any filing of Assembly Biosciences, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing. 42 Â Â In accordance with the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Â Assembly Biosciences, Inc. Date: November 7, 2024 By: /s/ Jason A. Okazaki Jason A. Okazaki Chief Executive Officer and President (Principal Executive Officer and Principal Financial Officer) Â 43 EX-31.1 2 asmb-ex31_1.htm EX-31.1 EX-31.1 Â EXHIBIT 31.1 CERTIFICATION I, Jason A. Okazaki, certify that: 1.I have reviewed this Quarterly Report on Form 10â€‘Q of Assembly Biosciences, Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4.The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13aâ€‘15(e) and 15dâ€‘15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13aâ€‘15(f) and 15dâ€‘15(f)) for the registrant and have: a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c.Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d.Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and 5.The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Date: November 7, 2024 Â Â Â Â Â Â By: /s/ Jason A. Okazaki Â Â Jason A. Okazaki Â Â Chief Executive Officer and President Â Â (Principal Executive Officer and Principal Financial Officer) Â Â EX-32.1 3 asmb-ex32_1.htm EX-32.1 EX-32.1 EXHIBIT 32.1 Â CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report on Form 10â€‘Q of Assembly Biosciences, Inc. (the Company) for the period ended September 30, 2024 as filed with the Securities and Exchange Commission on or about the date hereof (the Report), I, Jason A. Okazaki, Chief Executive Officer and President, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge: (1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and (2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of, and for, the periods presented in the Report. Â Â Â /s/ Jason A. Okazaki Jason A. Okazaki Chief Executive Officer and President (Principal Executive Officer and Principal Financial Officer) Date: November 7, 2024 Â Â EX-101.SCH 4 asmb-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 100020 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100030 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 100040 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - Nature of Business link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - Related Party link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Fair Value Measurements and Investments in Marketable Securities link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - Other Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Restructuring link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Sale of Common Stock and Warrants link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Collaboration Agreements link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Milestones and Research Agreements link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Subsequent Event link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - Fair Value Measurements and Investments in Marketable Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - Other Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Restructuring (Tables) link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Collaboration Agreements (Tables) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Nature of Business - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Summary of Significant Accounting Policies - Schedule of Earnings Per Share, Basic and Diluted (Details) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Related Party - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Fair Value Measurements and Investments in Marketable Securities - Schedule of Investments in Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - Fair Value Measurements and Investments in Marketable Securities - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Fair Value Measurements and Investments in Marketable Securities - Schedule of Fair Value of Financial Assets (Details) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Other Accrued Expenses - Schedule of Other Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - Restructuring - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - Restructuring - Schedule of Accrued Restructuring Charges (Details) link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - Sale of Common Stock and Warrants- Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure - Stock-Based Compensation - Schedule of Recognized Stock-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 995775 - Disclosure - Stock-Based Compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995785 - Disclosure - Stock-Based Compensation - Summary of Assumptions Used to Estimate Fair Values of Stock Options Grants (Details) link:presentationLink link:calculationLink link:definitionLink 995795 - Disclosure - Collaboration Agreements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995805 - Disclosure - Collaboration Agreements - Schedule of Changes in Contract Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 995815 - Disclosure - Collaboration Agreements - Schedule of Collaboration Revenue Recognized with the Period (Details) link:presentationLink link:calculationLink link:definitionLink 995825 - Disclosure - Milestones and Research Agreements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995835 - Disclosure - Leases - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995845 - Disclosure - Subsequent Event - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink Statement [Line Items] Statement [Line Items] Accounts receivable from collaboration Increase (Decrease) in Accounts Receivable Schedule Of Research And Development Arrangement Contract To Perform For Others [Table] Research and Development, Contract to Perform for Others [Table] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Restructuring charges Costs incurred Restructuring Charges Restructuring Charges, Total Other comprehensive loss Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Proceeds from issuance of common stock and warrants in registered direct offering and private placement net of issuance costs. Proceeds from Issuance of Common Stock and Warrants in Registered Direct Offering and Private Placement Net of Issuance Costs Proceeds from the issuance of common stock and warrants in a registered direct offering and a private placement, net of issuance costs Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table] Subsidiary or Equity Method Investee, Sale of Stock, Type [Table] Unrecognized stock-based compensation expense Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Operating segments (in segments) Number of Operating Segments Amortized Cost, Short-term marketable securities Debt Securities, Available-for-Sale, Amortized Cost, Current Potential milestone payments Potential Milestone Payments Potential Milestone Payments. Reverse stock split description Stockholders' Equity, Reverse Stock Split Balance (in shares) Balance (in shares) Shares, Outstanding Level 2 Fair Value Hierarchy and NAV [Axis] Lessee, operating lease, lease not yet commenced, right-of-use asset. Lessee, Operating Lease, Lease Not yet Commenced, Right Of Use Asset Lessee, operating lease, lease not yet commenced, operating lease right-of-use asset Level 2 Fair Value, Inputs, Level 2 [Member] Share-based Compensation Arrangement by Share-based Payment Award Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Percentage of premium to weighted average price immediately prior to delivery of notice of closing date. Percentage of Premium to Weighted Average Price Immediately Prior to Delivery of Notice of Closing Date Percentage of premium to weighted average price immediately prior to delivery of notice of closing date Gross Unrealized Gain Cash Equivalents At Carrying Value And Available For Sale Debt Securities Gross Unrealized Gain Cash equivalents at carrying value and available for sale debt securities gross unrealized gain. Lessee, Operating Leases [Text Block] Leases Restructuring Cost [Table] Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures, Total Issuance of common stock for settlement of restricted stock units (RSUs) Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Milestones and Research Agreements Milestones And Research Agreements [Text Block] Milestones and Research Agreements Depreciation, Depletion and Amortization, Total Depreciation and amortization Depreciation, Depletion and Amortization Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Related Party Transaction [Line Items] Equity [Text Block] Sale of Common Stock and Warrants Deferred Compensation Liability [Abstract] Sale of Stock Sale of Stock [Domain] Cash and Cash Equivalents Cash and Cash Equivalents [Domain] Entity Central Index Key Entity Central Index Key Issuance of common stock and warrants in registered direct offering and private placement net of issuance costs shares. Issuance of Common Stock and Warrants in Registered Direct Offering and Private Placement Net of Issuance Costs Shares Issuance of common stock and warrants in a registered direct offering and a private placement, net of issuance costs (in shares) Investments in marketable securities: Debt Securities, Available-for-Sale [Line Items] Amortized Cost Cash Equivalents, at Carrying Value Amortized Cost Fifth year of collaboration. Fifth Year of Collaboration [Member] Fifth Year of Collaboration Agreement Warrant [Member] Warrants to purchase common stock Warrant to purchase common stock Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Common stock, shares issued Common Stock, Shares, Issued Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Other Assets Other Noncurrent Assets [Member] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Income Statement [Abstract] Entity Address, State or Province Entity Address, State or Province Issuance of common stock under Employee Stock Purchase Plan (ESPP) Stock Issued During Period, Value, Employee Stock Purchase Plan Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Loss before income taxes Loss before income taxes Other accrued expenses Increase (Decrease) in Other Accrued Liabilities Amounts

included in deferred revenue at the beginning of the period Contract with Customer, Liability, Revenue Recognized Regulatory and commercial milestones. Regulatory And Commercial Milestones [Member] Regulatory and Commercial Milestones Number of investments in unrealized loss position Debt Securities, Available-for-Sale, Unrealized Loss Position Debt Securities, Available-for-Sale, Unrealized Loss Position, Total Gross Unrealized Loss Cash And Cash Equivalent Gross Unrealized Loss Cash and cash equivalent gross unrealized loss. Collaboration Agreement [Abstract] Collaboration Agreement Cover [Abstract] Subsequent Event [Line Items] Earnings Per Share, Basic, Total Net loss per share - basic Net loss per share, basic Earnings Per Share, Basic Operating expenses Operating Expenses [Abstract] Deferred revenue from a related party - short-term Deferred revenue - short-term Contract with Customer, Liability, Current Investments, Debt and Equity Securities [Abstract] Common stock and warrant. Common Stock and Warrant [Member] Common Stock and Warrant Percentage share of profits and operating loss for products. Percentage Share of Profits and Operating Loss for Products Percentage share of profits and operating loss for products Stock-based compensation expense Share-Based Payment Arrangement, Expense Retained Earnings (Accumulated Deficit), Total Accumulated deficit Retained Earnings (Accumulated Deficit) Current assets Assets, Current [Abstract] Investment Type [Axis] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Property, Plant and Equipment, Net, Total Property and equipment, net Property, Plant and Equipment, Net Deferred revenue from a related party - long-term Deferred revenue - long-term Contract with Customer, Liability, Noncurrent Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Recurring Fair Value, Recurring [Member] Restructuring and Related Activities [Abstract] Common stock, par value Common Stock, Par or Stated Value Per Share Options to purchase common stock Unrealized gain (loss) on marketable securities OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Unrealized gain (loss) on marketable debt securities Deferred revenue from a related party Balance at End of Period Balance at Beginning of Period Contract liability/deferred revenue Contract with Customer, Liability Contract with Customer, Liability, Total Statement of Cash Flows [Abstract] Counterparty Name [Axis] Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Entity [Domain] Equity Components Equity Components [Axis] Entity Address, Address Line One Entity Address, Address Line One Schedule of Earnings Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Employee-related Liabilities, Current, Total Accrued compensation Employee-related Liabilities, Current Related Party Transaction [Table] Subsequent Event Type [Axis] Total other income Nonoperating Income (Expense) Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Risk-free rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Amendment Flag Amendment Flag Operating lease liabilities - long-term Operating Lease, Liability, Noncurrent Premium received on common stock purchase Premium Received On Common Stock Purchase Premium received on common stock purchase. U.S and foreign corporate debt securities Corporate Debt Securities [Member] Additional paid-in capital Additional Paid in Capital, Common Stock Long-term marketable securities Fair Value, Long-term marketable securities Debt Securities, Available-for-Sale, Noncurrent Sale of Stock, Price Per Share Sale of stock, price per share Net loss Net loss Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Issuance of common stock upon exercise of stock options (in shares) Research and Development Research and Development Expenses Research and Development Expense [Member] Equity Component Equity Component [Domain] Statistical Measurement Statistical Measurement [Domain] General and Administrative Expense, Total General and administrative General and Administrative Expense Fair Value Measurements and Investments in Marketable Securities Fair Value Measurements And Investments In Marketable Securities [Text Block] Fair value measurements and investments in marketable securities. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Preferred stock, shares issued Preferred Stock, Shares Issued Proceeds from Stock Options Exercised Proceeds from the exercise of stock options Schedule of Collaboration revenue recognized with the period Schedule Of Collaboration Revenue Recognized With Period Table [Text Block] Schedule of Collaboration Revenue Recognized with the Period Fair Value Cash Equivalents At Carrying Value And Available For Sale Debt Securities Estimated Fair Value Cash equivalents at carrying value and available for sale debt securities estimated fair value. Payables and Accruals [Abstract] Percentage cover of research and development costs. Percentage Cover of Research and Development Costs Percentage cover of research and development costs Issuance of common stock under Employee Stock Purchase Plan (ESPP) (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Proceeds from Collaborators Proceeds received in collaboration agreement Number of fellow-contributed programs. Number of Fellow-contributed Programs Number of fellow-contributed programs Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Severance Costs Employee severance and related benefits Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Common Stock, Shares, Outstanding, Ending Balance Common Stock, Shares, Outstanding, Beginning Balance Common stock, shares outstanding Common Stock, Shares, Outstanding Short-term marketable securities Short-Term Investments [Abstract] Seventh year of collaboration. Seventh Year of Collaboration [Member] Seventh Year of Collaboration Agreement Potential milestone payment Purchase Commitment, Remaining Minimum Amount Committed Purchases of marketable securities Payments to Acquire Debt Securities, Available-for-Sale Preferred stock, par value Preferred Stock, Par or Stated Value Per Share Restructuring one time termination cost. Restructuring one-time termination Cost Restructuring one-time termination Cost Number of directors right to designate in board. Number of Directors, Right to Designate in Board Number of directors, right to designate in company board Proceeds from maturities of marketable securities Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale Threshold payment of opt-in fee. Threshold Payment of Opt-in Fee Threshold payment of opt-in fee Antidilutive Securities Antidilutive Securities [Axis] Proceeds from Issuance or Sale of Equity, Total Proceeds from Issuance or Sale of Equity Gross proceeds from issuance of common stock and warrant Entity Interactive Data Current Entity Interactive Data Current Warrants exercised during period shares Warrants Exercised During Period Shares Warrants exercised during period shares. FDA approved products (in products) Number Of Approved Products Represents the number of approved products. Cumulative Restructuring Charges Cumulative Restructuring Charges Cumulative restructuring charges Accounting Standards Update [Domain] Document Quarterly Report Document Quarterly Report Related Party Transaction [Domain] Related Party Related Party Transactions Disclosure [Text Block] Balance Sheet Location Statement of Financial Position Location, Balance [Axis] Statistical Measurement Statistical Measurement [Axis] Gross Unrealized Gain, Short-term marketable securities Available for Sale Debt Securities Accumulated Gross Unrealized Gain before Tax Current Available for sale debt securities accumulated gross unrealized gain before tax current. Percentage of Premium to Weighted Average Price Immediately Prior to Date of Purchase or to Delivery of Notice of Closing Date Percentage of premium to weighted average price immediately prior to date of purchase or to delivery of notice of closing date. Total assets measured at fair value Assets, Fair Value Disclosure Related and Nonrelated Parties [Domain] Initial non-cancellable term Initial Non Cancellable Term Initial non-cancellable term. Exercise price Share Based Compensation Arrangement Fair Value Assumptions Exercise Price Share based compensation arrangement fair value assumptions exercise price. U.S. and foreign commercial paper Commercial Paper [Member] Unrecognized stock-based compensation expense expected to be recognized, term Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Accrued research and development expenses Increase Decrease In Accrued Research And Development Expenses Increase (decrease) in accrued research and development expenses. Income Statement Location Statement of Income Location, Balance [Axis] Number of trading days volume considered for weighted average price to calculate premium Number of Trading Days Volume Considered for Weighted Average Price to Calculate Premium Number of trading days volume considered for weighted average price to calculate premium. Cash and Cash Equivalents Cash and Cash Equivalents [Axis] Total assets Assets Expected term (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term 2020 At the Market Offerings Two Thousand And Twenty At The Market Offerings [Member] Two thousand and twenty at the market offerings. New Accounting Pronouncements, Policy [Policy Text Block] Recently Adopted Accounting Standards Entity Address, City or Town Entity Address, City or Town AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Loss Equity [Abstract] Reductions for cash payments Payments for Restructuring Monthly sublease base rent Monthly Sublease Base Rent Monthly sublease base rent. Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Closing bid price of stock Share Price Numerator: Net Income (Loss) Attributable to Parent [Abstract] Purchase price per share of additional shares description. Purchase Price Per Share of Additional Shares Description Purchase price per share of additional shares description Private Placement [Member] Private Placement Share-Based Payment Arrangement [Text Block] Stock-Based Compensation Incremental costs Incremental Costs Incremental costs. Issuance of common stock under at-the-market (ATM) equity offering program, net of issuance costs Stock Issued During Period, Value, New Issues Stock Issued During Period, Value, Stock Options Exercised Issuance of common stock upon exercise of stock options Current liabilities Liabilities, Current [Abstract] Purchase of warrant in a Private Placement Purchase of warrant in a Private Placement Purchase of warrant in private placement Document Type Document Type Accounting Standards Update [Axis] U.S and foreign corporate debt securities US Government Agencies Debt Securities [Member] Title of 12(b) Security Title of 12(b) Security Amortized Cost11 Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Proceeds from issuance of common stock under employee stock purchase plan. Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan Proceeds from the issuance of common stock under ESPP Balance Sheet Location Statement of Financial Position Location, Balance [Domain] Statement of Stockholders' Equity [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Research and Development Expense, Total Research and development expense Research and development Research and Development Expense Subsequent Event Type [Domain] Summary of Assumptions Used to Estimate Fair Values of Stock Options Grants Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Accrued restructuring charges Accrued Restructuring Charges Current Accrued restructuring charges current. Accrued balance as of December 31, 2022 Accrued balance as of September 30, 2023 Accrued research and development expenses Accrued Research And Development Expenses Current Accrued research and development expenses current. Financial Instruments Financial Instruments [Domain] Sale of Stock Sale of Stock [Axis] Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Gross Unrealized Loss Cash Equivalents At Carrying Value And Available For Sale Debt Securities Gross Unrealized Loss Cash equivalents at carrying value and available for sale debt securities gross unrealized loss. Investments [Domain] Maximum percentage of then-outstanding voting capital stock Maximum Percentage Of Then Outstanding Voting Capital Stock Maximum percentage of then-outstanding voting capital stock. Other accrued expenses Other Accrued Liabilities, Current Increase (Decrease) in Accounts Payable, Total Accounts payable Increase (Decrease) in Accounts Payable Entity Address, Address Line Two Entity Address, Address Line Two LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Document Period End Date Document Period End Date Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Operating lease liabilities Increase Decrease In Operating Lease Liabilities Increase decrease in operating lease liabilities. Antidilutive securities excluded from computation of loss per share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Proceeds received from transaction Sale of Stock, Consideration Received on Transaction Upfront equity investment Total accrued expenses Accrued Liabilities, Current Other Risks and Uncertainties Other Risks And Uncertainties Policy [Text Block] Other risks and uncertainties. Income Tax Expense (Benefit), Total Income Tax Expense (Benefit) Income tax expense Income tax expense Trading Symbol Trading Symbol Total stockholders' equity Balance Balance Equity, Attributable to Parent Lessee, Operating Lease, Lease Not yet Commenced, Existence of Option to Extend [true false] Unvested RSUs RSUs Restricted Stock Units (RSUs) [Member] Number of shares sold Sale of Stock, Number of Shares Issued in Transaction Related Party Transactions [Abstract] Change in Accounting Principle, Accounting Standards Update, Adopted [true false] Schedule of Recognized Stock-Based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Restructuring costs reversal of stock-based compensation expense Restructuring Costs Reversal of stock-based compensation expense Restructuring costs reversal Number of years of standstill and lockup provisions. Number of Years of Standstill and Lockup Provisions Number of years of standstill and lockup provisions Cash equivalents Cash Equivalents At Fair Value [Abstract] Cash equivalents at fair value. Leases [Abstract] Use of Estimates Use of Estimates, Policy [Policy Text Block] Lessee, operating lease, lease not yet commenced, payments due. Lessee, Operating Lease, Lease Not yet Commenced, Payments Due Lessee, operating lease, lease not yet commenced, future lease payments Upfront cash payment received Upfront Cash Payment Received Upfront cash payment received. Scenario [Axis] Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Schedule of Changes in Contract Liabilities Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Security Exchange Name Security Exchange Name Schedule of Investments in Marketable Securities Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Counterparty Name [Domain] Schedule of Accrued Restructuring Charges Schedule Of Accrued Restructuring Charges [Table TextBlock] Schedule of accrued restructuring charges. Total operating expenses Operating Expenses Milestones And Research Agreements [Abstract] Milestones and Research Agreements Legal Entity [Axis] Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Subsequent Event [Member] Subsequent Event Maximum Maximum [Member] Restructuring Restructuring and Related Activities Disclosure [Text Block] Total liabilities and stockholders' equity Liabilities and Equity Percentage of workforce reduced Restructuring and Related Cost, Number of Positions Eliminated, Period Percent Operating lease right-of-use (ROU) assets Operating Lease, Right-of-Use Asset Fair value assets transfers between level 1, level 2 or level 3 Fair Value Assets Between Levels Transfers Amount Fair value assets between levels transfers amount. Earnings Per Share, Diluted, Total Net loss per share - diluted Net loss per share, diluted Earnings Per Share, Diluted Number of shares issued in connection with reverse stock split Stock Issued During Period, Shares, Reverse Stock Splits Total liabilities Liabilities Reverse Stock Split Reverse Stock Split [Policy Text Block] Reverse stock split. Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Total current assets Assets, Current Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities Forecast [Member] Forecast Stock Issued During Period, Shares, New Issues Issuance of common stock under at-the-market (ATM) equity offering program, net of issuance costs (in shares) Realized gains and losses Realized Investment Gains (Losses) Realized Investment Gains (Losses), Total Entity Filer Category Entity Filer Category Nature of Business Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Amortized Cost Cash Equivalents At Carrying Value And Available For Sale Debt Securities Amortized Cost Cash equivalents at carrying value and available for sale debt securities amortized cost. Other income Nonoperating Income (Expense) [Abstract] Current Fiscal Year End Date Current Fiscal Year End Date Share-Based Payment Arrangement, Noncash Expense, Total Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Related Party Transaction [Axis] Lessee, operating lease, lease not yet commenced, option to extend Lessee, Operating Lease, Lease Not yet Commenced, Option to Extend Related and Nonrelated Parties [Axis] Entity Registrant Name Entity Registrant Name Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Entity Emerging Growth Company Entity Emerging Growth Company BeiGene Agreement Bei Gene Agreement [Member] BeiGene agreement. Investment, Type [Extensible Enumeration] ASU 2016-13 Accounting Standards Update 2016-13 [Member] Money market fund Money Market Funds [Member] Weighted average common shares outstanding - basic Weighted Average Number of Shares Outstanding, Basic, Total Weighted average common shares outstanding, basic Weighted Average Number of Shares Outstanding, Basic Common stock, shares authorized Common Stock, Shares Authorized Proceeds from the issuance of common stock under ATM equity offering program, net of issuance costs Proceeds from Issuance of Common Stock Securities Purchase Agreement Securities Purchase Agreement [Member] Securities Purchase Agreement Level 1 Fair Value, Inputs, Level 1 [Member] Third year of collaboration. Third Year of Collaboration [Member] Third Year of Collaboration Agreement Schedule Of Available For Sale Securities1 [Table] Schedule of available for sale securities1. Financial Instrument Financial Instrument [Axis] Significant Accounting Policies [Line Items] Significant Accounting Policies [Line Items] Significant accounting policies. Net Loss per Share Earnings Per Share, Policy [Policy Text Block] Percentage of then-outstanding voting capital stock subject to stockholder approval. Percentage of Then-outstanding Voting Capital Stock Subject to Stockholder Approval Percentage of then-outstanding voting capital stock subject to stockholder approval General and Administrative General and Administrative Expenses General and Administrative Expense [Member] Share-Based Payment Arrangement [Abstract] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Milestone payment, diligence maintenance fees Milestone Payment Diligence Maintenance Fees Milestone payment, diligence maintenance fees. Accounting Policies [Abstract] Stockholders' equity Equity, Attributable to Parent [Abstract] Contract with customer liability in additions. Contract With Customer Liability In Additions Additions Long-term marketable securities Long-Term Investments [Abstract] Collaboration term. Collaboration Term Collaboration term Reimbursable expenses Reimbursable Expenses Reimbursable expenses.

U.S. and foreign commercial paper U S And Foreign Commercial Paper [Member] U.S. and foreign commercial paper. Interest and other income, net Interest Income, Other Statement [Table] Statement [Table] Silicon Valley Bank Silicon Valley Bank Member Silicon Valley Bank. Lease not yet commence, term of contract Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract Subsequent Event [Table] Preferred stock, shares authorized Preferred Stock, Shares Authorized Collaboration revenue from a related party Revenue recognized Collaboration revenue Entity File Number Securities Act File Number Asset-backed securities Asset-Backed Securities [Member] Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Gilead sciences incorporated. Gilead Sciences Incorporated [Member] Gilead Sciences, Inc. Cash equivalents Cash Equivalents [Member] Statement of Financial Position [Abstract] Loss from operations Operating Income (Loss) Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Entity Shell Company Entity Shell Company Lessee, operating lease, lease not yet commenced, lease liability. Lessee, Operating Lease, Lease Not yet Commenced, Lease Liability Lessee, operating lease, lease not yet commenced, operating lease liability Accrued professional fees and other Accrued Professional Fees, Current Entity Tax Identification Number Entity Tax Identification Number ASSETS Assets [Abstract] Number of timepoints of program. Number of Timepoints of Program Number of timepoints of program Entity Current Reporting Status Entity Current Reporting Status Arbutus Biopharma Agreement Arbutus Biopharma Agreement [Member] Arbutus biopharma agreement. Milestone and Research Agreements: Research And Development Arrangement Contract To Perform For Others [Line Items] Research and Development Arrangement, Contract to Perform for Others [Line Items] Subsequent Events [Abstract] Deferred revenue from a related party Increase (Decrease) in Contract with Customer, Liability Net accretion of investments in marketable debt securities (Accretion) amortization of investments in marketable debt securities. (Accretion) Amortization Of Investments In Marketable Debt Securities Document Fiscal Year Focus Document Fiscal Year Focus Change in Accounting Principle, Accounting Standards Update, Adoption Date Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding Preferred Stock, Value, Issued Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total Cash and cash equivalents at the beginning of the period Cash and cash equivalents at the end of the period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Net proceeds from the issuance of common stock through equity plans Proceeds from Issuance Initial Public Offering City Area Code City Area Code Total current liabilities Liabilities, Current Performance obligations satisfied in previous period Contract with Customer, Performance Obligation Satisfied in Previous Period Percentage of outstanding voting of common stock held Percentage of Outstanding Voting of Common Stock Held Percentage of Outstanding Voting of Common Stock Held Significant Accounting Policies [Table] Significant Accounting Policies [Table] Significant accounting policies. Organization, Consolidation and Presentation of Financial Statements [Abstract] Local Phone Number Local Phone Number Preferred Stock, Shares Outstanding, Ending Balance Preferred Stock, Shares Outstanding, Beginning Balance Preferred stock, shares outstanding Preferred Stock, Shares Outstanding Antidilutive Securities Excluded from Computation of Earnings Per Share Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Subsidiary Sale Of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] Operating lease liabilities - short-term Operating Lease, Liability, Current Warrant excercise price Warrant Excercise Price Warrants exercise price Accumulated Deficit Retained Earnings [Member] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Payments to Acquire Property, Plant, and Equipment, Total Accrued expenses: Accrued Liabilities, Current [Abstract] Schedule of Fair Value of Financial Assets Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Document Transition Report Document Transition Report Expected equity financing completion date. Expected Equity Financing Completion Date Expected equity financing completion date Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Minimum Minimum [Member] Common Stock Common Stock [Member] Compensation expense: Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Issuance of common stock and warrants in registered direct offering and private placement net of issuance costs value. Issuance of Common Stock and Warrants in Registered Direct Offering and Private Placement Net of Issuance Costs Value Issuance of common stock and warrants in a registered direct offering and a private placement, net of issuance costs Other Accrued Expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Non-cash rent expense Noncash Rent Expense Represent non cash rent expense. Common stock subject to purchase under Employee Stock Purchase Plan Common Stock Subject To Purchase Under Employee Stock Purchase Program [Member] Common stock subject to purchase under employee stock purchase program. Other assets Increase (Decrease) in Other Noncurrent Assets Additional Paid-in Capital Additional Paid-in Capital [Member] Common stock shares outstanding due to reverse stock split Stock Outstanding During Period Shares Reverse Stock Splits Stock outstanding during period shares reverse stock splits. Marketable securities Fair Value, Short-term marketable securities Short-term marketable securities Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Income Statement Location Statement of Income Location, Balance [Domain] Other assets Other Assets, Noncurrent Potential proceeds from equity financing. Potential Proceeds from Equity Financing Potential proceeds from equity financing Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Gross Unrealized Gain Cash And Cash Equivalent Gross Unrealized Gain Cash and cash equivalent gross unrealized gain. Potential proceeds from collaboration extension fees. Potential Proceeds from Collaboration Extension Fees Potential proceeds from collaboration extension fees Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Scenario [Domain] Collaboration Agreements Collaborative And License Arrangement Disclosure [Text Block] Collaborative and License Arrangement Disclosure. Common stock, $0.001 par value; 150,000,000 shares authorized as of September 30 2024 and December 31, 2023; 6,354,414 and 5,482,752 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively Common Stock, Value, Issued Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Fair Value Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Gilead Collaboration Agreement Option, license and collaboration agreement. Option, License and Collaboration Agreement [Member] Option, License and Collaboration Agreement Number of days volume considered for weighted average price to calculate premium. Number of Days Volume Considered for Weighted Average Price to Calculate Premium Number of days volume considered for weighted average price to calculate premium Measurement Frequency Measurement Frequency [Axis] Schedule of Other Accrued Expenses Schedule of Accrued Liabilities [Table Text Block] Commitments and contingencies Commitments and Contingencies Initial public offering value of shares authorized Initial Public Offering Value Of Shares Authorized The value of common stock authorized to issue in a public offering. Weighted average common shares outstanding - diluted Weighted Average Number of Shares Outstanding, Diluted, Total Weighted average common shares outstanding, diluted Weighted Average Number of Shares Outstanding, Diluted Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Accounts Receivable, after Allowance for Credit Loss, Current, Total Accounts Receivable, after Allowance for Credit Loss, Current Accounts receivable from collaboration Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Gross Unrealized Loss, Short-term marketable securities Available for Sale Debt Securities Accumulated Gross Unrealized Loss before Tax Current Available for sale debt securities accumulated gross unrealized loss before tax current. Equity agreements. Equity Agreements [Member] Gilead Equity Agreements Denominator: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Warrants and Rights Outstanding, Maturity Date Warrants expiration date Entity Small Business Entity Small Business Accured Interest Receivable Accured Interest Receivable Accrued interest receivable Reverse stock split ratio Stockholders' Equity Note, Stock Split, Conversion Ratio U.S. treasury securities US Treasury Securities [Member] Collaboration revenue recognized in period [Abstract] Collaboration Revenue Recognized In Period [Abstract] Collaboration revenue recognized in the period from Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Issuance of common stock for settlement of restricted stock units (RSUs) (in shares) Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Contract with customer liability in deduction. Contract With Customer Liability In Deduction Deductions Restructuring costs incurred Restructuring charges Restructuring And Related Cost Incurred Cost Benefit Restructuring and related cost incurred cost benefit Measurement Frequency Measurement Frequency [Domain] Level 3 Fair Value, Inputs, Level 3 [Member] Percentage of premium to weighted average price immediately prior to date of purchase. Percentage of Premium to Weighted Average Price Immediately Prior to Date of Purchase Percentage of premium to weighted average price immediately prior to date of purchase Subsequent Events [Text Block] Subsequent Event Accounts Payable, Current, Total Accounts payable Accounts Payable, Current Lease expiration, month and year. Lease Expiration, Month And Year Lease expiration month and year Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false] XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Document and Entity Information - shares 9 Months Ended Sep. 30, 2024 Nov. 01, 2024 Cover [Abstract] Â Â Document Type 10-Q Â Document Quarterly Report true Â Document Transition Report false Â Document Period End Date Sep. 30, 2024 Â Entity File Number 001-35005 Â Entity Registrant Name ASSEMBLY BIOSCIENCES, INC. Â Entity Incorporation, State or Country Code DE Â Entity Tax Identification Number 20-8729264 Â Entity Address, Address Line One Two Tower Place Â Entity Address, Address Line Two 7th Floor Â Entity Address, City or Town South San Francisco Â Entity Address, State or Province CA Â Entity Address, Postal Zip Code 94080 Â City Area Code 833 Â Local Phone Number 509-4583 Â Amendment Flag false Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q3 Â Entity Central Index Key 0001426800 Â Current Fiscal Year End Date --12-31 Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Non-accelerated Filer Â Trading Symbol ASMB Â Security Exchange Name NASDAQ Â Title of 12(b) Security Common Stock, par value $0.001 Â Entity Common Stock, Shares Outstanding Â 6,356,286 Entity Shell Company false Â Entity Emerging Growth Company false Â Entity Small Business true Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine2 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type:

na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 7 R2.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Current assets Â Â Cash and cash equivalents $ 28,452 $ 19,841 Marketable securities 66,502 110,406 Accounts receivable from collaboration 0 43 Prepaid expenses and other current assets 3,259 3,497 Total current assets 98,213 133,787 Property and equipment, net 316 385 Operating lease right-of-use (ROU) assets 1,421 2,339 Other assets 312 312 Total assets 100,262 136,823 Current liabilities Â Â Accounts payable 1,335 461 Accrued research and development expenses 1,586 885 Other accrued expenses 4,765 5,744 Deferred revenue from a related party - short-term 32,620 30,915 Operating lease liabilities - short-term 1,329 1,220 Total current liabilities 41,635 39,225 Deferred revenue from a related party - long-term 32,511 55,379 Operating lease liabilities - long-term 113 1,122 Total liabilities 74,259 95,726 Commitments and contingencies Stockholders' equity Â Â Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding Common stock, $0.001 par value; 150,000,000 shares authorized as of September 30 2024 and December 31, 2023; 6,354,414 and 5,482,752 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively 6 5 Additional paid-in capital 841,743 826,921 Accumulated other comprehensive loss (156) (81) Accumulated deficit (815,590) (785,748) Total stockholders' equity 26,003 41,097 Total liabilities and stockholders' equity $ 100,262 $ 136,823 X - DefinitionAccrued research and development expenses current. + ReferencesNo definition available. + Details Name: asmb_AccruedResearchAndDevelopmentExpensesCurrent Namespace Prefix: asmb_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionValue received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapitalCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized

in other comprehensive income (available-for-sale), classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19:

http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 8 R3.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares Sep. 30, 2024 Dec. 31, 2023 Statement of Financial Position [Abstract] Â Â Preferred stock, par value $ 0.001 $ 0.001 Preferred stock, shares authorized 5,000,000 5,000,000 Preferred stock, shares issued 0 0 Preferred stock, shares outstanding 0 0 Common stock, par value $ 0.001 $ 0.001 Common stock, shares authorized 150,000,000 150,000,000 Common stock, shares issued 6,354,414 5,482,752 Common stock, shares outstanding 6,354,414 5,482,752 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher

FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 9 R4.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Income Statement [Abstract] Â Â Â Â Collaboration revenue from a related party $ 6,845 $ 0 $ 21,163 $ 0 Operating expenses Â Â Â Â Research and development 13,515 10,824 41,653 37,894 General and administrative 4,286 4,224 13,398 14,201 Total operating expenses 17,801 15,048 55,051 52,095 Loss from operations (10,956) (15,048) (33,888) (52,095) Other income Â Â Â Â Interest and other income, net 1,343 628 4,452 1,829 Total other income 1,343 628 4,452 1,829 Loss before income taxes (9,613) (14,420) (29,436) (50,266) Income tax expense 0 0 406 0 Net loss (9,613) (14,420) (29,842) (50,266) Other comprehensive loss Â Â Â Â Unrealized gain (loss) on marketable securities 137 50 (75) 528 Comprehensive loss $ (9,476) $ (14,370) $ (29,917) $ (49,738) Net loss per share, basic $ (1.51) $ (3.29) $ (5.12) $ (11.61) Net loss per share, diluted $ (1.51) $ (3.29) $ (5.12) $ (11.61) Weighted average common shares outstanding, basic 6,351,431 4,380,444 5,827,750 4,329,260 Weighted average common shares outstanding, diluted 6,351,431 4,380,444 5,827,750 4,329,260 X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -

URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest income earned from interest bearing assets classified as other. + ReferencesNo definition available. + Details Name: us-gaap_InterestIncomeOther Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11 + Details Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units

not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 10 R5.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($) $ in Thousands Total Common Stock Additional Paid-in Capital Accumulated Other Comprehensive Loss Accumulated Deficit Balance at Dec. 31, 2022 $ 82,664 $ 4 $ 807,983 $ (803) $ (724,520) Balance (in shares) at Dec. 31, 2022 Â 4,074,552 Â Â Â Issuance of common stock under at-the-market (ATM) equity offering program, net of issuance costs 4,546 Â 4,546 Â Â Issuance of common stock under at-the-market (ATM) equity offering program, net of issuance costs (in shares) Â 261,170 Â Â Â Issuance of common stock under Employee Stock Purchase Plan (ESPP) 80 Â 80 Â Â Issuance of common stock under Employee Stock Purchase Plan (ESPP) (in shares) Â 7,533 Â Â Â Issuance of common stock for settlement of restricted stock units (RSUs) (in shares) Â 41,230 Â Â Â Unrealized gain (loss) on marketable debt securities 528 Â Â 528 Â Stock-based compensation 4,162 Â 4,162 Â Â Net Income (Loss) (50,266) Â Â Â (50,266) Balance at Sep. 30, 2023 41,714 $ 4 816,771 (275) (774,786) Balance (in shares) at Sep. 30, 2023 Â 4,384,485 Â Â Â Balance at Jun. 30, 2023 54,949 $ 4 815,636 (325) (760,366) Balance (in shares) at Jun. 30, 2023 Â 4,370,863 Â Â Â Issuance of common stock for settlement of restricted stock units (RSUs) (in shares) Â 13,622 Â Â Â Unrealized gain (loss) on marketable debt securities 50 Â Â 50 Â Stock-based compensation 1,135 Â 1,135 Â Â Net Income (Loss) (14,420) Â Â Â (14,420) Balance at Sep. 30, 2023 41,714 $ 4 816,771 (275) (774,786) Balance (in shares) at Sep. 30, 2023 Â 4,384,485 Â Â Â Balance at Dec. 31, 2023 41,097 $ 5 826,921 (81) (785,748) Balance (in shares) at Dec. 31, 2023 Â 5,482,752 Â Â Â Issuance of common stock and warrants in a registered direct offering and a private placement, net of issuance costs 12,395 $ 1 12,394 Â Â Issuance of common stock and warrants in a registered direct offering and a private placement, net of issuance costs (in shares) Â 814,000 Â Â Â Issuance of common stock under Employee Stock Purchase Plan (ESPP) 55 Â 55 Â Â Issuance of common stock under Employee Stock Purchase Plan (ESPP) (in shares) Â 7,252 Â Â Â Issuance of common stock for settlement of restricted stock units (RSUs) (in shares) Â 49,996 Â Â Â Issuance of common stock upon exercise of stock options 4 Â 4 Â Â Issuance of common stock upon exercise of stock options (in shares) Â 414 Â Â Â Unrealized gain (loss) on marketable debt securities (75) Â Â (75) Â Stock-based compensation 2,369 Â 2,369 Â Â Net Income (Loss) (29,842) Â Â Â (29,842) Balance at Sep. 30, 2024 26,003 $ 6 841,743 (156) (815,590) Balance (in shares) at Sep. 30, 2024 Â 6,354,414 Â Â Â Balance at Jun. 30, 2024 34,682 $ 6 840,946 (293) (805,977) Balance (in shares) at Jun. 30, 2024 Â 6,345,561 Â Â Â Issuance of common stock for settlement of restricted stock units (RSUs) (in shares) Â 8,853 Â Â Â Unrealized gain (loss) on marketable debt securities 137 Â Â 137 Â Stock-based compensation 797 Â 797 Â Â Net Income (Loss) (9,613) Â Â Â (9,613) Balance at Sep. 30, 2024 $ 26,003 $ 6 $ 841,743 $ (156) $ (815,590) Balance (in shares) at Sep. 30, 2024 Â 6,354,414 Â Â Â X - DefinitionIssuance of common stock and warrants in registered direct offering and private placement net of issuance costs shares. + ReferencesNo definition available. + Details Name: asmb_IssuanceOfCommonStockAndWarrantsInRegisteredDirectOfferingAndPrivatePlacementNetOfIssuanceCostsShares Namespace Prefix: asmb_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionIssuance of common stock and warrants in registered direct offering and private placement net of issuance costs value. + ReferencesNo definition available. + Details Name: asmb_IssuanceOfCommonStockAndWarrantsInRegisteredDirectOfferingAndPrivatePlacementNetOfIssuanceCostsValue Namespace Prefix: asmb_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11 + Details Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued during the period as a result of an employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X -

DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAggregate change in value for stock issued during the period as a result of employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 11 R6.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Cash flows from operating activities Â Â Net loss $ (29,842) $ (50,266) Adjustments to reconcile net loss to net cash used in operating activities: Â Â Depreciation and amortization 97 366 Stock-based compensation 2,369 4,160 Net accretion of investments in marketable debt securities (3,065) (534) Non-cash rent expense 1,064 2,525 Changes in operating assets and liabilities: Â Â Accounts receivable from collaboration 43 944 Prepaid expenses and other current assets 238 951 Other assets 0 337 Accounts payable 874 (1,735) Accrued research and development expenses 701 (1,503) Other accrued expenses (979) (3,429) Deferred revenue from a related party (21,163) 0 Operating lease liabilities (1,047) (2,720) Net cash used in operating activities (50,710) (50,904) Cash flows from investing activities Â Â Proceeds from maturities of marketable securities 96,500 46,315 Purchases of marketable securities (49,605) (25,615) Purchases of property and equipment (28) (184) Net cash provided by investing activities 46,867 20,516 Cash flows from financing activities Â Â Proceeds from the issuance of common stock and warrants in a registered direct offering and a private placement, net of issuance costs 12,395 0 Proceeds from the issuance of common stock under ATM equity offering program, net of issuance costs 0 4,546 Proceeds from the issuance of common stock under ESPP 55 80 Proceeds from the exercise of stock options 4 0 Net cash provided by financing activities 12,454 4,626 Net increase (decrease) in cash and cash equivalents 8,611 (25,762) Cash and cash equivalents at the beginning of the period 19,841 52,418 Cash and cash equivalents at the end of the period $ 28,452 $ 26,656 X - Definition(Accretion) amortization of investments in marketable debt securities. + ReferencesNo definition available. + Details Name: asmb_AccretionAmortizationOfInvestmentsInMarketableDebtSecurities Namespace Prefix: asmb_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIncrease (decrease) in accrued research and development expenses. + ReferencesNo definition available. + Details Name: asmb_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses Namespace Prefix: asmb_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIncrease decrease in operating lease liabilities. + ReferencesNo definition available. + Details Name: asmb_IncreaseDecreaseInOperatingLeaseLiabilities Namespace Prefix: asmb_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRepresent non cash rent expense. + ReferencesNo definition available. + Details Name: asmb_NoncashRentExpense Namespace Prefix: asmb_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProceeds from issuance of common stock and warrants in registered direct offering and private placement net of issuance costs. + ReferencesNo definition available. + Details Name: asmb_ProceedsFromIssuanceOfCommonStockAndWarrantsInRegisteredDirectOfferingAndPrivatePlacementNetOfIssuanceCosts Namespace Prefix: asmb_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProceeds from issuance of common stock under employee stock purchase plan. + ReferencesNo definition available. + Details Name: asmb_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan Namespace Prefix: asmb_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in other expenses incurred but not yet paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 +

Details Name: us-gaap_IncreaseDecreaseInOtherAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherNoncurrentAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11 + Details Name: us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 12 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Pay vs Performance Disclosure - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Pay vs Performance Disclosure Â Â Â Â Net Income (Loss) $ (9,613) $ (14,420) $ (29,842) $ (50,266) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting

Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 13 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended Sep. 30, 2024 Trading Arrangements, by Individual Â Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 14 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Nature of Business 9 Months Ended Sep. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Nature of Business Note 1 - Nature of BusinessOverviewAssembly Biosciences, Inc. (together with its subsidiaries, Assembly or the Company), incorporated in Delaware in October 2005, is a biotechnology company developing innovative therapeutics. The Company's pipeline includes two clinical-stage helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes, an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, a clinical-stage capsid assembly modulator candidate designed to disrupt the replication cycle of hepatitis B virus (HBV) and research programs focused on a non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses and a small molecule interferon-Î± (IFN-Î±) receptor (IFNAR) agonist targeting HBV and HDV. The Company operates in one segment and is headquartered in South San Francisco, California.LiquidityThe Company has not derived any revenue from product sales to date and currently has no approved products. Once a product has been developed, it will need to be approved for sale by the U.S. Food and Drug Administration (FDA) or an applicable foreign regulatory agency. Since inception, the Companyâ€™s operations have been financed through the sale of equity securities, the proceeds from the exercise of warrants and stock options, the issuance of debt, and upfront payments related to collaboration agreements. The Company has incurred losses from operations since inception and expects to continue to incur substantial losses for the next several years as it continues its product development efforts. Management believes the Company currently has sufficient funds to meet its operating requirements for at least the next twelve months following the date these unaudited condensed consolidated financial statements are issued. The Company intends to obtain any additional funding it requires through strategic relationships, public or private equity or debt financings, grants or other arrangements. The Company cannot assure such funding will be available on reasonable terms, if at all. Market volatility, inflation or other factors could also adversely impact the Companyâ€™s ability to access capital when and as needed.If the Company is unable to secure additional sources of funding or generate enough revenue from its collaborations, it may be necessary to significantly reduce the current rate of spending through reductions in staff and delaying, scaling back, or stopping certain research and development programs, including more costly clinical trials. X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 15 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Summary of Significant Accounting Policies Note 2 - Summary of Significant Accounting PoliciesBasis of PresentationThe accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial information and pursuant to the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the SEC. In managementâ€™s opinion, the unaudited condensed consolidated financial statements have been prepared on the same basis as the annual audited consolidated financial statements and include normal recurring adjustments necessary for the fair presentation of the Companyâ€™s financial position and its results of operations and comprehensive loss and its cash flows for the periods presented. These statements do not include all disclosures required by U.S. GAAP and should be read in conjunction with the Companyâ€™s audited consolidated financial statements and accompanying notes for the fiscal year ended December 31, 2023, which are contained in the 2023 Annual Report. The results for the three and nine months ended September 30, 2024 are not necessarily indicative of results to be expected for the entire year ending December 31, 2024 or future operating periods.Use of EstimatesThe preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.Significant estimates inherent in the preparation of the accompanying unaudited condensed consolidated financial statements include estimates for revenue recognition and costs incurred but not yet invoiced for research and development accruals.The Companyâ€™s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible these external factors could have an effect on the Companyâ€™s estimates and could cause actual results to differ materially from those estimates and assumptions.Other Risks and Uncertainties U.S. and global financial markets have experienced volatility and disruption due to macroeconomic and geopolitical events such as rising inflation, changes in interest rates to combat inflation, the war between Russia and Ukraine, the Israel-Hamas war and the Israel-Hezbollah war in Lebanon. The Company cannot predict at this time to what extent, if at all, it and its employees, contract research organizations, vendors and/or collaborators could potentially be negatively impacted by these events.Reverse Stock SplitIn September 2023, the Company received a letter from the Listing Qualifications Department of the Nasdaq Stock Market notifying the Company, as the bid price for its common stock had closed below $1.00 per share for the last 30 consecutive business days, it was not in compliance with Nasdaq Listing Rule 5450(a)(1), which is the minimum bid price requirement for continued listing on the Nasdaq Global Select Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided a 180-calendar day period, or until March 25, 2024, to regain compliance with the minimum bid price requirement. The continued listing standard would be met once the closing bid price of the Companyâ€™s common stock was at least $1.00 per share for a minimum of ten consecutive business days during the 180-calendar day period. In January 2024, the Company's stockholders approved a reverse stock split of its common stock at a range of ratios between 1-for-7 to 1-for-17, and the Company's board of directors approved the implementation of the reverse stock split at a ratio of 1-for-12 (the Reverse Stock Split). The Reverse Stock Split was effective as of February 9, 2024 and the Company regained compliance with the minimum bid price requirement in February 2024. As of the effective time of the Reverse Stock Split, every 12 issued and outstanding shares of the Companyâ€™s common stock was automatically reclassified into one issued and outstanding share of the Companyâ€™s common stock. This reduced the number of shares outstanding from 65.8 million shares to 5.5 million shares. The Reverse Stock Split did not affect the number of authorized shares of common stock or the par value of the common stock. No fractional shares of common stock were issued in connection with the Reverse Stock Split and all fractional shares were rounded down to the nearest whole share with respect to outstanding shares of common stock. Any holders of common stock who would have otherwise received a fractional share of common stock pursuant to the Reverse Stock Split, received cash in lieu of the fractional share. All prior period share and per share amounts of the Company's common stock presented have been retroactively adjusted to reflect the 1-for-12 Reverse Stock Split, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital.Net Loss per ShareBasic net loss per share of common stock excludes dilution and is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share of common stock reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity unless inclusion of such shares would be anti-dilutive. Diluted net loss per share is the same as basic net loss per share, since the effects of potentially dilutive securities are antidilutive given the net loss for each period presented.A reconciliation of the numerators and the denominators of the basic and diluted net loss per common share computations is as follows (in thousands, except for share and per share amounts): Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Numerator: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net loss Â $ (9,613) Â $ (14,420) Â $ (29,842) Â $ (50,266) Denominator: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Weighted average common shares outstanding - basic and diluted Â Â 6,351,431 Â Â Â 4,380,444 Â Â Â 5,827,750 Â Â Â 4,329,260 Â Net loss per share - basic and diluted Â $ (1.51) Â $ (3.29) Â $ (5.12) Â $ (11.61) Securities excluded from the computation of diluted net loss per share because including them would have been antidilutive are as follows: Â Â September 30, Â Â Â 2024 Â Â 2023 Â Warrants to purchase common stock Â Â 814,000 Â Â Â â€” Â Options to purchase common stock Â Â 937,268 Â Â Â 828,789 Â Common stock subject to purchase under ESPP Â Â 7,513 Â Â Â 6,711 Â Unvested RSUs Â Â 69,217 Â Â Â 90,740 Â Total Â Â 1,827,998 Â Â Â 926,240 Â X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 16 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Related Party 9 Months Ended Sep. 30, 2024 Related Party Transactions [Abstract] Â Related Party Note 3 â€“ Related PartyIn October 2023, the Company entered into an Option, License and Collaboration Agreement (the Gilead Collaboration Agreement), and a Common Stock Purchase Agreement and an Investor Rights Agreement (collectively, the Gilead Equity Agreements) under which it received aggregate gross proceeds of $100.0 million from Gilead Sciences, Inc. (Gilead). During the three and nine months ended September 30, 2024, the Company recognized $6.8 million and $21.2 million of collaboration revenue under the Gilead

Collaboration Agreement, respectively (see Note 8).Pursuant to the Investor Rights Agreement, Gilead designated two directors to the Companyâ€™s board of directors, who were appointed in December 2023 and February 2024. In June 2024, the Company entered into a Securities Purchase Agreement with Gilead for the issuance and sale of 179,500 shares of the Companyâ€™s common stock and a warrant to purchase up to 179,500 shares of the Companyâ€™s common stock in a private placement (see Note 6). The common stock and warrant were sold at a combined offering price of $15.46, for aggregate gross proceeds to the Company of approximately $2.8 million. Also in June 2024, the Gilead Equity Agreements were amended to extend deadlines relating to the Companyâ€™s efforts to complete an equity financing and its ability to require Gilead to purchase additional shares of the Companyâ€™s common stock by three months. The extended deadlines lapsed in October 2024. The amendments also explicitly include the shares of the Company's common stock and warrant sold to Gilead in June 2024 in the definition of registrable securities. The amendments to the Gilead Equity Agreements did not have an impact to the Company's condensed consolidated financial statements.As of September 30, 2024, Gilead held approximately 19.9% of the Companyâ€™s outstanding voting common stock. Under the Gilead Equity Agreements, Gilead may elect to purchase additional shares to increase its holdings up to a maximum of 29.9% of the Companyâ€™s then-outstanding voting common stock. The purchase price per share for additional shares purchased by Gilead under the Gilead Common Stock Purchase Agreement will be equal to the lesser of (1) a 35% premium to the 30 trading day volume weighted average price immediately prior to the date of purchase or (2) a 35% premium to the 30 trading day volume weighted average price immediately prior to delivery by Gilead of notice of the anticipated closing date. X - ReferencesNo definition available. + Details Name: us-gaap_RelatedPartyTransactionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(e)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/850/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1 + Details Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 17 R12.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements and Investments in Marketable Securities 9 Months Ended Sep. 30, 2024 Investments, Debt and Equity Securities [Abstract] Â Fair Value Measurements and Investments in Marketable Securities Note 4 â€“ Fair Value Measurements and Investments in Marketable SecuritiesThe carrying amounts of cash equivalents and marketable securities approximate their fair value based upon quoted market prices. Certain of the Companyâ€™s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as cash, accounts receivable, accounts payable and accrued expenses.The Company uses the following three-level hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs to value its financial instruments:Level 1: Observable inputs such as unadjusted quoted prices in active markets for identical instruments.Level 2: Quoted prices for similar instruments that are directly or indirectly observable in the marketplace.Level 3: Significant unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.Investments in marketable securities consisted of the following (in thousands): Â Â September 30, 2024 Â Â Â AmortizedCost Â Â GrossUnrealizedGain Â Â GrossUnrealizedLoss Â Â Fair Value Â Cash equivalents Â Â Â Â Â Â Â Â Â Â Â Â Money market fund Â $ 27,840 Â Â $ â€” Â Â $ â€” Â Â $ 27,840 Â Total cash equivalents Â Â 27,840 Â Â Â â€” Â Â Â 27,840 Â Short-term marketable securities Â Â Â Â Â Â Â Â Â Â Â Â U.S. and foreign corporate debt securities Â Â 16,468 Â Â Â 42 Â Â Â â€” Â Â Â 16,510 Â U.S. treasury securities Â Â 47,298 Â Â Â 64 Â Â Â â€” Â Â Â 47,362 Â U.S. and foreign commercial paper Â Â 2,619 Â Â Â 11 Â Â Â â€” Â Â Â 2,630 Â Total short-term marketable securities Â Â 66,385 Â Â Â 117 Â Â Â â€” Â Â Â 66,502 Â Total cash equivalents and marketable securities Â $ 94,225 Â Â $ 117 Â Â $ â€” Â Â $ 94,342 Â Â Â December 31, 2023 Â Â Â AmortizedCost Â Â GrossUnrealizedGain Â Â GrossUnrealizedLoss Â Â Fair Value Â Cash equivalents Â Â Â Â Â Â Â Â Â Â Â Â Money market fund Â $ 18,982 Â Â $ â€” Â Â $ â€” Â Â $ 18,982 Â Total cash equivalents Â Â 18,982 Â Â Â â€” Â Â Â â€” Â Â Â 18,982 Â Short-term marketable securities Â Â Â Â Â Â Â Â Â Â Â Â U.S. and foreign corporate debt securities Â Â 17,595 Â Â Â 41 Â Â Â (3) Â Â 17,633 Â U.S. treasury securities Â Â 76,891 Â Â Â 127 Â Â Â â€” Â Â Â 77,018 Â U.S. and foreign commercial paper Â Â 15,728 Â Â Â 27 Â Â Â â€” Â Â Â 15,755 Â Total short-term marketable securities Â Â 110,214 Â Â Â 195 Â Â Â (3) Â Â 110,406 Â Total cash equivalents and marketable securities Â $ 129,196 Â Â $ 195 Â Â $ (3) Â $ 129,388 Â Â There were no realized gains and losses for the three and nine months ended September 30, 2024 and 2023. As of September 30, 2024, there were no investments in an unrealized loss position. The Company did not recognize any credit losses related to its investments and all unrealized gains and losses on available-for-sale securities are recorded in accumulated other comprehensive loss on the condensed consolidated balance sheets as of September 30, 2024 and December 31, 2023. Accrued interest receivable was $0.4 million and $0.3 million as of September 30, 2024 and December 31, 2023, respectively, and was recorded in prepaid expenses and other current assets on the condensed consolidated balance sheets. The Company did not write off any accrued interest receivable during the three and nine months ended September 30, 2024 and 2023.The following tables present the fair value of the Companyâ€™s financial assets measured at fair value on a recurring basis (in thousands):Â Â Â September 30, 2024 Â Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Â Fair Value Â Cash equivalents Â Â Â Â Â Â Â Â Â Â Â Â Money market fund Â $ 27,840 Â Â $ â€” Â Â $ â€” Â Â $ 27,840 Â Total cash equivalents Â Â 27,840 Â Â Â â€” Â Â Â â€” Â Â Â 27,840 Â Short-term marketable securities Â Â Â Â Â Â Â Â Â Â Â Â U.S. and foreign corporate debt securities Â Â â€” Â Â Â 16,510 Â Â Â â€” Â Â Â 16,510 Â U.S. treasury securities Â Â â€” Â Â Â 47,362 Â Â Â â€” Â Â Â 47,362 Â U.S. and foreign commercial paper Â Â â€” Â Â Â 2,630 Â Â Â â€” Â Â Â 2,630 Â Total short-term marketable securities Â Â â€” Â Â Â 66,502 Â Â Â â€” Â Â Â 66,502 Â Total assets measured at fair value Â $ 27,840 Â Â $ 66,502 Â Â $ â€” Â Â $ 94,342 Â Â Â December 31, 2023 Â Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Â Fair Value Â Cash equivalents Â Â Â Â Â Â Â Â Â Â Â Â Money market fund Â $ 18,982 Â Â $ â€” Â Â $ â€” Â Â $ 18,982 Â Total cash equivalents Â Â 18,982 Â Â Â â€” Â Â Â â€” Â Â Â 18,982 Â Short-term marketable securities Â Â Â Â Â Â Â Â Â Â Â Â U.S. and foreign corporate debt securities Â Â â€” Â Â Â 17,633 Â Â Â â€” Â Â Â 17,633 Â U.S. treasury securities Â Â â€” Â Â Â 77,018 Â Â Â â€” Â Â Â 77,018 Â U.S. and foreign commercial paper Â Â â€” Â Â Â 15,755 Â Â Â â€” Â Â Â 15,755 Â Total short-term marketable securities Â Â â€” Â Â Â 110,406 Â Â Â â€” Â Â Â 110,406 Â Total assets measured at fair value Â $ 18,982 Â Â $ 110,406 Â Â $ â€” Â Â $ 129,388 Â Â The Company estimates the fair value of its investments in marketable securities by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data, and other observable inputs.There were no transfers between Level 1, Level 2 or Level 3 investments during the periods presented. X - DefinitionFair value measurements and investments in marketable securities. + ReferencesNo definition available. + Details Name: asmb_FairValueMeasurementsAndInvestmentsInMarketableSecuritiesTextBlock Namespace Prefix: asmb_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 18 R13.htm IDEA: XBRL DOCUMENT v3.24.3 Other Accrued Expenses 9 Months Ended Sep. 30, 2024 Payables and Accruals [Abstract] Â Other Accrued Expenses Note 5 â€“ Other Accrued ExpensesOther accrued expenses consist of the following (in thousands): Â Â September 30,2024 Â Â December 31,2023 Â Accrued expenses: Â Â Â Â Â Â Accrued compensation Â $ 4,124 Â Â $ 5,484 Â Accrued professional fees and other Â Â 641 Â Â Â 260 Â Total accrued expenses Â $ 4,765 Â Â $ 5,744 Â X - DefinitionThe entire disclosure for accounts payable and accrued liabilities at the end of the reporting period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 19 R14.htm IDEA: XBRL DOCUMENT v3.24.3 Sale of Common Stock and Warrants 9 Months Ended Sep. 30, 2024 Equity [Abstract] Â Sale of Common Stock and Warrants Note 6 â€“ Sale of Common Stock and WarrantsIn June 2024, the Company entered into a Securities Purchase Agreement with an investor for the issuance and sale of 634,500 shares of the Company's common stock and a warrant to purchase up to 634,500 shares of the Company's common stock in a registered direct offering, pursuant to its shelf registration statement on Form S-3 on file with the SEC. The common stock and warrant were sold at a combined offering price of $15.46 for aggregate gross proceeds to the Company of approximately $9.8 million. The Company also entered into a Securities Purchase Agreement with Gilead for the issuance and sale of 179,500 shares of the Company's common stock and a warrant to purchase up to 179,500 shares of the Company's common stock in a private placement. The common stock and warrant were sold at a combined offering price of $15.46 for aggregate gross proceeds to the Company of approximately $2.8 million. The sale of common stock to Gilead maintains Gilead's ownership of approximately 19.9% of the Company's outstanding voting common stock as of the date of closing pursuant to the terms of Gilead's existing Investor Rights Agreement with the Company entered into in October 2023 and amended in June 2024 (see Note 3). The warrants sold to both parties have an exercise price equal to $17.00 per share, became immediately exercisable on the date of issuance and expire on June 18, 2029. Neither party may exercise any portion of the warrants to the extent it would beneficially own more than the limits defined in the warrant agreements. The exercise price and number of shares of common stock issuable upon the exercise of the warrants are subject to adjustment in the event of any stock dividends and distributions, stock splits, stock combinations or stock reclassifications, as described in the respective warrant agreements. Under certain circumstances, the warrants may be exercised on a â€œcashlessâ€ basis. The warrants were classified as a component of permanent stockholdersâ€™ equity within additional paid-in-capital and were recorded at the issuance date. The warrants are equity classified because they are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, permit the holders to receive a fixed number of common shares upon exercise, are indexed to the Companyâ€™s common stock and meet the equity classification criteria. In addition, such warrants do not provide any guarantee of value or return. There were no warrants exercised during the three and nine months ended September 30, 2024.In August 2020, the Company entered into a sales agreement under which the Company may offer and sell shares of its common stock having an aggregate offering price of up to $100.0 million through â€œat-the-marketâ€ offerings (2020 ATM), pursuant to its shelf registration statement on Form S-3 on file with the SEC. During the three months ended September 30, 2024 and 2023 and during the nine months ended September 30, 2024, the Company did not sell any shares of common stock under the 2020 ATM. During the nine months ended September 30, 2023, the Company sold 261,170 shares of common stock under the 2020 ATM, for which the Company received net proceeds of $4.5 million, after deducting commissions, fees and expenses. X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R15.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation 9 Months Ended Sep. 30, 2024 Share-Based Payment Arrangement [Abstract] Â Stock-Based Compensation Note 7 â€“ Stock-Based CompensationThe following table summarizes the components of total stock-based compensation expense included in the condensed consolidated statements of operations and comprehensive loss (in thousands): Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Research and development Â $ 395 Â Â $ 512 Â Â $ 1,152 Â Â $ 1,747 Â Â General and administrative Â Â 402 Â Â Â 623 Â Â Â 1,217 Â Â Â 2,413 Â Â Total stock-based compensation expense Â $ 797 Â Â $ 1,135 Â Â $ 2,369 Â Â $ 4,160 Â Â As of September 30, 2024, there was $2.9 million of total unrecognized stock-based compensation related to outstanding equity awards, which is expected to be recognized over a weighted average remaining amortization period of 1.6 years.The fair value of stock options granted during the periods indicated was estimated using the Black-Scholes option pricing model, based on the following assumptions: Â Â Three Months Ended September 30, Â Nine Months Ended September 30, Â Â 2024 Â 2023 Â 2024 Â 2023 Exercise price Â $13.24 Â $11.76 Â $12.90Â - $15.06 Â $10.68Â - $18.36 Expected volatility Â 80.8% - 86.2% Â 77.5% - 83.1% Â 79.1% - 86.9% Â 77.5% - 83.1% Risk-free rate Â 4.39% - 4.40% Â 4.23% - 4.24% Â 4.16% - 4.57% Â 3.59% - 4.24% Expected term (years) Â 5.5Â - 7.0 Â 5.5Â - 7.0 Â 5.5Â - 7.5 Â 5.5Â - 7.5 Expected dividend yield Â 0% Â 0% Â 0% Â 0% X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 21 R16.htm IDEA: XBRL DOCUMENT v3.24.3 Collaboration Agreements 9 Months Ended Sep. 30, 2024 Collaboration Agreement [Abstract] Â Collaboration Agreements Note 8 - Collaboration AgreementsGilead AgreementIn October 2023, the Company entered into the Gilead Collaboration Agreement and the Gilead Equity Agreements under which it received total proceeds of $100.0 million. Under the Gilead Collaboration Agreement, Gilead exclusively licensed to the Company its HPI program and NNPI program, while retaining opt-in rights to these programs and has an option to take an exclusive license, on a program-by-program basis, to all of the Companyâ€™s other current and future pipeline programs. During the 12-year collaboration term (subject to payment of certain extension fees) and for a specified period thereafter, Gilead may exercise its opt-in rights, on a program-by-program basis, at one of two timepointsâ€”completion of a certain Phase 1 study or completion of a certain Phase 2 study for the first product within the programâ€”upon payment of an opt-in fee ranging from $45.0 million to $125.0 million per program depending on the type of program and when the option is exercised. If Gilead exercises its opt-in right to any current or future program under the collaboration, the Company is eligible to receive up to $330.0 million in potential regulatory and commercial milestones on that program, in addition to royalties ranging from the high single-digits to high teens, depending on the clinical stage of the program at the time of the opt-in. Following Gileadâ€™s exercise of its option for each of the Companyâ€™s programs, the Company may opt in to cover 40% of the research and development costs in the United States and share 40% of the profits and operating loss in the United States for products within the program in lieu of receiving milestones and royalties for that program in the United States, unless the Company later opts out of the cost/profit share for the program. Prior to Gileadâ€™s potential exercise of its opt-in, the Company will be primarily responsible for all discovery, research and development on its programs and the two Gilead-contributed programs. Following Gileadâ€™s opt-in, Gilead will control the further discovery, research, development, and commercialization on any optioned programs. During the term, Gilead will continue to support the collaboration through extension fees of $75.0 million in each of the third, fifth and seventh years of the collaboration.The Gilead Collaboration Agreement is subject to termination by either party for the other partyâ€™s uncured, material breach or insolvency. Subject to certain limitations, the Company and Gilead both have certain termination for convenience rights, upon sufficient prior written notice, with respect to programs that one party in-licenses from the other (subject to Gileadâ€™s option rights), and with respect to Gilead, for programs it has option rights to (subject to certain time limitations with respect to existing Company programs). Gilead also has a right to terminate the collaborative activities under the Gilead Collaboration Agreement at certain specified points during the collaboration term. Other customary termination rights are further provided in the Gilead Collaboration Agreement.The Company concluded Gilead is a customer and accordingly, the Gilead Collaboration Agreement is within the scope of the revenue from contracts with customers guidance. The Company identified a single combined performance obligation for the discovery, research and development services during the collaboration term (the R&D Services). As of September 30, 2024, the total transaction price of the Gilead Collaboration Agreement was determined to be $90.7 million. The Company will reevaluate the transaction price in each reporting period as uncertain events are resolved or other changes in circumstances occur.The transaction price is reflected as collaboration revenue when realized in the Companyâ€™s condensed consolidated statements of operations. The Company will recognize revenue over time using a cost-based input method over the initial non-cancellable term of three years since this method best reflects the transfer of services to Gilead. In applying a cost-based input method of revenue recognition, the Company uses actual costs incurred relative to estimated total costs to fulfill each performance obligation. The Company recognized collaboration revenue of $6.8 million and $21.2 million during the three and nine months ended September 30, 2024. The transaction price for future collaborative activities was recorded as deferred revenue on the condensed consolidated balance sheet as of September 30, 2024, of which $32.6 million was short-term and $32.5 million was long-term. The reimbursable expenses incurred by the Company during the three months ended September 30, 2024 were insignificant. During the nine months ended September 30, 2024, the Company incurred $0.3 million in reimbursable expenses due to Gilead. The following table presents changes in the Companyâ€™s contract liabilities (in thousands): Â Â Balance atBeginningof Period Â Â Additions Â Â Deductions Â Â Balance atEnd ofPeriod Â Nine Months Ended September 30, 2024 Â Â Â Â

Â Â 4,329,260 Â Net loss per share - basic and diluted Â $ (1.51) Â $ (3.29) Â $ (5.12) Â $ (11.61) Securities excluded from the computation of diluted net loss per share because including them would have been antidilutive are as follows: Â Â September 30, Â Â Â 2024 Â Â 2023 Â Warrants to purchase common stock Â Â 814,000 Â Â Â â€” Â Options to purchase common stock Â Â 937,268 Â Â Â 828,789 Â Common stock subject to purchase under ESPP Â Â 7,513 Â Â Â 6,711 Â Unvested RSUs Â Â 69,217 Â Â Â 90,740 Â Total Â Â 1,827,998 Â Â Â 926,240 Â X - DefinitionOther risks and uncertainties. + ReferencesNo definition available. + Details Name: asmb_OtherRisksAndUncertainties Namespace Prefix: asmb_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionReverse stock split. + ReferencesNo definition available. + Details Name: asmb_ReverseStockSplitPolicyTextBlock Namespace Prefix: asmb_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 + Details Name: us-gaap_EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies (Tables) 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Schedule of Earnings Per Share, Basic and Diluted A reconciliation of the numerators and the denominators of the basic and diluted net loss per common share computations is as follows (in thousands, except for share and per share amounts): Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Numerator: Â Â Â Â Â Â Â Â Â Â Â Â Net loss Â $ (9,613) Â $ (14,420) Â $ (29,842) Â $ (50,266) Denominator: Â Â Â Â Â Â Â Â Â Â Â Â Weighted average common shares outstanding - basic and diluted Â Â 6,351,431 Â Â Â 4,380,444 Â Â Â 5,827,750 Â Â Â 4,329,260 Â Net loss per share - basic and diluted Â $ (1.51) Â $ (3.29) Â $ (5.12) Â $ (11.61) Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Securities excluded from the computation of diluted net loss per share because including them would have been antidilutive are as follows: Â Â September 30, Â Â Â 2024 Â Â 2023 Â Warrants to purchase common stock Â Â 814,000 Â Â Â â€” Â Options to purchase common stock Â Â 937,268 Â Â Â 828,789 Â Common stock subject to purchase under ESPP Â Â 7,513 Â Â Â 6,711 Â Unvested RSUs Â Â 69,217 Â Â Â 90,740 Â Total Â Â 1,827,998 Â Â Â 926,240 Â X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements and Investments in Marketable Securities (Tables) 9 Months Ended Sep. 30, 2024 Investments, Debt and Equity Securities [Abstract] Â Schedule of Investments in Marketable Securities Investments in marketable securities consisted of the following (in thousands): Â Â September 30, 2024 Â Â Â AmortizedCost Â Â GrossUnrealizedGain Â Â GrossUnrealizedLoss Â Â Fair Value Â Cash equivalents Â Â Â Â Â Â Â Â Â Â Money market fund Â $ 27,840 Â Â $ â€” Â Â $ â€” Â Â $ 27,840 Â Total cash equivalents Â Â 27,840 Â Â Â â€” Â Â Â â€” Â Â 27,840 Â Short-term marketable securities Â Â Â Â Â Â Â Â Â Â Â Â U.S. and foreign corporate debt securities Â Â 16,468 Â Â Â 42 Â Â Â â€” Â Â Â 16,510 Â U.S. treasury securities Â Â 47,298 Â Â Â 64 Â Â Â â€” Â Â Â 47,362 Â U.S. and foreign commercial paper Â Â 2,619 Â Â Â 11 Â Â Â â€” Â Â Â 2,630 Â Total short-term marketable securities Â Â 66,385 Â Â Â 117 Â Â Â â€” Â Â Â 66,502 Â Total cash equivalents and marketable securities Â $ 94,225 Â Â $ 117 Â Â $ â€” Â Â $ 94,342 Â Â Â Â December 31, 2023 Â Â Â AmortizedCost Â Â GrossUnrealizedGain Â Â GrossUnrealizedLoss Â Â Fair Value Â Cash equivalents Â Â Â Â Â Â Â Â Â Â Money market fund Â $ 18,982 Â Â $ â€” Â Â $ â€” Â Â $ 18,982 Â Total cash equivalents Â Â 18,982 Â Â Â â€” Â Â Â â€” Â Â 18,982 Â Short-term marketable securities Â Â Â Â Â Â Â Â Â Â Â Â U.S. and foreign corporate debt securities Â Â 17,595 Â Â Â 41 Â Â Â (3) Â Â 17,633 Â U.S. treasury securities Â Â 76,891 Â Â Â 127 Â Â Â â€” Â Â Â 77,018 Â U.S. and foreign commercial paper Â Â 15,728 Â Â Â 27 Â Â Â â€” Â Â Â 15,755 Â Total short-term marketable securities Â Â 110,214 Â Â Â 195 Â Â Â (3) Â Â 110,406 Â Total cash equivalents and marketable securities Â $ 129,196 Â Â $ 195 Â Â $ (3) Â $ 129,388 Â Schedule of Fair Value of Financial Assets The following tables present the fair value of the Companyâ€™s financial assets measured at fair value on a recurring basis (in thousands):Â Â Â September 30, 2024 Â Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Â Fair Value Â Cash equivalents Â Â Â Â Â Â Â Â Â Â Â Â Money market fund Â $ 27,840 Â Â $ â€” Â Â $ â€” Â Â $ 27,840 Â Total cash equivalents Â Â 27,840 Â Â Â â€” Â Â Â â€” Â Â 27,840 Â Short-term marketable securities Â Â Â Â Â Â Â Â Â Â Â Â U.S. and foreign corporate debt securities Â Â â€” Â Â Â 16,510 Â Â Â â€” Â Â Â 16,510 Â U.S. treasury securities Â Â â€” Â Â Â 47,362 Â Â Â â€” Â Â Â 47,362 Â U.S. and foreign commercial paper Â Â â€” Â Â Â 2,630 Â Â Â â€” Â Â Â 2,630 Â Total short-term marketable securities Â Â â€” Â Â Â 66,502 Â Â Â â€” Â Â Â 66,502 Â Total assets measured at fair value Â $ 27,840 Â Â $ 66,502 Â Â $ â€” Â Â $ 94,342 Â Â Â Â December 31, 2023 Â Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Â Fair Value Â Cash equivalents Â Â Â Â Â Â Â Â Â Â Â Â Money market fund Â $ 18,982 Â Â $ â€” Â Â $ â€” Â Â $ 18,982 Â Total cash equivalents Â Â 18,982 Â Â Â â€” Â Â Â â€” Â Â 18,982 Â Short-term marketable securities Â Â Â Â Â Â Â Â Â Â Â Â U.S. and foreign corporate debt securities Â Â â€” Â Â Â 17,633 Â Â Â â€” Â Â Â 17,633 Â U.S. treasury securities Â Â â€” Â Â Â 77,018 Â Â Â â€” Â Â Â 77,018 Â U.S. and foreign commercial paper Â Â â€” Â Â Â 15,755 Â Â Â â€” Â Â Â 15,755 Â Total short-term marketable securities Â Â â€” Â Â Â 110,406 Â Â Â â€” Â Â Â 110,406 Â Total assets measured at fair value Â $ 18,982 Â Â $ 110,406 Â Â $ â€” Â Â $ 129,388 Â Â X - DefinitionTabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Other Accrued Expenses (Tables) 9 Months Ended Sep. 30, 2024 Payables and Accruals [Abstract] Â Schedule of Other Accrued Expenses Other accrued expenses consist of the following (in thousands): Â Â September 30,2024 Â Â December 31,2023 Â Accrued expenses: Â Â Â Â Â Â Accrued compensation Â $ 4,124 Â Â $ 5,484 Â Accrued professional fees and other Â Â 641 Â Â Â 260 Â Total accrued expenses Â $ 4,765 Â Â $ 5,744 Â X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accrued liabilities. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation (Tables) 9 Months Ended Sep. 30, 2024 Share-Based Payment Arrangement [Abstract] Â Schedule of Recognized Stock-Based Compensation Expense The following table summarizes the components of total stock-based compensation expense included in the condensed consolidated statements of operations and comprehensive loss (in thousands): Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Research and development Â $ 395 Â Â $ 512 Â Â $ 1,152 Â Â $ 1,747 Â General and administrative Â Â 402 Â Â Â 623 Â Â Â 1,217 Â Â Â 2,413 Â Â Total stock-based compensation expense Â $ 797 Â Â $ 1,135 Â Â $ 2,369 Â Â $ 4,160 Â Summary of Assumptions Used to Estimate Fair Values of Stock Options Grants The fair value of stock options granted during the periods indicated was estimated using the Black-Scholes option pricing model, based on the following assumptions: Â Â Three Months Ended September 30, Â Nine Months Ended September 30, Â Â 2024 Â 2023 Â 2024 Â 2023 Exercise price Â $13.24 Â $11.76 Â $12.90Â - $15.06 Â $10.68Â - $18.36 Expected volatility Â 80.8% - 86.2% Â 77.5% - 83.1% Â 79.1% - 86.9% Â 77.5% - 83.1% Risk-free rate Â 4.39% - 4.40% Â 4.23% - 4.24% Â 4.16% - 4.57% Â 3.59% - 4.24% Expected term (years) Â 5.5Â - 7.0 Â 5.5Â - 7.0 Â 5.5Â - 7.5 Â 5.5Â - 7.5 Expected dividend yield Â 0% Â 0% Â 0% Â 0% X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Collaboration Agreements (Tables) 9 Months Ended Sep. 30, 2024 Collaboration Agreement [Abstract] Â Schedule of Changes in Contract Liabilities The following table presents changes in the Companyâ€™s contract liabilities (in thousands): Â Â Balance atBeginningof Period Â Â Additions Â Â Deductions Â Â Balance atEnd ofPeriod Â Nine Months Ended September 30, 2024 Â Â Â Â Â Â Â Â Â Â Â Â Contract liabilities: Â Â Â Â Â Â Â Â Â Â Â Â Deferred revenue Â $ 86,294 Â Â $ â€” Â Â $ (21,163) Â $ 65,131 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Schedule of Collaboration Revenue Recognized with the Period Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Collaboration revenue recognized in the period from Â Â Â Â Â Â Â Â Â Â Â Â Amounts included in deferred revenue at the beginning of the period Â $ 6,845 Â Â $ â€” Â Â $ 21,163 Â Â $ â€” Â Performance obligations satisfied in previous period Â $ â€” Â Â $ â€” Â Â $ â€” Â Â $ â€” Â X - DefinitionCollaboration Agreement + ReferencesNo definition available. + Details Name: asmb_CollaborationAgreementAbstract Namespace Prefix: asmb_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionSchedule of Collaboration revenue recognized with the period + ReferencesNo definition available. + Details Name: asmb_ScheduleOfCollaborationRevenueRecognizedWithPeriodTableTextBlock Namespace Prefix: asmb_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 + Details Name: us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Nature of Business - Additional Information (Details) 9 Months Ended Sep. 30, 2024 Product Segment Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â FDA approved products (in products) | Product 0 Operating segments (in segments) | Segment 1 X - DefinitionRepresents the number of approved products. + ReferencesNo definition available. + Details Name: asmb_NumberOfApprovedProducts Namespace Prefix: asmb_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating

decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfOperatingSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration XML 30 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies - Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($) $ / shares in Units, $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Numerator: Â Â Â Â Net loss $ (9,613) $ (14,420) $ (29,842) $ (50,266) Denominator: Â Â Â Â Weighted average common shares outstanding - basic 6,351,431 4,380,444 5,827,750 4,329,260 Weighted average common shares outstanding - diluted 6,351,431 4,380,444 5,827,750 4,329,260 Net loss per share - basic $ (1.51) $ (3.29) $ (5.12) $ (11.61) Net loss per share - diluted $ (1.51) $ (3.29) $ (5.12) $ (11.61) X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetIncomeLossAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing

of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 31 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Antidilutive Securities Excluded from Computation of Earnings Per Share Â Â Antidilutive securities excluded from computation of loss per share 1,827,998 926,240 Warrants to purchase common stock Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share Â Â Antidilutive securities excluded from computation of loss per share 814,000 0 Options to purchase common stock Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share Â Â Antidilutive securities excluded from computation of loss per share 937,268 828,789 Common stock subject to purchase under Employee Stock Purchase Plan Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share Â Â Antidilutive securities excluded from computation of loss per share 7,513 6,711 Unvested RSUs Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share Â Â Antidilutive securities excluded from computation of loss per share 69,217 90,740 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=asmb_CommonStockSubjectToPurchaseUnderEmployeeStockPurchaseProgramMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 32 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies - Additional Information (Details) 1 Months Ended 9 Months Ended Feb. 09, 2024 shares Feb. 08, 2024 shares Jan. 31, 2024 Sep. 30, 2024 shares Dec. 31, 2023 shares Sep. 30, 2023 $ / shares Significant Accounting Policies [Line Items] Â Â Â Â Â Â Reverse stock split description Â Â Â In January 2024, the Company's stockholders approved a reverse stock split of its common stock at a range of ratios between 1-for-7 to 1-for-17, and the Company's board of directors approved the implementation of the reverse stock split at a ratio of 1-for-12 (the Reverse Stock Split). The Reverse Stock Split was effective as of February 9, 2024 and the Company regained compliance with the minimum bid price requirement in February 2024. Â Â Reverse stock split ratio 0.0833 Â 0.0833 Â Â Â Common stock, shares outstanding Â Â Â 6,354,414 5,482,752 Â Common stock shares outstanding due to reverse stock split 5,500,000 65,800,000 Â Â Â Â Number of shares issued in connection with reverse stock split 0 Â Â Â Â Â Â Maximum Â Â Â Â Â Â Significant Accounting Policies [Line Items] Â Â Â Â Â Â Reverse stock split ratio Â Â 0.0588 Â Â Â Closing bid price of stock | $ / shares Â Â Â Â Â $ 1 Minimum Â Â Â Â Â Â Significant Accounting Policies [Line Items] Â Â Â Â Â Â Reverse stock split ratio Â Â 0.1429 Â Â Â Closing bid price of stock | $ / shares Â Â Â Â Â $ 1 X - DefinitionSignificant accounting policies. + ReferencesNo definition available. + Details Name: asmb_SignificantAccountingPoliciesLineItems Namespace Prefix: asmb_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionStock outstanding during period shares reverse stock splits. + ReferencesNo definition available. + Details Name: asmb_StockOutstandingDuringPeriodSharesReverseStockSplits Namespace Prefix: asmb_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPrice of a single share of a number of saleable stocks of a company. + ReferencesNo definition available. + Details Name: us-gaap_SharePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionReduction in the number of shares during the period as a result of a reverse stock split. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details Name: us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionRatio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4 + Details Name: us-gaap_StockholdersEquityNoteStockSplitConversionRatio1 Namespace Prefix: us-gaap_ Data Type: xbrli:pureItemType Balance Type: na Period Type: duration X - DefinitionDescription of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4 + Details Name: us-gaap_StockholdersEquityReverseStockSplit Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 33 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Related Party - Additional Information (Details) $ / shares in Units, $ in Thousands 1 Months Ended 3 Months Ended 9 Months Ended Jun. 30, 2024 USD ($) $ / shares shares Oct. 31, 2023 USD ($) Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Related Party Transaction [Line Items] Â Â Â Â Â Â Revenue recognized Â Â $ 6,845 $ 0 $ 21,163 $ 0 Common Stock | Securities Purchase Agreement Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Number of shares sold | shares 634,500 Â Â Â Â Â Warrant to purchase common stock | Securities Purchase Agreement | Maximum Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Number of shares sold | shares 634,500 Â Â Â Â Â Â Common Stock and Warrant | Securities Purchase Agreement Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Sale of stock, price per share | $ / shares $ 15.46 Â Â Â Â Â Gross proceeds from issuance of common stock and warrant $ 9,800 Â Â Â Â Â Gilead Sciences, Inc. | Common Stock | Securities Purchase Agreement | Private Placement Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Number of shares sold | shares 179,500 Â Â Â Â Â Â Gilead Sciences, Inc. | Warrant to purchase common stock | Securities Purchase Agreement | Maximum | Private Placement Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Number of shares sold | shares 179,500 Â Â Â Â Â Â Gilead Sciences, Inc. | Common Stock and Warrant | Securities Purchase Agreement | Private Placement Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Sale of stock, price per share | $ / shares $ 15.46 Â Â Â Â Â Gross proceeds from issuance of common stock and warrant $ 2,800 Â Â Â Â Â Gilead Sciences, Inc. | Gilead Equity Agreements | Common Stock Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Number of trading days volume considered for weighted average price to calculate premium Â 30 days Â Â Â Â Purchase price per share of additional shares description Â The purchase price per share for additional shares purchased by Gilead under the Gilead Common Stock Purchase Agreement will be equal to the lesser of (1) a 35% premium to the 30 trading day volume weighted average price immediately prior to the date of purchase or (2) a 35% premium to the 30 trading day volume weighted average price immediately prior to delivery by Gilead of notice of the anticipated closing date. Â Â Â Â Percentage of outstanding voting of common stock held 19.9 Â 19.9 Â 19.9 Â Maximum percentage of then-outstanding voting capital stock Â 29.90% Â Â Â Â Gilead Sciences, Inc. | Gilead Equity Agreements | Common Stock | Maximum Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Percentage of premium to weighted average price immediately prior to date of purchase Â 35.00% Â Â Â Â Â Percentage of premium to weighted average price immediately prior to delivery of notice of closing date Â 35.00% Â Â Â Â Gilead Sciences, Inc. | Gillead Collaboration Agreement Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Proceeds received in collaboration agreement Â $ 100,000 Â Â Â Â Revenue recognized Â Â $ 6,800 Â $ 21,200 Â X - DefinitionMaximum percentage of then-outstanding voting capital stock. + ReferencesNo definition available. + Details Name: asmb_MaximumPercentageOfThenOutstandingVotingCapitalStock Namespace Prefix: asmb_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionNumber of trading days volume considered for weighted average price to calculate premium. + ReferencesNo definition available. + Details Name: asmb_NumberOfTradingDaysVolumeConsideredForWeightedAveragePriceToCalculatePremium Namespace Prefix: asmb_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionPercentage of Outstanding Voting of Common Stock Held + ReferencesNo definition available. + Details Name: asmb_PercentageOfOutstandingVotingOfCommonStockHeld Namespace Prefix: asmb_ Data Type: xbrli:pureItemType Balance Type: na Period Type: instant X - DefinitionPercentage of premium to weighted average price immediately prior to date of purchase. + ReferencesNo definition available. + Details Name: asmb_PercentageOfPremiumToWeightedAveragePriceImmediatelyPriorToDateOfPurchase Namespace Prefix: asmb_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of premium to weighted average price immediately prior to delivery of notice of closing date. + ReferencesNo definition available. + Details Name: asmb_PercentageOfPremiumToWeightedAveragePriceImmediatelyPriorToDeliveryOfNoticeOfClosingDate Namespace Prefix: asmb_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPurchase price per share of additional shares description. + ReferencesNo definition available. + Details Name: asmb_PurchasePricePerShareOfAdditionalSharesDescription Namespace Prefix: asmb_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCash received from collaborators during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_ProceedsFromCollaborators Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_RelatedPartyTransactionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10

-Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=asmb_SecuritiesPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=asmb_CommonStockAndWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=asmb_GileadSciencesIncorporatedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=asmb_EquityAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=asmb_OptionLicenseAndCollaborationAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 34 R29.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements and Investments in Marketable Securities - Schedule of Investments in Marketable Securities (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Investments in marketable securities: Â Â Amortized Cost $ 27,840 $ 18,982 Investment, Type [Extensible Enumeration] Cash Equivalents [Member] Cash Equivalents [Member] Gross Unrealized Gain $ 0 $ 0 Gross Unrealized Loss 0 0 Fair Value 27,840 18,982 Amortized Cost, Short-term marketable securities 66,385 110,214 Gross Unrealized Gain, Short-term marketable securities 117 195 Gross Unrealized Loss, Short-term marketable securities 0 (3) Fair Value, Short-term marketable securities 66,502 110,406 Amortized Cost 94,225 129,196 Gross Unrealized Gain 117 195 Gross Unrealized Loss 0 (3) Fair Value 94,342 129,388 Money market fund Â Â Investments in marketable securities: Â Â Amortized Cost 27,840 18,982 Gross Unrealized Gain 0 0 Gross Unrealized Loss 0 0 Fair Value 27,840 18,982 U.S and foreign corporate debt securities Â Â Investments in marketable securities: Â Â Amortized Cost, Short-term marketable securities 16,468 17,595 Gross Unrealized Gain, Short-term marketable securities 42 41 Gross Unrealized Loss, Short-term marketable securities 0 (3) Fair Value, Short-term marketable securities 16,510 17,633 U.S. treasury securities Â Â Investments in marketable securities: Â Â Amortized Cost, Short-term marketable securities 47,298 76,891 Gross Unrealized Gain, Short-term marketable securities 64 127 Gross Unrealized Loss, Short-term marketable securities 0 0 Fair Value, Short-term marketable securities 47,362 77,018 U.S. and foreign commercial paper Â Â Investments in marketable securities: Â Â Amortized Cost, Short-term marketable securities 2,619 15,728 Gross Unrealized Gain, Short-term marketable securities 11 27 Gross Unrealized Loss, Short-term marketable securities 0 0 Fair Value, Short-term marketable securities $ 2,630 $ 15,755 X - DefinitionAvailable for sale debt securities accumulated gross unrealized gain before tax current. + ReferencesNo definition available. + Details Name: asmb_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent Namespace Prefix: asmb_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAvailable for sale debt securities accumulated gross unrealized loss before tax current. + ReferencesNo definition available. + Details Name: asmb_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent Namespace Prefix: asmb_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCash and cash equivalent gross unrealized gain. + ReferencesNo definition available. + Details Name: asmb_CashAndCashEquivalentGrossUnrealizedGain Namespace Prefix: asmb_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCash and cash equivalent gross unrealized loss. + ReferencesNo definition available. + Details Name: asmb_CashAndCashEquivalentGrossUnrealizedLoss Namespace Prefix: asmb_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCash equivalents at carrying value and available for sale debt securities amortized cost. + ReferencesNo definition available. + Details Name: asmb_CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesAmortizedCost Namespace Prefix: asmb_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCash equivalents at carrying value and available for sale debt securities estimated fair value. + ReferencesNo definition available. + Details Name: asmb_CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesEstimatedFairValue Namespace Prefix: asmb_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCash equivalents at carrying value and available for sale debt securities gross unrealized gain. + ReferencesNo definition available. + Details Name: asmb_CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesGrossUnrealizedGain Namespace Prefix: asmb_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCash equivalents at carrying value and available for sale debt securities gross unrealized loss. + ReferencesNo definition available. + Details Name: asmb_CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesGrossUnrealizedLoss Namespace Prefix: asmb_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionIndicates type of investment. Includes, but is not limited to, common stock, preferred stock, convertible security, fixed income security, government security, option purchased, warrant, loan participation and assignment, commercial paper, bankers' acceptance, certificates of deposit, short-term security, repurchase agreement, and other investment company. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.12-12A(Column A)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)(Footnote 7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.12-12A(Column C)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2 + Details Name: us-gaap_InvestmentTypeExtensibleEnumeration Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3 + Details Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 35 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements and Investments in Marketable Securities - Additional Information (Details) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Investments in marketable securities: Â Â Â Â Â Realized gains and losses $ 0 $ 0 $ 0 $ 0 Â Number of investments in unrealized loss position 0 Â 0 Â Â Accrued interest receivable 400,000 Â 400,000 Â $ 300,000 Fair value assets transfers between level 1, level 2 or level 3 $ 0 Â $ 0 Â $ 0 X - DefinitionAccured Interest Receivable + ReferencesNo definition available. + Details Name: asmb_AccuredInterestReceivable Namespace Prefix: asmb_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value assets between levels transfers amount. + ReferencesNo definition available. + Details Name: asmb_FairValueAssetsBetweenLevelsTransfersAmount Namespace Prefix: asmb_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of realized gain (loss) on investment. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 + Details Name: us-gaap_RealizedInvestmentGainsLosses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial

concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3 + Details Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 36 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements and Investments in Marketable Securities - Schedule of Fair Value of Financial Assets (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Cash equivalents Â Â Cash equivalents $ 27,840 $ 18,982 Short-term marketable securities Â Â Short-term marketable securities 66,502 110,406 U.S. treasury securities Â Â Short-term marketable securities Â Â Short-term marketable securities 47,362 77,018 U.S and foreign corporate debt securities Â Â Short-term marketable securities Â Â Short-term marketable securities 16,510 17,633 Money market fund Â Â Cash equivalents Â Â Cash equivalents 27,840 18,982 Recurring Â Â Cash equivalents Â Â Cash equivalents 27,840 18,982 Short-term marketable securities Â Â Short-term marketable securities 66,502 110,406 Long-term marketable securities Â Â Total assets measured at fair value 94,342 129,388 Recurring | U.S and foreign corporate debt securities Â Â Short-term marketable securities Â Â Short-term marketable securities 16,510 17,633 Recurring | U.S. treasury securities Â Â Short-term marketable securities Â Â Short-term marketable securities 47,362 77,018 Recurring | U.S. and foreign commercial paper Â Â Short-term marketable securities Â Â Short-term marketable securities 2,630 15,755 Recurring | Money market fund Â Â Cash equivalents Â Â Cash equivalents 27,840 18,982 Recurring | Level 1 Â Â Cash equivalents Â Â Cash equivalents 27,840 18,982 Short-term marketable securities Â Â Short-term marketable securities 0 0 Long-term marketable securities Â Â Total assets measured at fair value 27,840 18,982 Recurring | Level 1 | U.S and foreign corporate debt securities Â Â Short-term marketable securities Â Â Short-term marketable securities 0 0 Recurring | Level 1 | U.S. treasury securities Â Â Short-term marketable securities Â Â Short-term marketable securities 0 0 Recurring | Level 1 | U.S. and foreign commercial paper Â Â Short-term marketable securities Â Â Short-term marketable securities 0 0 Recurring | Level 1 | Money market fund Â Â Cash equivalents Â Â Cash equivalents 27,840 18,982 Recurring | Level 2 Â Â Cash equivalents Â Â Cash equivalents 0 0 Short-term marketable securities Â Â Short-term marketable securities 66,502 110,406 Long-term marketable securities Â Â Total assets measured at fair value 66,502 110,406 Recurring | Level 2 | U.S and foreign corporate debt securities Â Â Short-term marketable securities Â Â Short-term marketable securities 16,510 17,633 Recurring | Level 2 | U.S. treasury securities Â Â Short-term marketable securities Â Â Short-term marketable securities 47,362 77,018 Recurring | Level 2 | U.S. and foreign commercial paper Â Â Short-term marketable securities Â Â Short-term marketable securities 2,630 15,755 Recurring | Level 2 | Money market fund Â Â Cash equivalents Â Â Cash equivalents 0 0 Recurring | Level 3 Â Â Cash equivalents Â Â Cash equivalents 0 0 Short-term marketable securities Â Â Short-term marketable securities 0 0 Long-term marketable securities Â Â Total assets measured at fair value 0 0 Recurring | Level 3 | U.S and foreign corporate debt securities Â Â Short-term marketable securities Â Â Short-term marketable securities 0 0 Recurring | Level 3 | U.S. treasury securities Â Â Short-term marketable securities Â Â Short-term marketable securities 0 0 Recurring | Level 3 | U.S. and foreign commercial paper Â Â Short-term marketable securities Â Â Short-term marketable securities 0 0 Recurring | Level 3 | Money market fund Â Â Cash equivalents Â Â Cash equivalents $ 0 $ 0 X - DefinitionCash equivalents at fair value. + ReferencesNo definition available. + Details Name: asmb_CashEquivalentsAtFairValueAbstract Namespace Prefix: asmb_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value portion of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_AssetsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LongTermInvestmentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ShortTermInvestmentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=asmb_USAndForeignCommercialPaperMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 37 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Other Accrued Expenses - Schedule of Other Accrued Expenses (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Accrued expenses: Â Â Accrued compensation $ 4,124 $ 5,484 Accrued professional fees and other 641 260 Total accrued expenses $ 4,765 $ 5,744 X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AccruedLiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedProfessionalFeesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 38 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Sale of Common Stock and Warrants- Additional Information (Details) $ / shares in Units, $ in Millions 1 Months Ended 3 Months Ended 9 Months Ended Jun. 30, 2024 USD ($) $ / shares shares Sep. 30, 2024 shares Sep. 30, 2023 shares Sep. 30, 2024 shares Sep. 30, 2023 USD ($) shares Aug. 31, 2020 USD ($) Subsidiary Sale Of Stock [Line Items] Â Â Â Â Â Â Â Warrants exercised during period shares Â 0 Â 0 Â Â Gilead Sciences, Inc. | Gilead Equity Agreements | Common Stock Â Â Â Â Â Â Â Subsidiary Sale Of Stock [Line Items] Â Â Â Â Â Â Â Percentage of outstanding voting of common stock held 19.9 19.9 Â 19.9 Â Â Securities Purchase Agreement Â Â Â Â Â Â Â Subsidiary Sale Of Stock [Line Items] Â Â Â Â Â Â Â Warrants exercise price | $ / shares $ 17 Â Â Â Â Â Â Warrants expiration date Jun. 18, 2029 Â Â Â Â Â Â Securities Purchase Agreement | Common Stock Â Â Â Â Â Â Â Subsidiary Sale Of Stock [Line Items] Â Â Â Â Â Â Â Number of shares sold 634,500 Â Â Â Â Â Â Securities Purchase Agreement | Common Stock and Warrant Â Â Â Â Â Â Â Subsidiary Sale Of Stock [Line Items] Â Â Â Â Â Â Â Sale of stock, price per share | $ / shares $ 15.46 Â Â Â Â Â Â Gross proceeds from issuance of common stock and warrant | $ $ 9.8 Â Â Â Â Â Â Maximum | Securities Purchase Agreement | Warrant to purchase common stock Â Â Â Â Â Â Â Subsidiary Sale Of Stock [Line Items] Â Â Â Â Â Â Â Number of shares sold 634,500 Â Â Â Â Â Â 2020 At the Market Offerings Â Â Â Â Â Â Â Subsidiary Sale Of Stock [Line Items] Â Â Â Â Â Â Â Initial public offering value of shares authorized | $ Â Â Â Â Â Â $ 100.0 Number of shares sold Â 0 0 0 261,170 Â Net proceeds from the issuance of common stock through equity plans | $ Â Â Â Â Â $ 4.5 Â Private Placement | Securities Purchase Agreement | Gilead Sciences, Inc. | Common Stock Â Â Â Â Â Â Â Subsidiary Sale Of Stock [Line Items] Â Â Â Â Â Â Â Number of shares sold 179,500 Â Â Â Â Â Â Private Placement | Securities Purchase Agreement | Gilead Sciences, Inc. | Common Stock and Warrant Â Â Â Â Â Â Â Subsidiary Sale Of Stock [Line Items] Â Â Â Â Â Â Â Sale of stock, price per share | $ / shares $ 15.46 Â Â Â Â Â Â Gross proceeds from issuance of common stock and warrant | $ $ 2.8 Â Â Â Â Â Â Private Placement | Maximum | Securities Purchase Agreement | Gilead Sciences, Inc. | Warrant to purchase common stock Â Â Â Â Â Â Â Subsidiary Sale Of Stock [Line Items] Â Â Â Â Â Â Â Number of shares sold 179,500 Â Â Â Â Â Â X - DefinitionThe value of common stock authorized to issue in a public offering. + ReferencesNo definition available. + Details Name: asmb_InitialPublicOfferingValueOfSharesAuthorized Namespace Prefix: asmb_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPercentage of Outstanding Voting of Common Stock Held + ReferencesNo definition available. + Details Name: asmb_PercentageOfOutstandingVotingOfCommonStockHeld Namespace Prefix: asmb_ Data Type: xbrli:pureItemType Balance Type: na Period Type: instant X - DefinitionWarrant excercise price + ReferencesNo definition available. + Details Name: asmb_WarrantExcercisePrice Namespace Prefix: asmb_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWarrants exercised during period shares. + ReferencesNo definition available. + Details Name: asmb_WarrantsExercisedDuringPeriodShares Namespace Prefix: asmb_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe cash inflow associated with the amount received from entity's first offering of stock to the public. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceInitialPublicOffering Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SubsidiarySaleOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExpiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingMaturityDate Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=asmb_GileadSciencesIncorporatedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=asmb_EquityAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=asmb_SecuritiesPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=asmb_CommonStockAndWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=asmb_TwoThousandAndTwentyAtTheMarketOfferingsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 39 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation - Schedule of Recognized Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Compensation expense: Â Â Â Â Stock-based compensation expense $ 797 $ 1,135 $ 2,369 $ 4,160 Research and Development Â Â Â Â Compensation expense: Â Â Â Â Stock-based compensation expense 395 512 1,152 1,747 General and Administrative Â Â Â Â Compensation expense: Â Â Â Â Stock-based compensation expense $ 402 $ 623 $ 1,217 $ 2,413 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 40 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation - Additional Information (Details) $ in Millions 9 Months Ended Sep. 30, 2024 USD ($) Share-Based Payment Arrangement [Abstract] Â Unrecognized stock-based compensation expense $ 2.9 Unrecognized stock-based compensation expense expected to be recognized, term 1 year 7 months 6 days X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 41 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation - Summary of Assumptions Used to Estimate Fair Values of Stock Options Grants (Details) - $ / shares 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Share-based Compensation Arrangement by Share-based Payment Award Â Â Â Â Exercise price $ 13.24 $ 11.76 Â Â Expected dividend yield 0.00% 0.00% 0.00% 0.00% Minimum Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award Â Â Â Â Exercise price Â Â $ 12.9 $ 10.68 Expected volatility 80.80% 77.50% 79.10% 77.50% Risk-free rate 4.39% 4.23% 4.16% 3.59% Expected term (years) 5 years 6 months 5 years 6 months 5 years 6 months 5 years 6 months Maximum Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award Â Â Â Â Exercise price Â Â $ 15.06 $ 18.36 Expected volatility 86.20% 83.10% 86.90% 83.10% Risk-free rate 4.40% 4.24% 4.57% 4.24% Expected term (years) 7 years 7 years 7 years 6 months 7 years 6 months X - DefinitionShare based compensation arrangement fair value assumptions exercise price. + ReferencesNo definition available. + Details Name: asmb_ShareBasedCompensationArrangementFairValueAssumptionsExercisePrice Namespace Prefix: asmb_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 42 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Collaboration Agreements - Additional Information (Details) $ in Thousands 1 Months Ended 3 Months Ended 9 Months Ended Oct. 31, 2023 USD ($) Timepoint Program Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Dec. 31, 2023 USD ($) Research And Development Arrangement Contract To Perform For Others [Line Items] Â Â Â Â Â Â Research and development expense Â $ 13,515 $ 10,824 $ 41,653 $ 37,894 Â Collaboration revenue Â 6,845 0 21,163 0 Â Contract liability/deferred revenue Â 65,131 Â 65,131 Â $ 86,294 Deferred revenue - short-term Â 32,620 Â 32,620 Â 30,915 Deferred revenue - long-term Â 32,511 Â 32,511 Â $ 55,379 Arbutus Biopharma Agreement Â Â Â Â Â Â Research And Development Arrangement Contract To Perform For Others [Line Items] Â Â Â Â Â Â Research and development expense Â 300 $ 100 300 $ 1,200 Â Option, License and Collaboration Agreement | Gilead Sciences, Inc. Â Â Â Â Â Â Research And Development Arrangement Contract To Perform For Others [Line Items] Â Â Â Â Â Â Collaboration revenue Â 6,800 Â 21,200 Â Â Proceeds received in collaboration agreement $ 100,000 Â Â Â Â Â Collaboration term 12 years Â Â Â Â Â Number of timepoints of program | Timepoint 2 Â Â Â Â Â Percentage cover of research and development costs 40.00% Â Â Â Â Â Percentage share of profits and operating loss for products 40.00% Â Â Â Â Â Number of fellow-contributed programs | Program 2 Â Â Â Â Â Contract liability/deferred revenue Â 90,700 Â $ 90,700 Â Â Initial non-cancellable term Â Â Â 3 years Â Â Deferred revenue - short-term Â 32,600 Â $ 32,600 Â Â Deferred revenue - long-term Â $ 32,500 Â 32,500 Â Â Reimbursable expenses Â Â Â $ 300 Â Â Option, License and Collaboration Agreement | Minimum | Gilead Sciences, Inc. Â Â Â Â Â Â Research And Development Arrangement Contract To Perform For Others [Line Items] Â Â Â Â Â Â Threshold payment of opt-in fee $ 45,000 Â Â Â Â Â Option, License and Collaboration Agreement | Maximum | Gilead Sciences, Inc. Â Â Â Â Â Â Research And Development Arrangement Contract To Perform For Others [Line Items] Â Â Â Â Â Â Threshold payment of opt-in fee 125,000 Â Â Â Â Â Option, License and Collaboration Agreement | Regulatory and Commercial Milestones | Maximum | Gilead Sciences, Inc. Â Â Â Â Â Â Research And Development Arrangement Contract To Perform For Others [Line Items] Â Â Â Â Â Â Potential milestone payments 330,000 Â Â Â Â Â Seventh Year of Collaboration Agreement | Gilead Sciences, Inc. Â Â Â Â Â Â Research And Development Arrangement Contract To Perform For Others [Line Items] Â Â Â Â Â Â Potential proceeds from collaboration extension fees $ 75,000 Â Â Â Â Â Â X - DefinitionCollaboration term. + ReferencesNo definition available. + Details Name: asmb_CollaborationTerm Namespace Prefix: asmb_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionInitial non-cancellable term. + ReferencesNo definition available. + Details Name: asmb_InitialNonCancellableTerm Namespace Prefix: asmb_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of fellow-contributed programs. + ReferencesNo definition available. + Details Name: asmb_NumberOfFellowContributedPrograms Namespace Prefix: asmb_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionNumber of timepoints of program.

+ ReferencesNo definition available. + Details Name: asmb_NumberOfTimepointsOfProgram Namespace Prefix: asmb_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionPercentage cover of research and development costs. + ReferencesNo definition available. + Details Name: asmb_PercentageCoverOfResearchAndDevelopmentCosts Namespace Prefix: asmb_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage share of profits and operating loss for products. + ReferencesNo definition available. + Details Name: asmb_PercentageShareOfProfitsAndOperatingLossForProducts Namespace Prefix: asmb_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPotential Milestone Payments. + ReferencesNo definition available. + Details Name: asmb_PotentialMilestonePayments Namespace Prefix: asmb_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPotential proceeds from collaboration extension fees. + ReferencesNo definition available. + Details Name: asmb_PotentialProceedsFromCollaborationExtensionFees Namespace Prefix: asmb_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionReimbursable expenses. + ReferencesNo definition available. + Details Name: asmb_ReimbursableExpenses Namespace Prefix: asmb_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThreshold payment of opt-in fee. + ReferencesNo definition available. + Details Name: asmb_ThresholdPaymentOfOptInFee Namespace Prefix: asmb_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCash received from collaborators during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_ProceedsFromCollaborators Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1 + Details Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_TypeOfArrangementAxis=asmb_ArbutusBiopharmaAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=asmb_OptionLicenseAndCollaborationAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=asmb_GileadSciencesIncorporatedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=asmb_RegulatoryAndCommercialMilestonesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=asmb_SeventhYearOfCollaborationMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 43 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Collaboration Agreements - Schedule of Changes in Contract Liabilities (Details) $ in Thousands 9 Months Ended Sep. 30, 2024 USD ($) Collaboration Agreement [Abstract] Â Balance at Beginning of Period $ 86,294 Additions 0 Deductions (21,163) Balance at End of Period $ 65,131 X - DefinitionCollaboration Agreement + ReferencesNo definition available. + Details Name: asmb_CollaborationAgreementAbstract Namespace Prefix: asmb_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionContract with customer liability in additions. + ReferencesNo definition available. + Details Name: asmb_ContractWithCustomerLiabilityInAdditions Namespace Prefix: asmb_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionContract with customer liability in deduction. + ReferencesNo definition available. + Details Name: asmb_ContractWithCustomerLiabilityInDeduction Namespace Prefix: asmb_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 44 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Collaboration Agreements - Schedule of Collaboration Revenue Recognized with the Period (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Collaboration revenue recognized in the period from Â Â Â Â Amounts included in deferred revenue at the beginning of the period $ 6,845 $ 0 $ 21,163 $ 0 Performance obligations satisfied in previous period $ 0 $ 0 $ 0 $ 0 X - DefinitionCollaboration revenue recognized in period [Abstract] + ReferencesNo definition available. + Details Name: asmb_CollaborationRevenueRecognizedInPeriodAbstract Namespace Prefix: asmb_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details Name: us-gaap_ContractWithCustomerLiabilityRevenueRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12A -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12A + Details Name: us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 45 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Milestones and Research Agreements - Additional Information (Details) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Milestones And Research Agreements [Abstract] Â Â Â Â Potential milestone payment $ 800,000 Â $ 800,000 Â Milestone payment, diligence maintenance fees $ 0 $ 0 $ 100,000 $ 100,000 X - DefinitionMilestone payment, diligence maintenance fees. + ReferencesNo definition available. + Details Name: asmb_MilestonePaymentDiligenceMaintenanceFees Namespace Prefix: asmb_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionMilestones and Research Agreements + ReferencesNo definition available. + Details Name: asmb_MilestonesAndResearchAgreementsAbstract Namespace Prefix: asmb_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionMinimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 46 R41.htm IDEA: XBRL DOCUMENT v3.24.3 Subsequent Event - Additional Information (Details) - Gilead Sciences, Inc. $ in Millions 1 Months Ended Oct. 31, 2023 USD ($) Timepoint Program Option, License and Collaboration Agreement Â Subsequent Event [Line Items] Â Collaboration term 12 years Proceeds received in collaboration agreement $ 100.0 Number of timepoints of program | Timepoint 2 Percentage cover of research and development costs 40.00% Percentage share of profits and operating loss for products 40.00% Number of fellow-contributed programs | Program 2 Option, License and Collaboration Agreement | Minimum Â Subsequent Event [Line Items] Â Threshold payment of opt-in fee $ 45.0 Option, License and Collaboration Agreement | Maximum Â Subsequent Event [Line Items] Â Threshold payment of opt-in fee 125.0 Option, License and Collaboration Agreement | Regulatory and Commercial Milestones | Maximum Â Subsequent Event [Line Items] Â Potential milestone payments 330.0 Seventh Year of Collaboration Agreement Â Subsequent Event [Line Items] Â Potential proceeds from collaboration extension fees $ 75.0 X - DefinitionCollaboration term. + ReferencesNo definition available. + Details Name: asmb_CollaborationTerm Namespace Prefix: asmb_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of fellow-contributed programs. + ReferencesNo definition available. + Details Name: asmb_NumberOfFellowContributedPrograms Namespace Prefix: asmb_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionNumber of timepoints of program. + ReferencesNo definition available. + Details Name: asmb_NumberOfTimepointsOfProgram Namespace Prefix: asmb_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionPercentage cover of research and development costs. + ReferencesNo definition available. + Details Name: asmb_PercentageCoverOfResearchAndDevelopmentCosts Namespace Prefix: asmb_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage share of profits and operating loss for products. + ReferencesNo definition available. + Details Name: asmb_PercentageShareOfProfitsAndOperatingLossForProducts Namespace Prefix: asmb_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPotential Milestone Payments. + ReferencesNo definition available. + Details Name: asmb_PotentialMilestonePayments Namespace Prefix: asmb_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPotential proceeds from collaboration extension fees. + ReferencesNo definition available. + Details Name: asmb_PotentialProceedsFromCollaborationExtensionFees Namespace Prefix: asmb_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThreshold payment of opt-in fee. + ReferencesNo definition available. + Details Name: asmb_ThresholdPaymentOfOptInFee Namespace Prefix: asmb_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCash received from collaborators during the current period. + ReferencesReference 1:

http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_ProceedsFromCollaborators Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDetail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. +- ReferenceReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_CounterpartyNameAxis=asmb_GileadSciencesIncorporatedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=asmb_OptionLicenseAndCollaborationAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=asmb_RegulatoryAndCommercialMilestonesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=asmb_SeventhYearOfCollaborationAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 47 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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{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`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|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vAVVDC)='UX,[QZ,Z'UO.'? M6JU]Y[,@3^;6/M*7[_+7AP,R2!4J"R1!XL^3>JN*@@3!C()YF&CDC9V/]?2 MOV;?XO76%K_H/"Q?'TX/1:X6LBK"G5U_JY(_9R0OLX7G?\4ZXIV,#T56 M^6!7:3,L6&D3_\I/*0Z=#=/!G@VCM&'$=D=%;.4[&>3U*V?7PM%J2*,/["KO MAG':4%)FP>&MQKYP/8O)$'8A9OK!Z(7.I GB)LML98(V#^+6%CK3RK\Z#=!' MNTZS)/M-E#W:(._M2_&<!-6'KQWN0JW]Q_"CL;8T>UL6]&+PJ& U& MDQ?DC1OGQRQOO$?>#B_%OV_F/CB Y3^['([P)KOE40%=~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{<0'K;[3^7A(WJ@YVJ=6X!*['A64DG M%#4?\0[)6,V5$^,AMX]Q3ZR7.EL*H(/T!W0 G$3D7&G2NM"+/@Z^+6> ML'1*L3$&V\4JMKNH<4;5&%6FCL6Z** U,C3*5IL<14FC":6T5H"B0O#4IQ+# M"\4@Z8/O"'CC%SF^[=A$8.VB"LA0#1!BC)CMOKCWK.>]#WK%Q$!NQ2K90.3_ M2M"TB,A#A^>8YQ88"2Z^4_3DYTH^PK'&'LZLQXQ8)GI9RH UX+?% L%@XQRG M!$;(5=,#L$VP9,FZ5RY$W"[HYD M_H6MM]5+F'3J29F*O,LL;&N(*K,^[@MC]4@7'_K,C*)ZNSA&GB'NFH"BE- M$%;8DG$!BQVBXV/9;?-$:T16\TQ$1^0B]0D-S<%#*:6KUKW /&%=;2%W M)(F1(H(X=:/]?L4@TLY,5IXRN

$66)V00LN=Y@%@%VBVRZDO?H1B)^ZT?XPO M[S%D.&(_ACY7*P>AL'/RHL$"!L!'5?=60C@&*T-Y?++4W@LJ^%1LKF)E@+^* M!9XYVP0S1MB6EHJ-
2)H@Q/,:P0"AU9Z2A!$D3@T]D2TERI7)A4<5."<<.P?A M /9Z;A!?BF%_"#*Q4A"W;=N MI(4$B,8#)CX,;]Q^YQ60A[X,XG_VG*(UU,8!B(.CX7$]7.AH-DX1>E6M.N:G7LC16'
FJ2E5BAI1E)@H(NGY)I;CC&\S4JQX M@-X^*>RT:SH<'&'7'1^/CHYOCS322AZ6S3SKG5 ZG@Q/4)% &R",,J5GU:*:@ MLT=!JN'7Z"S.&CW"N /$=D3H=QV/A?
2YY^@ZI#\7ZYK<5XHH,XL'/THP+6ME M[AFB-Z!!CJ+X"D6)WPD+V5A+\13GXCUN7]\3,<[-/R0&2(S *5*MB7_WT:JE M+7)%Y5Q2#C@+#I5BM-IS*<*>SZ!.1 (6!#'RV$@UYAO*&Y[
H9,+2D[\.+P0 MO8;?6B/FEL*._3E2$MM58PJ?\Y!13M7&-+'+Q&0.EM&JI'0DCFC]#G8YCKG? MQ3N4J-@E*>Z2!ZJOU=QQ)"_K07K3E01!E?]Y$%)M-^))-@:SYDZAM8/Y/#W=
M876/J!0"X+)&LZ5,PD);!<8R@YIPMGU9\0)4JV#I)XQCR,Y("P/,N4C"M)J M<=IX2=,?440YX%DFK[*4<%,QW6-S;6]',!/\^5E_BH@6!0$B+8(]9_VSK:?[
M,YPC#\2JG8&^U0O'E];IWU3>"=E&>.KS*^KM2195X^JF;Q\L[(U7.C3([A:U MQC!1AS$>78S:.]+NKXT2O+G:"O1'(]PJ(M7*%5U1R5ME3$RS<4'A(7R3&IYINEAH([YZ=-DMHTK[ZMZ-
SQ.!60N&$M5LL\ M'AWH*D?J_(1@)DL=9 &,HJU]3]G_=7=[AU9 M 7E_P/*4E#@9-=-JZP@6\SVHZ0E,+6ELBKV,;>L> M$6IUW1#'X@RZ>?> ?TSBL:2#)B8EX40JZ(S:>##[7K5P^%$>8
M9\Z'8W',GX>3WF0T2%]&E[WI9)2^G UZH_S<7SPK@W7U<$OVS77M\[.0TCJ9[JV"NXN5(]VI'K;H]D/O# M!I0YV0U*K0@[VY.[@%^DP74=R04_,EM)O\BK@Q_K"\M]&R[' M%XCH5$Q'T][%]/+@;?
>EK^:_ICF@V4UCA!/O9[>W9J)W!]"<]RZ&PX-[L!AW MN+0O91?G2!/&^\M!]V(R./C9HK.((>?Q\G(J+D?GO=%D(;]_'C:^=48\'$@ MW\;Y&L&$^ -R\[3Y^?
TF_NK<+H^_W>-4^*#A>Z$6V#KH7YP="A=_#X]?@BWY M-^BY#1AL^>-22;A'" _!^8<%)Z0LI:/Y3PO5_ 5!+ P04 " !@V=99,ES M<+4% "4#@ &0 'AL+W=ON)D_:ATP>(7(F8@
0#@)+=K^]9@&+D6++; MSO1%(L&]G=VS^`!T9=TG7S 'NBE-Y<]2I0CU\'09P67R@]LS16^S*TK5<"K M6PQ[5CE4:DTP\EH=#0LE:YZYZ=Q["9!,K/VD[R\S<3-5(&]Z(PF(#6=!+"\C\+?
DE&R.&$,;GUF:OY:DQX;U<_'I=Y9S?U1\BE"Z> MR3J>R\F#!J^Y'M!TU*?):'+P@+UIAV\:[4W_"3[ZX%3E5>2#IS\N9CXXO/VY M#7[#=K+3*C7+-@9.\G[M$^A8'IIRUI5M\158 =1705+"I*U
MY*]//^L,SDSXT?+U.)>UY MA!T)= Q *(UO%/(-.HBIG07IK[WD[/6BBGP+*TNY!A@H^+6%%F/DYK,7GF96 MN5Q0=))]5,K2"CPD5=<65(R$I%,AK27-&2IH%X9EHC'ST[ZAZ,1^4(AA;*R#6"6
MJ.XCU1(5]JY-JGUVG]3R^M_(G,*#!7+X7'M<$H2 W2U?&(4,@/,'ODG4< M,=?>&L2&UA.Y&3@K59ES)#3,9]QVQ>'@X(CZ,3,[^^=NK441E73V1F-K%9*! MPU]8/:
+XZW@^*IZNQJZY4:9F@F^^';@&=13N# M$_IV5R%Q\H6'*A>N+&UDW&8N!_3QZR%\#VOGO%284[*E/<*I(*V2X5".K\+- M C6"8]].$"4G1ETVI<0\>3!ZK%7?/PI!2M>%DP9!#4PQFC0%
[H6X%L^%W"V\ M+=O1PT> %:8#S5B:$I;;TAOV..,(H+WQ/K!.#P$/!Y]2 W K,QT1&!@!Y M]B5E\(XF:">O>$%+HJOKR/',6) QQJRP\" /1D !D !X M;"]W;W)K&ULW5E;
<]LV%G[WK\"HG4X[0TLB=7=L MSSA.;S/-;K9VVX>=?8!(2$1,$@P 6E%_ 7X'(*G*EAP[31]V'Q*1(,[]X)SO MP.<;I>],*H1E' .L;!>]U-KR;# P<2IR;OJ]% 6^K)3.N<6K7@],J05/'%&>
M#:+A<#K(N2QZE^=N[9V^/%>5S60AWFEFJCSG>OM:9&ISTOM[S<*O%D:I@6JPN>E?AV>LQ[7<;?I=B8SK/C"Q9*G5' M+S\G%[TA*20R$5OBP/%*5YEA$CJ/&AYMEK11)A]
[GA_H.S';8LN1'7*OM# M)C:]Z,U[+!$K7F7V5[7Y2=3V3(A?K#+C_F<;OW M_L"E9K_SK!+LK>"FT@(>MX;Q(F$_%_?"6/\N"_:6ZSMA^3(3[$;$E996"G,^ ML-""><
WB6N)K+S$Z(G'!WJK"IH9]7R0BV:0$+V-\ M6 8=M-3\EA<]"6C-#WHG?YS5?A=/CJ"0O&K07CI[C_+4%]6N(_E!5LS+[Y M:AZ%X2OV5Q5@MZE@,==Z*XLUX[FJ:+=:88[%F;'@I>E5A\E M#JY@-
A50:$5:W3NMZ" GK"I1%SY4T+UAPDHM8V'Z[%IHBY)&,D',KE5>\F+K M[)N],FPE"U[$DF

9IP0IE6>YM3ABW7:%4A%#(H*$FLZ"#1(8M*^L(M\4'IQ!,U%MN47IXR),$_J^KU3,(S"5,HNJG2]M0*G;."6^@2H.S&*>/&N3! M-8R]"(@5\":[;*J% M.,W$ON MD/9(7,[8+TZ9\
(S]\Q%YXY:JX,E[U%M86F>$3P7*4=\ZZA2!$##A8)N LXWU! M_5I0=,;^M<>#* S,R;C>2Q@?7P0_D8B#S;84.UGLWKKJ.D=X'QA'S5R3%66R QHMMPB7:S%'H@L5)/_SE0J=!2#ENQPNF]2A; X
MY_O<3P1E'$H#CI:A5"#SZ3=7BJ#-QHOCL[08^*E*W3:J MDZL<@4"")^Q'K8RI_]5SI/K![7N!'U3;)M K2H$Z&L6S8+Y>(@'5YJB5WM/ M_N/)K;*(W*?269,VVYO?
FNAF5T$.6G_R6 _^F[[(${0#V*> .C=RB*I50T^PX M*IP&X^F@+)44X#Q;SZA2^(_'S*E)'R9%3?1%DV(63!83 M-@[9MVS$OJ/WZ6AT/"5FTV"^"%D8[2(SFP7##C]G*P(HT40+J;TM*#D\
S]^F@^I_:*6KH1#DR@;/', M)<0:<,0SSI 3=5.AJN/ZK?M0H/2BUCIT+0A=L\=UQVVD7.NS*P>I#FP)B&]' M![E?#7F!)M/J1=JP4AGI*^EX[^3Y> ':GY'VB,O$*BZYV@7\/,I7']J^ ,EA?[1;>9&\ .Q-
*1R$R;!VT12NCZ! M^267.XSG-M7. 5J£!LGA;?LRQ^PCQ287-H@+#;F5RP7^A"^22GL\^1=R_'8? MFA)?P$(!9MBA);*8X.'(_D39,#9N], .TP0EM8ZJFEF52XZV.K47^.X"Q(>IS0F[N9! M
@[=4:^Y6P USC;3CM==>3X(9]7!M-4^$Z]*D M[%*K.Z$"'3 ,)+G;A;:1&IZ+[LB["PG,-Z:B#NSA4GWI'K"E*.*4'+"WV;7P M+45Y4%]*8TF]Y??IK[P@M 4$Z02[N8"/9L'G5;_Z-Z@_P"+PJS"K(0&.V$W
M0A3-Q4K0%B>8TM2G;MYU6CF.FU1)VX1%TCJTXSGH7&GCJ*[=Q3V-W%5A_>UV MN]K^;>#*7XGOMOL_++SE>DV@,1,KD [[LTF/:7]9[U^L*MT%.9+,JMP]IG"U MT+0!WU<*$:M?2$#
[%Y/+_P)02P,$% @ 8-G61\UN\'@ N@4 !D M !X;"]W;W)K&ULE91-;]LP#(;O_16$.Q0;$-0? M<=(L30PD;8?MT"UH]W$8=E!L.C8J2YXD-^V_'R4[7K:E 7!>)(I\]-(,.=M* M]: +1 -/%=I2[A7&U%/?
UVF!%=/GLD9!-[E4%3-T5!M?UPI9YH(J[D=!,/8K M5@HOF3G;2B4SVI1A>"EPIT$U5,?6\1"ZW(_F2[U2 M=/)[2E96*0I!2C,Y]XBG"YCZ^\3?RLP4I(TVLNJ"24%5BG9E3]UWV N8!"\$1%U Y'2W#SF5
MU\RP9*;D%I3U)IK=N%1=-(DKA2W*O5%T6U*<23Z9 A4LTE0UF,'-$Q5;HY[Y MAMC6PT\[SK+E1"]PWL*M%*;0<",RS/Z,]TE3+RS:"5M&1X'W6)_#,!A %$3Q M$=ZP3W3H>,,7>"OVS-8<-3"1M?
DRKN'[8JV-HK_&CT,IM\3X,-&VRU37+,6Y M1_V@43VBEYR=AN/@\HC>N-<;'Z/_1V&.<@ZK_"@-P@C.3B=1&%["X;/U6H-FYJV,0;8=K6ZJW]8%JT_?C;O9UJMTQM M2J&!8TZAP?G%R
/53HKV8&3MNG,M#?6ZVQ8T7%%9![K/)=6J.]@'^G&=_)0 M2P,$% @ 8-G6&ULS5C;(7(E(M2((!0,G^^YY=D)3D6RZ3AS[8(DA@.="]+BGPX&8T.AH4V9>_L1.Z]<6F-4[XN"NVNGE)NUZ>]
<:^]\=8LL\ WAFIJ>]$0.BG)+ %C1^5O2,\IP- M <;GQF:OVY(7;E^WUG\3W^'+7'MZ9O,/)@W9:>^HIU):Z#H/;^WZ#VK\V6=[MB&IP;IP=J%S4G:AGMFB $D7P2:?E"Y3]4$[
MI\0@3X8!V_#D8=*8?!I-3NXP>:Q>V3)D7KTH4TIWUP\!K\,X:3$^G=QK\(*] M@9J.^FHRFLSNL3?M?)Z*O>D=]EY\KDVX4O^BWMF#G\8'HR?W>]QU &?W6?^-H-QO\K4-I [4@Y^.)N/Q$_7%
M'=3+4OU9ER2<]U7(B.=6NKQ25 9RE"I3!JNTNJ"D=B88\NI-[9(,):+.EXX(MI1N0S2TQ>$9+9*>B(6#/>U[I,2';U#9R#Z:R_/QHIGVFPRG>V-O[5JR3" M]1U/!$<0ES^%%A-
;.U;FWWQ'PW^&P3N^/]?CP^,?%^IN,2:Q!X8JY MJG)4,2/_O\5D<< MJ'*'I9T2H,L*\L)3!/+X2%K;L1JHUP0"L ?CND)(KS:(F(W*.E&:)@2=3PWE M=!F81
,>;0TOYU32PB1&YP"'9%"%Q;8ATQ%;;@I6,IQA))--N6T4J=L$Q4<" MKU'#?I1UP;$ FDW=[58:>\ULU%?#1V?EN@N:RZN>?V3599E@/^+P(SG1X*^5 M*.M"B(CF4[,R*<+O!4W*2FSF-
3/D^\T47^7PL1W%J6U!EC7W(72Y)I[ZIT MLU@S+3Z!N0TQ<+ B.43>RM%[I*%3"3DN0I48E]0%EU)"OK_K*H=UOJ$BY430 MTIHGHR>)]EE.WLL0G1I'3N.OI;!H48L9ZX%6% DD-QPA3PLM
W$Q0\Y#":3[M'S[AM.8#$!<;:V&:&G8;F5YID^Z9L!W:>FV7L[FTS:Y4) M2>JH:T/Q2,!%T!?R3>2I(3Y.3HAS1\92]HNGK9D8@U]J;2YT>!%:O&2W:;1 M1/.63EGPV]P6
;OIK9#6$%6C!WS(:Z./$JF3;!%A@KT#*XQ*;IEK?D92?&N M=%X3UY"C4+O8H@!5LJ6T&SN;+$]KZ9/2&S($/TH;I >R).\+40A!X/+KW.,I=TF*4]52ENO,)+N-A8M0>G>327F^)6(NP!QQ[>
7^1*&M\M:65P_90W7^ M[M6C'W[F?'X] %_@79CI&NU6^+XF:&HW2JE).2U"9%HD_/:6$>/%2ULB=H!_MQ=;3W9VEWT\.QOWQX>CK-^U+O=],FZ:*X0R%S6E.3GVSP7X7<]3M FD)P4KK
MI#M%035C>UD0^?8D0*4G/[CMK7&X]5I?D%O*QPM.S+H,\0V_N]M]'SF/GP4V MT^/'E5?:+?EHF-,"2T>#P_V>CL_\ 4$L#!!0 (UG?<43U4P0 ,) 9 >&PO=V]R M:W-
H965TVVT/G1X@U,9LSTEBCD?a[$P>.':[ZIC?TP6U%;(,W:'[?7BG2 M1@>4BC?8:BY;+4=B>!Q?Q^3*S_L[A#XŸ[?22#K60EY9U5/E?S(+()H<#26 L&
MPPXO40@+1&E\ZS&#PY0V\%A^1/_%U4ZUK)C&2RG^Y)6IY\$D@ K7K!/F6NY_MP[Z>W.*54FCW#WOOFZ4!E?TVLNF#*8.&MWYD]_TZ' 5,HE<"DCX@<7G[B5R6 M/S/#%C,E]Z"L-
Z%9P97JHBDYWMJFW!A%5DYQ9G%C9'EWMJ2Z*KB4#?5:,[M< MLY$A=.LS*GNDI4=*7D&:PA?9FEK#I[;"ZGG\B+(ZI)8\IK9,3@+>X#:$-!I" M$B79";ST4&KJ\-
+7\&JFL"_UBCT0LPQ<*,7:#3KYKXN5-HIH\O=+Q7OL[&5L MNW7.]9:5.]H;VA4.PP6[][$X^CCBSW+?^.&@R92_*7+2VRN&5QWAZ
M;V4$WI:B(WJ0T(,065KOWFHI>,4,*=K0T#QBTPFD'(P&UGI@A;4]&'8(0FH- M[QV<[#39]8?SP6VM$)_Q$8A-!+E"Y2CUE=;EA'U@*6=YE\)!&EQ37YDJ:Y=$ MA3LZT+:..&\AG>;TG\
<) #VW^WC&^AF!9^KM3.G S3\93&;$B,@PNW:L\+MF4,[9(KA#W3 M-B:I66UE:8+?.FX>@.V9JO00 M]C6GQ>+:95WV_BN$HQGDCM)CL'=G)^F,=+H*R,?>)Q:3-5(9_MW/2SS@LK+9
MQN$8'J@;.O1495S!CHD.K='E3:SQE-G0#K?85:<-S^)\(^>D> M51NY+%(XG_LLD3,<$T;=F)ZFE7-C^ M3:)P C^1TV0<)B0419A[/0UCJT_=X.S3?]H'UUS?G:UMO41THGF83ITY"[.(
MA"RD(KQ.R5H]'O=Z7I"0AOGTR/Z4HD'5P'O7]0^0TYQG4(31"U+^)#U%5WS' MZ:BIX(&CJ,!F'=VJ#-J->SMHV@E=:_P%>_AZ>)Y<^%OŸR=V_;;XP MM>'$18%K"HW"(@] ^?
>"5XSOP+C9CCTCR;)L)\[-,W;2;O/0U).DW8>= M?0!)4,*&)!@ M*+]]?N=_!F2;;;V7VQ91(XE^_QO7M0+*B^]E4;FW MAROOZUYL:7^-,N3UQMEEU-7AU1M^ M=FNOWIC&%
[I2MU:XIBREW=RHPJS?'IX>M@\^Z>7*TX.3JS>U7*K/RO)%WUK\ M==)1R72I*J=-):S*WQY>G[ZZ.:?S?. /K=9N\%F0)HDQ7^F/#]G;PSD)I J5 M>J(@\>M.O5-%080@QK=(\
[!C21>'GUOJ/[/NT"613KTSQ3]TYE=O#R\/1:9R MV13^DUG_HJ(^%T0O-87CGV(=SIY='(JT<=Z4\3(D*'45?LOO$8?!A&'!<@=&+.5[Z>75&VO6PM)I4*,/K"K?AG"(Z(-\]A9O->[Y*VA3R,18R1A=
M+ZU2@-R[-R<>U.G,21HIW01*BSV47HI?3>573OQ492H;WS^!5)UHBU:TF\6# M!#^K>B;.YA.QF" .'Z!WUJEZQO3. IRJXI_7B?,6[O&O74H'FN>[:5+(O'*U M3-7;0\2$4_9.'5[]^,/I_GK!R0^[R0^?
XCZGS+.@Y1VR_G1>"4NQ53LXR^ MK@L$^@"K#Y7X+?4F49:LD"B&,2\;+0M36I$IE3IA M)IMI*PD2DW83NBR+@@ 9B/WC#Y>+TQ>O@1,>6B05:UOT\8W%N+H6I"='+-
MQ/O&DOQ$YG0QW2B)BR,$8>I2'+DF^3?R*S&NY8:M"N:IL@0 %/ Q?>=*N>/ MTEBHX&J5ZEP#XEI9;=@/4%-R4.TL4DJXU'=E4PW$"/H1F(]B(2$*5"(LUL 4 ME:0V\$S'<"Q>IP"G4*P*CLA.YEN8
SH+YYML(PRI_=#!13Q(:A%8N;;.DU19 M UC6VJ]PE%Y$Z2+WI@:Y 6+!_J0=M U5D"/[>FA&N?7_2>34C#V1?#1X"P M<\E,H5QG['J!K]_4#,+09]1O%8ZPIG$" ,(FJ;F#>
<[GXF\M%7H(JX9DI M)$)3LWNFQH%W=./?*^T1M9^]]"JD+[>2,/N0$OCG)"Z]1?=(AH=NA7%[J) ^ M,6+&=;MR).4_1J5B<-0=)G ;V>V,H;$P.+RB30
ML'+::RP7EQW238:B3>Y%J_Y/J":4RZM-=/"12(-"1"5G6P1=-9P\7%/7QOKM ME(,GUC0(W'$Y"FW#BXMQAAG&%1S19A.D]-P'C!T408LKJ!RZWC\&O&;BR^-] M#[+>H&Z25KH*9Q)4/,U
UM+ZQJ]8_EEGDJ9"\E60KR2W)2=+;)#>0A%G"LB: M;F;B<\^J+5V%+K5GCO=R!"D9A4_$ZT)LG%[:RAHSH6Q @L-+JJKR5S77)/G M.M6D:LV1L;;: WI1&8]&9L(QSL[=M@ZMHW+
<4M4.ZNMJ&CL?UV?F@,6P\]CV M59X86:3CW\W.88KDS;U!.X(<.K%1O?I\)!7!P;E\0&.6QS4=^TX[[78MFR. M9RW$LG F=']]46U!5O=]"X;@"59SDFN>V-Y2V6E%'O1YTQNW_$P0+@=)B
U=]JTN7XRU-H 36($T6E&EJ M+)7;8C-YBN)Z5$J0E6K55SKX+9(&NQ1G,=E6GHZG$\M&9Q*^/984&B+E,(HR M]@>4SA)=A5Z6UR04$29!8],'"_%]2NJFT0PN_XAQQ!$]__2C+.O7[\?G> >>
M=W5X +)F87"'OI6382N* $T[8!Z!= U7S51P@S 1S H^R64::+ M,\T*_9OB]B+5-FU*M& 5H6A2),D@U [&CM9*M!]2S&R,<^LEW"PCLZ)6]-%J54?@6@PLD50:FŸW:A,-4S&!G6B.4+-
%.N<:XEDZ"A M:A%QO;%R:HKRWC.[]#FC=8"LZV+SB\AYIU/4][EDW@]2>W,_A2%);[/@MIF"A0)04?(X MC^SVR406#$S8^%5#!B8O1B<)4RVFH M(U\XY>HR::QC;U3?ZU#3.Q.C[QDZPQ:LCZ
IULJ2\SL-BZ+UD%1?!HWC4RQR M;S!M)7LFYK.S88.X6Y,L]*!M7)#*>==+>S[+>S?*!(-DM2>5<$%"=R$3702; M'_%ATSC [8Y?'=Q$(Z*\7\>!UHGWBD8H_MB_/_A(R@]7LSN4/WBW@^FK@_?W
M/>N9N'P^6;P\QX>XR,"G(\3$Y/3YF3BF@+F8G)Z='GQALSW]1&I#MBLM&(4 MW:>#=SOC=!#([=P8R@>5)X/KTC15R":AP<"9K8")LWFBEKH*:[M\2 A:32[/ M+T9*1Y6[1P>W.W,.0@6_'?
<+M+\ 1PTK]I1[B@]]NK:8U'#M1IL:(V@IQRO9 MZV:)MH5 FF_W\]MWWQE;MR@>;;T^`N]Q<;S=:WSA*6-?=\ MR0."'H>U0\6+ M,4D;E\R49#9,_ U&]VG*?"=4)M'WRT05W8ZM6ZUX%H';Z[HP-
K043N;*HZD* M'%/S%;Z%02/,O<@%2)P6MV(*W73CG=5UU[W)=L%WIQ*-W(HKXNB/FT^8'ZYO MIB\6+P,Q435IH8P[\L?H!/%,%F;)?F1=S.F2<8"<#(&U]"+2D'W@A&##(/'PQ7W ZA#?.
<05L4^9^"51M:O&BCX M^\$SU-<>,%IE?$.-IB:G)DYN!K4*T:82W0: M/30.[@47 & >)R@J>9EMEA@I"8X>@EFO3ZB#XPU)]*^0^-'9W',GU5B%YJ(PE<@CP#<371A![/"I=&2$:8Q$ZDJ:T$_
MOYRNE?]*HC[UZ$(]QUI('S/Q*0H>>\RP6T$31G)S(TT--;D5CSK;LH5N>M " M$Q:QB(2V;<^8$O'X/S7'[_]J6S7.?H/*\)@B<1LTK/7D3A5U2+&" "=,W3*N MJG=@25]>Q.\
*AD:^BI%.'6IY9[).;;@ST^E;]6H[<- ;)NGJ?8_Z ?_NE'. M]AKE3SI;9Z/3>RWYL".?##(!53SE"0Y${N^K#T9?*M>*KOD_QT@;X:YPA?L MW=/NWQ.NP[?R_?'POPV_2HO6 EVQRG$5_+%85BAM'JX4_-
W](GQWI3\<85. M4EDZ@/>Y,;[]@QAT_[1Q]5]02P,$% @ 8-G625*UDIA! 5 H !D M !X;"]W;W)K&ULG59M;]LV$/XK!W4H-L#U>Y,T M30S8V8H$6(8@+]V'81]HZ2P1H4B5I.+XW_>Z./)ZL
MC;UW%;.GQUII=YI5WC?'@X'+*ZZ%ZYN&-?ZLC*V%Q]"6]=8%D4TJM5@/!P> M#&HA=38[B7-7=G9B6J^DYBM+KJUK83<+5F9]FHVRIXEK658^3 QF)XTH^8;] M77-
E,1IL40I9LW2;:+*\.LWFH^/%-*R/"[Y*7KN=;PI*EL;MT]KI049YZ[RI.V,P]*5.; '8Q6'%KA&X,QA' MWLE19/F[\)V9LV:;%@-M/ 1I49KD),Z).7&6_R5L/.S2ZD83cO[$KJ@:W8L M;%
[1O+3,"+YW)P,//'U(.\P%PES_KF)[HTVE>._M %%R_M!^W)3E^(KD8 MOPEXPTV?)L,>C8?CZ1MXDZWH2<2;_%ST?+]H^F>^=-ZB9O[=IS_!3_?#AWUT M[!J1\VF&C>+8/G V>_]N===#\
;YZ9;\]"WT_YFQMS'_,I[I$WV@GX/3^>+K MGGF4K:_H0A=2:$%W&EO-.NDW="-USH0,>JZ7;)'"T:1'OF(Z,W4C](;6PE$C M+-9Z
Z_$C[EJ'0#H3YEC^_.ET)X+G;0)KT(^KW+=&@YI;S2AMER@U\V\98 M$0^&7R_NKF_/?J.5-36M*SRD)Y5<%R1<@P/$D5GMDG[_[F@\.ORB03T+-#++>F+2N0HX=ZUC'*P8]%JC<#0HXK
U$^=&'^/E* M^#CN-/9>,.K%].)"T!2:&+\\3MD!QL.-54EA\A^ @].^_3%*#3M(%+"O.!< MQEX,G$*Z'&>\#,)7K047^R+#P E;6K,-U@%VOKCX<#XYG/RP^3U;=+64O=<+
MBWBUXMB_:=Y8J6(CB/&%D*A&FZ0@E,BST**-_@,RZI 1XM28.#2FW6.DZRV! M-]X3>IF["]H00[&.GHJ5I'XK?9WWI4%!!PH:I^Y/&83<)0K[>L5@1]/7;,MX MGW&4AUV;PO/R=-^Z%+:4VJ$.5C
=]@\ 9F33'28-O&GBO0'\ M<0N)GQ6N?6S# OQ?&72-;A <;"^2L^]02P,$% @ 8-G66+:(/2-# MA"(!D !X;"]W;W)K&ULK5K;)4JQ525?+.T;BT+ M?'4/YSYW2J:\:9V=CP:#B _UU.;XY@4_NW,W+VQ99-
JH.R=\N5Y+]_Q*97;S M\GAX7#VXUP^K@AZUT M,6.]P$&OY1A;RYH6S&^%H-:31 M!S:5=T,Y;2@H\\+AK<:^XF8>@B'L4LSU@9]+G4A3B-LDL:4IM'D0=S;3B59> MG%2?
3E^<%SB:!)PG\9A7X9C1GF.NQ(_6%"LOWII4I=0[SZ%RK?>HTOO5Z*# MN:5]-I3S.Y(MBDD(,Q+R;\@1ORR M4DB6Q*YS:9[)(:619:H+E8K$(GS&AT\>?DHE/5YJ(TVB928\9"CD;.&%-DE6
MIDH445Q)#W$6?7\=A MI4]'QV)<+KU,M'=S>%[=9AMV%K ZVK34P[+^WV52$+G&=1_4$8YF67/|%[E45=:_]ZP,G,ZB[UTNU8.J2A.WO?O?G??'M[>W= MJ0 %'[_H=4L_;0(U,\?!/WGT
$DY7%@6K0U 7$9_X1F1F1@.SG[FU?=EINC; M8$BGWJN',@NBYF?_KJ(U?_NZ+[XWH!7#GB97?/7%;#2_!J:YMI@=8_7_6U. MM<$I7JX542XP*GUPJS$E=K>.^0/A#+ (1$-NRE!)DM(YBHQ,?
P/!AH5& 5^> MF)"\3&* HHPZ&8) ;PF+3JVHNL\ MS'I?;TJD7XDEJJ6O=<%>;5-?J:-2AK17;5-3"PN+VEK 3*3:)Q!=8A=4^5!J M(V(.->Y=85(>$KYU?G
M%"NG%"MCL%VL0T$*)\XI&\.1L:;P6>30"AD:::M-BJ2D(H)"6AV I(+SU,<< MG0;Y(X'V^'PVBXR?->PB<#:95D@0A5 B#%"M/L'"L6T+A33@PS_WK.F3;WVA
MUT0M737B\R2P:T.F;F7%7RT2M@(3!?/ 6L-."-D?8MXR-=K^0CGUOHPNCR: MRCQ2W$H66 ..72X1$%;.,2R@A%S7=0A[5 1GIN5"9TC=*%{)&UI(@$-8Z/1] M>\(I9&?ECKV)T*4*00<.0PZ73$R-
R@T<4!:3HF3^"JA+.&M3#2N!(6?7V&9] MRS/]K8ZN<9@V*^7(FI@_'<'\&\M_>%6GY9'42\XKX3SIB @H3A&4V9UQ 8P?O^)#ZNUS5*)%47!?0$?A0?411 M-="?#&2E?"\:$,)!?BV-
_@#-8U5M=S"QK O89.Q:)RTQJ)NP@-A7>FOD AR" M(N'U(N/&B,)5G;U$3V-=I2%718FV)H X5L3]=@4GTLY$EIXBN 46:!V10LN= MYB:D"S2[Z72(A"Y]$KHX2'$_074G[K5_#.+?
HU5RQ.&4/%V,]'^("_3!4%5JHGDI4$?S#;M%^KWA*7./P'M9"F MZH R(!9X8-LW1*<$4E,@)Y;T'N#!QZ)N6-0ZS^RS4D@: MXDJ:F)I$M>Y!&OV[C%D%5Z6$N"#2^47
M&EHAPDS@N;/(IYCN!V02'.SA5#CW'07H9EI$PB8 M4,$Z))W(5%$T7*[$#]IS ?@9FKE MZ)0&$XPL/%1P.5FC(P*#DXP5^D"]@.1JNK<17XIA?S"@4H1V MD3JCJLG))+ \'G!!0&/-K=&B1
*@9T)!?/.,E V.#E^N6^K%'8&\L&5!4K$M%!3I(C-09S_DVL,*< MKX6BKWBXV9WB.O6:#0G)^/3D]G0[C&1A[NR33CF4P]G@+0 L"/SX(98 MQ*O4[]%D='OI#PT,^?VHYJC&=GXI-5?36BDI)$H9R
M"C M:V3N&7"VH$&&@@,R18'OA(6LM25YRNS'1KO?V>,QCLT_)9I[C&;14XV* M_!!JY7-4D6LDE,,. (NIF+0VG,J0I]/H$Y\!C(&/W-+3SGF:^8=GL&@LTL*
M3O@XO[2]FF8;]1:6W(S]*4(2RGBM"L_@B"B':JO+ZE(QJH-EM"H>.A(GM+Z# M74Ÿ#[+MXAP(5N@?RN^1&\QNU<.S)JVK(V38E0E"EGP]"RNU:/,E&PUK?]S1Z
M<%F)3SNT[A&C0P!,UFA"*)+0T)8%8ŸE!33C;O4@Z -6RL'0YDG Y07! 6!YD MRN,CPFHQ"1XZZ<\<1#'@'B\MDQAP4S+=8W.E;TLP$_S%M#^#1[., !$709]I M?[KS='^$4\2!6+4UZ#3GPO"5=?
IWE;9ZFX!^?8DL[(V==NT=Q;ZANLV M:O"[16W0TU1N#"..=43O7!UT&<*^991'L$"' 8GH-+4;4_7=1DENGS9>15# MQ&?@:L'O@LFW6+L<8GUJQL!$QN%2WUFQOM5;M6[ZK\B9#=:[A.L-<"
M^(<#&*Q$/@ CG&H_G6Z@UERY35+;ZE4W2:W[-Z<*9\.? M2>B*DF_'",]4F999!;&:DSHM:J:F.M>X"<HQ03H Q8%+W"-<- @?%;2-S2 M%JME&D8JNF:3.CTCF,E<%S([U/W-
ZNYO=K!Q>X?"^ -=PI$?Y^3'KN;OH(SN M*_]/!0NZ=4\ Y")<^S61V[5:?>01&F529V5SK\B1S,O8!Z<:/0=?JE4"0W., M%*(_2!%8$2;YT),)NX30RIM69:X*\1O2
O+^A.81+Z%IJ_OYQ@ZˆHPG=ODTP M\]-@02V'"'_JCB>=YL.*S^MH!Z\^''Y[4 M09_&EIHJKCVBX.O%'H^MT#_C&18N,9U,PI M"2,BV[1NGV_Y!@=S-7J$=DL#C*DXS%6M1:IH;#;A85P6C
G#=H<#JDBLPGTO M@3W./N%/ 4M,C70]?L)!L:6') P:R!<,6JSV 6O1[ZA6^"VW^1W+D ?D<7 MQ/O?'W'OQ/?.]:>C=Y7IUTO?*.^%"=HM2Z&8W*GX>3WF0TB%]&5[W99!2_ M3
>]T<6%.#UZT[CK^NC7W1QN>V:[J3CK<.I%;SP=]B;CH9CTQK-!;S*9B&EO M-KKL74X'] PJC"X&;Z-L[K$L07]Z3"J/.Z/KBKM^\/*D.&P?T$KY@W6(H^^E
MS63;BFGHFO=FP4*%^ZSV;9Q:M\LSEZXM*'.P:Y1<'^V)W=&OTJ'Q#^2" M31V.$V_G=W?BLC<%4"YZE\/AT7NP&!???^_E[+RX0)DP>5X/>Y61P](M%T1-# MCN/5U4Q&PO=V]R:W-H
M965T2Z9ZL4-#.5J]2&9J75]7"EGFC,JB'X?AJ%\R+OSEW*VMU'(N M:U-P@2L5WPGWVB+IOZ]P4+N%WID'Q8>^"XW=]&_G%=LAVLT3]5*?S:H62\1*&Y M%*!PN_"0EM8ZJFF:3-5(9_MW/2SS@LK+9
MQN$8'J@;.O1495S!CHD.K='E3:SQE-G0#K?85:<-S^)\(^>D> M51NY+%(XG_LLD3,<$T;=F)ZFE7-C^ M3:)P C^1TV0<)B0419A[/0UCJT_=X.S3?]H'UUS?G:UMO41THGF83ITY"[.(
MA"RD(KQ.R5H]'O=Z7I"0AOGTR/Z4HD'5P'O7]0^0TYQG4(31"U+^)#U%5WS' MZ:BIX(&CJ,!F'=VJ#-J->SMHV@E=:_P%>_AZ>)Y<^%OŸR=V_;;XP MM>'$18%K"HW"(@] ^?
>"5XSOP+C9CCTCR;)L)\[-,W;2;O/0U).DW8>= M?0!)4,*&)!@ M*+]]?N=_!F2;;;V7VQ91(XE^_QO7M0+*B^]E4;FW MAROOZUYL:7^-,N3UQMEEU-7AU1M^ M=FNOWIC&%
[I2MU:XIBREW=RHPJS?'IX>M@\^Z>7*TX.3JS>U7*K/RO)%WUK\ M==)1R72I*J=-):S*WQY>G[ZZ.:?S?. /K=9N\%F0)HDQ7^F/#]G;PSD)I J5 M>J(@\>M.O5-%080@QK=(\
[!C21>'GUOJ/[/NT"613KTSQ3]TYE=O#R\/1:9R MV13^DUG_HJ(^%T0O-87CGV(=SIY='(JT<=Z4\3(D*'45?LOO$8?!A&'!<@=&+.5[Z>75&VO6PM)I4*,/K"K?AG"(Z(-\]A9O->[Y*VA3R,18R1A=
M+ZU2@-R[-R<>U.G,21HIW01*BSV47HI?3>573OQ492H;WS^!5)UHBU:TF\6# M!#^K>B;.YA.QF" .'Z!WUJEZQO3. IRJXI_7B?,6[O&O74H'FN>[:5+(O'*U M3-7;0\2$4_9.'5[]^,/I_GK!R0^[R0^?
XCZGS+.@Y1VR_G1>"4NQ53LXR^ MK@L$^@"K#Y7X+?4F49:LD"B&,2\;+0M36I$IE3IA M)IMI*PD2DW83NBR+@@ 9B/WC#Y>+TQ>O@1,>6B05:UOT\8W%N+H6I"='+-
MQ/O&DOQ$YG0QW2B)BR,$8>I2'+DF^3?R*S&NY8:M"N:IL@0 %/ Q?>=*N>/ MTEBHX&J5ZEP#XEI9;=@/4%-R4.TL4DJXU'=E4PW$"/H1F(]B(2$*5"(LUL 4 ME:0V\$S'<"Q>IP"G4*P*CLA.YEN8
SH+YYML(PRI_=#!13Q(:A%8N;;.DU19 M UC6VJ]PE%Y$Z2+WI@:Y 6+!_J0=M U5D"/[>FA&N?7_2>34C#V1?#1X"P M<\E,H5QG['J!K]_4#,+09]1O%8ZPIG$" ,(FJ;F#>
<[GXF\M%7H(JX9DI M)$)3LWNFQH%W=./?*^T1M9^]]"JD+[>2,/N0$OCG)"Z]1?=(AH=NA7%[J) ^ M,6+&=;MR).4_1J5B<-0=)G ;V>V,H;$P.+RB30
ML'+::RP7EQW238:B3>Y%J_Y/J":4RZM-=/"12(-"1"5G6P1=-9P\7%/7QOKM ME(,GUC0(W'$Y"FW#BXM

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|>N/&:' MGAWPMA1KD@H9'0@)I_7NK9:"5\Q01QMJFATV74O*P6A@K0=66-O;8H,@I-9P MX>#D6M.\OKSN/=<*\1MM BF+ (.>HG+Q^I4TX,]^S\K.:3&%O]1YIB MP@W=)VR)O' QK**]YE9O]GJ"+$I@2"O$ M_20N(.EG<=I[_F_;^ &*<>'72NW*23\=CJG-^J0^.*.^?*^ ^ +SZ_;5M=_]& MT\&O_/9_L8R,A'MM.%V3"!\95_ "5B36ZDW+JA-\Z[T]49T:?4N3YO9WX+/#& M EMN=Y*QCM+567 M%):S@X25XJ5U:&2%H@]^YZ67Z*$,V&$G_B>)W;^B*CD=L"5DCSE.0YJC-@Z+ MH6V3#:HENZ)H*G$UJWQW']'JZ/X54JBL |TOI#2[CEU@_S:;_0-02P,$% @ M 8-G68)/9G V P T0< !D !X;"]W;W)K&UL ME57;CMLV$'WW5PR4(M@%C)4M7^)X;0.VMT$+-,%B=]L^%'V(@1)%$A")5DEHG M_?H,*5FV"T=M7Z0A.7/FS(6TOU:/FE9AAY+R$J7A2H+&;!ULQ\O=S.E[A=\X M'LR9#"Z26*G/;O%SN@Y&CA *3*Q#8/1[Q3T*X8"(QE\M9M"Y=(;G\A'}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{J"NYHQ 38A3/L,F'=PJR15!C[(HNG^-A*[G6G.]WS]"CA$ILS M&":O($W2$2RT*MJ<8(FE_6'H"/^PK\O0\P^?X;>O+-A*:>9^&IAIS62)CAN8M+)[8=U2A![]8A*>@[Y\L)P0UN;'H8H% :/# EPS7IB&Y3B-;+<9U!N,L1@9.N.R-4 B**^A\|&%^.[.E=XV^R M9!)O#B@:]XK&1Q7=->CJ)DLPX1&#G)WAY!Q\W2!G_)^J5&?Z2A(8MR%4K*;1+?]H/FUGHL;_N85+=,EUR:4#@VD*3LS^XE2+;OWY; MV8&)VCG8^[52M#-<@'X$9W\ 4$L#!!0 (UGY714FFP, *,- 9 M >&PO=V]R:W-H965T)M?:)$ZYUR>RRM^+(Y< M?)<%(0K[]$HFEU:A5#VW;9D5I,)RPFO"X,V.BPHK:(J]+6M!<-Z2]M+V""">R M*TR9E2S:OHU(%KQ1)65D(Y!LJ@]+/OU>DY,>EY5HO'5_HOE"ZPTX6-=Z3+5%/ MJ49 RQY4.?^N&W_D2\O1 R(E MR916P/!W((^D+++40#..O7M,:0FKBZ?.+^L?6.WAYQI(\|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}2%_TK]SYHVOH3^$&TET8?LIW MUY=/6.PIDZ@D.PCE3*90FZ*[$G0-Q>OVS/O,%9R@V\<";E%$: "\|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}4:.]=NF'0FMKY!TT\FZU0^K(0^DT$%I;IT._Z/:V6K]L MC_AGM1^.7?]TAYQ;!:'K7M@?A_[.[6_P7O(MD0IR?XY?NK\1>OVO7L&!T-IL M#XV?.[Y9I0_:(Z%UM;IT"*ZO=W5+ZOTX+R&(|\-3TO]W"QRPK.NWS[Z/L^(MV)AK"XG,)W;U+E&%N 5ZY4CPSCpsc)!]%&\|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

*{#M:%O77]MJ[F!\YH[FKF8\E'6P*K6>Y>LB^@;3558R ME,-23.5<#D0*HW5=6GG&ULK53!;MLP#/T5PBN&%FACQTG;M7,,).V&]5 @:-#M,.R@V$PL M5)8\24F.?? THR7$S(,UI%XN2^!X?*9/91ND74R%:>*V%-*.HLK:YC6-35%@S MTU,-2KI9*%TS2UN]C$VCD94>5(LX39*KN&9<1GGFSZ8ZS}3*'BYQJL&LZIKI M[02%VHRB? K0[>.++RKJ#.,\:ML09VN=FJFD7=RPEKU$:KB1H7(RBG]V@9%^8,3H!+ M>.1"T+')8DMR'&E%325@:^R!++?_$QI='EDNYRF:1'"6?8 M]&"0G$..I$-XGMW#Z>^S2*_:?&5V?C(? &!OA\YQI%G:>]FRQ>'QI\UV8FZ_'^B_%18 MNK4*Y@AOT'.PJ.M#HH^'|\,6FT8KJ,/?=P4EVYI#Q8[WVJI&O?3#PY#,R<.Z2A MP[K3,CZ-0UN^N8?A!LCTDDL# A<$37K71%&'@1$V5C6^2>?*4LM[LZ(9B]HY MT/U"*;O,N -#=U,[_ E!+ P04 "-!@V=9W,*I)GL$ #F& &0 'AL M+W=O?".3[.]$##9&]]B M+,:[''5\9FV%2.]MFZ^V.$:\1U.VZSA#.T8D ML>93/?,$YE.Z$Q%)\!,#?!?'B!T7.**'F06MCX%GLMD*-6#/IRG:X!(FC2#')=?R3DUK%G I8OOY@_Z*5E\]\(HZ7-/;A&(I\)86"/$: M[2+Q3]_X%RA@>);T8CK;W#(91T+K'9GX$- ^!8QS*>VD"JH MA=BK?+F;+,+ENPW(]\$@3L>4@2$(<&O!^.W[2&K>EZ0K[N1_V6[BMA"\X[0'/ M^16XCMLWK&=Y.=PSJ7/;[,$/SUXQAE<$DZ?YO"8^7Y=6{U^^#Z8'),-A@F6 $ M>#V"LMP3.NKAAP-B)H"(V,09T30+9G& MJ1GOO(A_7B1H%.EH.2RT'+9J^4@2$N]BDU:MP&M?S2[)_"[)@H[(*M8?%=8? M_?V!D[I0^LY5[-<,8,+FW-FZ0'=/43M^K.6C9)*BV>A65 MFP1AK7('#8+>8-*@=]D+@9?Y76 6@T]'C!C_,-2^G6< -!0,0.SW^:9WY78* M_W.:*X":*]I7=DY7=]E*.WIM*>3ORVG34*9O?*5O0%5O5!Z<6"? X//1+LM$GJ ME,WOE"WHBJWJO5.C!&_ME-H)KG9%EVP^-#1H@Y[S79HWB(U[WK AR9_:)7AA MO}1>W'.6>G4?NO7Z9I;S8+V\-7#5-S3G^:IZGQHHV-Y!75#3A^8*7&^PF^3J MG;C?)#@8U94^SUC5^M2XP-,]]14E09UGE%5"X]OQHTC_,F1[,^%(K.I73]W MC3',Z_S#E9TEXCLU*T8+0[E'_11=&U\ >^7T##NJT\!4$Y\HL_^ 7A$;,$,2 M#B*\EE/)K:L,?*
I8=]F&PO=V]R:W-H965T#<3\-XZQW M=5%NNY=7%*MDCCC]Y+DZS0-Y=L-3\3+9<_IO6]XB!=+56SH7UVLP@5_Y.KW MU;W4W_I;RBQ.>9;'(B.2SR]
{U\XYUM8Q85=S^_TX/RX/7!/(4YOQ7)/^*9 M6E[VICTRX_-PG:@'\?)W7AW0J.!%(LG+O^2E*COHD6B=*Y%6E?4>1'&V^1^^ M5B=BI\+P4 5:5:!
{%2@]4,&M*KC'5AA6%8;'5AA5%4,'5AA7%<;'5IA4%D4)N&3D&$1 MC.N%Y%P+3>7DA%S/9G&O-4S(7;81?5'F9X^K,$[R7\A/),[(JZ58YV$VRR_Z M2N]/0>U'5>R;36QZ(+9#OHI,+7/B9S,^;ZE_:Z_O?E3?M]<_L]3OZ_X/9GT M_63>4"OP6Z1.B>M\(71 7?+[HT=^_ND7\EU?NBL19XK<2[&08=IVI';P(U]I M* $#]_!+1CO>(QKP? B8O0DP>\/L&('S9-N2:.[O3+X#[PG(*I_F_VZZ/S1X,V_>@Z(7.!U48\[F9R+I]Y[^JO?W'&@[^U20@)\Y P M'PD+D# &@AD"&VX%-K31.X'IUE/WGK7
^*N^TN62IHEG(GTf,]%@,=I)&4T38I(VM2 MS/Y0ZJ@DZ]9,6#%=,[&!C7;.RW@ZW$]$L]!@+PG-$M1QOOM)^)###0,=F)&\" M3<#X@P14+6H2AT[Q$JNWOKZSY%+RF2T=5FC7=
(R;Z1@YKK.7#V1(_ZB0 3(D M&SQ+6ES0KK MFC8DS$/"?"0L0,(8"&9HQ1G4H_W!IP]]JET :0Q*\Z T'TH+H#2&HIE"V[&5 M'/C@QH[L+!RGI9OA\]2-I/1060&D,13/E4=N#SD?
^X*X2#KD3'T <2MYT M9]4V9WEKK]19%U"7$$H+H#2&HIFZJ'U'QVX_K9.G[@D8D[4^WQK7GQ;;>9< M]>WL=AZV53!-4XWN-QA($\^#TGPH+8#2&(IF"J/V-
1V[L:EO,_5@1X4+KN1 MYXU$Y*1.21RU;Z281/$H;O3)I?#?8D@_4(/2O.AM_!*8RB:*9:0G7L'NJ. M1/)E*E'G5;LQCW804"A$K7O0WV8(D(L^)'K44/_6T0&MG!VE%:A["J7Y4%H MI3$4S5SA4SNHU&J<[?0S*W/317!UM?8 M=Z*K.* T'TH+H#2&HIGBJ%U/:G<]?W#RVD[M.E"E3;OR;#!IC%2A07W:M#], M@@;0H Q%,[-
=NZG4[];>9,&*PX1D(CN)PBSBQ<@DX0<')79 MT]KF9>-?#6/V3H L',ZYQ=J5$)I/FV:K_+S5U*9(9685OI:K$G(B5.HDS,N?MH]7F.L;AJ#F_9@_< M61!0+Q1*"Z TAJ*9@JB]4&KW0COV;^%KY_X-N@052O.@-!]*"Z TAJ*9C];5 M+]K{^>M07>@Z5"C-@)!*"V TAB*9@JM=F1=NR/[_V;V_1'=K2P=DC=U8$
MU(CZ%T@(IHC:%HIB)]U]9%KH%]X(MU$BHAWZJ":-9060&D,13/E M4%O9KMW*?BPF*M22_%.W/L4=$> A$'O$SLT,U/2&TGPH+8#2&(IFZJIVQ]WQ MY_=G4(,<2O.@-!]*"Z
TAJ*90JL-^W+?NSU;OSPO,I4CW'A3@KZIZ:YH> MZ[7WR?ZX^2R**!_GPNMV.1+$6#[LL&K_P%02P,$% M @ 8-G64!^D:^2 @ 3 8 !D
!X,"]W;W)K&ULE55K;],P%/TK5IC0)K'ET3;=1AJI#Q!(3*I6!A\0']SD-K'FV,%VY_'O MN7;24%A6P9?&CWO/.??8ODWV4CWJ$L"0IXH+/?%*8^I;W]=9"1755[(&@3L, MJ2If<*H*7]
<*:.Z2*NY'01#[%67"2Q.WME1(K>&,%

http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 8 false false R9.htm 995455 - Disclosure - Nature of Business Sheet http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureNatureOfBusiness Nature of Business Notes 9 false false R10.htm 995465 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 995475 - Disclosure - Related Party Sheet http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRelatedParty Related Party Notes 11 false false R12.htm 995485 - Disclosure - Fair Value Measurements and Investments in Marketable Securities Sheet http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecurities Fair Value Measurements and Investments in Marketable Securities Notes 12 false false R13.htm 995495 - Disclosure - Other Accrued Expenses Sheet http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureOtherAccruedExpenses Other Accrued Expenses Notes 13 false false R14.htm 995515 - Disclosure - Sale of Common Stock and Warrants Sheet http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSaleOfCommonStockAndWarrants Sale of Common Stock and Warrants Notes 14 false false R15.htm 995525 - Disclosure - Stock-Based Compensation Sheet http://www.assemblybio.com/20240930/taxonomy/role/DisclosureStockbasedCompensation Stock-Based Compensation Notes 15 false false R16.htm 995535 - Disclosure - Collaboration Agreements Sheet http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreements Collaboration Agreements Notes 16 false false R17.htm 995545 - Disclosure - Milestones and Research Agreements Sheet http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureMilestonesAndResearchAgreements Milestones and Research Agreements Notes 17 false false R18.htm 995575 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies 18 false false R19.htm 995585 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies 19 false false R20.htm 995595 - Disclosure - Fair Value Measurements and Investments in Marketable Securities (Tables) Sheet http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesTables Fair Value Measurements and Investments in Marketable Securities (Tables) Tables http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecurities 20 false false R21.htm 995605 - Disclosure - Other Accrued Expenses (Tables) Sheet http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureOtherAccruedExpensesTables Other Accrued Expenses (Tables) Tables http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureOtherAccruedExpenses 21 false false R22.htm 995625 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.assemblybio.com/20240930/taxonomy/role/DisclosureStockbasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.assemblybio.com/20240930/taxonomy/role/DisclosureStockbasedCompensation 22 false false R23.htm 995635 - Disclosure - Collaboration Agreements (Tables) Sheet http://www.assemblybio.com/20240930/taxonomy/role/DisclosureCollaborationAgreementsTables Collaboration Agreements (Tables) Tables http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreements 23 false false R24.htm 995645 - Disclosure - Nature of Business - Additional Information (Details) Sheet http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails Nature of Business - Additional Information (Details) Details 24 false false R25.htm 995655 - Disclosure - Summary of Significant Accounting Policies - Schedule of Earnings Per Share, Basic and Diluted (Details) Sheet http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEarningsPerShareBasicAndDilutedDetails Summary of Significant Accounting Policies - Schedule of Earnings Per Share, Basic and Diluted (Details) Details 25 false false R26.htm 995665 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Sheet http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfE Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Details 26 false false R27.htm 995675 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) Sheet http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails Summary of Significant Accounting Policies - Additional Information (Details) Details 27 false false R28.htm 995685 - Disclosure - Related Party - Additional Information (Details) Sheet http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails Related Party - Additional Information (Details) Details 28 false false R29.htm 995695 - Disclosure - Fair Value Measurements and Investments in Marketable Securities - Schedule of Investments in Marketable Securities (Details) Sheet http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfInvestmentsInMarketableSecu Fair Value Measurements and Investments in Marketable Securities - Schedule of Investments in Marketable Securities (Details) Details 29 false false R30.htm 995705 - Disclosure - Fair Value Measurements and Investments in Marketable Securities - Additional Information (Details) Sheet http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesAdditionalInformationDetails Fair Value Measurements and Investments in Marketable Securities - Additional Information (Details) Details 30 false false R31.htm 995715 - Disclosure - Fair Value Measurements and Investments in Marketable Securities - Schedule of Fair Value of Financial Assets (Details) Sheet http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfFairValueOfFinancialAssetsDe Fair Value Measurements and Investments in Marketable Securities - Schedule of Fair Value of Financial Assets (Details) Details 31 false false R32.htm 995725 - Disclosure - Other Accrued Expenses - Schedule of Other Accrued Expenses (Details) Sheet http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureOtherAccruedExpensesScheduleOfOtherAccruedExpensesDetails Other Accrued Expenses - Schedule of Other Accrued Expenses (Details) Details 32 false false R33.htm 995755 - Disclosure - Sale of Common Stock and Warrants- Additional Information (Details) Sheet http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSaleOfCommonStockAndWarrantsAdditionalInformationDetails Sale of Common Stock and Warrants- Additional Information (Details) Details 33 false false R34.htm 995765 - Disclosure - Stock-Based Compensation - Schedule of Recognized Stock-Based Compensation Expense (Details) Sheet http://www.assemblybio.com/20240930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRecognizedStockbasedCompensationExpenseDetails Stock-Based Compensation - Schedule of Recognized Stock-Based Compensation Expense (Details) Details 34 false false R35.htm 995775 - Disclosure - Stock-Based Compensation - Additional Information (Details) Sheet http://www.assemblybio.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails Stock-Based Compensation - Additional Information (Details) Details 35 false false R36.htm 995785 - Disclosure - Stock-Based Compensation - Summary of Assumptions Used to Estimate Fair Values of Stock Options Grants (Details) Sheet http://www.assemblybio.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedToEstimateFairValuesOfStockOptionsGrantsDetails Stock-Based Compensation - Summary of Assumptions Used to Estimate Fair Values of Stock Options Grants (Details) Details 36 false false R37.htm 995795 - Disclosure - Collaboration Agreements - Additional Information (Details) Sheet http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails Collaboration Agreements - Additional Information (Details) Details 37 false false R38.htm 995805 - Disclosure - Collaboration Agreements - Schedule of Changes in Contract Liabilities (Details) Sheet http://www.assemblybio.com/20240930/taxonomy/role/DisclosureCollaborationAgreementsScheduleOfChangesInContractLiabilitiesDetails Collaboration Agreements - Schedule of Changes in Contract Liabilities (Details) Details 38 false false R39.htm 995815 - Disclosure - Collaboration Agreements - Schedule of Collaboration Revenue Recognized with the Period (Details) Sheet http://www.assemblybio.com/20240930/taxonomy/role/DisclosureCollaborationAgreementsScheduleOfCollaborationRevenueRecognizedWithThePeriodDetails Collaboration Agreements - Schedule of Collaboration Revenue Recognized with the Period (Details) Details 39 false false R40.htm 995825 - Disclosure - Milestones and Research Agreements - Additional Information (Details) Sheet http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureMilestonesAndResearchAgreementsAdditionalInformationDetails Milestones and Research Agreements - Additional Information (Details) Details 40 false false R41.htm 995845 - Disclosure - Subsequent Event - Additional Information (Details) Sheet http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails Subsequent Event - Additional Information (Details) Details 41 false false All Reports Book All Reports asmb-20240930.htm asmb-20240930.xsd http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 false false JSON 54 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "asmb-20240930.htm": { "nsprefix": "asmb", "nsuri": "http://www.assemblybio.com/20240930", "dts": { "inline": { "local": ["asmb-20240930.htm"] }, "schema": { "local": ["asmb-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] } }, "keyStandard": 161, "keyCustom": 50, "axisStandard": 14, "axisCustom": 0, "memberStandard": 21, "memberCustom": 11, "hidden": { "total": 21, "http://fasb.org/us-gaap/2024": 17, "http://xbrl.sec.gov/dei/2024": 4 }, "contextCount": 164, "entityCount": 1, "segmentCount": 35, "elementCount": 497, "unitCount": 8, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 498, "http://xbrl.sec.gov/dei/2024": 30, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://www.assemblybio.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_08e00cfd-7db0-4191-8c68-9e50478896d6", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_08e00cfd-7db0-4191-8c68-9e50478896d6", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS", "longName": "100010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C_9cd26644-dd90-4986-b47c-71e567305461", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9cd26644-dd90-4986-b47c-71e567305461", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "longName": "100020 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C_9cd26644-dd90-4986-b47c-71e567305461", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9cd26644-dd90-4986-b47c-71e567305461", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "longName": "100030 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "C_8b25f0a5-81cb-4773-8246-e885b767dedd", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm",

"first": true }, "uniqueAnchor": { "contextRef": "C_8b25f8a5-81cb-4773-8246-e885b767dedd", "name": "us-gaap:GeneralAndAdministrativeExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "unique": true } }, "R5": { "role": "http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY", "longName": "100040 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C_a12cf6e1-81c9-4e0d-a9c8-4f9194d1e9d0", "name": "us-gaap:StockholdersEquity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a12cf6e1-81c9-4e0d-a9c8-4f9194d1e9d0", "name": "us-gaap:StockholdersEquity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "longName": "100050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "C_08e00cfd-7db0-4191-8c68-9e50478896d6", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_08e00cfd-7db0-4191-8c68-9e50478896d6", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true } }, "R7": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "C_8b25f8a5-81cb-4773-8246-e885b767dedd", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": null }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "C_8b25f8a5-81cb-4773-8246-e885b767dedd", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8b25f8a5-81cb-4773-8246-e885b767dedd", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureNatureOfBusiness", "longName": "995455 - Disclosure - Nature of Business", "shortName": "Nature of Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "C_08e00cfd-7db0-4191-8c68-9e50478896d6", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_08e00cfd-7db0-4191-8c68-9e50478896d6", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies", "longName": "995465 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C_08e00cfd-7db0-4191-8c68-9e50478896d6", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_08e00cfd-7db0-4191-8c68-9e50478896d6", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRelatedParty", "longName": "995475 - Disclosure - Related Party", "shortName": "Related Party", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C_08e00cfd-7db0-4191-8c68-9e50478896d6", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_08e00cfd-7db0-4191-8c68-9e50478896d6", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecurities", "longName": "995485 - Disclosure - Fair Value Measurements and Investments in Marketable Securities", "shortName": "Fair Value Measurements and Investments in Marketable Securities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_08e00cfd-7db0-4191-8c68-9e50478896d6", "name": "asmb:FairValueMeasurementsAndInvestmentsInMarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_08e00cfd-7db0-4191-8c68-9e50478896d6", "name": "asmb:FairValueMeasurementsAndInvestmentsInMarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureOtherAccruedExpenses", "longName": "995495 - Disclosure - Other Accrued Expenses", "shortName": "Other Accrued Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C_08e00cfd-7db0-4191-8c68-9e50478896d6", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_08e00cfd-7db0-4191-8c68-9e50478896d6", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSaleOfCommonStockAndWarrants", "longName": "995515 - Disclosure - Sale of Common Stock and Warrants", "shortName": "Sale of Common Stock and Warrants", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_08e00cfd-7db0-4191-8c68-9e50478896d6", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_08e00cfd-7db0-4191-8c68-9e50478896d6", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureStockbasedCompensation", "longName": "995525 - Disclosure - Stock-Based Compensation", "shortName": "Stock-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "C_08e00cfd-7db0-4191-8c68-9e50478896d6", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_08e00cfd-7db0-4191-8c68-9e50478896d6", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreements", "longName": "995535 - Disclosure - Collaboration Agreements", "shortName": "Collaboration Agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "C_08e00cfd-7db0-4191-8c68-9e50478896d6", "name": "asmb:CollaborativeAndLicenseArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_08e00cfd-7db0-4191-8c68-9e50478896d6", "name": "asmb:CollaborativeAndLicenseArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureMilestonesAndResearchAgreements", "longName": "995545 - Disclosure - Milestones and Research Agreements", "shortName": "Milestones and Research Agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "C_08e00cfd-7db0-4191-8c68-9e50478896d6", "name": "asmb:MilestonesAndResearchAgreementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_08e00cfd-7db0-4191-8c68-9e50478896d6", "name": "asmb:MilestonesAndResearchAgreementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "995575 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "18", "firstAnchor": { "contextRef": "C_08e00cfd-7db0-4191-8c68-9e50478896d6", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_08e00cfd-7db0-4191-8c68-9e50478896d6", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables", "longName": "995585 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "19", "firstAnchor": { "contextRef": "C_08e00cfd-7db0-4191-8c68-9e50478896d6", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_08e00cfd-7db0-4191-8c68-9e50478896d6", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesTables", "longName": "995595 - Disclosure - Fair Value Measurements and Investments in Marketable Securities (Tables)", "shortName": "Fair Value Measurements and Investments in Marketable Securities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "C_08e00cfd-7db0-4191-8c68-9e50478896d6", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "asmb:FairValueMeasurementsAndInvestmentsInMarketableSecuritiesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_08e00cfd-7db0-4191-8c68-9e50478896d6", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "asmb:FairValueMeasurementsAndInvestmentsInMarketableSecuritiesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureOtherAccruedExpensesTables", "longName": "995605 - Disclosure - Other Accrued Expenses (Tables)", "shortName": "Other Accrued Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "C_08e00cfd-7db0-4191-8c68-9e50478896d6", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_08e00cfd-7db0-4191-8c68-9e50478896d6", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureStockbasedCompensationTables", "longName": "995625 - Disclosure - Stock-Based Compensation (Tables)", "shortName": "Stock-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "C_08e00cfd-7db0-4191-8c68-9e50478896d6", "name": "us-

gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_08e00cfd-7db0-4191-8c68-9e50478896d6", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureCollaborationAgreementsTables", "longName": "995635 - Disclosure - Collaboration Agreements (Tables)", "shortName": "Collaboration Agreements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "C_08e00cfd-7db0-4191-8c68-9e50478896d6", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_08e00cfd-7db0-4191-8c68-9e50478896d6", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails", "longName": "995645 - Disclosure - Nature of Business - Additional Information (Details)", "shortName": "Nature of Business - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "C_08e00cfd-7db0-4191-8c68-9e50478896d6", "name": "asmb:NumberOfApprovedProducts", "unitRef": "U_Product", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_08e00cfd-7db0-4191-8c68-9e50478896d6", "name": "asmb:NumberOfApprovedProducts", "unitRef": "U_Product", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEarningsPerShareBasicAndDilutedDetails", "longName": "995655 - Disclosure - Summary of Significant Accounting Policies - Schedule of Earnings Per Share, Basic and Diluted (Details)", "shortName": "Summary of Significant Accounting Policies - Schedule of Earnings Per Share, Basic and Diluted (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "C_8b25f8a5-81cb-4773-8246-e885b767dedd", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true }, "uniqueAnchor": null }, "R26": { "role": "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetails", "longName": "995665 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)", "shortName": "Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "C_08e00cfd-7db0-4191-8c68-9e50478896d6", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_08e00cfd-7db0-4191-8c68-9e50478896d6", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "longName": "995675 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)", "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "C_08e00cfd-7db0-4191-8c68-9e50478896d6", "name": "us-gaap:StockholdersEquityReverseStockSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "asmb:ReverseStockSplitPolicyTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_08e00cfd-7db0-4191-8c68-9e50478896d6", "name": "us-gaap:StockholdersEquityReverseStockSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "asmb:ReverseStockSplitPolicyTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails", "longName": "995685 - Disclosure - Related Party - Additional Information (Details)", "shortName": "Related Party - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "C_8b25f8a5-81cb-4773-8246-e885b767dedd", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_dee892a2-2d90-4712-8b5d-c4d7b2058eba", "name": "asmb:NumberOfTradingDaysVolumeConsideredForWeightedAveragePriceToCalculatePremium", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "asmb:PurchasePricePerShareOfAdditionalSharesDescription", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "unique": true } }, "R29": { "role": "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfInvestmentsInMarketableSecuritiesDetails", "longName": "995695 - Disclosure - Fair Value Measurements and Investments in Marketable Securities - Schedule of Investments in Marketable Securities (Details)", "shortName": "Fair Value Measurements and Investments in Marketable Securities - Schedule of Investments in Marketable Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "C_9cd26644-dd90-4986-b47c-71e567305461", "name": "us-gaap:CashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "div", "asmb:FairValueMeasurementsAndInvestmentsInMarketableSecuritiesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9cd26644-dd90-4986-b47c-71e567305461", "name": "us-gaap:CashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "div", "asmb:FairValueMeasurementsAndInvestmentsInMarketableSecuritiesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesAdditionalInformationDetails", "longName": "995705 - Disclosure - Fair Value Measurements and Investments in Marketable Securities - Additional Information (Details)", "shortName": "Fair Value Measurements and Investments in Marketable Securities - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "C_8b25f8a5-81cb-4773-8246-e885b767dedd", "name": "us-gaap:RealizedInvestmentGainsLosses", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["us-gaap:RealizedInvestmentGainsLosses", "span", "p", "asmb:FairValueMeasurementsAndInvestmentsInMarketableSecuritiesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8b25f8a5-81cb-4773-8246-e885b767dedd", "name": "us-gaap:RealizedInvestmentGainsLosses", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["us-gaap:RealizedInvestmentGainsLosses", "span", "p", "asmb:FairValueMeasurementsAndInvestmentsInMarketableSecuritiesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfFairValueOfFinancialAssetsDetails", "longName": "995715 - Disclosure - Fair Value Measurements and Investments in Marketable Securities - Schedule of Fair Value of Financial Assets (Details)", "shortName": "Fair Value Measurements and Investments in Marketable Securities - Schedule of Fair Value of Financial Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "C_9cd26644-dd90-4986-b47c-71e567305461", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "div", "asmb:FairValueMeasurementsAndInvestmentsInMarketableSecuritiesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_91c6408c-3d8c-4b3e-8096-9628fc845755", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "unique": true } }, "R32": { "role": "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureOtherAccruedExpensesScheduleOfOtherAccruedExpensesDetails", "longName": "995725 - Disclosure - Other Accrued Expenses - Schedule of Other Accrued Expenses (Details)", "shortName": "Other Accrued Expenses - Schedule of Other Accrued Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "C_9cd26644-dd90-4986-b47c-71e567305461", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9cd26644-dd90-4986-b47c-71e567305461", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSaleOfCommonStockAndWarrantsAdditionalInformationDetails", "longName": "995755 - Disclosure - Sale of Common Stock and Warrants- Additional Information (Details)", "shortName": "Sale of Common Stock and Warrants- Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "C_8b25f8a5-81cb-4773-8246-e885b767dedd", "name": "asmb:WarrantsExercisedDuringPeriodShares", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8b25f8a5-81cb-4773-8246-e885b767dedd", "name": "asmb:WarrantsExercisedDuringPeriodShares", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRecognizedStockbasedCompensationExpenseDetails", "longName": "995765 - Disclosure - Stock-Based Compensation - Schedule of Recognized Stock-Based Compensation Expense (Details)", "shortName": "Stock-Based Compensation - Schedule of Recognized Stock-Based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "C_8b25f8a5-81cb-4773-8246-e885b767dedd", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8b25f8a5-81cb-4773-8246-e885b767dedd", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails", "longName": "995775 - Disclosure - Stock-Based Compensation - Additional Information (Details)", "shortName": "Stock-Based Compensation - Additional Information (Details)",

```
"isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "C_9cd26644-dd90-4986-b47c-71e567305461", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9cd26644-dd90-4986-b47c-71e567305461", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedToEstimateFairValuesOfStockOptionsGrantsDetails", "longName": "995785 - Disclosure - Stock-Based Compensation - Summary of Assumptions Used to Estimate Fair Values of Stock Options Grants (Details)", "shortName": "Stock-Based Compensation - Summary of Assumptions Used to Estimate Fair Values of Stock Options Grants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "C_8b25f8a5-81cb-4773-8246-e885b767dedd", "name": "asmb:ShareBasedCompensationArrangementFairValueAssumptionsExercisePrice", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8b25f8a5-81cb-4773-8246-e885b767dedd", "name": "asmb:ShareBasedCompensationArrangementFairValueAssumptionsExercisePrice", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails", "longName": "995795 - Disclosure - Collaboration Agreements - Additional Information (Details)", "shortName": "Collaboration Agreements - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "C_8b25f8a5-81cb-4773-8246-e885b767dedd", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_6de7a32b-230a-4e03-8981-efda046209d6", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "us-gaap:ResearchAndDevelopmentExpense", "span", "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "asmb-20240930.htm", "unique": true } }, "R38": { "role": "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureCollaborationAgreementsScheduleOfChangesInContractLiabilitiesDetails", "longName": "995805 - Disclosure - Collaboration Agreements - Schedule of Changes in Contract Liabilities (Details)", "shortName": "Collaboration Agreements - Schedule of Changes in Contract Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "C_30d25f78-4b19-4adb-b706-2db281ef4555", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_08e00cfd-7db0-4191-8c68-9e50478896d6", "name": "asmb:ContractWithCustomerLiabilityInAdditions", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "asmb-20240930.htm", "unique": true } }, "R39": { "role": "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureCollaborationAgreementsScheduleOfCollaborationRevenueRecognizedWithThePeriodDetails", "longName": "995815 - Disclosure - Collaboration Agreements - Schedule of Collaboration Revenue Recognized with the Period (Details)", "shortName": "Collaboration Agreements - Schedule of Collaboration Revenue Recognized with the Period (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "C_8b25f8a5-81cb-4773-8246-e885b767dedd", "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "asmb:ScheduleOfCollaborationRevenueRecognizedWithPeriodTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8b25f8a5-81cb-4773-8246-e885b767dedd", "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "asmb:ScheduleOfCollaborationRevenueRecognizedWithPeriodTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureMilestonesAndResearchAgreementsAdditionalInformationDetails", "longName": "995825 - Disclosure - Milestones and Research Agreements - Additional Information (Details)", "shortName": "Milestones and Research Agreements - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "C_9cd26644-dd90-4986-b47c-71e567305461", "name": "us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "asmb:MilestonesAndResearchAgreementsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_8b25f8a5-81cb-4773-8246-e885b767dedd", "name": "asmb:MilestonePaymentDiligenceMaintenanceFees", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "asmb:MilestonePaymentDiligenceMaintenanceFees", "span", "p", "asmb:MilestonesAndResearchAgreementsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "asmb-20240930.htm", "unique": true } }, "R41": { "role": "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails", "longName": "995845 - Disclosure - Subsequent Event - Additional Information (Details)", "shortName": "Subsequent Event - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "C_7d5e0208-0e1d-456a-aa1b-02017a12509c", "name": "asmb:CollaborationTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "asmb-20240930.htm", "first": true }, "uniqueAnchor": null } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountingStandardsUpdate201613Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingStandardsUpdate201613Member", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ASU 2016-13", "label": "Accounting Standards Update 2016-13 [Member]", "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments." } } }, "auth_ref": [ "r194" ] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureOtherAccruedExpenses" ], "lang": { "en-us": { "role": { "terseLabel": "Other Accrued Expenses", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r28", "r30", "r33", "r791" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Accounts Payable, Current, Total", "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r28", "r641" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable from collaboration", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r772" ] }, "asmb_AccretionAmortizationOfInvestmentsInMarketableDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "AccretionAmortizationOfInvestmentsInMarketableDebtSecurities", "crdr": "credit", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Net accretion of investments in marketable debt securities", "documentation": "(Accretion) amortization of investments in marketable debt securities.", "label": "(Accretion) Amortization Of Investments In Marketable Debt Securities" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureOtherAccruedExpensesScheduleOfOtherAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total accrued expenses", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r30" ] }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrentAbstract", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureOtherAccruedExpensesScheduleOfOtherAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses:", "label": "Accrued Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureOtherAccruedExpensesScheduleOfOtherAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued professional fees and other", "label": "Accrued Professional Fees, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r30" ] }, "asmb_AccruedResearchAndDevelopmentExpensesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "AccruedResearchAndDevelopmentExpensesCurrent", "crdr": "credit", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued research and development expenses", "label": "Accrued Research And Development Expenses Current", "documentation": "Accrued research and development expenses current." } } }, "auth_ref": [] }, "asmb_AccruedRestructuringChargesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "AccruedRestructuringChargesCurrent", "crdr": "credit", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRestructuringScheduleOfAccruedRestructuringChargesDetails", "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureOtherAccruedExpensesScheduleOfOtherAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued restructuring charges", "label": "Accrued Restructuring Charges Current", "documentation": "Accrued restructuring charges current.", "periodStartLabel": "Accrued balance as of December 31, 2022", "periodEndLabel": "Accrued balance as of September 30, 2023" } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total", "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r10", "r11", "r43", "r92", "r477", "r503", "r507" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Loss", "documentation": "Accumulated increase (decrease)
```

```
in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r1", "r6", "r11", "r363", "r366", "r418", "r498", "r499", "r754", "r755", "r756", "r760", "r761", "r762", "r764" ] }, "asmb_AccruedInterestReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "AccuredInterestReceivable", "crdr": "debit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Accured Interest Receivable", "label": "Accured Interest Receivable", "verboseLabel": "Accrued interest receivable" } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r692" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r38" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r518", "r760", "r761", "r762", "r764", "r793", "r822" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r705" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation" } } }, "auth_ref": [ "r705" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r705" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r705" ] }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update [Axis]", "documentation": "Information by amendment to accounting standards." } } }, "auth_ref": [ "r79", "r80", "r81", "r82", "r83", "r84", "r119", "r120", "r121", "r122", "r133", "r157", "r158", "r196", "r197", "r198", "r199", "r201", "r202", "r203", "r204", "r205", "r206", "r217", "r218", "r221", "r326", "r327", "r328", "r329", "r330", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r395", "r396", "r405", "r406", "r407", "r413", "r414", "r415", "r416", "r417", "r418", "r464", "r465", "r466", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total", "terseLabel": "Stock-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r21", "r22", "r286" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": [ "r738" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r664", "r674", "r684", "r716" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r667", "r677", "r687", "r719" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": [ "r739" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r705" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r712" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r668", "r678", "r688", "r712", "r720", "r724", "r732" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r730" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRecognizedStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r315", "r320" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive securities excluded from computation of loss per share", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r141" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r15" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r15" ] }, "asmb_ArbutusBiopharmaAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "ArbutusBiopharmaAgreementMember", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Arbutus Biopharma Agreement", "label": "Arbutus Biopharma Agreement [Member]", "documentation": "Arbutus biopharma agreement." } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSaleOfCommonStockAndWarrantsAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r349" ] }, "us-gaap_AssetBackedSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetBackedSecuritiesMember", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfFairValueOfFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset-backed securities", "label": "Asset-Backed Securities [Member]", "documentation": "Securities that are primarily serviced
```

by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans." } } }, "auth_ref": ["r623", "r642", "r775", "r776", "r777"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r61", "r69", "r91", "r112", "r144", "r146", "r152", "r153", "r193", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r351", "r355", "r397", "r472", "r547", "r616", "r617", "r641", "r655", "r785", "r786", "r806"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r86", "r93", "r112", "r193", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r351", "r355", "r397", "r641", "r785", "r786", "r806"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfFairValueOfFinancialAssetsDe
], "lang": { "en-us": { "role": { "totalLabel": "Total assets measured at fair value", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r383", "r384", "r631"] },
"asmb_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.assemblybio.com/20240930", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent", "crdr": "credit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfInvestmentsInMarketableSec
], "lang": { "en-us": { "role": { "terseLabel": "Gross Unrealized Gain, Short-term marketable securities", "label": "Available for Sale Debt Securities Accumulated Gross Unrealized Gain before Tax Current", "documentation": "Available for sale debt securities accumulated gross unrealized gain before tax current." } } }, "auth_ref": [] },
"asmb_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.assemblybio.com/20240930", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent", "crdr": "debit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfInvestmentsInMarketableSec
], "lang": { "en-us": { "role": { "negatedLabel": "Gross Unrealized Loss, Short-term marketable securities", "label": "Available for Sale Debt Securities Accumulated Gross Unrealized Loss before Tax Current", "documentation": "Available for sale debt securities accumulated gross unrealized loss before tax current." } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AvailableForSaleSecuritiesDebtSecuritiesCurrent", "crdr": "debit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfFairValueOfFinancialAssetsDe
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfInvestmentsInMarketableSec
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Marketable securities", "verboseLabel": "Fair Value, Short-term marketable securities", "label": "Short-term marketable securities", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current." } } }, "auth_ref": ["r161", "r212"] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "crdr": "debit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfFairValueOfFinancialAssetsDe
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Long-term marketable securities", "verboseLabel": "Fair Value, Long-term marketable securities", "label": "Debt Securities, Available-for-Sale, Noncurrent", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent." } } }, "auth_ref": ["r89", "r161", "r212"] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": ["r727"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": ["r728"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": ["r723"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": ["r723"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": ["r723"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": ["r723"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": ["r723"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": ["r723"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": ["r726"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r725"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": ["r724"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": ["r724"] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location", "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": ["r220", "r817", "r818"] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location", "label": "Statement of Financial Position Location, Balance [Domain]", "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": ["r23", "r24", "r220", "r817", "r818"] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] },
"asmb_BeiGeneAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "BeiGeneAgreementMember", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "BeiGene Agreement", "label": "Bei Gene Agreement [Member]", "documentation": "BeiGene agreement." } } }, "auth_ref": [] },
"asmb_CashAndCashEquivalentGrossUnrealizedGain": { "xbrltype": "monetaryItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname":
"CashAndCashEquivalentGrossUnrealizedGain", "crdr": "credit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfInvestmentsInMarketableSec
], "lang": { "en-us": { "role": { "terseLabel": "Gross Unrealized Gain", "label": "Cash And Cash Equivalent Gross Unrealized Gain", "documentation": "Cash and cash equivalent gross unrealized gain." } } }, "auth_ref": [] }, "asmb_CashAndCashEquivalentGrossUnrealizedLoss": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.assemblybio.com/20240930", "localname": "CashAndCashEquivalentGrossUnrealizedLoss", "crdr": "debit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfInvestmentsInMarketableSec
], "lang": { "en-us": { "role": { "negatedLabel": "Gross Unrealized Loss", "label": "Cash And Cash Equivalent Gross Unrealized Loss", "documentation": "Cash and cash equivalent gross unrealized loss." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "totalLabel": "Amortized Cost11", "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r14", "r88", "r608"] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAxis", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfFairValueOfFinancialAssetsDe
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfInvestmentsInMarketableSec
], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": ["r88"] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfFairValueOfFinancialAssetsDe
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfInvestmentsInMarketableSec
], "lang": { "en-us": { "role": { "verboseLabel": "Fair Value", "terseLabel": "Cash equivalents", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they

present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": { "r795", "r796" } }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total", "periodStartLabel": "Cash and cash equivalents at the beginning of the period", "periodEndLabel": "Cash and cash equivalents at the end of the period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": { "r14", "r49", "r109" } }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": { "r0", "r49" } }, "us-gaap_CashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfInvestmentsInMarketableSec
], "lang": { "en-us": { "role": { "terseLabel": "Amortized Cost", "label": "Cash Equivalents, at Carrying Value", "totalLabel": "Amortized Cost", "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": { "r752", "r816" } },
"asmb_CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.assemblybio.com/20240930", "localname": "CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesAmortizedCost", "crdr": "debit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfInvestmentsInMarketableSec
], "lang": { "en-us": { "role": { "totalLabel": "Amortized Cost", "label": "Cash Equivalents At Carrying Value And Available For Sale Debt Securities Amortized Cost",
"documentation": "Cash equivalents at carrying value and available for sale debt securities amortized cost." } } }, "auth_ref": [] },
"asmb_CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesEstimatedFairValue": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.assemblybio.com/20240930", "localname": "CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesEstimatedFairValue", "crdr": "debit",
"presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfInvestmentsInMarketableSec
], "lang": { "en-us": { "role": { "verboseLabel": "Fair Value", "label": "Cash Equivalents At Carrying Value And Available For Sale Debt Securities Estimated Fair Value",
"documentation": "Cash equivalents at carrying value and available for sale debt securities estimated fair value." } } }, "auth_ref": [] },
"asmb_CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesGrossUnrealizedGain": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.assemblybio.com/20240930", "localname": "CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesGrossUnrealizedGain", "crdr": "credit",
"presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfInvestmentsInMarketableSec
], "lang": { "en-us": { "role": { "terseLabel": "Gross Unrealized Gain", "label": "Cash Equivalents At Carrying Value And Available For Sale Debt Securities Gross Unrealized
Gain", "documentation": "Cash equivalents at carrying value and available for sale debt securities gross unrealized gain." } } }, "auth_ref": [] },
"asmb_CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesGrossUnrealizedLoss": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.assemblybio.com/20240930", "localname": "CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesGrossUnrealizedLoss", "crdr": "debit",
"presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfInvestmentsInMarketableSec
], "lang": { "en-us": { "role": { "negatedLabel": "Gross Unrealized Loss", "label": "Cash Equivalents At Carrying Value And Available For Sale Debt Securities Gross Unrealized
Loss", "documentation": "Cash equivalents at carrying value and available for sale debt securities gross unrealized loss." } } }, "auth_ref": [] },
"asmb_CashEquivalentsAtFairValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname":
"CashEquivalentsAtFairValueAbstract", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfFairValueOfFinancialAssetsDe
], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents", "label": "Cash Equivalents At Fair Value [Abstract]", "documentation": "Cash equivalents at fair value." } } },
"auth_ref": [] }, "us-gaap_CashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashEquivalentsMember",
"presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfInvestmentsInMarketableSec
], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents", "label": "Cash Equivalents [Member]", "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } },
"auth_ref": ["r88"] }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": {
"label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]", "documentation": "Indicates (true false) whether accounting standards update was adopted." } } }, "auth_ref": ["r76", "r77", "r84", "r118", "r157", "r195", "r196", "r197", "r203", "r204", "r217", "r221", "r328", "r332", "r333", "r341", "r342", "r344", "r358", "r359", "r371", "r372", "r395", "r396", "r406", "r413", "r414", "r464", "r465", "r496", "r497"] }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": {
"label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date", "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format." } } }, "auth_ref": ["r76", "r77", "r84", "r157", "r195", "r196", "r197", "r203", "r204", "r205", "r217", "r221", "r328", "r332", "r333", "r341", "r342", "r343", "r344", "r345", "r357", "r358", "r359", "r360", "r371", "r372", "r373", "r376", "r395", "r396", "r406", "r413", "r414", "r464", "r465", "r496", "r497", "r744"] }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": {
"label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]", "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial." } } }, "auth_ref": ["r119", "r132", "r200"] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": {
"role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r703"] },
"ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label":
"Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": ["r700"] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } },
"auth_ref": ["r698"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": ["r704"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label":
"Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": ["r704"] }, "asmb_CollaborationAgreementAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "CollaborationAgreementAbstract", "lang": { "en-us": { "role": { "label": "Collaboration
Agreement [Abstract]", "documentation": "Collaboration Agreement" } } }, "auth_ref": [] }, "asmb_CollaborationRevenueRecognizedInPeriodAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "CollaborationRevenueRecognizedInPeriodAbstract", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureCollaborationAgreementsScheduleOfCollaborationRevenueRecognizedWithThePeriodDetails"], "lang": { "en-us": { "role": { "documentation": "Collaboration revenue recognized in period [Abstract]", "label": "Collaboration Revenue Recognized In Period [Abstract]", "terseLabel":
"Collaboration revenue recognized in the period from" } } }, "auth_ref": [] }, "asmb_CollaborationTerm": { "xbrltype": "durationItemType", "nsuri":
"http://www.assemblybio.com/20240930", "localname": "CollaborationTerm", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": {
"documentation": "Collaboration term.", "label": "Collaboration Term", "terseLabel": "Collaboration term" } } }, "auth_ref": [] },
"asmb_CollaborativeAndLicenseArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname":
"CollaborativeAndLicenseArrangementDisclosureTextBlock", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreements"], "lang": { "en-us": { "role": { "terseLabel": "Collaboration Agreements",
"label": "Collaborative And License Arrangement Disclosure [Text Block]", "documentation": "Collaborative and License Arrangement Disclosure." } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Collaborative
Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r349"] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialPaperMember", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfInvestmentsInMarketableSec
], "lang": { "en-us": { "role": { "terseLabel": "U.S. and foreign commercial paper", "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": ["r55", "r238", "r649", "r650", "r651", "r652"] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr":

```
"credit", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r34", "r62", "r474", "r534" ] }, "asmb_CommonStockAndWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "CommonStockAndWarrantMember", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSaleOfCommonStockAndWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Common stock and warrant.", "label": "Common Stock and Warrant [Member]", "terseLabel": "Common Stock and Warrant" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSaleOfCommonStockAndWarrantsAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r645", "r646", "r647", "r649", "r650", "r651", "r652", "r760", "r761", "r764", "r793", "r821", "r822" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r37" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r37", "r535" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r37" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance", "terseLabel": "Common stock, shares outstanding", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r7", "r37", "r535", "r553", "r822", "r823" ] },
"asmb_CommonStockSubjectToPurchaseUnderEmployeeStockPurchaseProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "CommonStockSubjectToPurchaseUnderEmployeeStockPurchaseProgramMember", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfI
], "lang": { "en-us": { "role": { "terseLabel": "Common stock subject to purchase under Employee Stock Purchase Plan", "label": "Common Stock Subject To Purchase Under Employee Stock Purchase Program [Member]", "documentation": "Common stock subject to purchase under employee stock purchase program." } } }, "auth_ref": [] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.001 par value; 150,000,000 shares authorized as of September 30 2024 and December 31, 2023; 6,354,414 and 5,482,752 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r37", "r476", "r641" ] },
"ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r709" ] },
"ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r708" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r710" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r707" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r12", "r97", "r99", "r103", "r467", "r487", "r488" ] }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureCollaborationAgreementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in Contract Liabilities", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": [ "r788" ] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureCollaborationAgreementsScheduleOfChangesInContractLiabilitiesDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Deferred revenue from a related party", "periodEndLabel": "Balance at End of Period", "periodStartLabel": "Balance at Beginning of Period", "terseLabel": "Contract liability/deferred revenue", "label": "Contract with Customer, Liability", "totalLabel": "Contract with Customer, Liability, Total", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r267", "r268", "r272" ] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred revenue from a related party - short-term", "terseLabel": "Deferred revenue - short-term", "label": "Contract with Customer, Liability, Current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r267", "r268", "r272" ] }, "asmb_ContractWithCustomerLiabilityInAdditions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "ContractWithCustomerLiabilityInAdditions", "crdr": "credit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureCollaborationAgreementsScheduleOfChangesInContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Contract with customer liability in additions.", "label": "Contract With Customer Liability In Additions", "terseLabel": "Additions" } } }, "auth_ref": [] },
"asmb_ContractWithCustomerLiabilityInDeduction": { "xbrltype": "monetaryItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "ContractWithCustomerLiabilityInDeduction", "crdr": "debit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureCollaborationAgreementsScheduleOfChangesInContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Contract with customer liability in deduction.", "label": "Contract With Customer Liability In Deduction", "negatedLabel": "Deductions" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityNoncurrent", "crdr": "credit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue from a related party - long-term", "verboseLabel": "Deferred revenue - long-term", "label": "Contract with Customer, Liability, Noncurrent", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r267", "r268", "r272" ] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureCollaborationAgreementsScheduleOfCollaborationRevenueRecognizedWithThePeriodDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amounts included in deferred revenue at the beginning of the period", "label": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r273" ] }, "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod", "crdr": "credit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureCollaborationAgreementsScheduleOfCollaborationRevenueRecognizedWithThePeriodDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance obligations satisfied in previous period", "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period", "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price." } } }, "auth_ref": [ "r269" ] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateDebtSecuritiesMember", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfFairValueOfFinancialAssetsDe
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfInvestmentsInMarketableSec
], "lang": { "en-us": { "role": { "terseLabel": "U.S and foreign corporate debt securities", "label": "Corporate Debt Securities [Member]", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": [ "r623", "r625", "r631", "r642", "r644", "r820" ] },
"srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": [
```

```
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty
Name [Axis]" } } }, "auth_ref": [ "r113", "r114", "r248", "r254", "r424", "r445", "r471", "r609", "r611" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] },
"asmb_CumulativeRestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname":
"CumulativeRestructuringCharges", "crdr": "credit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Cumulative
Restructuring Charges", "label": "Cumulative Restructuring Charges", "terseLabel": "Cumulative restructuring charges" } } }, "auth_ref": [] },
"dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date",
"label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-
gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DebtSecuritiesAvailableForSaleAmortizedCostCurrent", "crdr": "debit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfInvestmentsInMarketableSec
], "lang": { "en-us": { "role": { "totalLabel": "Amortized Cost, Short-term marketable securities", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Current",
"documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-
sale), classified as current." } } }, "auth_ref": [ "r212", "r774" ] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "crdr": "debit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesAdditionalInformationDetails" ], "lang":
{ "en-us": { "role": { "verboseLabel": "Number of investments in unrealized loss position", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position", "totalLabel":
"Debt Securities, Available-for-Sale, Unrealized Loss Position, Total", "documentation": "Amount of investment in debt security measured at fair value with change in fair
value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss." } } }, "auth_ref": [ "r70", "r214", "r619" ] },
"us-gaap_DeferredCompensationLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DeferredCompensationLiabilityAbstract", "lang": { "en-us": { "role": { "label": "Deferred Compensation Liability [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DepreciationDepletionAndAmortization", "crdr": "debit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": {
"totalLabel": "Depreciation, Depletion and Amortization, Total", "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization",
"documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that
benefit from use of the assets." } } }, "auth_ref": [ "r4", "r144", "r149", "r153", "r616", "r617" ] }, "us-
gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureStockbasedCompensation" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text
Block]", "terseLabel": "Stock-Based Compensation", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r284", "r288", "r316",
"r317", "r319", "r627" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement
[Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"DocumentFiscalPeriodFocus", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": {
"role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and
3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] },
"dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus",
"label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide
financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": {
"xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date",
"label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported, for the
EDGAR submission types of Form N-1A: the filing date, for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." }
} }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport",
"presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document
Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r659" ]
}, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report",
"label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r691" ] },
"dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label":
"Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the
supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise
Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total
Compensation for Covered Year" } } }, "auth_ref": [ "r702" ] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "EarningsPerShareBasic", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEarningsPerShareBasicAndDilutedDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": {
"en-us": { "role": { "totalLabel": "Earnings Per Share, Basic, Total", "verboseLabel": "Net loss per share - basic", "terseLabel": "Net loss per share, basic", "label": "Earnings
Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } },
"auth_ref": [ "r104", "r123", "r124", "r125", "r126", "r127", "r128", "r134", "r136", "r138", "r139", "r140", "r143", "r339", "r348", "r380", "r381", "r468", "r489", "r613" ] }, "us-
gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEarningsPerShareBasicAndDilutedDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": {
"en-us": { "role": { "totalLabel": "Earnings Per Share, Diluted, Total", "verboseLabel": "Net loss per share - diluted", "terseLabel": "Net loss per share, diluted", "label":
"Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during
the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or
units outstanding during the reporting period." } } }, "auth_ref": [ "r104", "r123", "r124", "r125", "r126", "r127", "r128", "r136", "r138", "r139", "r140", "r143", "r339", "r348",
"r380", "r381", "r468", "r489", "r613" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EarningsPerSharePolicyTextBlock", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Net
Loss per Share", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss
per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the
computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of
the financial statements." } } }, "auth_ref": [ "r15", "r16", "r142" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureOtherAccruedExpensesScheduleOfOtherAccruedExpensesDetails" ], "lang": { "en-us": { "role": {
"totalLabel": "Employee-related Liabilities, Current, Total", "terseLabel": "Accrued compensation", "label": "Employee-related Liabilities, Current", "documentation": "Total of
the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as
accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle
if longer)." } } }, "auth_ref": [ "r30" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRecognizedStockbasedCompensationExpenseDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Compensation expense:", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line
items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many
axes to the table." } } }, "auth_ref": [] }, "us-
gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Unrecognized stock-based compensation expense expected to be recognized, term", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized,
Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment
arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r318" ] },
"us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation":
[ "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Unrecognized stock-based compensation expense", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
"documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r790"
] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember",
"presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfI
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option",
"verboseLabel": "Options to purchase common stock", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to
purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype":
"normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [
```

```
"http://www.assemblybio.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] },
"dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r657" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r657" ] },
"dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r657" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation" ],
"lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r741" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityRegistrantName", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": {
"terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r657" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityShellCompany", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": {
"role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r657" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntitySmallBusiness", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": {
"role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } },
"auth_ref": [ "r657" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityTaxIdentificationNumber", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": {
"role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r657" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang":
{ "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": [ "r696" ] },
"ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": [ "r737" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]",
"terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": [ "r737" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": {
"en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": [ "r737" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] },
"asmb_EquityAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "EquityAgreementsMember",
"presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSaleOfCommonStockAndWarrantsAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"documentation": "Equity agreements.", "label": "Equity Agreements [Member]", "terseLabel": "Gilead Equity Agreements" } } }, "auth_ref": [] }, "us-
gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSaleOfCommonStockAndWarrantsAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "lang": { "en-
us": { "role": { "terseLabel": "Equity Component", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r7", "r81", "r100", "r101", "r102", "r115", "r116", "r117",
"r120", "r127", "r129", "r131", "r145", "r199", "r206", "r218", "r266", "r326", "r327", "r335", "r336", "r337", "r340", "r347", "r348", "r361", "r363", "r364", "r365", "r366",
"r368", "r379", "r398", "r399", "r400", "r401", "r402", "r403", "r406", "r409", "r418", "r485", "r498", "r499", "r500", "r518", "r577" ] },
"ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r706" ] },
"ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r664", "r674", "r684", "r716" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label":
"Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r661", "r671", "r681", "r713" ] },
"ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r712" ] },
"asmb_ExpectedEquityFinancingCompletionDate": { "xbrltype": "dateItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname":
"ExpectedEquityFinancingCompletionDate", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
], "lang": { "en-us": { "role": { "documentation": "Expected equity financing completion date.", "label": "Expected Equity Financing Completion Date", "terseLabel": "Expected equity financing completion date" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
"presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesTables" ], "lang": {
"en-us": { "role": { "terseLabel": "Schedule of Fair Value of Financial Assets", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
"documentation": "Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity." } } }, "auth_ref": [ "r631", "r795", "r796", "r801" ] }, "asmb_FairValueAssetsBetweenLevelsTransfersAmount": { "xbrltype": "monetaryItemType",
"nsuri": "http://www.assemblybio.com/20240930", "localname": "FairValueAssetsBetweenLevelsTransfersAmount", "crdr": "credit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesAdditionalInformationDetails" ], "lang":
{ "en-us": { "role": { "terseLabel": "Fair value assets transfers between level 1, level 2 or level 3", "label": "Fair Value Assets Between Levels Transfers Amount",
```

```
"documentation": "Fair value assets between levels transfers amount." } } }, "auth_ref": [] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfFairValueOfFinancialAssetsD
], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and
fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r249", "r275", "r276", "r277", "r278", "r279", "r280", "r382", "r384", "r385",
"r386", "r387", "r390", "r391", "r393", "r432", "r433", "r434", "r620", "r621", "r623", "r624", "r625", "r631", "r634" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfFairValueOfFinancialAssetsD
], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency."
} } }, "auth_ref": [ "r383", "r384", "r385", "r387", "r631", "r798", "r802" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfFairValueOfFinancialAssetsD
], "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or
liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r249", "r275", "r280", "r384", "r391", "r432", "r623", "r624", "r625", "r631" ] },
"us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member",
"presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfFairValueOfFinancialAssetsD
], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level
1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or
quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r249", "r275", "r280", "r384", "r385", "r391", "r433", "r620", "r621", "r623",
"r624", "r625", "r631" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueInputsLevel3Member", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfFairValueOfFinancialAssetsD
], "lang": { "en-us": { "role": { "terseLabel": "Level 3", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own
assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r249", "r275", "r276", "r277", "r278", "r279", "r280", "r384", "r385", "r386",
"r387", "r391", "r434", "r620", "r621", "r623", "r624", "r625", "r631", "r634" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfFairValueOfFinancialAssetsD
], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } },
"auth_ref": [ "r383", "r384", "r385", "r387", "r631", "r798", "r802" ] }, "asmb_FairValueMeasurementsAndInvestmentsInMarketableSecuritiesTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "FairValueMeasurementsAndInvestmentsInMarketableSecuritiesTextBlock",
"presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecurities" ], "lang": { "en-us": {
"role": { "terseLabel": "Fair Value Measurements and Investments in Marketable Securities", "label": "Fair Value Measurements And Investments In Marketable Securities
[Text Block]", "documentation": "Fair value measurements and investments in marketable securities." } } }, "auth_ref": [] }, "us-
gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueMeasurementsFairValueHierarchyDomain", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfFairValueOfFinancialAssetsD
], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to
prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r249", "r275", "r276", "r277", "r278", "r279", "r280", "r382", "r384", "r385", "r386",
"r387", "r390", "r391", "r393", "r432", "r433", "r434", "r620", "r621", "r623", "r624", "r625", "r631", "r634" ] }, "us-gaap_FairValueMeasurementsRecurringMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfFairValueOfFinancialAssetsD
], "lang": { "en-us": { "role": { "terseLabel": "Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not
limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r631", "r795", "r796", "r797", "r798",
"r799", "r802" ] }, "asmb_FifthYearOfCollaborationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname":
"FifthYearOfCollaborationMember", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ],
"lang": { "en-us": { "role": { "documentation": "Fifth year of collaboration.", "label": "Fifth Year of Collaboration [Member]", "terseLabel": "Fifth Year of Collaboration
Agreement" } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FinancialInstrumentAxis", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfFairValueOfFinancialAssetsD
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfInvestmentsInMarketableSec
], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } }
}, "auth_ref": [ "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181",
"r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r207", "r208", "r209", "r210", "r211", "r213", "r215", "r216", "r250", "r264", "r369", "r394",
"r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r446", "r447", "r448", "r449", "r450", "r451", "r452",
"r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r486", "r619", "r631", "r632", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r642", "r745", "r746",
"r747", "r748", "r749", "r750", "r751", "r778", "r779", "r780", "r781", "r794", "r797", "r798", "r799", "r800", "r802" ] },
"ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone
Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r668", "r678",
"r688", "r720" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone
Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r668", "r678", "r688", "r720"
] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone
Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r668", "r678",
"r688", "r720" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone
Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r668", "r678", "r688", "r720" ] },
"ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r668",
"r678", "r688", "r720" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet
Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet
Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [ "r701" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": {
"en-us": { "role": { "totalLabel": "General and Administrative Expense, Total", "terseLabel": "General and administrative", "label": "General and Administrative Expense",
"documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or
indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r46", "r557" ] }, "us-
gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"GeneralAndAdministrativeExpenseMember", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRecognizedStockbasedCompensationExpenseDetails" ], "lang": { "en-
us": { "role": { "verboseLabel": "General and Administrative", "terseLabel": "General and Administrative Expenses", "label": "General and Administrative Expense [Member]",
"documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r46" ] },
"asmb_GileadSciencesIncorporatedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname":
"GileadSciencesIncorporatedMember", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSaleOfCommonStockAndWarrantsAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation":
"Gilead sciences incorporated.", "label": "Gilead Sciences Incorporated [Member]", "terseLabel": "Gilead Sciences, Inc." } } }, "auth_ref": [] }, "us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": {
"en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "verboseLabel": "Loss before income taxes",
"totalLabel": "Loss before income taxes", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments,
before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r44", "r64", "r68", "r469", "r482", "r615",
"r616", "r766", "r768", "r769", "r770", "r771" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRecognizedStockbasedCompensationExpenseDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Income Statement Location", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of
income where disaggregated amount has been reported." } } }, "auth_ref": [ "r219", "r220", "r226", "r388", "r389", "r392", "r493", "r495", "r562", "r607", "r633", "r819" ] },
"us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain",
"presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRecognizedStockbasedCompensationExpenseDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Income Statement Location", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income
where disaggregated amount has been reported." } } }, "auth_ref": [ "r220", "r226", "r388", "r389", "r392", "r493", "r495", "r562", "r607", "r633", "r819" ] }, "us-
gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit",
"presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": {
```

```
"en-us": { "role": { "totalLabel": "Income Tax Expense (Benefit), Total", "label": "Income Tax Expense (Benefit)", "verboseLabel": "Income tax expense", "negatedTerseLabel": "Income tax expense", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r71", "r78", "r130", "r131", "r144", "r150", "r153", "r324", "r325", "r331", "r491", "r628" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Accounts Payable, Total", "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable from collaboration", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r3" ] }, "asmb_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses", "crdr": "debit", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued research and development expenses", "label": "Increase Decrease In Accrued Research And Development Expenses", "documentation": "Increase (decrease) in accrued research and development expenses." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue from a related party", "label": "Increase (Decrease) in Contract with Customer, Liability", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r462", "r758" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "asmb_IncreaseDecreaseInOperatingLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "IncreaseDecreaseInOperatingLeaseLiabilities", "crdr": "debit", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Increase Decrease In Operating Lease Liabilities", "documentation": "Increase decrease in operating lease liabilities." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherAccruedLiabilities", "crdr": "debit", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Other accrued expenses", "label": "Increase (Decrease) in Other Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "crdr": "credit", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Other assets", "label": "Increase (Decrease) in Other Noncurrent Assets", "documentation": "Amount of increase (decrease) in noncurrent assets classified as other." } } }, "auth_ref": [ "r758" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r3" ] }, "asmb_IncrementalCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "IncrementalCosts", "crdr": "debit", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Incremental costs", "label": "Incremental Costs", "documentation": "Incremental costs." } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r668", "r670", "r688", "r712", "r720", "r724", "r732" ] }, "asmb_InitialNonCancellableTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "InitialNonCancellableTerm", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial non-cancellable term", "label": "Initial Non Cancellable Term", "documentation": "Initial non-cancellable term." } } }, "auth_ref": [] }, "asmb_InitialPublicOfferingValueOfSharesAuthorized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "InitialPublicOfferingValueOfSharesAuthorized", "crdr": "credit", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSaleOfCommonStockAndWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial public offering value of shares authorized", "label": "Initial Public Offering Value Of Shares Authorized", "documentation": "The value of common stock authorized to issue in a public offering." } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r730" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r660", "r736" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r660", "r736" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r660", "r736" ] }, "us-gaap_InterestIncomeOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeOther", "crdr": "credit", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Interest and other income, net", "label": "Interest Income, Other", "documentation": "Amount of interest income earned from interest bearing assets classified as other." } } }, "auth_ref": [] }, "us-gaap_InvestmentTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTypeAxis", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfInvestmentsInMarketableSec
], "lang": { "en-us": { "role": { "label": "Investment Type [Axis]", "documentation": "Information by type of investments." } } }, "auth_ref": [ "r520", "r521", "r522", "r523", "r524", "r585", "r588", "r590", "r594", "r595", "r596", "r598", "r599", "r600", "r601", "r602", "r647" ] }, "us-gaap_InvestmentTypeCategorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTypeCategorizationMember", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfInvestmentsInMarketableSec
], "lang": { "en-us": { "role": { "label": "Investments [Domain]", "documentation": "Asset obtained to generate income or appreciate in value." } } }, "auth_ref": [ "r520", "r521", "r522", "r523", "r524", "r585", "r588", "r590", "r594", "r595", "r596", "r598", "r599", "r600", "r601", "r602", "r647" ] }, "us-gaap_InvestmentTypeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTypeExtensibleEnumeration", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfInvestmentsInMarketableSec
], "lang": { "en-us": { "role": { "label": "Investment, Type [Extensible Enumeration]", "documentation": "Indicates type of investment. Includes, but is not limited to, common stock, preferred stock, convertible security, fixed income security, government security, option purchased, warrant, loan participation and assignment, commercial paper, bankers' acceptance, certificates of deposit, short-term security, repurchase agreement, and other investment company." } } }, "auth_ref": [ "r520", "r523", "r586", "r588", "r589", "r590", "r591", "r595", "r597", "r598" ] }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "auth_ref": [] }, "asmb_IssuanceOfCommonStockAndWarrantsInRegisteredDirectOfferingAndPrivatePlacementNetOfIssuanceCostsShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "IssuanceOfCommonStockAndWarrantsInRegisteredDirectOfferingAndPrivatePlacementNetOfIssuanceCostsShares", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "documentation": "Issuance of common stock and warrants in registered direct offering and private placement net of issuance costs shares.", "label": "Issuance of Common Stock and Warrants in Registered Direct Offering and Private Placement Net of Issuance Costs Shares", "terseLabel": "Issuance of common stock and warrants in a registered direct offering and a private placement, net of issuance costs (in shares)" } } }, "auth_ref": [] }, "asmb_IssuanceOfCommonStockAndWarrantsInRegisteredDirectOfferingAndPrivatePlacementNetOfIssuanceCostsValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "IssuanceOfCommonStockAndWarrantsInRegisteredDirectOfferingAndPrivatePlacementNetOfIssuanceCostsValue", "crdr": "credit", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "documentation": "Issuance of common stock and warrants in registered direct offering and private placement net of issuance costs value.", "label": "Issuance of Common Stock and Warrants in Registered Direct Offering and Private Placement Net of Issuance Costs Value", "terseLabel": "Issuance of common stock and warrants in a registered direct offering and a private placement, net of issuance costs" } } }, "auth_ref": [] }, "asmb_LeaseExpirationMonthAndYear": { "xbrltype": "gYearMonthItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "LeaseExpirationMonthAndYear", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Lease expiration, month and year.", "label": "Lease Expiration, Month And Year", "terseLabel": "Lease expiration month and year" } } }, "auth_ref": [] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Lease Not yet Commenced, Existence of Option to Extend [true false]", "documentation": "Indicates (true false) whether lessee has option to extend operating lease not yet commenced." } } }, "auth_ref": [ "r804" ] }, "asmb_LesseeOperatingLeaseLeaseNotYetCommencedLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "LesseeOperatingLeaseLeaseNotYetCommencedLeaseLiability", "crdr": "credit", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Lessee, operating lease, lease not yet commenced, lease liability.", "label": "Lessee, Operating Lease, Lease Not yet Commenced, Lease Liability", "terseLabel": "Lessee, operating lease, lease not
```

```
yet commenced, operating lease liability" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, operating lease,
lease not yet commenced, option to extend", "label": "Lessee, Operating Lease, Lease Not yet Commenced, Option to Extend", "documentation": "Description of terms and
conditions of option to extend lessee's operating lease that has not yet commenced. Includes, but is not limited to, information about option recognized as part of right-of-use
asset and lease liability." } } }, "auth_ref": [ "r804" ] }, "asmb_LesseeOperatingLeaseLeaseNotYetCommencedPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.assemblybio.com/20240930", "localname": "LesseeOperatingLeaseLeaseNotYetCommencedPaymentsDue", "crdr": "credit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Lessee, operating
lease, lease not yet commenced, payments due.", "label": "Lessee, Operating Lease, Lease Not yet Commenced, Payments Due", "terseLabel": "Lessee, operating lease, lease
not yet commenced, future lease payments" } } }, "auth_ref": [] }, "asmb_LesseeOperatingLeaseLeaseNotYetCommencedRightOfUseAsset": { "xbrltype": "monetaryItemType",
"nsuri": "http://www.assemblybio.com/20240930", "localname": "LesseeOperatingLeaseLeaseNotYetCommencedRightOfUseAsset", "crdr": "debit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Lessee, operating
lease, lease not yet commenced, right-of-use asset.", "label": "Lessee, Operating Lease, Lease Not yet Commenced, Right Of Use Asset", "terseLabel": "Lessee, operating lease,
lease not yet commenced, operating lease right-of-use asset" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": { "xbrltype":
"durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease not yet commence,
term of contract", "label": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract", "documentation": "Term of lessee's operating lease not yet commenced, in
'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r804" ] }, "us-
gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock",
"presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureLeases" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Leases [Text Block]",
"terseLabel": "Leases", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity
analysis of operating lease liability." } } }, "auth_ref": [ "r408" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "Liabilities", "crdr": "credit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total
liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
} } }, "auth_ref": [ "r9", "r29", "r30", "r31", "r32", "r33", "r34", "r35", "r112", "r193", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r352", "r355",
"r356", "r397", "r533", "r614", "r655", "r785", "r806", "r807" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total
liabilities and stockholders' equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to
noncontrolling interests, if any." } } }, "auth_ref": [ "r42", "r63", "r479", "r641", "r759", "r782", "r803" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel":
"LIABILITIES AND STOCKHOLDERS' EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total
current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following
twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r31", "r87", "r112", "r193", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247",
"r352", "r355", "r356", "r397", "r641", "r785", "r806", "r807" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LiabilitiesCurrentAbstract", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current
liabilities", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label":
"Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermInvestmentsAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermInvestmentsAbstract", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfFairValueOfFinancialAssetsDe
], "lang": { "en-us": { "role": { "terseLabel": "Long-term marketable securities", "label": "Long-Term Investments [Abstract]" } } }, "auth_ref": [] }, "srt_MaximumMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSaleOfCommonStockAndWarrantsAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedToEstimateFairValuesOfStockOptionsGrantsDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r234", "r235", "r236", "r237", "r282", "r321", "r387", "r461", "r492", "r494", "r508", "r525", "r526", "r587",
"r589", "r592", "r593", "r597", "r605", "r606", "r618", "r622", "r626", "r634", "r635", "r639", "r640", "r643", "r787", "r808", "r809", "r810", "r811", "r812", "r813" ] },
"asmb_MaximumPercentageOfThenOutstandingVotingCapitalStock": { "xbrltype": "percentItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname":
"MaximumPercentageOfThenOutstandingVotingCapitalStock", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum
percentage of then-outstanding voting capital stock", "label": "Maximum Percentage Of Then Outstanding Voting Capital Stock", "documentation": "Maximum percentage of
then-outstanding voting capital stock." } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } },
"auth_ref": [ "r704" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r704" ] },
"asmb_MilestonePaymentDiligenceMaintenanceFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname":
"MilestonePaymentDiligenceMaintenanceFees", "crdr": "debit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureMilestonesAndResearchAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Milestone payment, diligence maintenance fees", "label": "Milestone Payment Diligence Maintenance Fees", "documentation": "Milestone payment, diligence
maintenance fees." } } }, "auth_ref": [] }, "asmb_MilestonesAndResearchAgreementsAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://www.assemblybio.com/20240930", "localname": "MilestonesAndResearchAgreementsAbstract", "lang": { "en-us": { "role": { "label": "Milestones And Research
Agreements [Abstract]", "documentation": "Milestones and Research Agreements" } } }, "auth_ref": [] }, "asmb_MilestonesAndResearchAgreementsTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "MilestonesAndResearchAgreementsTextBlock", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureMilestonesAndResearchAgreements" ], "lang": { "en-us": { "role": { "terseLabel": "Milestones and
Research Agreements", "label": "Milestones And Research Agreements [Text Block]", "documentation": "Milestones and Research Agreements" } } }, "auth_ref": [] },
"srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSaleOfCommonStockAndWarrantsAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedToEstimateFairValuesOfStockOptionsGrantsDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r234", "r235", "r236", "r237", "r282", "r321", "r387", "r461", "r492", "r494", "r508", "r525", "r526", "r587",
"r589", "r592", "r593", "r597", "r605", "r606", "r618", "r622", "r626", "r634", "r635", "r639", "r643", "r787", "r808", "r809", "r810", "r811", "r812", "r813" ] },
"ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag",
"presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
"terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r723" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfFairValueOfFinancialAssetsDe
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfInvestmentsInMarketableSec
], "lang": { "en-us": { "role": { "terseLabel": "Money market fund", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market
instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly
liquid securities." } } }, "auth_ref": [ "r789" ] }, "asmb_MonthlySubleaseBaseRent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.assemblybio.com/20240930",
"localname": "MonthlySubleaseBaseRent", "crdr": "debit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Monthly sublease base
rent", "label": "Monthly Sublease Base Rent", "documentation": "Monthly sublease base rent." } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel":
"Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r731" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": {
"label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r705" ] }, "us-
gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": {
"totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow)
from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a
return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors
on long-term credit." } } }, "auth_ref": [ "r108" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": {
"terseLabel": "Cash flows from financing activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": {
"totalLabel": "Net cash provided by investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from
```

investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r108"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r49", "r50", "r52"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEarningsPerShareBasicAndDilutedDetails", "http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY", "http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "verboseLabel": "Net loss", "totalLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r45", "r52", "r65", "r85", "r96", "r98", "r102", "r112", "r119", "r123", "r124", "r125", "r126", "r127", "r130", "r131", "r137", "r193", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r339", "r340", "r381", "r397", "r484", "r555", "r575", "r576", "r653", "r785"] }, "us-gaap_NetIncomeLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAbstract", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEarningsPerShareBasicAndDilutedDetails"], "lang": { "en-us": { "role": { "terseLabel": "Numerator.", "label": "Net Income (Loss) Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "verboseLabel": "Recently Adopted Accounting Standards", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": ["r704"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": ["r668", "r678", "r688", "r712", "r720"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r695"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r694"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": ["r712"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r731"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r731"] }, "asmb_NoncashRentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "NoncashRentExpense", "crdr": "debit", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Non-cash rent expense", "label": "Noncash Rent Expense", "documentation": "Represent non cash rent expense." } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"], "lang": { "en-us": { "role": { "totalLabel": "Total other income", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": ["r47"] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"], "lang": { "en-us": { "role": { "terseLabel": "Other income", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "asmb_NumberOfApprovedProducts": { "xbrltype": "integerItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "NumberOfApprovedProducts", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "FDA approved products (in products)", "label": "Number Of Approved Products", "documentation": "Represents the number of approved products." } } }, "auth_ref": [] }, "asmb_NumberOfDaysVolumeConsideredForWeightedAveragePriceToCalculatePremium": { "xbrltype": "durationItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "NumberOfDaysVolumeConsideredForWeightedAveragePriceToCalculatePremium", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Number of days volume considered for weighted average price to calculate premium.", "label": "Number of Days Volume Considered for Weighted Average Price to Calculate Premium", "terseLabel": "Number of days volume considered for weighted average price to calculate premium" } } }, "auth_ref": [] }, "asmb_NumberOfDirectorsRightToDesignateInBoard": { "xbrltype": "integerItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "NumberOfDirectorsRightToDesignateInBoard", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails", "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Number of directors right to designate in board.", "label": "Number of Directors, Right to Designate in Board", "terseLabel": "Number of directors, right to designate in company board" } } }, "auth_ref": [] }, "asmb_NumberOfFellowContributedPrograms": { "xbrltype": "integerItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "NumberOfFellowContributedPrograms", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails", "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Number of fellow-contributed programs.", "label": "Number of Fellow-contributed Programs", "terseLabel": "Number of fellow-contributed programs" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Operating segments (in segments)", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": ["r617", "r767"] }, "asmb_NumberOfTimepointsOfProgram": { "xbrltype": "integerItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "NumberOfTimepointsOfProgram", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails", "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Number of timepoints of program.", "label": "Number of Timepoints of Program", "terseLabel": "Number of timepoints of program" } } }, "auth_ref": [] }, "asmb_NumberOfTradingDaysVolumeConsideredForWeightedAveragePriceToCalculatePremium": { "xbrltype": "durationItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "NumberOfTradingDaysVolumeConsideredForWeightedAveragePriceToCalculatePremium", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of trading days volume considered for weighted average price to calculate premium", "label": "Number of Trading Days Volume Considered for Weighted Average Price to Calculate Premium", "documentation": "Number of trading days volume considered for weighted average price to calculate premium." } } }, "auth_ref": [] }, "asmb_NumberOfYearsOfStandstillAndLockupProvisions": { "xbrltype": "durationItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "NumberOfYearsOfStandstillAndLockupProvisions", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Number of years of standstill and lockup provisions.", "label": "Number of Years of Standstill and Lockup Provisions", "terseLabel": "Number of years of standstill and lockup provisions" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r68", "r615", "r766", "r768", "r769", "r770", "r771"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities - short-term", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r411"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri":

```
"http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel":
"Operating lease liabilities - long-term", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease
payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r411" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel":
"Operating lease right-of-use (ROU) assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under
operating lease." } } }, "auth_ref": [ "r410" ] }, "asmb_OptionLicenseAndCollaborationAgreementMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.assemblybio.com/20240930", "localname": "OptionLicenseAndCollaborationAgreementMember", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Gilead
Collaboration Agreement", "documentation": "Option, license and collaboration agreement.", "label": "Option, License and Collaboration Agreement [Member]", "terseLabel":
"Option, License and Collaboration Agreement" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role":
{ "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureNatureOfBusiness" ], "lang": { "en-us": { "role": { "terseLabel": "Nature of Business", "label":
"Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and
basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r27", "r60", "r509", "r510" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other
accrued expenses", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or
the normal operating cycle, if longer." } } }, "auth_ref": [ "r30" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other
assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r90" ] }, "us-
gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": {
"en-us": { "role": { "terseLabel": "Other comprehensive loss", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]" } } },
"auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "crdr": "credit",
"presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": {
"en-us": { "role": { "terseLabel": "Unrealized gain (loss) on marketable securities", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before
Adjustment, after Tax", "verboseLabel": "Unrealized gain (loss) on marketable debt securities", "documentation": "Amount, after tax and before adjustment, of unrealized
holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes
unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r94", "r95", "r192"
] }, "us-gaap_OtherNoncurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncurrentAssetsMember",
"presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Other Assets", "label": "Other Noncurrent Assets [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent assets." }
} } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt",
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance
Measure, Amount" } } }, "auth_ref": [ "r704" ] }, "asmb_OtherRisksAndUncertaintiesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://www.assemblybio.com/20240930", "localname": "OtherRisksAndUncertaintiesPolicyTextBlock", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Other
Risks and Uncertainties", "label": "Other Risks And Uncertainties Policy [Text Block]", "documentation": "Other risks and uncertainties." } } }, "auth_ref": [] },
"ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding
Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r666", "r676", "r686", "r718" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": {
"role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r669", "r679", "r689", "r721" ] },
"ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [
"r669", "r679", "r689", "r721" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } }
}, "auth_ref": [ "r693" ] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PaymentsForRestructuring": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRestructuring", "crdr": "credit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRestructuringScheduleOfAccruedRestructuringChargesDetails" ], "lang": { "en-us": { "role": {
"negatedLabel": "Reductions for cash payments", "label": "Payments for Restructuring", "documentation": "Amount of cash payments made as the result of exit or disposal
activities. Excludes payments associated with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r225", "r757" ] }, "us-
gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PaymentsToAcquireAvailableForSaleSecuritiesDebt", "crdr": "credit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": {
"negatedLabel": "Purchases of marketable securities", "label": "Payments to Acquire Debt Securities, Available-for-Sale", "documentation": "Amount of cash outflow to acquire
investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r13", "r105",
"r160" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": {
"negatedLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "totalLabel": "Payments to Acquire Property, Plant,
and Equipment, Total", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to
produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r48" ] },
"ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation":
[ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote"
} } }, "auth_ref": [ "r703" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder
Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r703" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype":
"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": {
"en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r695" ] },
"ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r712" ] }, "ecd_PeoName": {
"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ],
"lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r705" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO
Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r694" ] }, "asmb_PercentageCoverOfResearchAndDevelopmentCosts": {
"xbrltype": "percentItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "PercentageCoverOfResearchAndDevelopmentCosts", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"documentation": "Percentage cover of research and development costs.", "label": "Percentage Cover of Research and Development Costs", "terseLabel": "Percentage cover of
research and development costs" } } }, "auth_ref": [] }, "asmb_PercentageOfOutstandingVotingOfCommonStockHeld": { "xbrltype": "pureItemType", "nsuri":
"http://www.assemblybio.com/20240930", "localname": "PercentageOfOutstandingVotingOfCommonStockHeld", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSaleOfCommonStockAndWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Percentage of outstanding voting of common stock held", "label": "Percentage of Outstanding Voting of Common Stock Held", "documentation": "Percentage of Outstanding
Voting of Common Stock Held" } } }, "auth_ref": [] }, "asmb_PercentageOfPremiumToWeightedAveragePriceImmediatelyPriorToDateOfPurchase": { "xbrltype":
"percentItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "PercentageOfPremiumToWeightedAveragePriceImmediatelyPriorToDateOfPurchase",
"presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage
of premium to weighted average price immediately prior to date of purchase.", "label": "Percentage of Premium to Weighted Average Price Immediately Prior to Date of
Purchase", "terseLabel": "Percentage of premium to weighted average price immediately prior to date of purchase" } } }, "auth_ref": [] },
"asmb_PercentageOfPremiumToWeightedAveragePriceImmediatelyPriorToDateOfPurchaseOrToDeliveryOfNoticeOfClosingDate": { "xbrltype": "percentItemType", "nsuri":
"http://www.assemblybio.com/20240930", "localname":
"PercentageOfPremiumToWeightedAveragePriceImmediatelyPriorToDateOfPurchaseOrToDeliveryOfNoticeOfClosingDate", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Percentage of Premium to
Weighted Average Price Immediately Prior to Date of Purchase or to Delivery of Notice of Closing Date", "documentation": "Percentage of premium to weighted average price
immediately prior to date of purchase or to delivery of notice of closing date." } } }, "auth_ref": [] },
"asmb_PercentageOfPremiumToWeightedAveragePriceImmediatelyPriorToDeliveryOfNoticeOfClosingDate": { "xbrltype": "percentItemType", "nsuri":
"http://www.assemblybio.com/20240930", "localname": "PercentageOfPremiumToWeightedAveragePriceImmediatelyPriorToDeliveryOfNoticeOfClosingDate", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage
```

of premium to weighted average price immediately prior to delivery of notice of closing date.", "label": "Percentage of Premium to Weighted Average Price Immediately Prior to Delivery of Notice of Closing Date", "terseLabel": "Percentage of premium to weighted average price immediately prior to delivery of notice of closing date" } } }, "auth_ref": [] } }, "asmb_PercentageOfThenOutstandingVotingCapitalStockSubjectToStockholderApproval": { "xbrltype": "percentItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "PercentageOfThenOutstandingVotingCapitalStockSubjectToStockholderApproval", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Percentage of then-outstanding voting capital stock subject to stockholder approval.", "label": "Percentage of Then-outstanding Voting Capital Stock Subject to Stockholder Approval", "terseLabel": "Percentage of then-outstanding voting capital stock subject to stockholder approval" } } }, "auth_ref": [] }, "asmb_PercentageShareOfProfitsAndOperatingLossForProducts": { "xbrltype": "percentItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "PercentageShareOfProfitsAndOperatingLossForProducts", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails", "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Percentage share of profits and operating loss for products.", "label": "Percentage Share of Profits and Operating Loss for Products", "terseLabel": "Percentage share of profits and operating loss for products" } } }, "auth_ref": [] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": ["r696"] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": ["r740"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": ["r695"] }, "asmb_PotentialMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "PotentialMilestonePayments", "crdr": "credit", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails", "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Potential milestone payments", "label": "Potential Milestone Payments", "documentation": "Potential Milestone Payments." } } }, "auth_ref": [] }, "asmb_PotentialProceedsFromCollaborationExtensionFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "PotentialProceedsFromCollaborationExtensionFees", "crdr": "debit", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails", "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Potential proceeds from collaboration extension fees.", "label": "Potential Proceeds from Collaboration Extension Fees", "terseLabel": "Potential proceeds from collaboration extension fees" } } }, "auth_ref": [] }, "asmb_PotentialProceedsFromEquityFinancing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "PotentialProceedsFromEquityFinancing", "crdr": "debit", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Potential proceeds from equity financing.", "label": "Potential Proceeds from Equity Financing", "terseLabel": "Potential proceeds from equity financing" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r36", "r252"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r36", "r535"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r36", "r252"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": { "en-us": { "role": { "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance", "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance", "terseLabel": "Preferred stock, shares outstanding", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r36", "r535", "r553", "r822", "r823"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r36", "r475", "r641"] }, "asmb_PremiumReceivedOnCommonStockPurchase": { "xbrltype": "monetaryItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "PremiumReceivedOnCommonStockPurchase", "crdr": "credit", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Premium received on common stock purchase", "label": "Premium Received On Common Stock Purchase", "documentation": "Premium received on common stock purchase." } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r753"] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrivatePlacementMember", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails", "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSaleOfCommonStockAndWarrantsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Private Placement [Member]", "terseLabel": "Private Placement", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromCollaborators": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromCollaborators", "crdr": "debit", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails", "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails", "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Proceeds from Collaborators", "terseLabel": "Proceeds received in collaboration agreement", "documentation": "Cash received from collaborators during the current period." } } }, "auth_ref": ["r51"] }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceInitialPublicOffering", "crdr": "debit", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSaleOfCommonStockAndWarrantsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds from the issuance of common stock through equity plans", "label": "Proceeds from Issuance Initial Public Offering", "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public." } } }, "auth_ref": ["r2"] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from the issuance of common stock under ATM equity offering program, net of issuance costs", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": ["r2"] }, "asmb_ProceedsFromIssuanceOfCommonStockAndWarrantsInRegisteredDirectOfferingAndPrivatePlacementNetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "ProceedsFromIssuanceOfCommonStockAndWarrantsInRegisteredDirectOfferingAndPrivatePlacementNetOfIssuanceCosts", "crdr": "debit", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of common stock and warrants in registered direct offering and private placement net of issuance costs.", "label": "Proceeds from Issuance of Common Stock and Warrants in Registered Direct Offering and Private Placement Net of Issuance Costs", "terseLabel": "Proceeds from the issuance of common stock and warrants in a registered direct offering and a private placement, net of issuance costs" } } }, "auth_ref": [] }, "asmb_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan", "crdr": "debit", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of common stock under employee stock purchase plan.", "label": "Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan", "terseLabel": "Proceeds from the issuance of common stock under ESPP" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails", "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSaleOfCommonStockAndWarrantsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "totalLabel": "Proceeds from Issuance or Sale of Equity, Total", "label": "Proceeds from Issuance or Sale of Equity", "terseLabel": "Gross proceeds from issuance of common stock and warrant", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": ["r2", "r512"] }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "crdr": "debit", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from maturities of marketable securities", "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale", "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r105", "r106", "r773"] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from the exercise of stock options", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": ["r2", "r8"] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "presentation": [

```
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": {
"totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total", "terseLabel": "Net loss", "label": "Net Income (Loss), Including Portion
Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the
noncontrolling interest." } } }, "auth_ref": [ "r85", "r96", "r98", "r107", "r112", "r119", "r127", "r130", "r131", "r193", "r239", "r240", "r241", "r242", "r243", "r244", "r245",
"r246", "r247", "r339", "r348", "r350", "r353", "r354", "r381", "r397", "r469", "r483", "r517", "r555", "r575", "r576", "r629", "r630", "r654", "r756", "r785" ] }, "us-
gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr":
"debit", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role":
{ "totalLabel": "Property, Plant and Equipment, Net, Total", "terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation":
"Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not
intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r5",
"r412", "r470", "r481", "r641" ] }, "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted", "crdr": "credit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureMilestonesAndResearchAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Potential milestone payment", "label": "Purchase Commitment, Remaining Minimum Amount Committed", "documentation": "Minimum amount to be expended
to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional
purchase obligations." } } }, "auth_ref": [ "r34", "r62" ] }, "asmb_PurchaseOfWarrantInAPrivatePlacement": { "xbrltype": "sharesItemType", "nsuri":
"http://www.assemblybio.com/20240930", "localname": "PurchaseOfWarrantInAPrivatePlacement", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Purchase of
warrant in a Private Placement", "label": "Purchase of warrant in a Private Placement", "terseLabel": "Purchase of warrant in private placement" } } }, "auth_ref": [] },
"asmb_PurchasePricePerShareOfAdditionalSharesDescription": { "xbrltype": "stringItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname":
"PurchasePricePerShareOfAdditionalSharesDescription", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Purchase
price per share of additional shares description.", "label": "Purchase Price Per Share of Additional Shares Description", "terseLabel": "Purchase price per share of additional
shares description" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } }
}, "auth_ref": [ "r693" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock",
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs
Performance Disclosure, Table" } } }, "auth_ref": [ "r693" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis",
"presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSaleOfCommonStockAndWarrantsAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedToEstimateFairValuesOfStockOptionsGrantsDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Statistical Measurement", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r234", "r235", "r236", "r237", "r274", "r282", "r311", "r312", "r313", "r321", "r387",
"r435", "r444", "r461", "r492", "r494", "r508", "r525", "r526", "r587", "r589", "r592", "r593", "r597", "r605", "r606", "r618", "r622", "r626", "r634", "r635", "r639", "r640",
"r643", "r647", "r783", "r787", "r798", "r809", "r810", "r811", "r812", "r813" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024",
"localname": "RangeMember", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSaleOfCommonStockAndWarrantsAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedToEstimateFairValuesOfStockOptionsGrantsDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Statistical Measurement", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r234", "r235", "r236", "r237", "r274", "r282", "r311", "r312", "r313", "r321",
"r387", "r435", "r444", "r461", "r492", "r494", "r508", "r525", "r526", "r587", "r589", "r592", "r593", "r597", "r605", "r606", "r618", "r622", "r626", "r634", "r635", "r639",
"r640", "r643", "r647", "r783", "r787", "r798", "r809", "r810", "r811", "r812", "r813" ] }, "us-gaap_RealizedInvestmentGainsLosses": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RealizedInvestmentGainsLosses", "crdr": "credit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesAdditionalInformationDetails" ], "lang":
{ "en-us": { "role": { "terseLabel": "Realized gains and losses", "label": "Realized Investment Gains (Losses)", "totalLabel": "Realized Investment Gains (Losses), Total",
"documentation": "Amount of realized gain (loss) on investment." } } }, "auth_ref": [ "r490" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded
Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r661", "r671", "r681", "r713" ] },
"asmb_RegulatoryAndCommercialMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname":
"RegulatoryAndCommercialMilestonesMember", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"documentation": "Regulatory and commercial milestones.", "label": "Regulatory And Commercial Milestones [Member]", "terseLabel": "Regulatory and Commercial
Milestones" } } }, "auth_ref": [] }, "asmb_ReimbursableExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname":
"ReimbursableExpenses", "crdr": "debit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Reimbursable expenses", "label": "Reimbursable Expenses", "documentation": "Reimbursable expenses." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSaleOfCommonStockAndWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label":
"Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which
investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be
prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r159", "r281", "r422", "r423", "r473", "r480",
"r528", "r529", "r530", "r531", "r532", "r552", "r554", "r584" ] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "RelatedPartyTransactionAxis", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSaleOfCommonStockAndWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label":
"Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r422", "r423", "r805" ] }, "us-
gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionDomain",
"presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSaleOfCommonStockAndWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label":
"Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionLineItems": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction
[Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with
domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r159", "r550", "r559", "r562" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions
[Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSaleOfCommonStockAndWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label":
"Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity
for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party
that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r159", "r281", "r422", "r423",
"r473", "r480", "r528", "r529", "r530", "r531", "r532", "r552", "r554", "r584", "r805" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRelatedParty" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related Party
Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions
between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r419",
"r420", "r421", "r423", "r425", "r514", "r515", "r516", "r560", "r561", "r562", "r581", "r583" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty
Name [Domain]" } } }, "auth_ref": [ "r113", "r114", "r248", "r254", "r424", "r445", "r471", "r610", "r611" ] }, "us-
gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Research and Development Arrangement, Contract to Perform for Others, Type", "label": "Research and Development Arrangement, Contract to Perform for Others, Type
[Axis]", "documentation": "Information by form of arrangement related to research and development." } } }, "auth_ref": [ "r323", "r792" ] }, "us-
gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel":
"Milestone and Research Agreements:", "terseLabel": "Research And Development Arrangement Contract To Perform For Others [Line Items]", "label": "Research and
Development Arrangement, Contract to Perform for Others [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are
used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r323", "r792" ] }, "us-
gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
```

```
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]", "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others." } } }, "auth_ref": [ "r323", "r792" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Research and Development Expense, Total", "verboseLabel": "Research and development expense", "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r322", "r607", "r616", "r814" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRecognizedStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Research and Development", "terseLabel": "Research and Development Expenses", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] },
"ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r662", "r672", "r682", "r714" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r663", "r673", "r683", "r715" ] },
"ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r670", "r680", "r690", "r722" ] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfFairValueOfFinancialAssetsD
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfInvestmentsInMarketableSec
], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r88" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfI
], "lang": { "en-us": { "role": { "verboseLabel": "Unvested RSUs", "terseLabel": "RSUs", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRestructuring" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring", "label": "Restructuring and Related Activities Disclosure [Text Block]", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } }, "auth_ref": [ "r222", "r223", "r225", "r228", "r233" ] }, "asmb_RestructuringAndRelatedCostIncurredCostBenefit": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "RestructuringAndRelatedCostIncurredCostBenefit", "crdr": "debit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring costs incurred", "verboseLabel": "Restructuring charges", "label": "Restructuring And Related Cost Incurred Cost Benefit", "documentation": "Restructuring and related cost incurred cost benefit" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": { "xbrltype": "percentItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of workforce reduced", "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent", "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)." } } }, "auth_ref": [] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCharges", "crdr": "debit", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Restructuring charges", "terseLabel": "Costs incurred", "label": "Restructuring Charges", "totalLabel": "Restructuring Charges, Total", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r4", "r229", "r230", "r784" ] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveLineItems", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Cost and Reserve [Line Items]", "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r224", "r225", "r226", "r227", "r230", "r231", "r232" ] }, "asmb_RestructuringCostsReversalOfStockBasedCompensationExpense": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "RestructuringCostsReversalOfStockBasedCompensationExpense", "crdr": "debit",
"presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"documentation": "Restructuring costs reversal of stock-based compensation expense", "label": "Restructuring Costs Reversal of stock-based compensation expense",
"terseLabel": "Restructuring costs reversal" } } }, "auth_ref": [] }, "asmb_RestructuringOneTimeTerminationCost": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.assemblybio.com/20240930", "localname": "RestructuringOneTimeTerminationCost", "crdr": "debit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Restructuring one time termination cost.", "label": "Restructuring one-time termination Cost", "terseLabel": "Restructuring one-time termination Cost" } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit",
"crdr": "credit", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": {
"role": { "totalLabel": "Retained Earnings (Accumulated Deficit), Total", "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)",
"documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r39", "r57", "r478", "r502", "r507", "r513", "r536", "r641" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } },
"auth_ref": [ "r81", "r115", "r116", "r117", "r120", "r127", "r129", "r131", "r199", "r206", "r218", "r326", "r327", "r335", "r336", "r337", "r340", "r347", "r348", "r361", "r364", "r365", "r368", "r379", "r406", "r409", "r498", "r500", "r518", "r822" ] }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": {
"en-us": { "role": { "label": "Collaboration revenue from a related party", "verboseLabel": "Revenue recognized", "terseLabel": "Collaboration revenue", "documentation":
"Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise." } } }, "auth_ref": [ "r66", "r67", "r144", "r147", "r148", "r151", "r153", "r154", "r155", "r156", "r270", "r271", "r463" ] },
"asmb_ReverseStockSplitPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname":
"ReverseStockSplitPolicyTextBlock", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Reverse Stock Split", "label": "Reverse Stock Split [Policy Text Block]", "documentation": "Reverse stock split." } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype":
"booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r731" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r731" ] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Proceeds received from transaction", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Upfront equity investment", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSaleOfCommonStockAndWarrantsAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Sale of Stock", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSaleOfCommonStockAndWarrantsAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares sold", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SaleOfStockPricePerShare", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSaleOfCommonStockAndWarrantsAdditionalInformationDetails",
```

```
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock, Price Per Share", "terseLabel": "Sale of stock, price per share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioForecastMember", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast" } } }, "auth_ref": [ "r283", "r763" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "auth_ref": [ "r133", "r283", "r742", "r763" ] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureOtherAccruedExpensesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Accrued Expenses", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "asmb_ScheduleOfAccruedRestructuringChargesTableTextblock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "ScheduleOfAccruedRestructuringChargesTableTextblock", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRestructuringTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accrued Restructuring Charges", "label": "Schedule Of Accrued Restructuring Charges [Table TextBlock]", "documentation": "Schedule of accrued restructuring charges." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfi ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]", "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": [ "r15" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r15" ] }, "asmb_ScheduleOfAvailableForSaleSecurities1Table": { "xbrltype": "stringItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "ScheduleOfAvailableForSaleSecurities1Table", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfInvestmentsInMarketableSec ], "lang": { "en-us": { "role": { "label": "Schedule Of Available For Sale Securities1 [Table]", "documentation": "Schedule of available for sale securities1." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesAdditionalInformationDetails", "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfInvestmentsInMarketableSec ], "lang": { "en-us": { "role": { "terseLabel": "Investments in marketable securities:", "label": "Debt Securities, Available-for-Sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Investments in Marketable Securities", "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value." } } }, "auth_ref": [] }, "asmb_ScheduleOfCollaborationRevenueRecognizedWithPeriodTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "ScheduleOfCollaborationRevenueRecognizedWithPeriodTableTextBlock", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureCollaborationAgreementsTables" ], "lang": { "en-us": { "role": { "documentation": "Schedule of Collaboration revenue recognized with the period", "label": "Schedule Of Collaboration Revenue Recognized With Period Table [Text Block]", "terseLabel": "Schedule of Collaboration Revenue Recognized with the Period" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r349" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r765" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRecognizedStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r20" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureStockbasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Recognized Stock-Based Compensation Expense", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r20" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": [ "r25", "r26", "r558", "r559", "r562" ] }, "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]", "label": "Research and Development, Contract to Perform for Others [Table]", "documentation": "Disclosure of information about research and development arrangement accounted for as contract to perform research and development for others. Includes, but is not limited to, royalty arrangement, purchase provision, license agreement, and commitment to provide additional funding." } } }, "auth_ref": [ "r323", "r792" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Cost [Table]", "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve." } } }, "auth_ref": [ "r224", "r225", "r226", "r227", "r230", "r231", "r232" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedToEstimateFairValuesOfStockOptionsGrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r285", "r287", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureStockbasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Assumptions Used to Estimate Fair Values of Stock Options Grants", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r59" ] }, "asmb_SecuritiesPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "SecuritiesPurchaseAgreementMember", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails", "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSaleOfCommonStockAndWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Securities Purchase Agreement", "label": "Securities Purchase Agreement [Member]", "terseLabel": "Securities Purchase Agreement" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r656" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r658" ] }, "asmb_SeventhYearOfCollaborationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "SeventhYearOfCollaborationMember", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails", "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Seventh year of collaboration.", "label": "Seventh Year of Collaboration [Member]", "terseLabel": "Seventh Year of Collaboration Agreement" } } }, "auth_ref": [] }, "us-gaap_SeveranceCosts1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeveranceCosts1", "crdr": "debit", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label":
```

"Severance Costs", "terseLabel": "Employee severance and related benefits", "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": ["r4"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": {
"totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total", "terseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r3"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedToEstimateFairValuesOfStockOptionsGrantsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Expected dividend yield", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": ["r312"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedToEstimateFairValuesOfStockOptionsGrantsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": ["r311"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedToEstimateFairValuesOfStockOptionsGrantsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Risk-free rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": ["r313"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedToEstimateFairValuesOfStockOptionsGrantsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r285", "r287", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314"] }, "asmb_ShareBasedCompensationArrangementFairValueAssumptionsExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "ShareBasedCompensationArrangementFairValueAssumptionsExercisePrice", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedToEstimateFairValuesOfStockOptionsGrantsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Exercise price", "label": "Share Based Compensation Arrangement Fair Value Assumptions Exercise Price", "documentation": "Share based compensation arrangement fair value assumptions exercise price." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314"] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharePrice", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Closing bid price of stock", "label": "Share Price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedToEstimateFairValuesOfStockOptionsGrantsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Expected term (years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r310"] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "periodStartLabel": "Balance (in shares)", "periodEndLabel": "Balance (in shares)", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_ShortTermInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestmentsAbstract", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfFairValueOfFinancialAssetsD
], "lang": { "en-us": { "role": { "terseLabel": "Short-term marketable securities", "label": "Short-Term Investments [Abstract]" } } }, "auth_ref": [] },
"asmb_SignificantAccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname":
"SignificantAccountingPoliciesLineItems", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Significant Accounting Policies [Line Items]", "label": "Significant Accounting Policies [Line Items]", "documentation": "Significant accounting policies." } } },
"auth_ref": [] }, "asmb_SignificantAccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname":
"SignificantAccountingPoliciesTable", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Significant Accounting Policies [Table]", "label": "Significant Accounting Policies [Table]", "documentation": "Significant accounting policies." } } }, "auth_ref":
[] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SignificantAccountingPoliciesTextBlock", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r53", "r110"] }, "asmb_SiliconValleyBankMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "SiliconValleyBankMember", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Silicon Valley Bank", "label": "Silicon Valley Bank Member", "documentation": "Silicon Valley Bank." } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis",
"presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSaleOfCommonStockAndWarrantsAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Equity Components", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r7", "r37", "r40", "r41", "r81", "r100", "r101", "r102", "r115", "r116", "r117", "r120", "r127", "r129", "r131", "r145", "r199", "r206", "r218", "r266", "r326", "r327", "r335", "r336", "r337", "r340", "r347", "r348", "r361", "r363", "r364", "r365", "r366", "r368", "r379", "r398", "r399", "r400", "r401", "r402", "r403", "r406", "r409", "r418", "r485", "r498", "r499", "r500", "r518", "r577"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfFairValueOfFinancialAssetsD
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r115", "r116", "r117", "r145", "r409", "r463", "r511", "r519", "r527", "r528", "r529", "r530", "r531", "r532", "r535", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r548", "r549", "r550", "r551", "r552", "r554", "r556", "r557", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r577", "r648"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] },
"srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": ["r133", "r283", "r742", "r743", "r763"] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfFairValueOfFinancialAssetsD
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r115", "r116", "r117", "r145", "r159", "r409", "r463", "r511", "r519", "r527", "r528", "r529", "r530", "r531", "r532", "r535", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r548", "r549", "r550", "r551", "r552", "r554", "r556", "r557", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r577", "r648"] },
"ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": ["r665", "r675", "r685", "r717"] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel":
"Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri":

```
"http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "lang": { "en-
us": { "role": { "terseLabel": "Issuance of common stock under Employee Stock Purchase Plan (ESPP) (in shares)", "label": "Stock Issued During Period, Shares, Employee
Stock Purchase Plans", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": [ "r7", "r36", "r37",
"r57" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodSharesNewIssues", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "lang": { "en-
us": { "role": { "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock under at-the-market (ATM) equity offering program, net of
issuance costs (in shares)", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r7", "r36", "r37", "r57", "r512", "r577", "r603" ] }, "us-
gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "lang": { "en-
us": { "role": { "totalLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total", "label": "Stock Issued During Period, Shares, Restricted
Stock Award, Net of Forfeitures", "terseLabel": "Issuance of common stock for settlement of restricted stock units (RSUs) (in shares)", "documentation": "Number of shares
issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": [ "r7", "r36", "r37", "r57" ] }, "us-
gaap_StockIssuedDuringPeriodSharesReverseStockSplits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodSharesReverseStockSplits", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Number of shares issued in connection with reverse stock split", "label": "Stock Issued During Period, Shares, Reverse Stock Splits", "documentation":
"Reduction in the number of shares during the period as a result of a reverse stock split." } } }, "auth_ref": [ "r7" ] }, "us-
gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "lang": { "en-
us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "terseLabel": "Issuance of common stock
upon exercise of stock options (in shares)", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r7", "r36",
"r37", "r57", "r297" ] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "lang": { "en-
us": { "role": { "terseLabel": "Issuance of common stock under Employee Stock Purchase Plan (ESPP)", "label": "Stock Issued During Period, Value, Employee Stock Purchase
Plan", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": [ "r7", "r36", "r37",
"r57" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "lang": { "en-
us": { "role": { "terseLabel": "Issuance of common stock under at-the-market (ATM) equity offering program, net of issuance costs", "label": "Stock Issued During Period,
Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary
public offering." } } }, "auth_ref": [ "r7", "r36", "r37", "r57", "r518", "r577", "r603", "r654" ] }, "us-
gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "lang": { "en-
us": { "role": { "totalLabel": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures, Total", "terseLabel": "Issuance of common stock for settlement of
restricted stock units (RSUs)", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "documentation": "Value of stock related to Restricted
Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": [ "r7", "r57" ] }, "us-
gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "lang": { "en-
us": { "role": { "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Issuance of common stock upon exercise of stock options",
"documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r7", "r37", "r40", "r41", "r57" ] },
"asmb_StockOutstandingDuringPeriodSharesReverseStockSplits": { "xbrltype": "sharesItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname":
"StockOutstandingDuringPeriodSharesReverseStockSplits", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Common stock shares outstanding due to reverse stock split", "label": "Stock Outstanding During Period Shares Reverse Stock Splits", "documentation": "Stock
outstanding during period shares reverse stock splits." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS",
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "lang": { "en-
us": { "role": { "totalLabel": "Total stockholders' equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent",
"documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r37",
"r40", "r41", "r54", "r537", "r553", "r578", "r579", "r641", "r655", "r759", "r782", "r803", "r822" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel":
"Stockholders' equity", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSaleOfCommonStockAndWarrants" ], "lang": { "en-us": { "role": { "label": "Equity [Text Block]", "terseLabel":
"Sale of Common Stock and Warrants", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r56", "r111", "r251", "r253", "r255", "r256", "r257", "r258",
"r259", "r260", "r261", "r262", "r263", "r265", "r266", "r370", "r580", "r582", "r604" ] }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "xbrltype":
"pureItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Reverse stock split ratio", "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "documentation": "Ratio applied to the conversion of stock split,
for example but not limited to, one share converted to two or two shares converted to one." } } }, "auth_ref": [ "r58" ] }, "us-gaap_StockholdersEquityReverseStockSplit": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityReverseStockSplit", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Reverse stock split description", "label": "Stockholders' Equity, Reverse Stock Split", "documentation": "Description of the reverse stock split arrangement. Also
provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements." } } }, "auth_ref": [ "r58" ] },
"us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event
[Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary
line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r404", "r427" ] }, "us-
gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent
Event [Member]", "terseLabel": "Subsequent Event", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued
or available to be issued." } } }, "auth_ref": [ "r404", "r427" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SubsequentEventTable", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ],
"lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between
statement of financial position date and date when financial statements were issued." } } }, "auth_ref": [ "r404", "r427" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent
Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } }
}, "auth_ref": [ "r404", "r427" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SubsequentEventTypeDomain", "presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent
Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } },
"auth_ref": [ "r404", "r427" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEvent" ], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "terseLabel":
"Subsequent Event", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial
statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement
of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } },
"auth_ref": [ "r426", "r428" ] }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSaleOfCommonStockAndWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table]", "label": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]",
"documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes,
but is not limited to, stock issued in business combination in exchange for share of acquired entity." } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSaleOfCommonStockAndWarrantsAdditionalInformationDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Sale of Stock", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-
gaap_SubsidiarySaleOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockLineItems",
"presentation": [ "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSaleOfCommonStockAndWarrantsAdditionalInformationDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Subsidiary Sale Of Stock [Line Items]", "label": "Subsidiary, Sale of Stock [Line Items]", "documentation": "Line items represent financial concepts
```

included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": ["r711"] }, "asmb_ThirdYearOfCollaborationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "ThirdYearOfCollaborationMember", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Third year of collaboration.", "label": "Third Year of Collaboration [Member]", "terseLabel": "Third Year of Collaboration Agreement" } } }, "auth_ref": [] }, "asmb_ThresholdPaymentOfOptInFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "ThresholdPaymentOfOptInFee", "crdr": "credit", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails", "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Threshold payment of opt-in fee.", "label": "Threshold Payment of Opt-in Fee", "terseLabel": "Threshold payment of opt-in fee" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": ["r703"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": ["r710"] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": ["r730"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": ["r732"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfFairValueOfFinancialAssetsD
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfInvestmentsInMarketableSec
], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": ["r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r250", "r264", "r369", "r394", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r486", "r631", "r632", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r642", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r778", "r779", "r780", "r781", "r794", "r797", "r798", "r799", "r800", "r802"] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": ["r733"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": ["r734"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": ["r734"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r732"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": ["r732"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": ["r735"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": ["r733"] }, "asmb_TwoThousandAndTwentyAtTheMarketOfferingsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "TwoThousandAndTwentyAtTheMarketOfferingsMember", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSaleOfCommonStockAndWarrantsAdditionalInformationDetails", "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "2020 At the Market Offerings", "label": "Two Thousand And Twenty At The Market Offerings [Member]", "documentation": "Two thousand and twenty at the market offerings." } } }, "auth_ref": [] }, "us-gaap_TypeOfAdoptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfAdoptionMember", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Accounting Standards Update [Domain]", "documentation": "Amendment to accounting standards." } } }, "auth_ref": ["r79", "r80", "r81", "r82", "r83", "r84", "r119", "r120", "r121", "r122", "r133", "r157", "r158", "r196", "r197", "r198", "r199", "r201", "r202", "r203", "r204", "r205", "r206", "r217", "r218", "r221", "r326", "r327", "r328", "r329", "r330", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r395", "r396", "r405", "r406", "r407", "r413", "r414", "r415", "r416", "r417", "r418", "r464", "r465", "r466", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507"] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails", "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSaleOfCommonStockAndWarrantsAdditionalInformationDetails", "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails", "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails", "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r349"] }, "asmb_USAndForeignCommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "USAndForeignCommercialPaperMember", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfFairValueOfFinancialAssetsD
], "lang": { "en-us": { "role": { "terseLabel": "U.S. and foreign commercial paper", "label": "U S And Foreign Commercial Paper [Member]", "documentation": "U.S. and foreign commercial paper." } } }, "auth_ref": [] }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USGovernmentAgenciesDebtSecuritiesMember", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfFairValueOfFinancialAssetsD
], "lang": { "en-us": { "role": { "terseLabel": "U.S and foreign corporate debt securities", "label": "US Government Agencies Debt Securities [Member]", "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)." } } }, "auth_ref": ["r612", "r623", "r815"] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USTreasurySecuritiesMember", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfFairValueOfFinancialAssetsD
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAndInvestmentsInMarketableSecuritiesScheduleOfInvestmentsInMarketableSec
], "lang": { "en-us": { "role": { "terseLabel": "U.S. treasury securities", "label": "US Treasury Securities [Member]", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": ["r612", "r623", "r625", "r631", "r815"] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": ["r729"] }, "asmb_UpfrontCashPaymentReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "UpfrontCashPaymentReceived", "crdr": "debit", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails", "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Upfront cash payment received", "label": "Upfront Cash Payment Received", "documentation": "Upfront cash payment received." } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r17", "r18", "r19", "r72", "r73", "r74", "r75"] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": ["r699"] }, "asmb_WarrantExcercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.assemblybio.com/20240930", "localname": "WarrantExcercisePrice", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSaleOfCommonStockAndWarrantsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Warrant excercise price", "label": "Warrant Excercise Price", "terseLabel": "Warrants exercise price" } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": ["http://www.assemblybio.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails", "http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSaleOfCommonStockAndWarrantsAdditionalInformationDetails", "http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfI
], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "terseLabel": "Warrants to purchase common stock", "verboseLabel": "Warrant to purchase common stock", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": ["r645", "r646", "r649", "r650", "r651", "r652"] }, "us-gaap_WarrantsAndRightsOutstandingMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingMaturityDate", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSaleOfCommonStockAndWarrantsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label":

```
"Warrants and Rights Outstanding, Maturity Date", "terseLabel": "Warrants expiration date", "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format." } } },
"auth_ref": [ "r797", "r798", "r799" ] }, "asmb_WarrantsExercisedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.assemblybio.com/20240930",
"localname": "WarrantsExercisedDuringPeriodShares", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/DisclosureSaleOfCommonStockAndWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Warrants exercised during period shares", "label": "Warrants Exercised During Period Shares", "documentation": "Warrants exercised during period shares." } } }, "auth_ref":
[] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEarningsPerShareBasicAndDilutedDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": {
"en-us": { "role": { "verboseLabel": "Weighted average common shares outstanding - diluted", "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
"terseLabel": "Weighted average common shares outstanding, diluted", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average
number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or
units in the period." } } }, "auth_ref": [ "r135", "r140" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEarningsPerShareBasicAndDilutedDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Denominator:", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [
"http://www.assemblybio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEarningsPerShareBasicAndDilutedDetails",
"http://www.assemblybio.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": {
"en-us": { "role": { "verboseLabel": "Weighted average common shares outstanding - basic", "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
"terseLabel": "Weighted average common shares outstanding, basic", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic]
shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within
a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r134", "r140" ] },
"ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label":
"Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in
Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r697" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r2": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10",
"Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5":
{ "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r8": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10",
"Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r11": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r13":
{ "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r16":
{ "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-
4" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph":
"8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-
9" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph":
"2", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r21": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r23": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r26": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting
Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-
10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r31": { "role",
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-
02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-
10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r36": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-
02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI",
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-
10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r42": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-
10-S99-2" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r46": { "role",
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r47": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-
03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI",
"https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r50": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher":
```

"FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "326", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "326", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",

"Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-3" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r183": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-2" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/420/tableOfContent" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name":

"Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12A" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r310": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-5" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r373": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",

"Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r437": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r438": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r439": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r440": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r441": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-
50-7" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r445": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-
50-50-3" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r449": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r450": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r451": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r452": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r453": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r454": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r455": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r456": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r457": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-
50-50-4" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r461": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478345/912-310-45-11" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-
65-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r466": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r471": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r472": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r473": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r474": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r475": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r476": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r477": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r478": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r479": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r480": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r481": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r482": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r483": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r484": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r485": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r486": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r487": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r488": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r489": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r490": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r491": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r492": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-
40-50-7A" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r496": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",

"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI":

```
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-
50-2" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r582": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-
45-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r586":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r587": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r588": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r589": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r590": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r591": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r592": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r593": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r594": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r595": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r596": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D",
"Subparagraph": "(SX 210.12-13D(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5D" }, "r597": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6",
"Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r598": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6",
"Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r599": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7",
"Subparagraph": "(SX 210.12-15(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r600": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7",
"Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r601": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7",
"Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r602": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7",
"Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r603": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-
50-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r607": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r608": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r610": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r611": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" },
"r612": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph":
"1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r613": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r614": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r615": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r616": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48",
```

```
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r617": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r618": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r619": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r620": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r621": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r622": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r623": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r626": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r627": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r628": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r629": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r630": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r631": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r632": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r633": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r634": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r635": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r636": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r637": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r638": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r639": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r640": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r641": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r642": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r643": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r644": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17" }, "r645": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r647": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r651": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r652": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r653": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r654": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r655": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r656": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b", "Paragraph": "1" }, "r657": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r658": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r660": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r661": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r662": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r663": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r664": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r665": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r666": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r667": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r668": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r669": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r670": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r671": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r672": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r673": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r674": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r675": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r676": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r677": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r678": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r679": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r680": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r681": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r682": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r683": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r684": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r685": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r686": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r687": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r688": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r689": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r690": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r691": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r693": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r694": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r695": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r696": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r697": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r698": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r699": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1",
```

```
"Subclause": "iii" }, "r700": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r701": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1",
"Subclause": "v" }, "r702": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r703": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r704": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2",
"Subparagraph": "vi" }, "r705": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "3" }, "r706": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "v", "Paragraph": "4" }, "r707": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r708": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r709": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5",
"Subparagraph": "iii" }, "r710": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r711": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r712": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r713": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" },
"r714": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w",
"Paragraph": "1", "Subparagraph": "i" }, "r715": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r716": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r717": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1",
"Subparagraph": "i", "Sentence": "C" }, "r718": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r719": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r720": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1",
"Subparagraph": "ii" }, "r721": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r722": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r723": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r724": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r725": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r726": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2",
"Subparagraph": "ii", "Sentence": "C" }, "r727": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r728": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r729": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2",
"Subparagraph": "ii", "Sentence": "F" }, "r730": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "408", "Subsection": "a" }, "r731": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "408", "Subsection": "a", "Paragraph": "1" }, "r732": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r733": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r734": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2",
"Subparagraph": "C" }, "r735": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408",
"Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r736": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r737": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r738": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii",
"Sentence": "A", "Number": "229" }, "r739": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402",
"Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r740": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i",
"Number": "229" }, "r741": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" },
"r742": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r743": { "role":
"http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number":
"229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)",
"Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r747": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r748": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher":
"SEC" }, "r749": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c",
"Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r750": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229",
"Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation
S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r752": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r753": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r754": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-
10-50-5" }, "r756": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r757": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17",
"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r758": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r759": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r760": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r761": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r764": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-
50-1" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r768": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-
10-50-32" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r772": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-
50-2" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r778": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9",
```

"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r779": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r780": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r781": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r782": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r783": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r784": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-
20-50-1B" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r789": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r790": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r791": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-
40-65-1" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
"35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r795": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r796": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r797": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r798": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r799": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r800": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-
50-6A" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r804": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r805": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-
50-7" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r809": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r810": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r811": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r812": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r813": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r814": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942",
"SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-
310-50-3" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r819": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r820": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1" }, "r821": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r822": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r823": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 55 0000950170-24-123402-xbrl.zip IDEA:
XBRL DOCUMENT begin 644 0000950170-24-123402-xbrl.zip M4$L#!!0 (UDPHQA!$NG.UZ57/>+W-TGU+8\H]ANVV/9NSOO%T==+4Q3 MA 8@;6M^_?/G[=# M*L=--9I.X%W-
MJ^.GA8(S1_^O(XV?UZ\L)-8[%!,.2($8?Z.R!W.=X3:%DRS M_P_C'8S/?:TZ/JG+CX>3X@?_8Y&_!>\>C^-H%$^*E^78CGU1\7!XJU;,$R_ M7>R.1L7;_+6F>!N;6'^*87OVT,,)K
>LR;CY^PCI.8&IQ M<3^L_!]?N3U?=K8YO?W+E?LOS"]?*=Q:?KGIN20/(Y,\4WQQ^[@:OP+*UZ6_ M_FMA4C^=G!S'IW C&L_N//U54UXW)I@!>?]_O_]VX_CD467IQ[BI=5OHM_^
M6'UZ^A>>9H98W#AMT$=KCTJO3K9Q[0OF%R[<7#85IT1]C02S.Q9?B#Y0&;;ZPO/(\BS! C M9Y2<(!C4A>\M!GE&R*>3VHZ;5-5'[;LSG07"^MQS;'JD+CS$-
DT\+D5$+A[2U).KI(8/+_+$I+Z1 MQ.8I7'WRR[\5/QU&&^#?XJ=).1G%7PA&?_OIZ>SW_.E1G-A6S:'XSVGYZ>M[GB:G_IT_MB?7!5.BF9R,HH_/SFR]<=-R
MO%/8Z:3Z/^71<54#LT^>'=N0-?).H8^_/;MK@ YC5E\[!?GVI\U$*#\MGA'* MYGAD3(L1KCZ4_EE)(\]UK-?RQ#BN/WU3%B+$KCWY8? K:7:2F2U=8@399$E M3B*LO#%1.&
<82.O8'N6WQ'+G^;2N86HO 0GLZ_.1UGOCD/7W?-)?)F]C@N7X M@'7$V*> 5' 8GFL(TEY]!,_$7&EM9)!/?D&(4."SGYY>&-KU(\4D&D]"0-QC
M&*GC&%G+$TJ212>B"#ZY\R/=&P.]3I[#8&L[VA^:^.6_XLG=AHE!'W$J-<.W M&FE0FDI%/0I.1<1%-,0B9$C/$@I E9&G!_1+N!FR-CY*O! MQ9BXU#0B3X5!7/& 0' 92L8%+30/$:?
S@UO@^'HSB;^)57@)G55W&^C?V VC M?%E,WUH#LV$RRR03B2#E*#R-NHA,8@P$GDO%#*.4D,4PYJ]\YWEU=%1.\F"; MW7'((@D"!*9-&:\,UOA I>0?WA_ M\
(T2%/NC,L1R'4]C2#2-PP]14PJZ%!N'-%N)1$Y+!,LA'8N"2^==?<8.L.! MBJ0TB ! MK@D%-8(AH@W4 MES1W&/)25SE19KVSR ->0#U@($)(00/%ZZVE27!#'+@^Y>EA-
0*=WNP!YDQ. M7E63V'YZ<#PJ)\ R6+J=^P%(G#@A+MD 1& *5A/;(82(BM9]!PF8K2=KT4*B5G-2PZC!C4,XX> M&6P\ @BQD4?.N0!=+0466M]R*0@+1"
<)@P'@1APX!&FI0!0M9LK!R*A-72\% MU=)&'$"M*@O+SQT@50H$ 5"1!"@1X*V=+85F[)9+$9T&T4B@\K7EH$&S>:*$ M1L^N5K#N6_/[?-85[W3[$ .B_@ZL4
MZUL99\#NFA&@L70)P"S!]+2@%D: $^71I<#TIL^1@=]F, /K,'*PXY7&2 . M XLYK2C75NN-GZ.6TMA('5A/F0X$9FNL4\AYG8AE(>EX!=8V;8[*@OH1#BRM
MX%A6T@RY$!5BBA/,O3!>BP[F>"M#;%ES3,83,)4XH@ YB.?(A<$ 251Z!W:4 M2]1=P>1-FZ,AQ]7LJ>A$P>97X&X9 HX7*"(^GG:P-$=8-GN.) 0)?BU(AI,6 M]"I8F"8:BA+ *_S?.:*N>)-
]GN/3BU&=UIT!,S$VO_R4([D]31LXA5$5;61W M)\<'?W[2E$?'HQQ%;3\[K/.@>V?[95-.Z_:N-5._ M9]XN\/,FH)[,\#3#3'!]%,P2)ODLA]I?-(LTNB?++X:V\C,X]\RY+]3&>NB M'7:\-
ESY?/^_+L9A+G]Y\;@F?LPTF_T9X&5?P.3QY62VDD4HCS(=J_$YWQN6 M/#O=%U=^]TO9//EE<<_OU3B>_&[K/^+DY70<3NER[4N^X]TO;5FW_N>O(Z>_
M_A5F8VM_>/);_:1'%\=Q>M/^^\@Z:=H[Z!(&\WNT>9NG#?S4\9]38(23&T9R M[M;F;?33NB['\QI*>7:/7T.L8X;F--IV52;@),?@%>98NHX<4KB[\7WWMZ M@5%OX%LA(_@X!D0
'#N%>B]H,':#E)B"@@&_E%?^?9TKVL?%J!N@W0S$F69 MWGE_#S]LJIC^7&^L; Z [_P!'C.\K:::N*4-IZY,#0)_7J?75SPGSN_5 MN\-JVMAQ *E^]QF>?
K([>7<89Y4*T.@%6+YU6>+8IV VM@DX&8/$RPGN3=K9D6P03^=[J(I]=.AQG.W6H0PV>OF%VY MVTI%$RS 4M02K',9-2@<\/,\TXICS'4*NJJF&%7EL0,DO\NV])!Q0DC!P M(SEW
K0QIDA'FT"%4(ET9'8_FKC'@)EEZ3)>T^,2B28YX@3#$#H\T8ZLSRI M("01N&^D:>K)SEL[_AAG),A__FZ_E$?3HR5;CMVMNJ,B:0L81WP.>RJ&-.42
M]+H63DD58@A]@SQ@.G5+R.,=0EZ4GG@OD.+!(,Z -6W>_P<@!,Y,.H2D^L:? MWZDZ=D,H

-D[$8L>1S'N?7%!@8RXLLLH'YHCU6O,7Z.]M'"*8')IF1BE!P#!!1 H-+ M9\!X59(CL,A"E'[O>,&^$7:5+L/E0-%M2=1AH,A(@ZTE!(&K,1$'$QH98AD*
M(F@&WH;1/8:082=C],I:&4TP)2B9"/Q""*CIR&,6:4<5BS:9PI(O$(1]"#1Y- M0$XRAKQ(DC/);*)NPZFRZ_WT:#]">\/KR6&L\WUU/,Q/^P16NZ^.XL;(D*/< M^Y10',4/DRD2&HO(Y
M:66/XCD;_R_E*-IPX,LV MXS!CS)Q"X;X*L,YNX*W9+:>'ODZ[=9W??V<#=#?2@!?BFUEWVAD735+ M']W]6,?V"TMW2 F^M4,*MY[E>-5'(,6$^B0CR1M>!@PE') U/B>'&F)X(& Y
M+7^\;\?M$M,-D)+ LB%(*[XO&4PYIX@9L!=%KEX5S,L>VQU?X^$1.W1N&M U^RHZB*9=(3I8%Z0KML VBDF:5($&(L5<++1Q/M*QYZDW_3: M7.PP-=0*["RG$;$0TK"TE$PSRC-
FVLF.&2$]4A2H([G0CG96_URR\#3 M_]AL='S+DNBYR?_H3*003=0.(^$IJ [F+#*Y^XEVTK#H.#:JM\E 0^[*@(+ M-
HZ!8.4CLA)'Q!68;XX*,/PE3=%A@,7ENZM+5J\KW&WI*M3EA%*4>H8\F">(-M4^&0=8!\PFBA>+)<^=[9),U+(^]!&8O+,:\X4RCF#3,NK4$VQRVQQH =5!*@-M:K^"0;->I)VH%B>IC

*<+0L;SY!/)J=]:(2X<-]$F%]B D(-GV,_-!F? KPB) M(4YD0ERGA"P1!'&,/<-4Y"81?67>KYGiN{6;3J;-KV5U?&CK({NZ8/PZLL.< M4\81;E$DX.3S%##2S!%$M$T8L-28_F[G]3C;I\,=Q<43<0X)#4'8>/P]PH M!3 96')1>Z'LAE-H=?9G9U3QU}J /4%!@Y ME_:LVU[SZ\GY*RO9E+]%TOU9K];R${SRS44(6'8@2BFW MU@Y@(M@4,0BL=R!2A"C6NRXXO4HHN=6V0R>L^8@32KP"1> ^L1MX$#[&'C5&+(@F+!&,.^B"Q8,VM -P HJZG^LJ,)ZRA%FEJ+5!6)>2L!,5N MI#6).J)t[ZK_^MD':(A? KCQ^Z9/%SDW5Y4H)$B1Y8 X) (OF,BR@K>V^#[NZMAS6_H64Y<]=$C*S3\|JTEY/;R=ZF'S[0(^C5OY!0ZYSDF 44M ^)!<*2MD\@! M#VC'"%X!{-_%HEY7<=4:$C"H2Y8'11$2\(-KQ9!NFT6'0P1TDC7NQ+-M1U_ MM"8I\L[&P -B##0I=SF;.U'",*>*Q*A8-+W====F8S?U%V%+18$2[H1:LC> 7 MA80T20XI!GZ CT3,_EG[ZSQ\;!TDBAPSRL$##R[$@H! H2)Z+[R"/)[-4PY? 3<=B8QBHT,4P#5RCFE!*.+6A% M#10B1IAHL-3}1)5)T>MMM<5WAJ>6P!\.:B1K+ATQ>;O9(:>P1#0XJDE,7"S_ MB(2U>=^,,BN384A:+V$%!$?..XTD=E[2?/: <[FVFXP/ROM=C+(C£/;78(H" ML+ ^D!+F=0A%1(QB& 2HSX.N93WTU.T0U%5(=) %_1"M3"62\4309YZ,#48BMJK OME%K&O+\%^FJI,4\6M42C17/;KM,NM'?,!0>!=&*X=};U-Y}R0*IGU!%29]H8) MQ1"@=VZ9HCPRR0=P1'(7Z1"EI;WU0?I9N="=_M9!1"$}TE9,Q 4-R!H-M \J M)T"Q'%O;<-*LK3G16E1HL%H @S#B$DB:X4A3C1&CQCA 8]_C[HB/<)N1.8*9 MQ0X)GNN&@O'(98-7YP-,<]-1TC_KJ9\)Z4-!\VK#$X%J'5E$WOL MGR:[GH 11SA(*X"&B;G<$3H@QZ-#VA/6]O.3IK>-.'I/TO4XC)QS$CDAR.)\ ML!RW//?8S)7OF#CBG8^J=YLC&Q8#[- 8X$!9)8A"7EF9.^%$Y#18L]8K&@PH+>I%KEH(6^#,H4LX[DQEHETZ)S0'^N)^V",$!11 M+QB0C+O<#E8B+,:EEU(%-Q7OKKWZ#6G<^D/K6 ^A-[\#EE%/R$%)R$M0^T_G(M-7 .-182@7QK3 EP#5DZ,}S!N]&@RVYIW9_J3[6C2 8(%,3D8@RMS=E/K>M MD"G0A%Q,QE#>6Q^DATVC'EP[T+6KM ZV3F]L MB#{(NS.4I+Q;(CEPD#0862,((4A<@]%;8[3W<9_U5',(\!]B;H]B5+:,_MN,PE[%0CC+7QGBF/;6\MHZ%Z= AJG+*QI."4-(JJ361B'++1+!],241@9$%D M;[&M=SGW'88O1""$^X"1,/F469/[OSDP/(S2EMCDP(+1;2_'#4DP6\\6D "G M.=F8*=D>11 (JOT; E*<*7@/33KNP??4F8]^!5($14+YF) CHF(K.8T.FM3E+W3 M):LL^EY.!VTIJ<2]M:9ZZ?E_VCD52M#I4F(MF=P!(#*)+,,6!>.4I"ZI$'I[!N?C;@*]'EM1&I$(! fJ,>M#JG&F*7-0.>>%4 MDMAIOOQFK&O,I)/.>TG 4"8&YI.(&RO?^ MV,O+]A(Q@^O?6Y8]U/<A>S(%10E)@C^B.@JLJ"(UD9A1!H"(- 3G!A61.$R\'PW@PC/NG?9AV MW/B$A& *<>P"T@I@,P&,FLB2BOTJE7$#3KM?DS*23'&E&%)@]@"NX'S*IL"(M,4FWMDV^">/6;&U9;,:7"GJNL<"6R M8"$!H%IB-3%,TMX:2$- VVIIYQTKMF0I(Y,U(;AA&FE&+=%+$:\J32+WMC-$O MO7.3!FXC#>\/P*IX6=6Q_#C^OOS;@7F_QKS),([S#FU."09_ CDG/)))QMQ&-/H2Y^^ ' KU<, P0R^6=*AZ0(?"%@R(ST'#W\@8;_JO4"8MXZ@ 3PA,VQ3+*0D%+"$;>M,_V5PF~G/76RBWC?\2PA,VQ3+4U$3+%&.)*0CP.U MR%KB$'Q&E"54X/X5Y@R;Y-^&GG5DY*F4- K62TW^GXW)&G_PSU7GC@?&OSZG4]K\XGS7/GK)SV_^)V//)A1_?I'SB]^ M_RC#U-_PR/G%[WSD^X,75QY7-A6G1(`_}.)[GP:_QM":.: TH/_"X2F]?9.U6 M-VVQP^F[0OD)1/+\ (UZ!^U;G@]?O.)PKW\\?OHCCZ@B>UMNN?"(IQ=' M?V$UGI9?=N!9U;0&2)G]>0@@TRH"^,(O_U84/\&_13,Y&8'N.K8A@-N')M7Q M#MX6Y?C9OU Y#0^\+#F+/X(7H$/$GB\D.@2O'5=-VOX?GC]=JF>N^'H*:\E_P M@!T #G@)@D^>P(>+YZ?0,;S+7&'X./)LR-;?X2!MF]UEY+[J@4E MG(^5+% {5P:Q/%W7VY&UQ/"E"-76C>,!%X5VMQX65N'G:WWS?S>0&\P3,I\OS M\]6HJG?^',?_/;MYMI]G[.NJ43A/%7K'^;]_M:?]N[T5Q\&WW=[!]R_#G7F^ M5XMPL/?_=O]=_M{!\7NJQ? %WO\^_^ONJ[_L%<|?_[[_L'!_NM7&[XRYIHX+ M\S^V.01-,*G&6\6+[>?,!<6"FYL685ZI++T[3&P3K?[T;&FZ1,)7+VH3W&J3 MIAJ587%OW2Y&.Q;QIV\Q<=TC%RQCND5"]U9N%Z^?OM[L9C\^?%(Q]+A)<@#[MXVK<6B.E;^VBEQ^(C$12\)N3T F\'DR1X5+E_A;""FTP-?%),;?*W\:4/26L M(\8^!:1"VP[#$*2]U,A$@;G2VL@@GQ1CF_V@$,N=%Y5O ^#9\>S'@H+3^+=3 M9KJP++_T0C(OH_P@EXO9_6/:@+-\LL[I32S86HL7S^F4WYPM7AAKOHI&J]2: M3N!I7V)X-GLRP7@;_VE'I6}]=C^,F@@M^;'-X!]X&#X>GUXM'?RJ;TI4C<,AW M%G?//;X*[PNG,VX?S/YVWN^<3F!G>3V_XB!'?^LY/3R?UY4'-3?^,AM>N^6>8 M'G)UM'_LM#]1_N":87^*]00\L-&VL M8),(!5TNQ]_>[[Y]M_?VM[\?;_?>O'([KGCS_NW!^]U7[XIWKPLPDM^!)5P0 M5KQ^6Q#Q0_BQ>/VR>/?7O>*<_7QJ.^\^?YNX$$_X_^N*Q4#RWQ,R'Q5G9E@(@ MT& F").D.JDK[?6FG+!1(07?M!/@$'<%,#O/74+ GZ"3:&L5Q+RAS$(\G MLS \PUO+(816@:<@)8+5%1E&,"*$"N2B25C%E$1W,/*R;$#[_AT6^"5\OTIO MB?.>P;?@Y'8V^]TQ* #NV>#UV\'MV)P*P.WXD,,5@=I$XI1! !F:9 1^6#! M:+C3VCLK96R_277NC^VU+]? #-TS0\Y$+9N<252D$FR/\30[-CO+\6J{CC09 MHA$ATN5^-@!@WG%$$Q$X18ICNK=7L}>F+ fV$N;QJIJ"+5<8Y_4@+%:]X<"^ M:W]]#9N!WQQ@OX6V@\TWK'!0D*$<89X5!PY3R(2CL>4+VA^;\MN)A-OX\>V MCGP\R>FF_=B$VSTXV/O}U]_^7ORZ__K@^?[>J^= [!UO%_JOGVWUU\^1A2 M%S_L?;%^TE*PJ%)Q1KG"-D5S"W.%0U%.2!*25/XP59"^&/O?>.5.LXOZZ"L+ M_/W.\K>_TYVS?-596_S_"W%Fj=X@~AY^D7! (*_B]BTG"P)XA$3H$JC8(G+@CU MS'1D3YSEX)>Y;@<8I4W2KT^>5R%>=9^;?,=Q77W*S^DD:GX3:+R((_O9YASE MY?K(?2!WU"Z&8#FEEGK M^/\&6E%#Y3? #WM":BNW!7B_5>Z]4OQC6I=-*-MJ*D#9 MWH63NE^_>VWVP?;Q,P??UUUZ]N[H.5WS?>:5/B-BB$.1NE@E'9I82(F;!8(*R20%Q',$J#HB@Y M+^/%OFH39NK\2=D.H8]/__FM'$>RS-V'SU7QKOH,L-&>EV_J;M/8-.N-&0W'&@_QC66Y]W-JYAV#XQI$MCRVIHR>]B;X]NP\`M:!D_\D39A1'H"(-`

M$6]B)[6BYZBVHE":<\IS*@-24<,H'%("@/L&+P#[O42:0_S(2)Y M@CO9AKDRJ[N';ZY.36XQP;I/$A8\(3E,P6=5KD(@R%'O48 ZEY@S##CRYE5ESPHMKBF6T1<MU]9F]8'"S)'G(H7?J5&W"GC4<831?HJC;^8V#5&%'DWWD405EJ9A!196)T%! MD2@++D:,R+GDX8HD[MX85,"265CW8S$2,':@<%;YQ74I%P-27EGC92EWIIB6>Z,00S#[F,*PFZ[H90 M9NZRH^+8E@&&7GA[7$[L: "+!RU? UA<'"%71}}4"L& BQZN,4LAP<@%3E0K-MK()DO LC]DS36G4(V MC/?'(-7Q-Y#E5W'R.KVS7VZ/50VL/?SV MS4R AQ4]OL@'-Y'\QT$'U;A!-!}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
{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{4Y$\23Q)/$D]N,BJXL"0MC\"T MKYSGO(=08A,.'$SQ 5F.]UZUMCOW1A/BB'S&\P#[0DLJ/M,9R7/?IG.Y\MF M;Q?;OM),?<>.K{[-P9/W^^G+]-/>"6!4'TTE7++%QF4YUI[66DM60:VNO8B MVH1.K(2#/&B#^?DD34^Q88N[F[HYE4#]Z=L9Q5X?6MCQEQIR9V7*ZT:B+Z) MOO>>OI7G,8$:.<-Y)4+X4J.N, LH8Y"D7@V7E?/!!^]X;I.]#W (G^B;Z)OH^ M6/J.S-O"A0 >5?6DBS,075&@G30RL6@B7PDK?-!V_;H6\JA&'1)W]2DD9HT M4B5SJF1.6DQB/;CADA;W4JP'-ES2XEZ*M5? #I2:-W35I7+S#V6#4+]FJ), X& M00=&&*3%!RK6 QLN:7$OQ7I@PR4M[J58>S5<:L^XK9.1YXVJX'S15EB?7EFN M# <3I':-_3],1 "!C2?U>2F2=090H02E0@#GG(3(TF! [*PO7>SQ;HN:::>7R)+(\KLK1+_)LOJ1163M(!O6[/0F 4XV[!#M]V43=\T6=)^+]$ET>4.*$2_Z3(4*[U.%EA=BX-*.D,03(.H]9QIES$ M2OS .ON]FU^*TZ[O#L0# [_969^=%U"-6I<2+;>#!(GR@OID'CS&R0'?&T>]M!29L*2(R"2RA!Q6SAV"+ 4PR*VFM#&5EB;!>S#8A:])HPF8?;Q^0)/Y]5P-F\RFX[K>E<'IMV75/, M#PT_M)ULJ@A)5H"LP,%:@9BF^L M %=#)1B9 3(#9 ,(#!R&&<@^QVPB!\X:,R!Y70QDQ@&9,<(AMZA6VG*L%QF^ M-V9 -^%&2U)V)S "9 3(#!V(&G,R!8;"@37&@$!F$Q -DY8TMJ+DQHNX[TQ M YH-A2$SL,TZ)X=6 +)S*]5DFG/QTECV)^QD7[2V'9Y;%32CH9+6MQ7L?9J MN!2(M7ZQAUHY_>A,^7(3Z_H03K.^W7L1O&7#W #/_"V;11!2>S> \Q@6U.[PZ MAR'%."2FU,+K8%M^, Z'G8682_W5AB(-,U:)U%V,$#%ECX!!3$D*<4!,;2)7 M*@@$3%%4UM,(@27>%.Q.6C(=.5\IZ,)~&$U'3+F:=,L.[;QS%Y!!5$D*<4!4 MJ;(,T5>/T#L60.E4?PK1@ F5 B/(-_*Q.'ZH2,D5.Y1MNVAU5B\EY',>QEO]V\8,TF:.?C+#5*R;@SD*SCU>=' M ,XTNR-1.*98T5;J3DH_XN)SJ.5>9\ON.U0W%R%_;69H&=$'=2%FWU-FM]SJ MBK^ZF&$Y56:OJY-8. =NE?$I>F[D2HN-M:I4;1+9MYL!N^J8)6HG:B=J{S^U MFYRD-A,!!...>NT&@K49LI*"1^EB$9WDR&Z4VH4?5MM"U${43M1.U${4?E$+ MS7D4.EAP@AE04B,X+A3XZ&4PR2FC.NGWM%%JWVZFZKYCM-1!)I"TF+28M/@0Q'I@PR4M[J58>S7O VCR>#/S5+E+X/I M99? X1^X",U9VAS3^6RT&%$7M8//G:*DPGOF54@,WH@,PF0#210 'IF!R$3* MBJN(PG615]'N.CRYNNFP/-;_C.^_3\=Y-'G[MXKRYJS_Y>3D$ZJ/9Z-Y_>AI M_77R]A7.1M/\ AVYVQW#M>R(0)>WM:=*>Y&A08 ;M=)./G1,X[>NOL<02F'4BKK2N7V>S_P8; MNJF%B!\J2QE\E)Q-/$\\3SQ_N6!RBILL+;@B!*B"'"H+& E)JXV.V/#C1Q4'#
M%GF>JZ&T5&)B/Z"Z+,0&)) (-$W(H"7X)A3D%06Q1B6$^ND>\(6 MB5[XH>=;"\;9=^02T1/1$!'WG^B=CAGFPL%XGD"95'U[EP5$$1.7#MVN8LC MD"T2O?)*# {=VHK'OR*7B2U1\B7*3*#>),NQ(BVFXI,6[%>N!#9>TN)=B[=5P M*:AJW67&9?NYP1G6F7L79C@C<\7F"FL]M=+?-J+ZPA,V\GT ML#':Q+(!IK(%Q0-"\"Z %EPSG[P,SG01(_4LS":CR=OY*YR=-,3P4T,+7^ZQ MU1\QGRS" N?\]NCB(%B)8K M4,4K"${4L6AAM;$BV1PV,? ZG2S+&C,EN2M2*\B%ZVK,F*NKC)@!T4>9,LR6K"O*ED;GD&%TH"7I=G*G#%4:ULNZT1T+>KQBSQ M8K.IP_#M6%2L-LFE^JL-6HM4;3I;25'J8OS?99N1'QG:9WR(-=MXO>7=/F-[M /O\=SM+F >ACB:\Q:,QRVE%87L8.1],SQ?S19@T14WH9++_+L-WJE744T_A M-LM>5$&,8$NH:S6F+40OJGGG6@3&G&(Y=G& =HGLXR6P7YR?1IR]++!<&KK5; M\Y>?X? V%Q5NB_ZHQ8VM9\5AB0%[?.Z>4JA5'#=&8^O*,"6YS$D:L=H'N;JPK M@USU;NX_4C.4F@^5)(N]{W1!RTY2BD.S({(5,PPGB&LCK>F75Q7+0+-B3KXJ/Q M"1@&#PH=@Q X!Y6SLUHXE>Q>G2'8]V(#=%#)^S0WM@6P(V1"R(;N@%/VV M(3FB(Y9"+RQ(48(\(E[2"D(%9F14F,7!S3;Y-6;1UIBB##+R#$EJT]@-#]K M-D&89/"%&HC=K=2#=D+>LZ1/BA,&1#'E!+O/[==)EL?]P)WK_R,%&?_=7'-MW774FQ[<9U:\)V%=>Y>O/7[YU>;.CT:+^MATZ_!/$?'*4U/Z[M\K# ;O)@\N MZJT6T\&3:=,;=8ZY^:DM@!^:T[.?1Y,P2:,P'K3'Q*?U-O-KLY='[P=I'.85 MEF<5V3"99KQ\9!UV_%J/_5-F#}\ CDXS+&#Y!',VQ!^*C.Q_GIY'$>S<_& MX>.CYM/"9R$W3'"E-/]H*=?+]#ZZ_^>SQ>C\O'R<>V%@)^\&PZ'{5WGN$X M+$;OL<+S05=.=IA)M=/\]PKI*X<,+,1V!M/\T+$^<
MC$>3^A:+,%L|"N>+Z>,O/ZC3NOSG5LK+4^50ZM@>A?$?X>/\\0_?M'BSM? MBK!%4"N_*RIP393=2FRK9+2N>&Z@X$OI["XE72W:U,$<')^_'DV8Nl,7]/ M7KYX^NS%R;.G@_K3RWWR__X_3G#[>/#L__OM^9O_Z9E]OC7B[OED ML'@W/9]7GW<^P \)I=8_=IED,H@G$[/]IK]Y5!FX[=).,]-1-KW"_$WQFBZ M]#XO6KE_88O;OO6ML;VP?,VK-(:POGOS=:A>TO2\^CNC#Y@?+Q_%&3MB?[J\ M(#5A?&=S?#3'LS"KU'4Y">T">GGO'ZZ'EKT?S4=Q-!XM/CZZO/ZFF+'V<5(< M2>O_=-5*7PQT:.9_O.4Z?L087^.R^U]BCZ0R6WG2]L9DCISHVVCB]+Q-G M1*XG@W*'6EE>S8F?R2$8Y__$QMXZE>B>-U.5"MU^{6#W\>A?2XH]JV*80=] MAWGYVANZ6D[>N&J1+O'B'@S?O9HB#7^N_OQLL.TVNIRG[,8.;+V)&Y$/D M\R7Y&.*>U6Z@3=K(R6*:_D%LTP%2UF_OO7=HND=MT%Y@Y3CG=@L_C!]V=SJI.ZG[$JTYWU9]B&:41>8$$ M+ +6P_8IFKB%=_4;.)O_>PNM9_\|'RT^$K(>LF?JM]7\L<[.+5/HF\G?&#]{ M5,&?PCA,$@["?# M@_]S/L&!9,.!8$)MO,[J9F?I>Q:G^.![CW5KEB=VH*G%] M6KL$Q_R@%P>?B(#F>K#5&9]:O%V/@Q3HC70'MLP?E44&(MJ@"S0EF1I'>;58@SW+;?P_7/WRX>]O10WUCNFS2^.XWO;KC;ZA.]T_+]$M)W M1F^7O24.E>L">1^5YL"%U$T9,@_160E:Q2*=9,RN]IM=B^NN>,/+W_?+\'@@G M3S]U.9!7.0_DMRB/[(ZH;G_D2U3WW:C.:*V%J-P6,,-*=5) 0,$!0\'JT_$@ MRDIE? &^]XZQ^J7@,]1H>ZC6F\0=YK++>JEWJ[--ISB@V]{L(CPMLC^1+A/6 S M9T5(M\S6C4W#ML^P&'WU"V6!(&P$A=Y!D)@KX?H03#:>^96%L_>*9>6J ZJ8 M,: {)$(V4D'0Q2HN@8,=,NS=>F8)+_M%LVO"L,OFCD3^R1Y(N])&*E0I19 M^6 AU=6\E0XBE]\NG-1IV2}6RF8FT(PFD#F%)UBV-$<(DKL})#-W[$ M=@Q/? 36$@D3"1,,}]XB$O\-I3O(&+2K@I1103:^WR#!"C$5+AS(YY-VN,,IU="XF]J1[S$>MA'L($6K#LS46KJ32^_TFCO?/#GUR>__MS;LT010CLOX.C2K#$C?!N=_R)3@? E+@)SOV6+\%Y. ^*F7<$>"9.PNY_BIF3+M93EMTD= M]+B^8AZ\#:/)8#H9U(?_Y<]I3+&Q6".Z7PV6HR^7:V,.'.GQDN<29S98W$3 MG/LM7X+S08F;X-QO^1* <#TK5Q4ZOQ>3DTX+X>#:.UX^NQCNU44UOPH>.(FBY[%DBP<[A MA'B0Y$MNSR3,_%AA A.,JF'!(69034"U2[PZ)48440I.*UV"" 4:D2&XIX!E*[134F4IKJ_ZCO/_GL\730K\ M_,Wt..=1\PYAW+3M>CZY:-C59M^V_O.3*^[S:_SG>5WT+!? $9^]'"9>KOM>8 MIF\G[5W^*XS/L:/5G_4'O_HC/B3YF[JY\R;TY^'$3G/LM7X(S'4@=1=FEI5"X9/#(!F1MM)? <"^4HMH'4.I&AILB]XH;2IM>#U A>#\1T: M]Y{]N76\WVX%%N1\(6E/<]^J$2?XDJRBEA"QD,H0L9"6$+$0 ML7QOE2%B(2TA8B&5(6(A8ME]8MF-]EY; [.9USW.%Z/03H4#.B&RD8&W+D/! ME(U0.2N;KY\K.=#5%*\|=J#$LG:H(078:51$M<+#-;FB26KOMV M^:!A&VP?L)M8-/5MM'&ZR[437OANZ;Q--]X^F@N0DL&G!)!E#*>'!:)BB5 MIDN*KA+U"D^O<_Y+/+U#/$YAJWTZ/LIC-MV9&'>M!P[P;,%GD:<#20;#@03 MBLZ".!*<.!(-Z/+TO*E!>H 6\.8)V T;N(:-NC/";FE@)DQP)EE @054] @^M*@.!:2E=-4].LY4NF&BY+CX'"%E2@,&[(61H(JBC#>&2ZV)4&9FW+L9?GB_DB M3)lL^0'(E6N R)%!. M(SB?'0A4&$>&15C7"=6NWW#XKX;(E,B4R)3(=-?)U(78[+ HT,&YIH*E!V]T M JFEL,BMXVJ%3!V:Q%/28%73HE>J D%$!/29:U95*\M[+ YRLIXS)F-T3K! M*Z4X*LXAL&)!J.":SNJRNMG55>8)K2E2X*_%V+_*]<'Z#BOB=C-'7<2Q?=2 M88CB>TKQRF:L/CL'580$92P#AP(AQ4K].)P*(:WX%X)+DN]1D4-RC)1KPD% MF!.)&>Z0!F%)BO^&,_U4'M&-H!L -D L@'[NZT29<;HT$)1G%52<1<$<1], M<,J59C- :J.N4[%,6QB@%.?MZC7<&HK()+$=MK&1:F4XI^:M,+,RP+@X.CXC7 M+TY0_V[:D;8 ,E+#FZ(5H_+Q3B3Y^?&F/OVK#[SKN)OA+?NN7L[8\E6;R7P4 MSA? 32]$VKS*:O&U>OODZC,/"Z?FBWOX#YL?+1]7UYQ'[T^4%%97C<#;'1W,\ M"[.PP,M9:#&]O/.D.)+6-_[T$Q*\W(7-M ZT3_>'Q#S_>6\]U=B%^2"+03K^51U/Z?ST? %S7M/D_XNS'O[:I?$C= M2=T/4*8'-5A2X+WDZS?3];DCM E ?+A)TMB)6Z7M+),Wj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{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{(9FED9: M9:T$6]>WH#1+X).NMY"&1V.,STQ=W]=YN7B\LR?3T_]:[W R'[W'YY,T/<7/ MZ^>_3\=Y- 'G[MS":_%)7TB\G)Y_6S<>ST;Q^='5#]$WD?Q,^W'W[9UZ%6'_Z M5N7KGA6(^5)A;M,-]N>_7U+=.98E#ZD7XB;L]DB8Y"%UXB&A<$(+%8$'GI?A M^#$X"]:C3KY(*50G9?'(0]H[#XE2R=,"67N.6T$TQ]HDDUU5;0^-'I$AVRO@ M[)PA(R>T^(F[/9{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{J%82P*\7$C%%>B5S=7)% N507\[(CN!)M]#D:S_3VV=8*-=1B@\7$]@B* MQ+@'(>;^,>YW<#=>QTE\QU5=D$D&QZF[ZJ#Q(DY2)3DM55E;O@8M4#')P)/FF MVUV&X%-U/(OG7F6./K/MK=[%L/)QOVAO"X? UEPE.AW%8?]N$/I_/S]O#^6FI M.MY6NI@WBEI5LRKJ("Q@\0ZAOL_<#'X_&;7_\RP%9YZP4%9Z/)\V'9,/IV M%DZ'@TG]2KW-Z/*6.3I??#,TD@S13HV73O>[[8NJA(B(7D(NW%9+ (2TX] PD M,\'+@KR4E5J]-A0O%>. 134%>ZV%&'4"4YRRPFJMYB\E*8V-PD'QSD])=A"A\ M]4 FUVA.'}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~)OQ[_"*^?/ EXGTT48MPFLK6?\Y(IC_+H1SJO SW!V?M1PN5Z M[C6FZ=M)>Y>VA$)G!<2Y$8>^LB/Z(V&2ZW0X&5=E=AMT:"")!E MAV196,XLA.P3J& (S>.LY<&E1/8#06N*^]O#)X^25.:NPU\>\S-)+$(J M02Q"*D,L0B!+$(L0BQ"++(#*D$L0BI#+$(JL546V>QN_1U(9$4VM\SAGR^G M;ZNG*

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l%-%V\?*CR7@TJ6^Q"+/%HW"^F# [^\H,ZKGFA>7;YT^,YH}>3FY;R MW^D5W10W^O79BS>3P>+=]*?>)GG^ MET,9J&^3<}KO?,V1[P.=W_3LM_'D6P]YFMFM7FT=\\,&+--NS0VKc;YZ\W6H M#L_TO+HNHP^8'R\)?Q1D[8G^ZO*"*;!S.YOAHCF=A5EGH<@[:Q>'RWC]<#U-_M/YJ/XFA<5U"/+]^_*0"]?9SE1X[S/UTUN!<#75K<'V^YCA\)[]>X;(U+V)'U MAGW^,YU[/P UTYGN E#=\UQN%>8_G[MNO5Q:%7RS2?_^8/YX>O#O%?]V>5; M,W!BNO-J;ZTW6%=!@U_KK^_F@V?51\Q?9K*LIRW[,8T=:1@1$!'0G0E($_%= MFSG!A'*6Z0 A#\BD)Q3U $?? 3#C=Y{G:O*UN%^RW5Z7NT%C?GOR\T4V#+M7M M29B_&Y3Q](_YH,RFIX/I&=8U?'/VTIQ!OF_;G9IY{>_F)IBMJ-0_>M&:<# M&RY1<2_%VJOAWM(6;K40R/>VA=^]0L,5]PXJ^N[RW$7BW&U3Q #V_6ZZ M\Q)4(6 JRENH7G8$%=&"CYX!"T&C=QQ#64F+80X92R6#S9&!XDT!D&0<>-1, M6>>\R2LEJ%[-IO5U-E%_2OBA4UOO]K,#:.DRKID8<=#=D2@RX=084#*.5BH-. M18#"7-F,\P)96LV$KOP)L=[X@2RJR(+6"&(,#%5I35BL& M<%%R9KR(W*X4/5QG2^HJ/NO/8VQ^.)[DXRLP[2A1U-M>K4I,]CL,Y^<9D;LC3FWQ :#U4([2=&"'T4L@D)%CC>#5J7H$3U?=F4BD9 M&&JS6CS\/FYWF)_&1\>7+'!U3^=E>?Z9#YY/?OW$!D\K&9Q\XH*NMGZ&S&RP MN/AWCXBA4$IB1V+'SOO-1\.EC;+R".K*CL* YPR!.\Q"!,\,KFQ*W,?EWQ5V MU'*#M5[WBQWMAWP[BX/!!-IXRUG]?8 +=MMV^,>+18-&+" M,C) K%XX*"Y\\)*E\[#_?0*R@:3K^N+/%LBLB{PJOVW2\+0_OB1U31>M M?+5/V1G0-B*HD!&BY@*$4+U%A2#GK!P6*;)::Q%"+?FT,;'-#_"&)12N.<-]] MWB? OPN0MSJ]E%\WGN)BW4=3C46A+T-XET^BZ*WR 7B]E=-!P]]!(BT^@.%N M=5-)=+&I)/;1P#:M>LZ;T^49)AR],X^6VR)R;4GW.)U1$*8MY6@I=_M2KMD7 M,DD{T)@C** <"1*\3E(C1&9V"SL85{18)PGP^297-YO@4EW\ GUQ"]_4GY'9= M2T+) U_ET0;4H8NRIZPE>& Z\4HYW)AEVTS'E0#G' MOF^^U6C-P_6=7\WP+(SRY5'LA ,VS"1-'+>1FW.<+]# [%@A6K^>*(Y'B27S8(/FZ!VWEY M2ND.W#211WWHHNPID17TAJF<05M;O6-9_>1@60">5/62650E\\UXU-^#R+SF M!TYDM#^]%1^[U6%RH\GZD/7YFO6)T2?) @-?.094TA&\XPJT25ZIH$-F9C-N M= O0)M1HN>*]K{FY:F?;_L3P+YQ-&\$[P<7C SG9Z)3.?MJO)P)&!NV7{1P8C Q> MB!F4B0Z"C@:<3L4$H556#]N;O-?,[1G?7R#W>)*?? L;MQ;EI5_5A+#OT M$U)RSP]=E'O/7MMQSPTOPK+LH?Y0W7-,6-FI']3*F%4LH2P&V+QB-W[VH G%Y*"M NMWKLFO4KJV2K'CMMD]\?0W+AMY-[3@:.#- QV:T)*6ZJO7AUVY:JQ*E958^4M M2.Y$3#J'1/4&HU,N#-TOGVN%=!X..:?O5PH(*Y1(1$BEN^#R2RTI[&L$RYD&% M$"$V\>/<*\$PYDIT*Z3880C,YDE1#I4@6]3- ^>VV65XF00QF=2DI,;^H91+] MK^.PJ/|\%F.+C^3YDY$C({<5(\=C=EDD \F+"$!* 3X6#Y$5]:TWG-FT&<__M2;UG\R[_/5]\>W(^K_,)LTMC]['SO$X^Y(:VM6@)L-LR)79\:!Q-Y9^D."21 M5'6_78+H2OTUH:Y\%DHN*VS6C$9M1M@W%K'JW'_WEIT*<XT:Y&!)?)<]\ M.!8G5OW$V:=?/:J3,)A/QZ,\N)3H7@!V3>OT[='OO?W:CG>?C37)QNJ;)U% M,97 ^2@A>)^UD1Y1:AXRRT'UY\(Y)?F]PWN8/%A?:7-&<6=1.'V_?ZO3,/2 MOC)Y:&N#G=0,XN=]X^?H4@XFE+K8D)6?8PK@F?:.5<*-2R5B&[N&]^+XC/XNA M%1OLS+V3*-SE,XAUEC. {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|\Q_]=3RG05N) [N?/YHRNG[V>ZJN2"(R'\1# M2H'IS*5+RJ1D"!<1C#(',%KX9_[:]J+/OK0">S;J22'385_'DXE50FY8O;S MX\T5,BM# [#'JD,A%)+NR0X<_F4J("N4#!Q'/)>2MY9%0L?0!NAK8BKK!58:O EN?:@M:U*&%.(VZ3!A/6"*2D M3Y2\&)^2<"'"/0\'6_Q(TIHQL@-5"V!\GB>#]_7X=1UNY>)]7=:]FFZ-W=PY M=M,;>)AX&YMG8"R55\]ST8 2TLG% F6_VA>Q[J M%\K2W$0X@(^#..<:::8Y4DHK{[!A'(=-A'&R,Y3_>[N0L]C.Q[U_#B&_,6K M05C]8.F7O\51;PC>4R>],Z92#._[DP"^U-MO_L0./L?? {3B^32GZ334JT$>2 MD /WJ2KR'?I2/GGD>YQV+5Q&JD6B2#!:NK,#("KI4,9*80$NN4J;B"SM*I*V ML'3PZOH>CTK2O<+4VO[EL:WZUU>9]HT=E\Q*%V$D@[P[.TSE@[/"]U6_'7@& M1$T2NIU.UY'A.^J MO_$ HD>;/).]RX?MRF|*VRTXTYYT\/I@@OI\R3484WIN#EN!%@\"6HXHAX MDL-GP2 -234*!,4N9,>"TK.E&XP.5D6<-#X,1-UHBQY5'BD0A%<."2[('NI'J M(RX>,,ZVHP*Z7OTPORKB{)33%%1>Z=0FW&):8HY-B1$_1.0H2DA*Z*W5C/I MN+/-(VBFZ$)+WR*D(2.]T0"80@> SG+ -N)1A?OJH+8^D>, LWAT5T+O[-/"O MA<&7ESN!M$O/IO#L[S{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}!B,>PP1#[(]M\Z4WFN0GO/G;\P9N,SI? M/!CN<7&4 (U Z<;.2'PV.PDV%DW@Y",4W@OCE/%"@;_ARX4]/)6?"5\/B^116_7P9-X$5 MGG4%V.?9;6XG8#S/AEU4N9\&#]YF4>_1.6 MZ5.JFL1A, O3+3HH?3OH #OUV",0!]FHCK\'/AN7'E\]U=>6> MF: {6@WO79N>B>#!?3V+'XUGS@<3"BAR*XG^75@0);,3)=`6&'9[%9Y#?E(;FP_5GL'C[C^O+,#KIZF8 V!,*>X"::O-]W5+,;\Q4Y M,?4H#QH0]ZSXU#Z.BI#- G;_NP@4*S9S!HZD[G2\Z!1U36KW"0&<>*[AZ(.'M M"NO\N!*]7-KH*)M2E\4Q/8_$1*)1D!S\(,; UL 8'5Z-;SK8OY,;!C6W)T)[!M>D#6H^3DY/LYB! M]"RM? +-8^F:V]LOLN]$(O>286^P]LD'GSJ^49?-,(\^"E_?9H1M@K-_LFVO M!0-\E:O/N[_WB[OO#8L6&F5F6-ZR.!2=E^T?NYP-%02TS;/BSO{UU:Q?NKAZ6?]=Z=+XP-(MWO_,WSJ;C+ (#.,Z6 M4?$'!V#;SZP<^.QG^'5#,/KO\NO?<]08WF&2G_I[Y_KF6WU$_^^,*3^^?7W< MO!N [37SI9\7K!A9@[QQH@Z'$S=9%/XIB".[?PV5M MD,G4GVY$E&KI(3- E]\.%03GS/Y/M99]G 7,79'1.@\6##9SDY<_&%JR?]3KJ7 MO.02\8*;C"+X#VW>E,FN[_RBX\(6{(SSM;#A3SP\\R*6IAF&)OLUF MF[<%PGS;N)UY?*5@_)RGNAC"27&(7-[XL#.0^,=DT(7 YBR]YA;=:A%6I^D MC"P(W=C&(?;ASD\2I<]X]\6.6QNZ1N#R2EV=E@LXXIHY>]_M1' ??+>/5K:TN@=T :DNSC$-2'5'L,9 \/F\\LOO3HQO,1('HTR3;M-Z'MJ8 M\WGUKLC5?H@(G:!*. (A9I<'$I&A8+PIRX32/EDN-K(5\T<;/Z2WH%-,V1> MXV_<9%"'"YV_\T044YT0\)&N@TS4KN'Y7:R[_**O@'",J:+F UWF8;;$Z2U#1 M_A/@84;V:02IG9R>397TB>T"';;4/9KM20.PY5V5T[G!F#>W1_#:[W51JEYW MNRW"RO70\;W81LV,WLUD/%4SHY]H9O1,44\UHEWI/W"C*-R=@G?TA_M%@2X9 M[IXH\?L)XL*DSQJ@H]+GDJEQA3(8+S:=IGKN2AO],AV3K=I!WI8+D]%L!ZO[MW<)>/&Y>^?&DN%:=0=SML(0>J'_1;!-SV"ZIO(,)/"S'3!<*OSZ,N,[QAI"4=X0R^O8F^UJS7>':.BF9#'K_ MZO;(+T8$I_&O^PM/EVMQF^/FW3COPLWW2<]S-*+ME2VY$BJ0/WMU'[2$ M7X'TL,,UIZ&7J^^5\4]^C?M*FQ1^2+*F61^_SSO+$%(]D, BY:O6L^Y{(& M6/(Z-CY{ {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| MGE=L[JY 09[H/-EWYV!)*J(2119$1+BSAF @920L4E;K76P<:.T+LJ3,>@+7 M2*)B#JP%Y)B(R&I.P>*R*4I?8>]J&+!S[LS\$P=78\R .T*'3F^[\F7*VP^_M;&)0'JPV8 ^"L&'Z<:80A8K)4-0ABNZD=30+"0G8"6!>?.V) (FO&8+,LCK^ MKQU,'"NQ)5(V*CD66?;;//R\RFL&0G8KFI+G7I("LF72 MSAV@^Z_H\I7Y<_]?4,GO1#BX,7/?P?195F3(Q]@<;CRL$(A6&2]]30I+HAC MVS'U" +V0(M]HY5_MB"WH&,>>"T2I\$1[9 44H'(6 \2I@G"5H.AI9F*TFYS M+"\W^,C\ MEB1W=V2V.V=81&PX&1>GJGA7V0"^F+J^'9]I DQI2\2Y"-_]23ZU"LYG/FX MXB!^]TDW>5 &D;+_E4]_=8 P*$>]N&\OZ7B?ZEPB2{OFPEFA@]$LG49S!U0L M*'*@71#)Q6@IL:0=4N=.DHUU2A*[,&%8QO^1<]C&O3U>B [^$!\3_?A//39W M)]-3F^H!K>]>3G7>.GQVFXL-Q/79]_]'7P;OWVTJOC;:VS3#-H]M0)VAJ^H! M31!X(7]?MJ6^.]G5H1@3(.6+,=L+^N,.AO[)>31.]& Z29]43^5]DB.#DLQ MI+?KQ9#NPSI/@YJ/+$_?(Y_E@5N0UQ6S4,JF%P.Y"B M%:0N5G]>*D]8D:@]_RI7&Y,K5N6JRE65JZJOJEQ5N7H"I"GY!_)06";6-'_QZYY^]GVZ,O-N^B/GX6P^-@TZ5,_1#S'V5FWK*&.LA) M5[[>^R4^R$E7OM[!)3[(25>^WOLEWL-)W]6- F>VLWNILLWQ5?3.?<1;=GFMQY,TZ\"8GV"8$NN?%@^)U)KX8>Z#'-L8*

*0H&=W/!UZNT/PSB?OM66(_^D1=XPA M:YA$-!B?K(T.QJA6*(4VY1%%KX914(89P,<<>\.#=P]/-M8S[TMU!N\>.;>;$%ME)L =[ECMCPZIJJ"^9($G;EJ?K9/K$D=/PRDL3.?>YPH&^B-816ZPQ%TAYS &M M(^ VIQXI(T4B< ^,Y\.B->%'G%Y="K<*887K"M<5KO< KD?TD?$@$",D 5P+ MA.PC^0 K$QZXY 6^5V.F1X%K:HY 7U2XKG!=X,K"]3[#M16\]40!=.D/B%N. MD1/8(8>EU412&CQ>BX7HH),!PYIP.N%"%Y"5$DQL'(GQPGK+'A>N!3ZB4E:X MOAM\O6FT7QAYKR5+<:ZZ0K7Q_:$A_DI"M?[_T2^2D*U_O_1+OX.1K MRM.C.S[_<{'B[G)- N]6>+6B]'%Y-E-KCN,2F:5!C@E?%\+ATC+M(D#!6(VZ4 M0I:2A'22CF*OI,5K.^1WR6>:"?NK3M;?E^+:'U++7U&.I_4RI('1-2P]\34CO MJ!F2%)4C@B&C.$4\2HNTSV5>@X_1$6(I78]6;FZFTY*H:Q.^YUSE1/DB#-R M203S(S:.NP0==>.1,L@!ZY8DA,>:1^1L[E?J,R-J#6BF @:@M;.VDUD7^V M,L'#3)Y#RO@ /HEF 4TB)Q@% 3;;!> ;9N(E5L^[K%R4@Q)Q&%W%ZJ6JEMVF4'V6[?(!2U1(%)& M@P,S,3W@3!_;Z'FB,JJ6^X)'??-[KO5IMA=]L!V?Y/K_7[GPKJ9]4"*> ^N< M\7A9[$]>|SY.AGKRS@JA&9(\QMQ]SR(;/.@J325GEC@N-K+GS2^E:5LBV5 IY1 M3'FKARD/SJ'",<32#"8F9$002$C)N%,6BR0VL;&SJRK%8!49 MT>!QI) 3\AQ'SEA0*2{!:-RS)- ;+=&Y@_EL)?)%C62-?-]$IJ_M9\,ZZ?IQ3 MJG2>Z7EX'WI?.C0'S?/NH^?_M<$>O]?YPQD\8SR:Q)NM^K546EUX.3N\UBW]/R;M MN)?. [X"YMUBGJ[AG0:HF3FG5)"\6,SXI!]1F%&N&:,9YUPS6]_A<[';2QJ8W MR/?(1]C@^M/FZW#2#\V)_9)_$0>-75JD)EJG6Y#U?G_XM5VN!;)@V<*Q,XI, M=YLS$>)67[RMZAOSX>3,;_TVI{K}7OC\Q>S:Z[>OBT/DO18&9:?]"TO1![6E+:PV-]>_O#C=Z\F MCW^A.,;X\<=+C^E^3O5)M>1^FE[!'L]P?NI>UF:,;WKI;!QSUE3#\%'MRKC9 M-*8*2A64[E*Y&E(5NV\O%4LJIV7JU55SLM;T/&/G:J!*VdRVY7DL.1'8S; M9CQLSB8C?V+;15F>\=#_1^[7/-'8Z2.?'GKRVS17-"@PE*<8):)4$\2UM0O:I0A6%E$=:X-H&Q FIF($DO<&4L=9_YB&/>>P=M7IP!Q MXVM.T;Q[__,U&PN:\",@W!{N)#RR-%20V\MEW5.0^[GL%^,1>4(Y%+PR.G\ M*D:-E8K1I5B)HPR*Y-A2%HO"YUI3QUS!@MS6[J&W4D"%O:ID)<7=;#@3BM11'4L1D M-HB+.B'C"$%:82L=#X3ZM4.B4BM#14F{F7S{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}+N-^3Q"?!VD1$P 6,#DC0^:4%VI>6<+YJH0#\P|_M#^:#Q88L3V#GA4CH0'Y1"U>P&"S)!U450RH1],Q20N UX4K)@_R)O&7K0+@P MI<@PZY$U!!:"1R>P7K<8OL3!)'R-1CG0?Q/,WSR&A3"$"R8= [,:GZ.:-L+_MAT_VVX;$3AY?'4O9GM!M<019?*H$+ +]@4YR$4A$'(+B"8.B4<$@G%0.+E+B MY)K-K (!.]L1E(P!">!9)>&0$,B+(TY;9QC9'0F@Y/BR?@D'+)@YO@50VW4 M+ <[48+K>GCN"*]JSF1G6/&M!+15S7S_/A1{&JS7=F('Y3A)IMB5-NO1C)@A MYFKLQ?,8?QTVH0CI+X_ F!TV7V,N\WQV M-@1KO=CLS1NP;$]GEGU!N) ^C&TWLZ+Q8 L=;Y+5#80=P&_O!(RR=_-]D13'7.Z00!X537]E4'+5.LQ< [;?;/@>)C/.UO?.\1 UW%*N/*(BFERN M4"-P%E4/<4X)B1BO)9E*0@&\##1 9-E'&<^R7%*-"$700_DZ[79UF.6+Z, MVD@?1AUG==`@37F0.QE#.6Y>]=MAAN@+AN=5 ?&IXW#:!0R!K8#\|\HH84,? M *H%KZX/GEZ.N7 M_/M1_M%H/KAE:)2&T,LTM?W;]"8'MRWQT"X,VD%R-Z.X/*?2:%%1QN;:1F_G? 5[OC<&]>K:[L0RCDM']7\NL;9F"]!@/TQQ.MGE):9.PAK@YPNRY4+"]A&0S'77L@6)@>C-2/+ZQF&3@0 M:9#)]]*LF[Q2J<++F-1%Z8+?1*S*;$"^KN&^- ;YB4%%8 M*N:[5+8]=2_ 2,@91O8S /R'R1B8=)!#AG\,9LSZD+K-Q6)3_!=0; 7\ 6RN ML!;(==:",;ZZ+LWC,\6?RX+'X8(@S9="D15\.F[!N!C<6\,/.<.=VO,F]B_6 M22EG'Z7%6/WX4\[<9{T\)WRTM3!M' CX- C)Z2X&+#3&.GD?$5BGN>"%\!"O%.MTX (CI9Y#RN(W5H5N1BU98B&DPNQ$PHTDX$Y'E0CF*AP?]5_;L]{8]@OO7LVWB"XS+KO.:GDBC N?#=."UW'M/]KDB8R@F9Y/P&FGO MP$##%FB%'L$$I.49<B(A9:41WG,6 [M2W_TVBJ>]R>FGX?^4K*@87GV)(_BF,-6[T],8>L4R M@/?#T:?A&W@##%TVI?5-(N@? M%V[R!$FHV#/MP{J#,_]AXM)L5OSG\ <=D1N@">B:3.7F MZY2RC>U(.\6_WD*N\B=Y/Z9CM>PO97"XR5J$N(E %&YRF%%QKQC3B28A< M-D"C& E@&/ H]FL!O4<%]MCOP0 ,/Z3WH/8]W.!U?]@6&1A7W+H';AF7 N9$ M(L9D+@8*IHVFPB,C34H :3BI-8^LXM8>XU:82MJ2K08(-BA2-[/-(O4S]^ UUJ1,@\+G]].1T\#+TVK. ^/?^1OWUVEDW:P>>EP^N]COZS MT#]P=A]4FCVN7(CB(+P| _*4.W=1TR]QN;WQ_*#+MQN>9R'T[G&S^[63NQ]7 MFI4%[ZTS);M9'YZ?CKXWB#'9!%X>]/Q"SL9#U^N?@%D[3XN]]P=H,<)YO," M]K\'MDP[12|O^&P)R\&)LGY++'!A*3>]8@]_X"IV==RO\U/,"T)U>6:@W*1 M."8*A:3!M_'!(B,4V T4IYALE-C!^QRC*9KC9]L;_C4(M7?115>?=N*L=_3.60U6+K)FKCM8TTS-4H&;&-YW%W\D-A7-[0>T]/Y3#YX=R M,D,TA2..998H^RI+3)'W3Q9LL91--2C[%"7SP(Y&YV6CK9S^+#L7WK8G92?N M"QC(,*=+BBUV%9:WDK(6A_HGC+QOQ3BNQ+/F9R!!_&OR3 , MU-.M.B/6Y> MQ]'8]@97A?,6FTB]00N2.5W%42P[4Z?=TL,B*6'#G.>R2B/L.1'P!AZ[5'C M)N-R83Z[_K=1,,9CT_RF^-),;'_G84-'_5{0)F0W;3V9#@:(} HP'!8QC+*

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l%-%V\?*CR7@TJ6^Q"+/%HW"^F# [^\H,ZKGFA>7;YT^,YH}>3FY;R MW^D5W10W^O79BS>3P>+=]*?>)GG^ MET,9J&^3<}KO?,V1[P.=W_3LM_'D6P]YFMFM7FT=\\,&+--NS0VKc;YZ\W6H M#L_TO+HNHP^8'R\)?Q1D[8G^ZO*"*;!S.YOAHCF=A5EGH<@[:Q>'RWC]<#U-_M/YJ/XFA<5U"/+]^_*0"]?9SE1X[S/UTUN!<#75K<'V^YCA\)[]>X;(U+V)'U MAGW^,YU[/P UTYGN E#=\UQN%>8_G[MNO5Q:%7RS2?_^8/YX>O#O%?]V>5; M,W!BNO-J;ZTW6%=!@U_KK^_F@V?51\Q?9K*LIRW[,8T=:1@1$!'0G0E($_%= MFSG!A'*6Z0 A#\BD)Q3U $?? 3#C=Y{G:O*UN%^RW5Z7NT%C?GOR\T4V#+M7M M29B_&Y3Q](_YH,RFIX/I&=8U?'/VTIQ!OF_;G9IY{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{PJOVW2\+0_OB1U31>M M?+5/V1G0-B*HD!&BY@*$4+U%A2#GK!P6*;)::Q%"+?FT,;'-#_"&)12N.<-]] MWB? OPN0MSJ]E%\WGN)BW4=3C46A+T-XET^BZ*WR 7B]E=-!P]]!(BT^@.%N M=5-)=+&I)/;1P#:M>LZ;T^49)AR],X^6VR)R;4GW.)U1$*8MY6@I=_M2KMD7 M,DD{T)@C** <"1*\3E(C1&9V"SL85{18)PGP^297-YO@4EW\ GUQ"]_4GY'9= M2T+) U_ET0;4H8NRIZPE>& Z\4HYW)AEVTS'E0#G' MOF^^U6C-P_6=7\WP+(SRY5'LA ,VS"1-'+>1FW.<+]# [%@A6K^>*(Y'B27S8(/FZ!VWEY M2ND.W#211WWHHNPID17TAJF<05M;O6-9_>1@60">5/62650E\\UXU-^#R+SF M!TYDM#^]%1^[U6%RH\GZD/7YFO6)T2?) @-?.094TA&\XPJT25ZIH$-F9C-N M= O0)M1HN>*]K{FY:F?;_L3P+YQ-&\$[P<7C SG9Z)3.?MJO)P)&!NV7{1P8C Q> MB!F4B0Z"C@:<3L4$H556#]N;O-?,[1G?7R#W>)*?? L;MQ;EI5_5A+#OT M$U)RSP]=E'O/7MMQSPTOPK+LH?Y0W7-,6-FI']3*F%4LH2P&V+QB-W[VH G%Y*"M NMWKLFO4KJV2K'CMMD]\?0W+AMY-[3@:.#- QV:T)*6ZJO7AUVY:JQ*E958^4M M2.Y$3#J'1/4&HU,N#-TOGVN%=!X..:?O5PH(*Y1(1$BEN^#R2RTI[&L$RYD&% M$"$V\>/<*\$PYDIT*Z3880C,YDE1#I4@6]3- ^>VV65XF00QF=2DI,;^H91+] MK^.PJ/|\%F.+C^3YDY$C({<5(\=C=EDD \F+"$!* 3X6#Y$5]:TWG-FT&<__M2;UG\R[_/5]\>W(^K_,)LTMC]['SO$X^Y(:VM6@)L-LR)79\:!Q-Y9^D."21 M5'6_78+H2OTUH:Y\%DHN*VS6C$9M1M@W%K'JW'_WEIT*<XT:Y&!)?)<]\ M.!8G5OW$V:=?/:J3,)A/QZ,\N)3H7@!V3>OT[='OO?W:CG>?C37)QNJ;)U% M,97 ^2@A>)^UD1Y1:AXRRT'UY\(Y)?F]PWN8/%A?:7-&<6=1.'V_?ZO3,/2 MOC)Y:&N#G=0,XN=]X^?H4@XFE+K8D)6?8PK@F?:.5<*-2R5B&[N&]^+XC/XNA M%1OLS+V3*-SE,XAUEC. {OUYIFG*W???.YYBO=2*I&O?^3BL7V@?,H>'2/MAN MV2F5G&>F:)"Z.%#*'G"RR4]SS#DG@S7(NC@EJ$A^4H'\:C9]/\J8?_KX6T7T M%7MU__G.75LJS8:6;]!4?7=&I0,"(D8BQJZ

M4=-._$ECVT+"HP9<^NX1W7FA3+RE#_L>2%G2:[R'1 GY&W#O)MV.'MEGY;R M$29M+/#%'7[13,$;4CU]BOSGI@6$*3O)¥MV)E0P"><W5TR:8OE.71M M'!5"*

!^<36:|VQNL_W0R6/\Q+'*WXGD+XE+V>W$H"_-+H3EYT7Q8H]*,R2<# M&_(8@6^G\|MT)=LGU*AG=4X%O2] 7G+A!.%^9@H/%^N^55*6S=D;IDUAT84=F+YB,,I9> N0;CRP5[M1LYV^'E8,KH6=M[O8 S HO9[9{(D@7 MS.++C;V&D!.EIGR\KR?\U*_'1W6W%B<_N.^>E3UWF M/+'L00/"Y)^COCT?3J.=,E]VXRZ'?_|\NZ FUO2ZE[,7I'LO5]98KDI3'9W MO/*.E^>ZNGC/K+.LX4EEGO0RG_FZI_LO@]MK2GOCOW]2?U$]] = MP/2_"_K# M>2\3^ >ZED-Q5Y+LZK_7VG/(TJ++:![H@ M5,'HSF!$*Q9=S+0_!5|^5Z+Y#S?Z\2^OA^VX8M$&9>?NK1^J?.V%?/TUGQ\L MLO7' +1+?RYJ?[6]016U*FI5U!YS+7.[VG/K_)JG=]3F5_EU3J_ MIS*_RJM[,;^[N06S':U;> !E2ODXSF!ZUYOTGKKH)RSG'96;+_\57TRDVD$W MXM?A()[/4A434/0F?'4,)1-R)FOBR'#ND=0\QBB,%7]M7FR. KQ=! %> MC5]/C]^4.-25-0,92HW!;ZOU]"-]F_YK>R,TFP6-N\O*OK2[W!0<$JG&/CZ]&B: M0A)*6X>PC0GQV"/2PBFDO258TA2<2O=']W+J-T/TJT%81=2RB;,8/\N{U'<# MU9)QCOX=1\,1>9H2^K(":@74"]@54++ G]NGC/K+ LX4EEGO0RG-FZI_LO@]MK2GOCOW]2?U$]] = MP/2_"_K# M>2\3^ >ZED-Q5Y+LZK_7VG/(TJ++:![H@ M5,'HSF!$*Q9=S+0_!5|^5Z+Y#S?Z\2^OA^VX8M$&9>?NK1^J?.V%?/TUGQ\L MLO7' +1+?RYJ?[6]016U*FI5U!YS+7.[VG/K_)JG=]3F5_EU3J_ MIS*_RJM[,;^[N06S':U;> !E2ODXSF!ZUYOTGKKH)RSG'96;+-\57TRDVD$W MXM?A()[/4A434/0F?'4,)1-R)FOBR'#ND=0\QBB,%7]M7FR. KQ=! %> MC5]/C]^4.-25-0,92HW!;ZOU]"-]F_YK>R,TFP6-N\O*OK2[W!0<$JG&/CZ]&B: M0A)*6X>PC0GQV"/2PBFDO258TA2<2O=']W+J-T/TJT%81=2RB;,8/\N{U'<# MU9)QCOX=1\,1>9H2^K(":@74"]@54++<\FXR@M>*3'J2*4OK?1<-M(V58 /7D (0H50ASRZ2TAL-+G8E^ M,V3A)<**.(\U=]'3^\#9KD8_)-\(5Q&N+NG^(URP6JE@'4I) %IY*I#'\&"_M$V&%D%SSM>WJ1T.X&OW<67&H"+=W2[JC"*>=5X(0@;0D'-!*1*2U%HARAE/2 M1I*WFW!)MQ/]!'^4R;I7?9_H9\T&W5PVZ.EI'/F>[3=G]BR.JLZIATWK&>V[M=F.Q7E(L!/("1\0M-<@Y++Y$*F*:0F&%]76_%0*RP$07N#.*&$F0%T58D*S(!!/*&Q[S1VRVC DF,YU; W! M82W?ZS:XNJLQ74{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}HAKIY'C/"+"20KP?X;*M72_1T/,G+KR0(C)}@XP;W9$\7E%SB>XMA4Y M-] !-A#+D]8P0"(19S0"YB6",,_1(%0ZJC? BZEX$NP70K<++>QOU5GUI8HS)&!=.57-E$ M<4S!(F6D0#Q@BUR4"0%R2L;[B2(D'/L ^Z1\+S:)G ^]Q!IMU MY,@:WSX0B:OJZG;J2E@5G: .8:9-SA562&NFD&$$>Z-2DGPC74RV%]#\(@2 M7E56=00JLNX68^PWLD.I)2& C3I9,.HC-\AB@i$.U#-.I?:4WKL"_

*!XU&${*9EBQB^7)*9&Q8Q)^+FG6W(KI>+&@O&NL46T -TRP31Y MGN;<&@:W]KHD/#!<9B(;X/(N /&],*QG&'MT'9_Y[D6Z@3/|>?K,_VPGMFY+ M(S|H#5|7E=,*

[M31NNOQB9?,LN\JN.\)XDY-Q@TV]TB/FX! 2ZXCG3)HT+WJLM]#" M&:E,'0"8#KE[7H2YYGJG$D<+ZXHNQ($H)2DR12\-LX4S? MH:XSF\;ZR2C1.".$83 MXW+KDEAO(FO& (\+7@1W,7V>5 MGJE6X*RS7&?HN$IS(EC,P7;"UI."9]0Y,J1B=VG5]"A:058\UM'\@?+,841# M?7=QGHDF\2+(:8#00X%OK7B>Q)+DEF,;*.TE+(I50A"4F8T8(@_-,82-99S'*

M(B&9C@6VFP$@%73K$@431O5YV:2F;a;,#D/_$1X5'V:2\;aZJ;NUXSGQ M?7#ZZ@1]#\C:1A>R.;P^UK$RZ91FC#:"5!G,4 R*U)"DSS#T"%G1:\IX2Q|$-UZ,AB#$%)+/-*

%GA(E,DTR:I,TXW$B^JULK]7IZ==JB/37@8\>[}>.')[7';\"W;"2YHHEN3$<>ITTQFLM<^^#;FX+WQ3^BC]J&JVZ_P.KK&#*2Q M^HV9UY=6UH|\"K/0X?41"7TB]38'V6"/"?*

*5AO:+G7+H!.Q;'Q,4.9*H@P#+W- M@I&,61Y;*W-E>F%'=^L"V.M-ZL:+,OTG MRSHZAY6Q"&^AFW 5UB8ZK>4$T=$L&V4\)&RB$I#7VR5>(0&X &'G^9-=^5/ M(U!\">Q/-<*&Q=,*

I$ A>,&X,G9T% 6(KT#P4330KGFMQVUZ&XIAE!_S6H77)_?GUGNOT%D6L^5#$^A#-.MNCWKW(&!V;=PVR__'R'ZK0_#0Z(&,6ET,)/.P[2>VGNO?M?0?B&C G8%D M[@MW;E<,*

*[GN!% >E"AYJ3MG[.I;696.]I_!:N6,',^L'Y;OK<<=7>YGLWMO)C M*7 H5T4L;3|6JPUOW7\]'ZL0:GI'$YI0(G:>D$"DGB8@5$XF,5=X[H;A)"I1L MQNK-]A.VD[J6DU.+AQ0?*

*9%GCN81=.9/H>. SLL#ZR3/\:-?|7B7#I>/9=F5T7>\IV,4@[>(^ID)\Q4#[PV\%WB/2YN)+,^(RG,L MW1(#'RF>$U-H%^>69OGME7NY2?|*4^()>IRE>^2|ZQ'GOGCQ (R6@1OORHW*

M0"Q+70%,E4@B"N4P#Q@^,I$#=S"F-CD1F-AUPI!24RS##O+:)+'E!-N=*QC M> XO\J?(C>RXV!T!>R\{'NB?7!74=R\{GR:9<0FC)%$B)T+&#.8)7&6@4E"*

M=1&+7IE88X6E($D=]@?B\%$*"YSPD0*8Z=4(3!U._QMZ'(<#S@\X/!C:D7* ML;Q@BJ0N\"-'R2E0*92E*2P*K(6<;3C.>]F"F);)BIG*0@N>CR/E M\HPI1HTE7 E.A),9*1++)L'M3JG0>Z[0?*

*D/7H;OC[W7GQP%%9@Q/^)4-OK-*4 M4@N*HDT5F L)Y@:(F-!89DF6I*G36^(Q'MD)?[\,^)T>P<|)>ED>%S$'L6F2 M":;>V0PC(BE1-(Y-*

*JACL97IP+OA[WOG=]2&'!KV#0^<9@K%*C'4NR8@5!G0@ M;7-2< QL498]WLL^>@.^/ME2;H[0NXY@7%&K=1H]UA+T96.)6(+5Y#" MY3$30FE:W"D_0GN?++*[Q=D*

*Q@.8W[IFK+DI&&.H$"T3"2DH*#Z.)8;EA5I M*FPO1.'1G>_WR9+\.'D93@DN96:5R$ S-A2#4S0D)-! D;]$QPN"'!3L;1*U\=^?7@?W]"HFY7:76MI0"CG=@$3'"!E:5S$0,$ M99ED5*6@5?*

9"FF_M15=7PY;ZR8GA5R#&?991WT4."1X?M[2PYP+EUTFYNEJ\ M[=AU-@TKSD U2T%;,YQ2W6LD>&N/|5/E@<*;XZG3%N=$Y4; M@#?#X2|%,>,)@?Z<4AW+WN;>VAG]5#?*

W/N!M<%T<+N#1C"5Q6A"6N!B/YO" M1F6$"A,GF6)Y@,\)\'1A6!Q+ N+,;85*MG:I/=7-O#GA#(/+> M_*&F/""^-G9CHLK0C,WA$GY! V?L1D&6Y3K(TP;A4@"R.A7!54A ILBR/$^9

M[MR69.Z]9_ \W!+R38Z KB6- 2E#MSW<)4AM,8($*=#E'F2 Z|QE.&.L=QWTV*Y@[<-X3"#'/ZQW+E.X; M9K=I<3OPX\"/*

S]>R8^.@X:)65.)B%,L7@V\)2G(QYCF<:H,3_)>OER>F]P5 M(!J8,##3!DB4U!P|JC20B=22S[PXSZCD^:0[, ^\Q9('0W/'MW#K8=B.^^>*

MW]IC=H^/<6Y^YMN\0SE5C=6$%#C,M#>6$]4HRG1J8YM875!\UX>X$TDC"\+ M^PY+MJ]]!BH^MR<3\[<2N+>O*_3\<]GH4=4 (7ZUVQNE^S&4D[DU)/K#OR?*

*M]'H@=,/^ZFL[>\?NZJOMH#8&>)O_]6:V:VNPD<:3QZ1:&7W 4A/3FOKM[Q9 MY>7#WJ3KK4&X%)_\IS!>_7.5?ES.,+2+)?BN:WKGE_G2?]*S"7K?8XNPH*

MFIW9"'65_:%=!|_E$L=4F8FL3&+@(MR: ",X>@1#,+X31MYM#+|[LKR: MP(^ZW^TW/9HW0+JCRV@4)"<2\1KSE$+0Q>3$:GZM9)CSQR__KK\X@CY8&2!

*M"6:RG)23TZB:SD@YB6]$^Z9]G.^)YZ]O_!/,)/X7+\61X37R#XO?+(;4#>@H M@=MD=S=1EZ0;B9)-V1SAS7(T0F9;&?;__E\YH]G;YA$)8DVAW*49PG\C/9(-_MD/Q4GEHRJ< $;!\"+*

(P_MZ/^#ZRIL=_>$/[6C>PW8DJ '5R]-S"?^7CRU!3-_M="0OW^"O;Z?2&-B+E=:691AJ=X@$'UO-[E[G;R2@Q;^=5DWIGUS;D5>LWJKJ-M&RX'//!-HF?

*FMVO:893=7;LH4_&K3>0LK4=#!^MV|GBU.Y=O3E9%1.8!@S M6<_>R/F1\>KO^ ZQK^-IO_+6*O5RM3G(|Y?Y6-@$[>)O@;AQ1 <#6GRC?:M]+RN._W.S6=@TD735ZC%$)A<$?*

*E:T?8@^;%Y2)-"&A%#J.6 M.R*5LR2-\T06*!P*H:U(YF"@JG M*T$MFL*I*F\7 '8C<*^TJ+$$$ZK-(OJTIH"=e*7^(F$H0. PG$.S%81)|5% MJB|!6I4J-T1R*TD1"\5RKI3)>C[)&Q.Z$*

Q8;9\'-S&0$I?O]"UEZ(1(O Y\|ZF2'-F3D0_44Y.X-+\8>6]M]WSZ?PN!5^":!HY MTJ[S1?PFIXBD#DRXPS-DF2AL@A5NA- Y$6F!D;,,D2PN\EAI8;2BF\2l,TI%

MCI'7+E9$F&R!#F9C0IE6&9+99MRN$>?7LJHV9]6H\X1_5J=8"M@BSG&2A=Y0I30AFA=..H<3VC<"S=L0\//%8ZA ME-?8 ^:&>BI+2SNRXT+KSU,-*

*3:FG:3!U(XG8_0>WWI@0]TL3'2(OPR[M:E M"4@I9TN_*#P"/3B=A[.N+N5H5L*5:XH54N 94"4P%>VL[fN8#G64!MF'7W4V"8X^@#,$!U@4*?*

-5Y2IE=U6SPU!\U")^ZCW.RM.>|/>'4[<0]"YGEU&&%8>Y1:Z"$OJQ1Z,SJ+VTP M',7@B =HQG"N'4"I$F"#I(PH1AV)]67;I;'EO&=^W(%X?$R.-XQA< W0SB=0 MUT"&34[_5C7-

AZK^\&R]9TY#TS!_3Q=5MP+1")9@_,T@>+56<+//%#,;+1]6= MX^.#N,?'K6 ZOF>)V\&Z7D+\UG<>P0; _"^/-K-]TC_LV;!+&\/GM;]M|%B<@$]DH.0HJT'3H5B%@"6.V%P4*

M1CDN>7ZG8^XUU]4'BR+U'3RL+M4<2\U7ZTSX|*I]?3=5X$(_3?M3%?\[CL5 MBXXB6SW>$Z-_1#4*$JIY[0\6MM#?T2KQ'6TH7^5_@H<7_:N3RU9?61O2RE$ MNH'[0*

3'N2N9CZ=5O6L;R' -W4U!SULW45\D$=K$C0UY$&Q<4"^]KL @$ M@8;G7"BJJ-0]D>2$XDXPN-RX!"M&,Y(G*B:6%; ,!HWGAL@'HG\++OR+;$_975.GXIAOS7 MJ^.NP*

!?,:=!CBTGX1UG&=G2@\14UK,EG[M:?K> F_E$&@!H#VS!&H8LB$D_; M<9-]V^F&L&6Z,OCZ,OR59TS?52.RYE_XX8@WO9#AX6IBPZD^=V<=?0\UW*

MU4_@%26\Q2[.@+RGO9D[5^H2ISKUP/-&DFI7:'GD-Q8OF[JB}$[-> MZ\!3HC!]6.(V.J99&I%A+59/NOHXC$,,0WH=T'3SC>&6HTYQ"F\']03C==;N MQXM7W[58##0Y5]:Q|P;

*[K6R\UM:M;?>;U\?=$@,F5'"%':.G?Z1,9;K(0; 3B MP7GI5;3Y-4.@T$+NAKQRQN>/9B*S%!O]L\3CZ)-?: W,! 1?7Z[M?|LX7I=K MQ1K,#Z/C3:Q]6&%80"55]#4H1ND@NCZZS*

*MO^6:O@^"Q=0N#5%@3Y#[GG.\(B({]\V#QSB8ZG9=&-@L?1ZLCQ32'62 6V7IL M4"-1Y20<$7LIAHQ?*5CB)2;@>Z^C7S>V/@?.OH(&HU?X_6__6XZG;W^.OK3W M*

.=>"'SQ4YG%E73B,=&'K'D]4ALT@;&PT).F55D /5B1Z|8RPN F,# MFX4 1.;!E#D|RIVR20]60VY,C.ZD%$OY<')U&KO"8DI=0\2PXS$(B-6% 46*

*MD:DR(TEM$@*6\0l/+-7SO%=2|'_'I|UX+KWTJH?&^^/>E;17Q\#Z7:!Q!<M^W73]@4:.9>C>2<8^B36J6BU10T?>;J-Y)!>5>@B0.Y)8#?B-O FZ@@&!84@ M4_49)I-X%X,N:ST?-*

S/D<> U#:K&BT+L+>O;P(]Y4:BW 6NZCE8=UOJS0E## MP&A;2L)-5S\RH089/@+-@$ &!_:H%\E!-X#7K1N'[A@*S7HZG0"[UB|\V'N> MO5(R1[A&L5(U,^)+Q< XIO-9-*

+:.S_Z'<.494DSI/2M_^Z13-N.$1L&$W&.8 MSHZfLBS1S,99 M9;ANVFLZXE&V MF75\'R1R\'7[R&PU^D+#/HX^3B(YG8XNKR!*MZ#DEK;[YY9S- .)-=RM/"E M^Z-0$W71P%*

*[Q!N@8>X8*TCA<"C^X^<@A|WB8W*[#/*'C_"<-K]V6+G#,[,#3 M'3#T,"],.7+49LP5CCB!!85$$&GN>,.Q-)(!KJ7C%6RB9T\Y89BATA,]]Z M&:*4HT0S[0K#GLP&%E@=P8J+*

(&A+R!,33(88PT5G360GZ%+I>P."XMQ7Y=TR<&JG@PUM<91. MM0GJOK&@XP15HY5,;7S=EU>R9%7+9HS:V=X_U9WQ1%^'=)K!QY?\'ABXY2J*

M3{!=X.NB^D%D$1N2QBF+N=-:|,/Q]^Y(@>!=B/|85_L6.!Z$9X%-E;R=2N2OYJRJ M9\2;FX.86^>IF&1,6L9%)(C"/TT=R8URQ$IN8PLZG^TV<-L['X#UK/?-!GX; M, -*

+5VHYF:%#UQ'K&Y$$W65)0FA"ATYA("Q\3PPL38QN^ MC-W9Q_7;"]&\;^ED3XP:']|#'_&GS<8@;^5+TV{IYF=?0?B/5K)K;|'_ODN M?*

*RVGFC*3$QDG&8@BXVN8,\)99K6+=9$GO0BSVQ10W":*T+J;^6I7K4CZ&ORX MV^M/W8?,+(6K#\EQYA;|9{Y\&Q@TMO$G!BMG-5N./S]1J-V*=\&>>4OKN8-M:%_-ZS?K!*

<|^Q4+_DG;6.7D%G!A66XC?^E_)2%Y6\QF,I9LU\,X?=&:/[UM M;_ VUK2O;QHIE6!IV96\"MEW_+I@RI_*;I8T?|O D-2D1'1?ZGU0t0[5]%-M"A_?*

*N=>>ARS6]YYR}OB8\K$P[YRF..SF',]YN*VHSW025{1^2'?VOCA,1KA MYL^E]/K3GQY0 ?[J,SJ^.!5%%:"N(M1T%GG'7-0)Z.O5V=W7XMRMMM-J-TSL>%:+,2S 2U^*

@1T&:A@68&"'@1J&!1C88;"&>SGIN8%5YN>,[>@F M[5.WSO+J/6C7$MUI85RSW+B"$V:D(").!,E=GA%EI6&4 M|8Q+6:C?$=L6.*RG A%"R*D441E<0[/4"RGUHDD2?*

*93.8VOI8CQ*U+J}O2(-M%6)GEMA3I?>[<_ >4^#O[8AOVCZTKI'#?3W' O0'V!M@=8 ^:+^]6.=\W M;.$DXA3 $XS6/,63L:2 G.RDU3HU+@\3^V|P^:OBQ'M&/B$2C1S3=76?@=>?/1*

MZP%3!TP=,/5&;5],H=,DSTF>:T>$<))(CIV/,I90%7-#M>ZUQ=6&I:D0Q)@B MQE:Z*5$BTR2C-DDS#A9X2A_#>DZ3(\KIL\. ^_;IR7'T"DS1";-<39Q=2}?.[S M&VAUF-]3F=]

*J\AGLK\!EI]%O-;U?KA;RPE=R#SV7CW=U!W ;EO-G4QY7GX M%N\]W/96H#X/2R++^*H1{(!/+6E,UT)"_?X*IOH)@X?J5M/ RS*,+G(&;9G#[G7^1FfG*

*MYNVT:OQ1RINNX^0#BBSZS9GZRGJQ:A\2V%|=OBUY!Z)D+Q3&^7P[V$*Z\\X#+0PY MS/&YSG&H8CJXL%^ZR;-NOJ9#*;Q>@7/L8+&[UM'!E,(ZH+5\4%;Z3G6P@=*T.*

MC40>L++7P&W]2d8=.8 MSHZfLBS1S,99 M9;ANVFLZXE&V MF75\'R1R\'7[R&PU^ZKEPU^"'DAFKG^Z|I<6T*7#MX7/1ZKQ=`CUU_Q:D_M_D?*

HQ<78T'&W8(QAKF]P3F-]#]_+ ^G,K^\5H?Y/97X#;3Z+.9WM^+G-S <;IG%M?CC6Q,ZND6-8F1GV8->CN0G&@MFHFA?)F3<@5->D-;K4CSWV.:?\&+.(N9):H0E@B,]U;,.L(

I;QB3!:::;48:YXHE+I<)R:E61&09 M)SD3;%YG[@LS8 7S8W2_'LAQ_O*^S_*13*D_0^0=NA;.D#:'B'-&*%,;C3) M%8AT3HAA="<4"F9DZ*(B[0':3:6<1Z+A&0Z%E@X#|!-*

*,'A$D2:."NWBF#\& MI W5\) &)>X,N#9'O$LSZCB7*95R#%03D2L'V{1I8YO?EY1PD;L"X >,&C+MWSZ,Z M*P"O#.AQV)PMBU7A"%4B3{1}>3X'C!LP;L"X >/N78^SC!DG<^(2P4"/$YI(*

ME4B2T 2P2^D\3N5]>4(C#L4[^BB)._VPK77]>YZ97G5W7-:%K2|Q_*NX5)\ M\IMR!N_5NP.[;S6?S9OHI[:GDD@I>CDM+9V#+^NKN5S6)1=2_'|Q$IW.3V$$*

M$8M9?.1#5M|58QC'920G)NHOT;N[GG:)=*|Z/[^./&1Z?_&LBN#R43E!WHF^ MUB7\NYZ(MUCNZ!6^^#O[\3]"I\&PL5<9/+6&L55C/$HYBL;ST:PD :]/HFIJ M)P1>84?

1YS/9V(A%NAO"S \'F2_36%QK9]M(YV=71Y%X8VZ^].<6.#VQD]? M3PD2>5%F38@@Y^7LLHOKA6=1Q;&-%/E),P&?CFW]M15#;=$K_[^TV^OCZ^3

MGTC&BO"P:#+7(ULUKV:O2VA.SFJ3GT$<=W@$^6DT?#8&0Z[G)R5]HQ5!? MZ]G'U_BFJ<2%A?'C $P%^L#;'.$\-;H_J 7WH;WA4T.8UCY^CCZ?6)L'5VQ MZC#\IK%C-*

=I%#,V9#$'0S13>WU9{15CV3]95,VM6%@R6T?Y[+D+8,UQ M'%@C^QR6IYZ?-D=^.99+<+RG/\4B#NMW9_/$4'MD;")+@] MN&> 9H%[,.MWRQ;@)M;6C8"P8!>;'#+VYZ)N,Y

*1;#^0)7X9 /,/*JF?!W; M;0=:MIAS#$NQDFG<@S]5+*%C:<)O!H'-_'I]7|3FQG\)PP<7@7@%4 32.GG MP/MPVIHQ\J1+E#63H &2Q-H=Q4UV@21<'FLR4VP(,O+!'!U;@:UU1;@-M9N|86.]%=8/HS4E#-]ZQH-*

=A^7PC.$A8&L]\#/R)6[T"%[C7QB.RN#A^-+CZ$,U&E47.$D\0$++ M.7 5X#FF;%H-%(8ZKY$L]1HOPW.0S"?6^Y_PL2<_?21_X1G?@/V-$Z4=D!)9 MY!J3M)-I78Z"2PS7%R;B9W-*

PZ.'2@KJB(#G+!2"!XT1E<4I$"H#-G-'*F;O$ M;_KSI_#%O_PB >G;W#)P*0&QG=6($YDADATF%J6BIPG'("C M7Y+|J!A%Q=^2H'3K&CLEDUK+"8O49G/3)(7"<*

P&LKCPP2F]ZU7BABYUO3(]DTV!K]-MU))))!=9 ^Y ?UCIAK_1)|TWM#>A[GG:P6 -\/'D+ZM-T)"]]R_NW79_U94N!-M&Z]?[9^\K\8-=]M NMXBQ0>/+O;M;)& WXZ^G(%*

*M#,.8@8;Z1LYGU=OU'V!=P]=^FT,6OC]=?B-'%_*R:=OSKNYXMX<<QM9OX H-_M;.SE?K?L_J/Z]^"^WA(1W.W.?4YQX?+R4@FF-OXG^R?<-]O]++.)_HADS;|"H M<2>&/UXV9?-*

*/=QA.WX\PVH@=1[\LAKOP-OV\&'4{TVM'#M;I 3F)HP\EBJ00 M93LQGN(I5_%%%QIGQ8!9"ND<4VB.'A7Z/5=QE]W!X>XQ2*NA-[A*O{(T!O1 MQLTV)&K.JCDZ,C'H1?*

HX01C8O^.3H.5Y)TT;U'-T4ZJF7<"@J4.5DP7D.L] M&T$M^-GJ5BN@(8"CG22^?>2??8]S/0]J$GP7XGPQT@=W!_2J$'"%9S6MX^F0. MC_O-HB\(O4@?*

P;,;$S^NIB/*U&O_/Z7'.BL9KE\OQ]_.0:=2(/&-BO/JZ7H$W MW_29G)QZJV52A\W#9\I7-'V'H0!ZV QMIMQ,L?I)U@W#*7VT5AAX,6G*E,Z!ZL"P$#8BC62#&[WV5G5H),+V*WQOKHZ*

*M*M&W*78!#;CO#*D-A<77^-AW62%OB,!C+7=6PQZ%>=C"<\36-G>'C8"_"1QO)-MBL5O/X-2$'V$E43\I2?'T6\PN^A#>{J_AK[M:**_!7X5UIYTC4?YW:C]_<=/-M"@CW+#*

(^G=OZO+073VH-[C;E?UB/-C)29;7B?.XR"EJ7]O? 3B;5N5<7/8[MJ9WJO!!08D^M3Q)H;*#XD"$"W&TE!K ML&9.X4O;G!/@JJH"SXI&\% /B5-X MON>EBZH>&1BO#3P\++:<6-*

>.NYCR\):G#.A(@UH=0:7:'@CF=9@4. FC#31 M]FJ\ OAZ@9/+V'\?@0?@5^,'L&914,#ZJEMTC(L . .#! 19'GLMRY(,5GNX?W$-B1,#0>N0S*99#^6DQC)}&@K3US,\%$4X! M;L,)A*

2). "%M_@TFWTRKT278FYNI-K_BLBUWV.?D@.$(=-:)Q;!8_N6M^)!1 M,_:G;]4(EG:$#P24!;B%-_[O_U6(Y&WTZN.'7|N_7_OCBJE_'7Q[\AN,_K2: M@-Q8>2\>;^*C88U?-D

*!+RPRR#YW^XHK\^[K"7D_ ?K$Y>I^>5)+=;>5^5KY M0WF4LFU6QP42'O#&1K(073],6WS[HX(!SXU/;,.CHH2G:?0*_WV-7#RJP+B6 M(1D*L,1#R2[D:+69287:B*

GD7XX7&BK6:6P?D#=]<[^-H$V- -M/D(N'[*V*(QS4/SP7[%H9I*&< &$! MUX^B"=("(+$6KUD-.9R&//.Q8O|2>B1+#}ZHX^BGR]7TK,5L,/!9$[-E,>S MLDOKPTE9B$D>O\-_7.]$:

(&,3E=\N=/N;D02E61&]PG]O3A)(]76IYC[@_C+Z M,VCA8-1\T25Z4$'6?)SHX-A5^/KU(EH!Q]A>NIXI^DJB]"'>/E @H2]]?Y'-M2PG+!>QH\$H27)FHWV+5VYH7

;O7MYA_6^SSG|M]_HO?YO__\N7OA 99!7^Q M)[5J=T/@/V\0/+O?H;KC50X@%OZ0_KVYP.M*ONMU5HFEU.@0E!>H]FU M^S(6+F-*

\1N+'319W48WP"L1#_|A'2]ZPQ)8HQU>TS17(Y|_4#+5,/% +329.[*T.Y0UP.%Y|:WZB[V8??2+7'MPVIHQ\)FLfX4R M*CPY6W1'"OKOPL$P*EU(.0DY]BCV?*

*7Q'.RA[M%2NPPHU4W26X*R"'"MC]C%Y] MC^P4YSWR"CB8]?.0@5MZC7R!W8R&U:,\&ZOLC+&[[^YIA.X7Y84Q8\P?. MTS;!N=%@'$O; PJTS.E9A"<7K<$.6X#9OZ"D*

EJ/6\,>7S;%V+FF72?0]GT$ M"A[Y8@8OC'R#WCKD1,1#N!V/6[<"/LM3X6)T'3FT UR^T@.M%SRZMCY8QRN\ MG0\DI.CXI&[$NW7+ "H$$LC /"B][<([[%%K6\$DY2G98/+-*

*#3@".@_DM79%LV2+3K0T M]MO<9Z*M3! 63LZ"F.K2T >CK4CM%0?/$>Q1A5G_?FH[15_E@-Z[5*]]M$/- MI])!T9@VE_]L\A]':!("8:\1E)Q*WTV DRELS5.1%7SV=]PCV!3O,.FVZ/V*

*M<@"%IV,)(QZ/YY,*5Q:D7HFKN# S<;]6!M;NUSERK>>ZND(A;U=VU\SM.H6L MT!W(9MS:?YR!O.I)_QUP&'"L"G^PHY7'-1[_']&Y1]VY,.SE5T9KW_.8BYA MC*7_F%[R!:XM>_]!5J?*

U$@ VO>\|#\8!BOQVUGF7D< Q&^/?(AQ/FBJ//I MC,&4&\W:5')(R^N';I;@VL(5RF[.[=?3]L\'MZ["IYQP-1S-%-T737-IAJ MQ3R08Z(5]T:H+=+XT+!V5;#T.?!SA6<#*74QD-*

4P@O_5EZ/PSE81QJ6=G5V. M2X-.!!N..-77_\;/"T $16N2QCVZI]QW11(%?*< C86K^"A:$E"XIAR/ MK4%X!);W =>;2DBK0/2F_2'$02)D])\J3]&E/HN^_I6@X8"&1^\1:U0REO^"*

*MK5@C/1Q+QD(^A%"9]9=W0)*F>LO53-;${UE]2MJPJ\N?BK/+4L) 2_L8@ MW3U3!MT*=[P*>>8+1,03BQA\IK-IO?I_P\LQV-85I:#H ?:B1;HY ;P>*CUU_0A+P^WOXO7"5F]?*

^5=XO0'K M]=7O?P4+X%U T_;&CBSNTSM#HXITX)/!IMH=G7 83\&O@8;SGUCFFS>RKM MT'[_.;_/M#2]P $$U<7#MRERK8fM4T?_]U5 M(@>'_-G"G/X=$5PY:^K6WVPN?E(%[0

/U!15ATX,+!92=<"#M=_!XEB[]}>'(1I>2<)3CFB*)=+]*Z: M^;IZM"+> P.TA.EKW4WP= 0P.(28+'.(T-^$!P)5\(LAL2|=<-Y,-'.], '#M MW#/H_#F.L)!LU%F1/E?CPE8:-!Y#R/J13O|-*

,O#=WQ#4W]IKC88 M-(2C^2S1KT9&IQ+,[O62^2M%9AS:?"[UPH1DO+$-PA7G;/+:Q>O\4KQ*]7VE>].A]BKC]U M&:&AJF,:8BYA MC*7_F%[R!:XM>_]!5J? U$@ VO>\|#\8!BOQVUGF7D< Q&^/?(AQ/FBJ//I MC,&4&\W:5')(R^N';I;@VL(5RF[.[=?3]L\'MZ["IYQP-1S-%-T737-IAJ MQ3R08Z(5]T:H+=+XT+!V5;#T.?!SA6<#*74QD-*

4P@O_5EZ/PSE81QJ6=G5V. M2X-.!!N..-77_\;/"T $16N2QCVZI]QW11(%?*< C86K^"A:$E"XIAR/ MK4%X!);W =>;2DBK0/2F_2'$02)D])\J3]&E/HN^_I6@X8"&1^\1:U0REO^"*

*MK5@C/1Q+QD(^A%"9]9=W0)*F>LO53-;${UE]2MJPJ\N?BK/+4L) 2_L8@ MW3U3!MT*=[P*>>8+1,03BQA\IK-IO?I_P\LQV-85I:#H ?:B1;HY ;P>*CUU_0A+P^WOXO7"5F]?*

^5=XO0'K M]=7O?P4+X%U T_;&CBSNTSM#HXITX)/!IMH=G7 83\&O@8;SGUCFFS>RKM MT'[_.;_/M#2]P $$U<7#MRERK8fM4T?_]U5 M(@>'_-G"G/X=$5PY:^K6WVPN?E(%[0

/U!15ATX,+!92=<"#M=_!XEB[]}>'(1I>2<)3CFB*)=+]*Z: M^;IZM"+> P.TA.EKW4WP= 0P.(28+'.(T-^$!P)5\(LAL2|=<-Y,-'.], '#M MW#/H_#F.L)!LU%F1/E?CPE8:-!Y#R/J13O|-*

,O#=WQ#4W]IKC88 M-(2C^2S1KT9&IQ+,[O62^2M%9AS:?"[UPH1DO+$-PA7G;/+:Q>O\4KQ]7VE>].A]BKC]U M&:&AJF,:8BYA MC*7_F%[R!:XM>_]!5J?*

*

*1[VP5ZN#QXU"QMP[ENM[/ZVH**N.)PWI6077\I30&!OA>-K,C M_R\87*4,N8/=?5\-WLZB$U_,4X9U;8-15\:(J3X8J[5 MZ,%D\W6#A/@]C:V M(^Q("V,+S 9"'*$=!?46#*:1&=*

*9H<%,O@B47[L%FQ2A;R7P(,P92AS5&.?'^ M]]<+NOAC4EUX;R]0GPV'40L"73U5[D%ZFZ"JO8$8C.5U:FV_PVR1NN.{fL@; M:H.6GO5QB:HTW4D3?$*G"WRJ.lLZ,#L8$1,[1$ \ON&W9"R$J9:(,% 1[":? MVM/+<"[WK P$N_VO%C](@F.WV9RRXZ7?O'X?9EO;B;11/6FC>$ETT95%7 >YKCQ7ZWA=Z$NKOIT521:$4P\F%[F'&]+F M.>[*-W#9PGZ^]!OP<;$-*

;8VE9[@N5>7J(@4! -^ 6D\N!C :0[F.!<8B^7D,(M2\%<-lN%*9[^-IX=[1G]$2\tUTWJ%M>D]2/#)MJ@<I+3R?(>2ZK:[14:\/;=UTWJ%M @3<0&3%!6@*_?X&;1J&5B?*

>HXGSF("UA49KVI1@%@YZ"3E>Z1&&BL+0 MQ'1GO0L%*D0\V[&"_]INHA$F),S'\%80GOK,1XD"-)'@$&Z#E:9V.D,GUZM? MO[[{##(5_X-*

*+VWHQ5^I/3KHT[.5XNK(B_X^]=^UNVTC6A?*5K95CKT6Q!&I MN_WN#XKC3+S/),YQ)GUOE^R0*!)8@P'"%PD,[_^K5LW&B_H42(E\=*SU\W9L*

M"9=&=U5U==533\7HB.4W/"+$\A^Q9V;/NC!DFBW=# .O)5%FEG MN_6+M+O//P;]>\'O1S5R5,>++V.6=3"\A3!PHB%KQ&?W89P141"=2C1?0=[-RT*

*{UR*E=%Z%7B85G=_+C#5 M"SNF0B"'"CVB>BPU1K'&HJQDF>]0XD\[+/2% ,GCDUU>7("0&&B<@VU[&'4-,% M6# N/A+07^%9V)K]H,HEVKCU$P*8I)ENBH9VT*^+*

*<;HH%EMR83/8:J/%LM+;. M-1!!9,*O:/JH"KA10:,+*L@:KU#&HS%A."!!8&M[.U9IA@1R\i#0+++;N8<@)# M!RB=9(QY8AQ:R)H,H:Q-KH*V;S'6,1#:E'/19P8Z"MBS]S"G\9'H82JHH:%*

MVT4FA"CCLVH#:@X3TXTEZYJ;%0N2&(R.&V>SM.B0Q/^Z;(:ZKB46]LT5H;0U MY [_\0\,3_WOHH6CHI\BU3\%OK:M4O7+++R^XB\8(7H/CB6FUU(%" Z/PBU: MI["CCD:*

92VX&RNO>%FH!BUZ.M(,1$*.8.NHA0_ZA ;A>#=:,0LZ*0(;>&,538=4WC,-NNE9^IXm4O3_ P(&,?W8#*EHV)(=C"'"W MS%3X"QH&8T3"A+&L9Y2.$?/CK, SAOT1?*

W&"\PU],,Z1: MU&%3S/]8\"=AOP9=0C-H'44Q5"MN^TD^PV*]SW/#M8VO)D]3I MH$R[^65P++!!KH:<%%VX4]R1],,K=2IG*,49D];I=+6X1S'"%*"6J+A6 M-*

KF))^%-2)IC9!.BCWB,*W5:@^, UMH&-#L0*(:W\]VCB=EBXY<#M:TO;"F M"P=K)VG@- P*Q& @UJJC$X-/S/X^!?0XIMCRI#.J78,!*

MI&%,N\!ATI:F!+%7H%,%>$0S7LI^A)2X26'TK/;!Q B,U+CL.4OT$,K@ON\In. M->FM)%]KWJZ"#K,ZV0<(P'0:4G-9 VZGH,+@[M.+'5FH)/ZXHP1S .!2((ME]9PMK(I" FFM5[/QO"?*

*-_OHH2_5& 1?EHI-'0;.9B6HSU_LU7'"%'%8EB..T MR("+X$+OO_IOA$^;8(^HL@MS<3C@Z MTV"XY3?ZC'9!?8Z4WB$*O!DQT0 @'4BBD,Q(>'(QX(6!!3T:T\C.&I>0[S(N*

M:!D,PO<(KNYKJG.-/\<:0R0_X,9.[&,V)P@?($ZO<-H+ZH[C:TW5PHD3IY'X M1!-68@1 P_R0/UB=.DA9E8(NS%14SZYAL%HE"61:0<2%QS^TWQXX*G" 9B2 M0SZB1U?*

*8&P1Y48.*HYD!=#IL&&T)H"?@OC">>3(=L0O=!<'+G<[MNJ_4-AER)E:-F,T_>G*0C5]WY;0T"F1.36?E?!JE M4?K=8,5D@E8/-;],&B\]3#\2V1Xf:&P4QYC"C'P*

*>8>OK=.4PD2U02O,**0G)=X4 M580S0K^5C]6L\S/BHBJRG'8J3':/^9-EH]NB8]4^*^)UF_9FB?C=:H?#XM+ MA%U*R'>@R<2TZJ0/KV.+ +$&]STKN&^0F"Q] M48Q; IH+] ?*

97)@01X.?:,$&]+P?[^.!\E?@F[+Z?BW&,?$[:A8B_M63RE# M3$6T_KJ]?-2#GQONX_=9]V; 5"\]V TGYD?90MSR"¡\N8 M,A?>OGC08)

-_%288Z&K,.5N&]\%$3@AM&X.WXZ)PULZF:APDF;13?2_+'WB4 M(H1W^(7P6.QGH<#[R\F29#+___C__H"SP >L):=0:-%Z&7<U:%U?$V]U9"B>:12M8 M0'/.I10R>5S_W%P0?

AR,\4C7E;RCBHI5[\0/JN_$#WM]\L:[7/%N^%ASMRZC-MT9]I3B]TL*%J7&E;8C>E@A>.$'-9ZRZKQG!E.YZO93!6V&:EBCI7BO@C"5) MS>Q6/T,/N$.LK!$V2A>T)+;$S"XO:?*

*3O:C3,0+H#^)A_ZW)GT+)1Z27(L<>L*SG/OUMZ[YL&,0@1U9M(XTE?4P+B@HT?H$$8$]RKR:LH^7M23)4 PEAEYI-B*:<[Q3TY$:.XC28P'*

*M&#LG2G#:&R2,6JC[-P\=>>]2.81T$94W3A@Q02F;PP%{&IOMiU3!E.,)-3=P M?;HT 0K<08IZ G>{"_SV?:0\]O:,HT0#%4K0%(Y5!:U6*SC%^12F?7A,4 M,2U8?*

<17AO$!UPK=_%ND+[>]H4P<1(.]]"ZET@G-_6Z^H?QU9/G;%3RCV 2P M^;&I@]TZ+CZY-TI=R;UK;D]^4U.S,=:I@;33;CB.,9_1HGDS<,$6-)"G4O=W MMX&"&HBG-

*#R8F=F470^&+.6WP=SF6N5B0:*500XY4HHD^FW(\ M*>FKZ_$,]D086(HY,,.8D#&@K,F<>[&DL8_EA+_3CE M6).ULM0W5=V8B'A.<)75.!C;RFUX*

>O"HO;F"L36QI9_!@VU0=G:4P$R9N M@I"B5I;&<[;(]%99E#"+D\+6PI[W#_06)/5E0LM&^!N?6C!C@2F";OO:#M*R MO9"62P=I<9"6[7%1E\U#%SWJ 6U(GVHBV/Z97[>LD.6@J?*

*2F!EI/& *+4I?)XW(]APDQ=2<1+M:9;//A5+UB/1XD-$1 MS_W\A^A_&$/2&!$W"1/!Y*V%/B=#&BAN5Q$.;!;/L)- -9\)>&8&%C M2F&9IMYK<+W_+3CZ63 W(*

E+]C&0G:D))IE(%5$@]0?O!/@A+@!@1FSY,YT MQBSWI\KYP(!?J,A/)R#&2PS[DR.CD[=02VIHQ7F.\NI'BYA.F(].KT[/>L2$

*M@HE^U1_8/YD1NR]_.OC^2BI6I51\/E.,"*LEE8+Y5%'+$D;$T#S-4<_[S=*) M^_7)6BSB>_1>79[V+LW8JAE\0H]HI(6)B/I=TR/G]SW/\']5A,E[B8D&5R$]D M@4TT;8/CAP7B,8^DB*

*RO"0VE?M,%RORT+CT-&EWL3 M*H7!505UL7+E>++(1+1]HZ;1G8S^17/8_]R20H6@SIQH!A=,H,G7E>E*4DP M,2***2]-*1]^,,:<,YG')0>GG,ZAN+,.V5AE"18858L(;OA1,8$U\IZ$,4E*

M)#Z=S0B:@QD>S&9T/H0]?Z6ZML.TX4U)K"IN,I\S&]9:$C[0K!=;,S'IIE[#T M5"E1AL&T)-1'$B?&M,)4]L_XP^1#]266!X+%HU0;3"3K:6I);%CD8BY0F].M" .^58'IC2G*

5,^13&TH3(MQ@=:![[B]?G4S0P?9RFU(ZW)X>*2(>3RL*+9D M]N.E J;'*FI.XY5D&&](#&GL&J)OC\]O*:$Y(W-'%I;;QI L%P&=@<4AQ"DG M^#2&9L& &,;'IJ. R_#]X]QI-*

U2=CO6HJ0=B0TJEQ.2,TY)OXM:.*Q7'5*V M[,N]VS9WRC"N&RZ?3FX.P2*26(05E0]-EG],R-[58IA45@>]E*%2[!TAMX@@ D M[%R!%4YI.*?*

*0IGZ5]H[:*2Y<11DS:0F!#O7%]O@(06X%A[4W2!Y5C?85+.MM MCITX$";/'1H%HYD3OP`IK5H1R1*AO\A?#3,K/G91;R@\!:;/NZB+W.(7A_1& M$DZM-_(MOC:F_/;8@\^-*

^_%B^UUF,G#[L=N"MM^@OA&X=PR+/YT1^Z&\YDU/ M3S%!2!C8:EP /C)DR]LG%]SNNK-X]NAYG^2@ M OL&%5+8ZR^30Y9>3!L&^^*HIGZY>V"'9 G^U5 L6O7F 1ME9

JS\WN)R'CP M_4,ZU5BKF%+. ^2,%AD%D/_/T7UN'[FRL:M"\O.K#?RK,?)C+4!NDIXW2W>D" M^(6L6EU;WH&+"I#[5W>TQ>2UICS&]]%-/YG??ZE__V;I669A< NG&'UN47PE

MA\7U6>U5_\SJ0H'=^7C:C/-9%5[?/[Z\]D\O!NR4&/]DD>]H.E&O(*^F3P, MSG6]ZI_TK@9TKJ,,>XT#<:(ME[Y/>\/HM9IW-=ZC!\5U\\&4B&:M3 W]1MZ1*

*MW5*L8G#5N_I>#QJF+CT"GXL*(?"W_QG9%_LE7'W0^ACS">PH+0Q47!['04MM[_M (<+2SD2O7#H C((%B,S@7=R]CTAO8FDC2\Y.4;AH.%%,$\W&%U'QE5!L!-@ M_==8#\PP)!*

2]Q#?]E^O&\K#]$LQL_S2NO2/1O-;?Z4?M%EI-P8S' CN M9<(F]M>(P^097R;2&B7(A9>1&[60Y3:HP0#>4K\%"&C3K!F=_{ M[!\)_XZVR]B\=*9i,,.?R1#72XE7RQ[FR<+]+E=;#E MEE']9$J9_@B'&HMA1[[2C''7ROL"T%-[[>)($,([?)KT?>YP61TXM]*4[GRUY MU=3[A?/AG#);6'CSR?99[]3Y^7.'1A[37$9+;D"V?&MH>YRM/?%W MK %A;Z=C1]0.<5S@WB)4"$7 I?*

D4D63&3C PLQ6,)FIL1$LY02,18R9?N=E#SUH-RDE_*Y7>.[61(V@>'[PC"$H1-C\Z48<3, ^[=4O(-[]$^S;2D M[)"%"?ZE+/@]GY2S?)818I&LB-7*

DAIAP[%8Q]]T>,KJ04L#),XF8KG_'3[G MIQRM9A%FOO<>/AAL7AIO@L9Q4VA&!\#87@#&E0-@. #&UMG,WV,-U\; S(P; M3.2L9S0MX!-:K#F#4=F'4.%UT[Z="

(EXX]"EI0/MWL/9Q@VH =% [4L.R#ET4 M]:F!Q%3ZF%6%9,X9.'K,,<-COO'DAB0Z#@?]]Q'<.C>"FI1;6M@H;N4T?C6 MX'2/V+H[5)W-B QLR;N892\\4$G8-S

*WQEXFAA)!01[H[^'LYJND"?)-H MT,^1',-=MTSA@*A1$E(\@R=)?0>7'%%G-LJ2..-]+(@+*?Y&Y/=N^4!K[_ZT MDD**H1I8V>7_/>N0Z>],P?I#\.535\3Q8T94D,9*04U6BI ^'/Y*

MA&;VB3_(Y,!TJ0REC-371@J:(.&@D2.(;1R8!4]E+3V+3=]Z9ZCNLR*T>QC@2EMU7& 8I61F5*$-38(]#2?24!VO MK-) 928V^?QPA_]>H!?E0S/Y,B/-*

*KKD'&0K+!]WA>*IQ*PV**BW#2I%Y+PP96B%]E]GYT@^QJ=]WM^OK[&QR1?F M18%?!59HI%*=HZR+0RHR;DCB:??+IADLBFHZL^1% HEK$+:.%N+DCR5(P"QNH*

*M,WY^$C.4G_BR97<0+E6QIKNEQFM[5AX3GQ7*$G-.?YW%8UY/3(F2T[*QVAM3QF^KE,\J/@HXYDY+;)55HK7&_2QCBVUA MQY#$=LKT1860H4Q:2:2C%,8CQ-*

_00"G6"A$(Z^_"#:.^2L D09[/*2$%%Z%J M69$6=$9C,5NP?AV"^WI\'70A G*XZ).<7S!S+#W"UPQ*;P/%-Q8/-IYW(\V M<+)3L[GYR,./79_9!7GR&3F'J[?*

%I'\A:CY#Q<,@]44@TE_"0L=%W0F6(?<2-,6 M/OOCMR!^-NC))B#QP!?\]DU%[_BK^L?'O>/OWD-_*!9H=X6[.4J^%)X.#S= MA*L1+L&%& UU7{17!69F"T]?'#5.[ZZ^-*

*X.)_OSK^[^\M-DE GC&<$B(DC3^_%'7F^_M)YR9]5*_MO^YW >XVV%\G 3MQCP^FT+=,1ULLXY/GG@"5LY)KZMA@WLT;!O6 M9/Z\\I[3_[PVI9V_[5@WS[V8&7^>R?SD?-07])#/9#-*

*|>-X, M0Q7B>7/%HV7G.:]R GO2&IH51&^U7'\3C.[I9J1$%G.?&&[W%#V!);1[ZZIKS#.[O*J M.P5V"GRX"NSVWJU:Z@/3Z -,W344N7[\O,L+O9KI_OZN, 3\%Q'9!P"47Q(^*

M$.XP9N/SI@RA4\MJ+H2]3ICO5)B-TUA78+XZMVGV5^5D.1="Q74+#HRF4;%G MKJBGNLV%\8 AG[PD]F^C"-H9B]!!TPXZBW\'$;2=$:?Z.'RVVBP]2<7Y0 MQ5^?[V4S01(#

[A2H^85@JU+369++E3K247-]N<]L_[.@CC0Q#39&KEE3A)$H MJ!N-FVM@G!56H#.1>,.'"[GMJ.E HBN N;B;V@8<,<%[3<'"']>&Z0\$B9TO= M-

2'-4M,>A(9B_F'(T7L@%\0]FT@OCIQZ<5)!>,*V6*97(DFIB;/1L9AY(N\ MJ_=1]UVZU;F8&A@U6H9HFA;B!*@T)8"LF!#3CO*@*/,])'85&"O7R#?8>0TY MO37%-*

*5P59AC1Q'3;"!QJ8]4(2S2!B!A#"7^9-X^+)02.H+)=,LG%JF-<4^ M(0;:)H.PD6K0^SF2'E@9^O*KOK5%]8^H67SF^LW3?2Q<9Z/PJ+49_JHR]!5*

*MX.*J_M\CBIVWOD#U_,P5J.YDL/10/M>5]+H2U6V'9FY+4,35Z[D:55>CZF3> MU:BN(_,2=VN(M7]VRYPV-R5:I,N-VZ^KH=DPQ7I,I76N0VH[U0(U=%Y\I4*

MG8(Y!=L,>7!\F>KFCYPOCJO]T)P;P(G.EK]U)T\74#C4SW52O)?+>F"?ZZ1X M+Y?5?>Z,?ZX3[/XW(I[MN.K[NGIV;SYFIY?

\S=XM^8%IMN/465FASW=YG5>DU.G4YR>G]G6!"IG_LY/S M!TF9W!:>W[IXOZ[ML]!.C?=Y====1XYW6X@V0^#IDQ%,":X'9P[BBG9.D+,_.V(]^_[@ZM(MM=/:.M+?A4^ZNW;K?

*=K:5VBKS/[^M:!SU+U,'!':IXG8ZSV_"Y3F=73ER=N6C#[BRT4^-]_M7MTUU/ADM]7881QV(-K0[U[<.2]HAJ3*F<_5O2!W/J_L_G.KU=`7{GB%B5UM%).H5V"MW@ASV(0,2&*

M"""4=]N%Q4O:'&L9AEM_$N??ZCQ\^NTC$HU7L_BZ9^VQN'!0C=$<-\OGF'*RM M%);G=|&VM/=WGO?/+*_M_9\LVC7[,Y[T+N&B6%7$99R"/@G*^'$;= ML>_.;&YW3\"<-*

=HD:'%SP%@G+%MHA)POLX4"L2_6XW7_\FR_I64[G9GM$!QG M6IQI>4+34I_F:FT4(4+6.U03-A% M_U<&$_L7%YOST/9YJ9W6[LU2[KS6GO]#LP>5DA[L4CNMW9NEW'FM'?

*AGKH?1 M#BVU4^]!7MUUNF/NJ-Z]S5PAV[VSKR$R'Z>0]]*X M4055H$153C4/IL2A7?D1QJ=>5*F 1%|=_?S8*Q.DS2.DU!JG"?XM0_744PRI]M>WMT\FZ4J&!'7$P"*

(\52@6J:OHOB8I8$\[?XVW>S((K@S5;4,69)TL$X^*=(-MKWX=W7@$HO!NEA4Q/9D<&"U;!2T"6=^6|%"] >/K_Y:+\"GGX-FJ84ED+^_MQ'6;F.BFC#Y.L>#\Y"*

0NE^J.YB]@7OG'M,PKU=G/PS_ZE6)'U%+P.20(?Q$M7.?4[!F MRH?'E2\73>NUK-U^K,N]JQ#3W.1-C6@G8OT|%>2XV66\J85!P3P!!//J6L:]$I.GZ^TI/-]F2]O]O"C3GK'@V>J)

*[OL79VE?/-M5]EXKO[>#RYW>-6=|CKE M/5SEO=A@A_!]5M[M6.@#T^-<#6]UU7.C^3E>HNP*YQ^#QNZ'MV .MT07N0:5Q M?K,V[KAW_H#6@<==K0-*

*;70&Y{&R:Y;K&Z$MA05U# !=_58*V-Y4!V(%0-U3" MME\!MWK+O5F6EZ,.WNH-@X2[()G&F;D*53PKL5;A%>'PS0"K&5;#X1#PB3 6_M+H;*

[>YRH(&KUQ(3/_!26F>X51C/_JC^P)F?)TRB$^%.DPC&!3=7)50X\%?;WOS%$+-H8(#_F"G5]TIL%/@PU5@ MMP'OV%H?F$H?V.]N4TET?+S+'"^T]B1Z E%\20)

*ZGQ0Q=/=UTHK3,*DB@=7G M*LS&*37LH8*,0=]JK57!(_+E)3;7XURI*8R+]VA4Q$4TK > M6#CR_//0;FFTM34KCRAI>.,RCM-]K%EYGH\ZZ?6?ZZ,N>Q>7CZA_VOJ.E?,S*

*M5[.RD\>G0_E<5[7BJE:V"VQXR'6@X7PN[*5@_W8@Y5Y5[:RNV4KN^.TW?FY MA]+[H8GY0!7MG"!=9#[^9,,5]FBS[UKD-J.!4",'K'>5*%!;FU+G()MASP[O&E*

M\T?.%X?;/&A,/WR#54F#Q"3(WI[3IPLH'.KG.BG>RV4]L,]U4KR7R^H^=|<_MUPGV 7SNPX\B.ONUXJF#OB-.(Q@(/_&1%6LR/VC-^3GV@X_;2-8M/+HTX--1

M7(2("W8%]OM7(^_+[^^P>?_[%F2OO<^[]#9_KU/?!ZGOA7[HFG4Y[M^)SG?H^ M6'U?]_WCBYWNT[G:HK_9NT4_,-

UV9?:KJ_0A..5L5.@G)_QSL0I]:ANYJ5=9_L]V6GHX;/&'!S2X9$RUG_R7N\\ M(&<^=\|+|GOAG)R[WXK1V&S[7::U#.CB]=4NYOWKK=MO=6F[GR/N\N@IX) . M6QQU.#TY>5!>R?

E!SGSNBOGTKKTY<|L5I[39\KM/:!VCM_.V(\7;K4Z>WV?[3 MV]5!VE>G.TU.Y[36:>W!:>WKG5=;OR?I5-JI=(-/\B#P#ALBE'2 A\=)V1_ M?'8NT0YIE:.?*

*!OAXM=7NCG]X=>_"(Q\4>GO?/+*_M_9\NL,EPUF7/_P\>CG0?_L0>PDSC&R/W<((J9R,]0> MG+Z\(DOBR-,KLL]V]OZOWWE+O&EGC$V=!GS#LE07I#S8'C'7"*

MXJR'$XA#LAZO]Y\/'_P9Q4[LAV"XTR+,RV[@9C92FG9:DS-=@=5U['K+UD9 M)!X\7N4J_66FTD(5+LBT0P%<%ZI?N0"@[Y\^K,GPP:ZU4]N]6D$8>_C@//PC++CPB_KB(7:-

*A%37(6<<43RZ5_?+G3'$ONQ.+4]O#4 M]L*_V&UTOE-;I[8'I[8G9VZKW9V%=F]\SZN[3G9NEY=YFUN@/>VOH;$_!2$ M<1*7%^O)P0O&F2-VH))M-X0(7==]PK@UZ*

*U2V**N&B=1^,7OU9#;Z>R)V MWDJ?]OWSL\VQ5VZI\+S0OMJZ'G>.W"JA9JA+94>)Q%<1,% M691GLBC^Q=G5OLO.EAF4I1 :9V.V5$[VQ;3TGRI&M37RL@$X%/PW@*^@OS[E*

M\/]=%64\FC]B>5LK4E05$.5ZA-RZX\Y1+0MB|M]X>FH>.*;Z]9>/:FG-4I4 M6!9>]DHOF&95"G_/U:A*(UP/K\R]Q'"'$>B=5TZ4-XI3"HW!$Q'-%6"?$B\ .M>6%6P(WP%[PH3.

*(4[\HK\QC^A&NC*L1"L%F5%U60EOA8O/ Z'U8E//^'.)M- M@GP:>-?C7"F,LOD>?'$X\6Z#PH.7P_BIE"Q.O9_4,*^"?.X-C@$)+U;E2OOUG6F_=^'!DQ-S'&:T&*

M+8+W!?[QZ]1W:;Z.TS!70:'PDGL#J;3(LSR&B8?9(OE&I-YR;IQ3XF 7> M(F^49U;.4Q#=!&E(KW+ZY\[^]OHH+H?Q?>S[!]A"G-QGDP]>%!+_S((I@5]P$3LR#TCD/^*^-*

*;ONMQ4W MU_[@019FB8_S_.:E!12$!9_<=TF)HDDHX]3U*BCH@SR\FU0E=F[YB]@7QG' MM,R<2:*-Y&V0W ;SXMUW?S,"(4_6:TA;/"V@)0.MM=SLDCU]V,)Z][WBL;K_MK5?GA?*

>)}[8AG\(RPVV]WPC%z_>")&GI,XL;!.TKO[@A8"US'T:C KPZ/E('U!AZ_(LT2G$?R\&]#8@AT%V;_;Q ^>-4(K M^,SDB]DEOQ<(LGV4Y7.=-8.O[#B$L/R%5^!I".9%,Y#@T4QYSN -OX+

<3(TD M/;GON&CQP<6B2_%)[^-2WAON'3E_]Y25"&:[^L(KH]+,B=#ZGU83'!O@8UY M8BU#[S+*DB2|)=^*)*VHIBBQ?\$#T-EBK_<(;<^1>,#A)$C'[)^B3(ZM20V:*

*MDVID^35<6TZRJH"+"A]^'H(;3NXU/!.W?]@NBS=O6Y,O ^(9D>T-)P%W.Q S M_.T1^$)9!5Y_$U%[_@;^\?'O>/O=> 9C()9H5Z6R@PBZ Z@NJP$"(W<0$^*

*MJZKP6WUU%_2#'CZXZAU?#;ZW-UZ93]YY_[;LOM|)>?.AMSWFEGYO<'GZ+*_: MRX\ZZ1T/GNFC+GM7@PNK7>K%\|RV=W7*MV<7[V!*^Z_>=U>6=!89H?F6E668)='2F?L5*

M@V>_Y1L&U8]T\JSROO/3G M;QO;_=>"?2O8@Y7YIYW.WNX[S4IS0E!]9JH8;M4G3@ZE.YW(ZEI-IT9I:_M=&[5RBI/E=,BIT7/LQ>1BV-Y=T7/<^KTC.IT;Q/B%,PIV-.?-UW=^YUS^O?*

[L]>N MYOVQV/T7%X7GJ!7;_6-$__D:G-T1?M0'IMFNS\/*"KW336$WP;_WP-+F'8;0KQ_ MD +5_DGO=_,%]OW3WN !!:K'5H&J*9^!2U9![;=*5+F)6@\IBBS\.O1$/X5*

MT3#A1]XEDH=X0Q4&%5?LX%"3#";#&^=8$!UA'[MNMRI"C'-/1,\%'F ^3Z=RK(4U",C MEP]#@>G#ZB_I/%8/<*R0?(<'$>3+ M2EI]8^"M?5

C"7\;]8&5>NU0GMD6']5B$1WD0MBS*IU'5%,\5.:=/L5(.^/CR&.K]^%I7F>_]<[8?.S!RKRKS'&5.:XRQX$UGPBLZ5QW{Z+7*5.4Z+G!:]]%[D M"@=*

<98Y3,=@6R%/KC+GL2B]!LYA(5GM0,%[!RE5H&"[@:1_>C;8Y35WF'ZG MOH>KOGW_GO;-'5>#XK1(]\L45<9VG--,M5C=&7 MPH*ZA@ N_]H$;6\[*

*[#37)5O10SUI0F\!!8@CI+'G*4P5N!89=IZBKHV&N M0A7/2]Q5>$4X?#/ :H;U;G=$?"",A9L6?]2S%82 +))W;O6@N]['BQ?6BV2- X=Y]K:MK=14O6XHT*

M.!#@U#:LNZMX>>E=92|^]F!EWE6\N(H75_'B0)!/!(]T+]=S.9T6N8H7IT5. MBUYZ+W ?%?QXA3,*=A6R).K>'E|Q4L[6>UPMGL'UG(X6[O*Y7BGJ;(=2-XI-M[^$J__ZK\M!?*

[#3]^X4V"GPX2]PVWUW::$/3)\/;'77]7$Y/M|EA78U+@^H M<5E LU-=R_%C.\M(X0E>C^U6ID&))2[!-P['W:>RDKPBFH&?TU+;Q,,IPK; M5E*

9R0W<4<'S\SL+14P]3.Y#3K,N:#X\,!NG,$61W?9EA2\;,4BS[\HNI;W MQ(YY,N=#S_Q'_IX[CN)QJ<_[8(95+=YG5615'C:;)V^_=CYR:E8OZ?F=)P4+ MK\R\[=0,K23S]>'P6S69ZA

*8+_1%4(]@DL&[>Y*I7^H8>-==!R MW:BT4KYWJ[QO<,,V)BN]H5(I7@=C)ON'+Z)?ZH=$7C;#OZ!A2K("6V05,5;6 MW2KN\84F+9JE?&VC/.[XK.?]2]XU]LB(X=?+|*

[(4ZYGRK!#/NJST#$QA&,^" M))E;R[!]$.C<2%?1%,Z7!W&!0X-5#<;C7(WQN['$[_RD;_4,@W%A021\:@4 M5D#A=U+S+S6.0R^T3?===3^U?GO4NS%/UN-[;O!89YBB^!<(D**

*(K__FX6C-51 MFD5*7PJ@+^6\?UU%,,2??M[=/)NE*AO1U$,.O/.!]9D5=/T7107LR28O\7? MOIL%400S9*5W8AZ4SGK /T7M].OHQB.0Z7>SK(CIR;E*J/V:76UB\D;?5G3,*

M^H/'6X;U,FGK+54KL09+(-7_BNDU,&DE&'Z<)N -1@<8.\?!M49?:N^0N85_XQ_M+3/GDJCX]6VOW+,S0BIW[!77:TC>+2V@)0.MM=SLDCU]S,=Z[!WBL?JA2Z_.

*_M=N]73[ZCO]=>;C\EV6UA/.]!;E78IJ/1,264=\%Y?-*27M,D;P17>%@<1?L,U M[HV2W9TH53V\\/4?46QXTKL:/$\YY_^_OCDV>L]]^P#';3^Y;MT]N-K7>VG-MJ_T\A*

*j@;7&*7;V(@X"Z>]!MA%8[+=HBR7#U/MNT63O\|)US^LE$Y^O8@<-P_M[1T4P&&XK,EX?7;L7_0/ #RQFGRWJVIT^26)E\=WWO.V/U5[]3DAWL].D9Q MZ%[/Q_0&L5O.Z\E5K7%*

*(UY4!Z^?^Y?F%9&]3M5^ZFK^]LNZ)!3I2_++,4BS[\HNI;W MQ(YY,N=#S_Q'_!TYZ]DUB M]AL?Q>KE<#4$ZJHK>+EUJUFM/"K-MJ[6[T7)[S%,]V:L1WA8<1T=//..DNW!*?[?D\U?F!58HG^#!>TX\!RK__$0 M0*6V\,7"%%(LC)EJ!W7QO3=10?2?*LC!RA9>@18%CA6^!\,.)SA]4Y6&O$"_ M9C<\X3A'5 O_@@7KN'1E/$5QR4;>#*-*

*T3^UFIH_0O+Q+KPMN/_:NO_SB487] [FV=D+835RGSQBCS&EU M#DDA_Z7(*4,)!3&;54C29+F]QF%#,J8\B"IB,3+*@*W;2?! /O'RN0K 8P/–MN<4?I? (V3NBFP"9EI@B B8\ G5 %U$D/DSB- Z)8\D:C?H6\XZ(%L-?B"23 M:G5N,=XM*#LH /VXHL$C:Y/-V61_&X>IF?G,XJH"K:Y%@L<*^G/>\WI,;A5\ M.-%/T9M2Q4A,@VPS\->12!I&QI,T94HB>$ Y$16G M^2+OT?!*];R/(WP-& 10> ^TMTY;'* MZ9.7X,IHW);5- M11.DP?27%;TH:8C()\M[0!@558I MJE-(&HRT8/5##55;E,'^461>6L$*X6-+^ARF2<-Q@1]26,_@4!.'|2Z'#FQ1 MD/ *M5FMC3Y\;5$2W61:DO6H|SY;Y6'$MLUH#I&D&<<)]4D!A^20%-/!- M]D&8^10L${V7;$9C%7&E] Z*#G[5%MU/94-LT;V*U)H|%"FIDC'-P(CD>6P M,K#L287&I,W98W&QP,"G1PE(U1%*Z)DT=#!@IH#63G.>]LX&E]\W"=BL:4.V MHTZN-2(+>T?S>81O+-Z"P"ND"UN8^7HFX&4G%]^_X%*<]B[.!OV+R_/3[\') MQ>G%X.Q[.\/5:D9#"PQTR$$;#0K=TP#<_>^C+BAS8C M8-;E19V.5 %_06T-\TS!3>|$A*3&H*RS#&Y";^4AV2-NP. DA[1QRWFAMH:P M-56X]Q1>SFR'<3I*>&NI?03O)L.? X5#]%$J3JLZ)M1/K1XFU0E]&:4,[R_R-ME,^A2A7<6EXPQ-;9T1\$<,-!*1!PX!:9;R:8T.N"T?4\D-HP\(M$7C:&/0V5R-JX1->ZYN8GC@ M4D%^>9=@EPND8_#>>-(73F@S>S1(4Q^"!.PS>SLPI,_|P,X_6&QX,;@LHC.^- MP.$QB7XO:[=|F&=!Y)OCJWZ@2C&M M0#D-BAZ7*DG DJ,? ^\"R01/BX".A60.1DHG23HN/=(X(1#W>&K%<9OV:I_C MN1^Q. 3>3BMDX@Q+#E-R2L)K[6/G<>S&)N\8#P=7U44Q(13I5AX@COJ5*= MJ[%,>('=3S 0'WR%^SD%2)[R=):H4EOG.;>EF#BKV|I0SEKA(P+P+6#@ >:) M)E4 M5V:HU#>31XZA^3Y,/EY]*,1IZ4PA98NI)_%4E!AGZ7V1_GC?:#?3NL:)"#O0)#D)/52&""7* M'B7EZ D,CZ)+({6SG\A+=@N35DSB&6U@8,CJ3ED(W9ED28285M),_UQ4I5H M=W32E_1!]V-C'=C";"7V91PW68;P3A7DD>D-*KQ8;P0_H M)'/-9KW,8IZ.6I$6W#[\ J0(>XD1"HS76K(Z\-pI95I5O6(X_SB<#PJF'<8G/$M-"DMI" <"$AI<#6*@5;7FLUZ0DUMXX"F[@V\W>V WV63!5/)L6O,=\|5 U?"8; MQ^-W@W@HL"^.@>T@V1">[BA^+E|9SZ;<8Z=<.V9(6^!;PAV1Z;K%#V3SM>0Y M,#0P9#=]FY371;.V-YIUYJ)9.QK->LI/-/NA%T<<+/OSY,__8%H>? >+<>?Q\ MHO^.IC')BNIY@[UKIW]2\C1+BC\|;A2A<&R1=IWV MO/NP M].7LCT_!=N!\]I#Z+H3&%1F?9KSG77/(A*#1_-U2+T98**Y=@^- G(*2G/XT"P25K/QFI M_QS3"PJU4 ,U=AJG*;2]#23=M~'FBS+I"A3HUAM3UAM!G(d38H9+$0-RXMS)>H% MUT@:BZ08PU:8$LDM*9[KK!G9YM8_ L.&UU8 %Z[9WG#-N0O7N'#-/4=(= (W^ MC.,_L_Q/RW/HA/DA\ _>QU]_^O3YE^LO M'S_]^N)A@/Z?B1H'R9_"HH!9WNU810H"]'O>/W\X6{1^?*+EF3H@+^5?G @C M-X=C:,,0C,WKH%'@N19@D20G|H@Q"3&1NVR:#A=$KA9,METP,1ZPS&?6-BV M@X^#P!G"FL%8N+20'D4%,@BU0=A22-DI=.,U5..EG&]+R8(_8;Q?_Y12WFU2 ML.N>|SG> (O4|OGH_\2SMH7+QI-0PH/R>45+$TK*AJ!WHPH|+\0 OCIJ,&I)=,PCX.52?1$#=\=30P3)!S!J0)S2SGE@ P3;/K%XTLS_%KD*Z)Q]WD M3TPD>1EA33RC6@9B)H'{1)LUXEEKOB[7,P"FS(+U&5;+H9#CF/(I@UH&TT@F M1P:LS6U=VL=5N@ME@MK{$,MCADNQ%+1N@@51W2VW7]SR%+:JYOMH?!0,\C4N31&" ($LWZ-$-,-*R#$=6ND@G? M^U#E5(C]?@+&OMYZP,BF98[XJ}$""5$$H5.API:OIQ1I KJ??KQF?"HRR6F(MN,)0O'U;54XRC59= .7K]Q#H16.8GW M^M'?N_!Y6XPX /:5U=,R&T&49$AQIOCRP 6/Z#DG MKW&+7E*#G\.<=97X>\!FZ|W F0=I@(YE8PAJ&X9/KWWFC##:ENI#4 F*:0AR-VXXIYWG'M0!.#E>"C<7^N+-HVSWJ17'U"(=89MB\Y> MVM6M(QP@'W 5>V8H5#@&<1TEF%I?8>2X+D'L^A2TRT0%/M*0: M*/6UR[$L%@YDK!=,0=?E0B1)VPIW3HR.8J"*.3>NMGH M=Z'W-'W(E#A&>;2+I-]%GO69V*H):Q1V7LO>T^"*Y.W.H.TULJJ*&3P5*AG MK5X/F3|8OKR;&=*#@*-*>*0,T]\8>L(3I12>"F.,!F_BDK|6B,/IXE$0)PRT MU)1J4ZQ[Y,Q1.H()*&FGY)A@ ;,GQ7 2*68"* ($%8HB\QNN8&M, >8&RY;5 MS:]>DR9HZFV.NH5,FU],830[1,? 1C)Y _:9B MQ52-;^OF^%/M[Q$XN-4 MQ[5I>:$.4?>7L>H.E2)/T;8/0&C!.3D>I56&<+/A]U,JD!E[&0$I M@RGTQ_:@=RL^^!P!%ZOO3>,DQ" 6X0OZG%;@A;F<=RR41?.4:A'1+OA:C:]< MKI,B(43BHC40^($=0 ;|%#&Y>] G.548J^=-O@4EEG=DA+YD5)6.A.?ZF1_ MOJ9D.O:*HQ,'|*93>Y1W\"$(!,,%4N$C)IB7!(>2' ^[:,?=&R__IK_0-R M")'_1&F&OFQ6'J'_,_(1',:NDV?<& :=<+Q64B%$UH.U;7HH>B ^=Z61VX^& M\R,|%.I.X],Y1798)>7=$;S0F :3%HPJRE0L<.+3<83,=;NC$A=7E?E\U5FG ME<)!R&5D!AKO%S0!4;,JAZ-X8;$@R5%=P$ZX#0BSH?4.=LG1_(/H3KQ@RF4S MS9XXUPFGJ,V/VH-K #A:@[2",TN&>$N!E++ ^*7;66Q.IFLS439T@ (B2)26CI$-+Z';4R4L;^BC&(O3P]!8< .VBFA! M(Q52-;^OF^%/M[V9U*$'2>$.4?>7L>H.E2)/T;8/0&C!.3D>I56&<+/A]U,JD!E[&0$I M@RGTO_:@=RL^^!P!%ZOO3>,DQ" 6X0OZG%;@A;F<=RR41?.4:A'1+OA:C:J< MKI,B(43BHC40^($=0 ;|%#&Y>] G.548J^=-O@4EEG=DA+YD5)6.A.?ZF1_ MOJ9D.O:*HQ,'|*93>Y1W\"$(!,,%4N$C)IB7!(>2' ^[:,?=&R__IK_0-R M")'_1&F&OFQ6'J'_,_(1',:NDV?<& :=<+Q64B%$UH.U;7HH>B ^=Z61VX^& M\R,|%.I.X],Y1798)>7=$;S0F :3%HPJRE0L<.+3<83,=;NC$A=7E?E\U5FG ME<)!R&5D!AKO%S0!4;,JAZ-X8;$@R5%=P$ZX#0BSH?4.=LG1_(/H3KQ@RF4S MS9XXUPFGJ,V/VH-K #A:@[2",TN&>$N!E++ ^*7;66Q.IFLS439T@ (B2)26CI$-+Z';4R4L;^BC&(O3P]!8< .VBFA! M(Q52-;^OF^%/M[V9U*$'2>$.4?>7L>H.E2)/T;8/0&C!.3D>I56&<+/A]U,JD!E[&0$I M@RGTO_:@=RL^^!P!%ZOO3>,DQ" 6X0OZG%;@A;F<=RR41?.4:A'1+OA:C:J< MKI,B(43BHC40^($=0 ;|%#&Y>] G.548J^=-O@4EEG=DA+YD5)6.A.?ZF1_ MOJ9D.O:*HQ,'|*93>Y1W\"$(!,,%4N$C)IB7!(>2' ^[:,?=&R__IK_0-R M")'_1&F&OFQ6'J'_,_(1';:NDV?<& :=<+Q64B%$UH.U;7HH>B ^=Z61VX^& M\R,|%.I.X],YL798)>7=$;S0F :3%HPJRE0L<.+3<83,=;NC$A=7E?E\U5FG ME<)!R&5D!AKO%S0!4;,JAZ-X8;$@R5%=P$ZX#0BSH?4.=LG1_(/H3KQ@RF4S MS9XXUPFGJ,V/VH-K #A:@[2",TN&>$N!E++ ^*7;66Q.IFLS439T@ (B2)26CI$-+Z';4R4L;^BC&(O3P]!8< .VBFA! M(Q52-;^OF^%/M[V9U*$'2>$.4?>7L>H.E2)/T;8/0&C!.3D>I56&<+/A]U,JD!E[&0$I M@RGTO_:@=RL^^!P!%ZOO3>,DQ" 6X0OZG%;@A;F<=RR41?.4:A'1+OA:C:J< MKI,B(43BHC40^($=0 ;|%#&Y>] G.548J^=-O@4EEG=DA+YD5)6.A.?ZF1_ MOJ9D.O:*HQ,'|*93>Y1W\"$(!,,%4N$C)IB7!(>2' ^[:,?=&R__IK_0-R M")'_1&F&OFQ6'J'_,_(1',:NDV?<& :=<+Q64B%$UH.U;7HH>B ^=Z61VX^& M\R,|%.I.X],YL798)>7=$;S0F :3%HPJRE0L<.+3<83,=;NC$A=7E?E\U5FG ME<)!R&5D!AKO%S0!4;,JAZ-X8;$@R5%=P$ZX#0BSH?4.=LG1_(/H3KQ@RF4S MS9XXUPFGJ,V/VH-K #A:@[2",TN&>$N!E++ ^*7;66Q.IFLS439T@ (B2)26CI$-+Z';4R4L;^BC&(O3P]!8< .VBFA! M(Q52-;^OF^%/M[V9U*$'2>$.4?>7L>H.E2)/T;8/0&C!.3D>I56&<+/A]U,JD!E[&0$I M@RGTO_:@=RL^^!P!%ZOO3>,DQ" 6X0OZG%;@A;F<=RR41?.4:A'1+OA:C:J< MKI,B(43BHC40^($=0 ;|%#&Y>] G.548J^=-O@4EEG=DA+YD5)6.A.?ZF1_ MOJ9D.O:*HQ,'|*93>Y1W\"$(!,,%4N$C)IB7!(>2' ^[:,?=&R__IK_0-R M")'_1&F&OFQ6'J'_,_(1';

M2V"]OX 3D:._[%QB;$BK]9F69=4YC|!^E,S=_"*;+Q@1W;E/!EW1&_^9_]D-MM=RN(K;N;$>>0"Q>T5XID@7DT)M5A-@%206R1-2MZ;+:/VW2IX@%D3(%A=V)-M[4#A,\"(O'(5!(K9J&A^]9&O8P\"1P4G(ELX&"RSGZ.80/,#RAI;&\A\LfTC6\H2-MFK@O}&+A=CLB0?'M3_V'K)}@_Y[H[]#24&2QEF@ .6A)><|&-[",/STY>0_< M+I K2=!&3U%5B4UA73E;-RCQE!P*&YE*:B&-3J6!;$NT> MC21+^Y?2>_QX,H8A!H:O9M^:R!]JCOC-8MP5P_M-/11/>%(8C/Q"GZ1YGXYN|WHA#?E.R\JX$IFADY<%|>-Z%"864IA6D"'E SD M$Q4V;C&!(:0%4,.^WAUJ4!Y3ZG53IO*ZC=@8F"TI(PD4+<9TDF[%%&^K"A M&#+0VLI9?$QO@<1\5.1Z12*$;>J.:R',WIN<5P M;T&>7^^O"?]YA])G^LHGMKDUH9(SIDN63C=(UF]01M]CN<_"5.&D-S/KN'A M"]\>3]Y{&>O_V5!01W382)RWD)C D!UD]4WBPV J,>DALB#.^A.9$%M)]0PC M(:9D"H&P%EOJ%5"YP/7,2P1OG5/X1!6+BUD;73KZ*%M;=G NO5O(;A7V!H0<35L,(O;L MCH%(:*"MN;8GRW8)S7VDR:ZX NY5XS@N]:DV|)TV2S#DRB"A"D:=AN*?^6$3K]30\0*F61T?&V3M7&C2HS16_149Q<3- O/%\CGDP>R8AP3[,+-M-.@6$+EOH:^(8\E8=F\YB;'!,+ M-.@6+O\M\?E[_PKH_9JK/WLAA=,FU5Q:+&(":@:LI9$\ZWRL%6>]XC$LD2#S M&-X@[ZO|/ \/>HF=R$0T<0\$G"\MTWX?+A9@7^:X M,#8LK3H"2U)#^\$2:!"H&/^+H2$N>GB0H^PVKW'S@GXO5#9A&(9;^_H:(M4^M,I@5*$Y(_)3GDN++R9X^!M]JG\"LJU\6+(B';KWYT@PL:LMO&*:1V>++|;F# M7W^3%MZ4<+8-P$Q47XZ|:I7C1H1R)0!C:#?B5&$_B!B)U?3^DE)/F78Q*L;S M)(#UAY^ITH@EH34T N5-/^2]VHE=QLAX3?:[Q>FX8N(\;US$$*UC=+DVVS M_!D*+=)6GMY6;PN!73ZX>V+%?)+,XM_C*H4L@I%@3O;.@$E5_VN[IOSV9_G] M(@2?M$-X_>SH>>RTLFNXK#(UNLZQ^.JT>GK|-8E>Z=,2%>+DG M>F4*81VRNJ[H/N/UGT&@2=+Z>F!2<0_?< FU%0M,AT\NT!8.V?#GZ$(UOG$=CS%-C$JB6BQI%#%>;!WKSCO0V:50'#;,D4|= MV ?ZH)L9-%'(,U/G%_F$OA;=&#/7;U?IWN0T&/0I.IJAGNZ1/9V);K96Y%29 M4*<6.4D_I&@!]>AZ%Y"[)Q\0DXJ3K,RIOH87UPOH-6[,U?Z:ESPS/<*9KSB MY]I8)U]_5C_$(%AU7I<] 6;)-0-034'?C-QQ^367MVKGU]+CA M+*G?T>KC2G_]V3#/ZF:H*'V*(]!R*2C&4$G'.WO/!\??N>?46*V#_1@>X\C MU*?'.*U#>&-]--'>)FC4I05P%2?MO?BNV^X(OL[+YZ/1R\,# _9?CO=>[+\8 M/_^%&@+[1Y^5F@<^.],!,!Y\1,"MKI@%TWN%X?&*5GC@4LZ,6CW=WO.D_] M5GQ%ZVAS,"$W,"E0 C5G2LEI01PH'05C-Q(N$/(T<\WX,X%]P_AP$^,8" MO#9OVUO.UW7#\${#.#WQ#W2Q"P"(9V_,)%Y\'H0]"?^]"CUKWY/TKPQ;!]YWH M1Z@W]PCO-]X=[=)/[S^<1"<&.?%S?.'^BJ5VT-(H]Q &B_7\6]GKBPJ1'%Z0Z2N$+"'!)3^P\4-N.LG8'=D8L1&$3 M@IZIWKR0GQ' 7+E[M#5.I8<-99LY"&#KZLV"BM5!5;4LRNST(!6=2W]^RG.IV]592YCSTE3MF>+HC5S(L(<#!4#"65^414$DH%KUC5(,ITGL"&|\^DOV0O?,THH*#.Q5-5[,CV*@58:88*P^/$4!!HTP *T'O M6A/@Y.9S.C32?M9-1U]Q$?+CP< !:!4":7) MZG+@T?M9=218H0RMH .Q+O?\EH V4PKDH(;\R6Y.';20\#V,8(2^0000[!P9^:)C<]._\|=-M("@60F@<47-9Y NY"\UCO6]ISIG8U>V&-.RC%Q \9FDC2U'XH^!F(0N]%$)3MP7C9D(#&_.]^Z3'4Q&)6S$:NP2(K+QCVH[567?,H)&V1NJ1/Q/)=HHEDB66F M'NSND)K/(,-2 NH9:^Q1;=OIZ6OM)V?)UH@Z16#[.1EF@:RFQF*V_Q^0O0\M MV?N@0SW@L,S3+%=FP?"I"B'1CA(2R;OKC#N^TQ=X_130|@6(;5EXV&=08_@9 M.;@)10$\"_\VF#;#4&5=$WHR/B#&(Z*<4JZ)6OOK*T"=R^C^HCF|+$?AY"ERZK MS{(R-W5/&5Y@LXZF71Z9WJ9#2,]Z$+L#1@R\$N("Z@G .29W!_F7;*%OYB"0 M4+RLEY[*G8B]$|\${GO1A-80TYCN&BMU_,2VQ+HT:\;JYY$|)L4*<7W>]L-R M.M1Z'!Q@L\2$1H(CB30+0P<{10[Z JAC0-G72^6:4!M^;F4[U:BVMRJ!*Z,) MD/P:PT){&K=SHJ\HK-B)/H+TF0\VR6AQ,Z@L;DAL%!(XD&03(@*\+O__\) M4X 48.YQ]EQ@O*]K-6CZGL&&4!KSE) YM":N S;WC+T0B[U$Y]9 -G(H*#8 ML|\W12>D!+B M_9250X1U-?3FLDY?,IT14Z E!&R(IX0^=2=ZH]? $/'UC7HJ M?O=&$K@T%D-MGA&G$ M,I.S'3S4&T=8623[F RS'[-2>()$8-QG =EE--DX8&W+%Z;M"Q/6 MXKQC*2T$BR-L+L!Q_&+1Z{@8XYIS$Q2'(12)N"9[>#U5+\@T\9Y?H[_E M5_!$P22(WD&-KX}>_NOC^U_?,4D475?B+]0)R77I0OKM?*U/'OTN7WCT#,:_M< E-9P*Y$FPB)WIH_'S(110NF6 ,2'TJL=4 ,|+7@,O6S&(00-B%B7Y649X, MH)BE)++D6,M?S?6\DP6IU\2$K"4G(QN,,.EZC8KY%S?G,,M3-'75IU6AG[$"+:S MXSPB(N)S/;04":{@\V/D,*UD[Q"(?NF 3106#? >@1P6/@ZD O/A6*O7%O:Y MN?:]3"\4$:N2>L"/IW#BSGYTNA0&,ZFYJQYELK.VO)\X"G#>(*AS2A$")!N©M6(A@UN!{70F[*9|//%U>5D_@]#98D":72"UPM(V~>2"-"R ME,I4\,,.=<6'MNM#PNFDSB2C70AX//=AV,F:T?.+Z MQZW(T4C,5I6DS[&<(+6!X>F/{@[#K C9*Q&2)'887Y>X#^?2D<@"D9&,22"%I M$EZ2QM22T??%IFD6PH:^)TK!1(#L#&?EQ<#GV"TKF;TOP3@JE2?24<,"8@QE2PV .|5[-MKS%KF1BFE!6!&,6LX7SB UO8J0[GMK;YC'5/Z90/QNEY5G-5H=\ZM71\":* MWKY-C?MX^0 M$PPQI0.B>S@Y8H,KB8-Z2 NV0E7?"QL.4M/L)R[8OXU8FY]9_3V6NA(!]["Y9"%F^PUC;V.Z{AQ1)-MZ"&WM5M\8W[(T4"ZW_NSE#*FX;9/G!.YMYQ E&'" N*%:OM:[!HB2D?MV M3B*%YN^ISN1OV*3GR;O+$-;,@WB[N^$(K&=08_@9 M.;@)10$\" \VF#;#4&5=$WHR/B#&(Z*<4JZ)6OOK*T"=R^C^HCF|+$?AY"ERZK MS{(R-W5/&5Y@LXZF71Z9WJ9#2,]Z$+L#1@R\$N("Z@G .29W!_F7;*%OYB"0 M4+RLEY[*G8B]$|\${GO1A-80TYCN&BMU_,2VQ+HT:\;JYY$|)L4*<7W>]L-R M.M1Z'!Q@L\2$1H(CB30+0P<{10[Z JAC0-G72^6:4!M^;F4[U:BVMRJ!*Z,) MD/P:PT){&K=SHJ\HK-B)/H+TF0\VR6AQ,Z@L;DAL%!(XD&03(@*\+O__\) M4X 48.YQ]EQ@O*]K-6CZGL&&4!KSE) YM":N S;WC+T0B[U$Y]9 -G(H*#8 ML|\W12>D!+B M_9250X1U-?3FLDY?,IT14Z E!&R(IX0^=2=ZH]? $/'UC7HJ M?O=&$K@T%D-MGA&G$ M,I.S'3S4&T=8623[F RS'[-2>()$8-QG =EE--DX8&W+%Z;M"Q/6 MXKQC*2T$BR-L+L!Q_&+1Z{@8XYIS$Q2'(12)N"9[>#U5+\@T\9Y?H[_E M5_!$P22(WD&-KX}>_NOC^U_?,4D475?B+]0)

K^1JR4_CODW]M?V\Z0^]&'/@OG+M4VXUPLP.U7E_.FO,7S=?I#"VE=]95U>,Z1U<+_IJM8P$&=_NHW]!SHL_MO1V.0R^KDXCMS/33G70:G3BQU@4QT4P\-I:U[.)?UM#'B%MXNN&Y@+)17",.*~WEAJ='EKS7.3W@>%=-H$'Y-#GB.9^"CH7\7-4]Z]WV-8U-M+UKN[Y1@T(+HW)XZB5-M>;8^KODSDW!]J4NP;-)7?6]=7C-TOL\WFRA\8G9A-M;2UI[:.Z?8&\;HLN48=^5UW>&-K&]<+V*H7*1RU]2:>ANX7S_;^V3D0_#[*[_MP1MJ;U:\1'5/G<V1N#%^V/S.V$2)NZ,1[T-A,#&('0)WQNTCQLFEP+)KN'UK.M'[WUANP7(-MGJ,/7+J?AK*R,Z;#:YI?A0G9N<3O^R*6N%P7!'"HZ71NFI[-MU3<LVY77EA%-N7'52.T'DAH+JFL'U:OI#4-F*-5;/78S-M[N)?0D)-C1-Z=/@>P-W3K5%U-R_#$X>X3$\1-W63Z;]%_J"8\N4^#0TKV/#"-MP'I'HY(Q<.G.?7L)S7V7$AKXYJ'I:MSLM4%B*

*WU/*9-M,K*;)\M'S!,I91^*!@C3/2D.F_+_3,]R",.:!\RT*_.I7WE$CO@Z)[^]XGVW6-M^-YDA]AP/]%_!2/EN,Z4O/SDF)&AFAMM=7Y_X$3XEG2-PD.#1Yj9Vj8X7EM"MRJ7'-1]57\,@>230BYV:@;ZZ4V-#Z3NT7'@$H&B+'KZ14_XLK7-6H=7A{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{F\3'E_U0B]N=<,3'DE_9Z!NK?M;]@2OZ.VH]6>5_/3'B(C@\YMZC&+0&4FV?)/44F;,7([&A]V#-BJ.FU3M\"WQB96BISJ38B\:0R8Z[:7#Z%=?:LXTIBP!-CA<:G>!BR-H3LDJVQN3XO9_M>>_LZ.7S(KP+QSC_J]K6G'5/6[K213;S[6Y]'Y**JSS_^V'#U@G=IRD.G7]P M..V/*]8%VY<^(,7+K#:$+J#O,.7/TXP"XMP=^_R/"NA/ZB+M?>G.VQIF@\) MQB+TXR?OS>U=&^APPSMCN$ID:8_*2G(QWTW23F(4)7)]27!K=\.6UX,+RCY"M9GQJTf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f)XO4\5^0W!V8]NP30T2S)W685A0%W*%/%1.%8Q7##TU;1*])(02I:S#.]>7*;.08O6ADS#W&.C4.CJT0!!DZ***?'9AMPSC^5 LG9A=O!& M9_.'R*..4)R]3I:'NJ:NG4NL0/#A\AT/+U7/?$R/(AE0M27@[+D)I\ MJ5\:TS.:.7_CUH1#,)3'DE_9Z!NK?M;]@2OZ.VH]6>5_/3'B(C@\YMZC&+0&4FV?)/44F;,7([&A]V#-BJ.FU3M\"WQB96BISJ38B\:0R8Z[:7#Z%=?:LXTIBP!-CA<:G>!BR-H3LDJVQN3XO9_M>>_LZ.7S(KP+QSC_J]K6G'5/6[K213;S[6Y]'Y**JSS_^V'#U@G=IRD.G7]P M..V/*]8%VY<^(,7+K#:$+J#O,.7/TXP"XMP=^_R/"NA/ZB+M?>G.VQIF@\) MQB+TXR?QS>U=&^APPSMCN$ID:8_*2G(QWTW23F(4)7)]27!K=\.6UX,+RCY"M9GQJTf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f)XO4\5^0W!V8]NP30T2S)W685A0%W*%/%1.%8Q7##TU;1*])(02I:S#.]>7*;.08O6ADS#W&.C4.CJT0!!DZ***?'9AMPSC^5 LG9A=O!& M9_.'R*..4)R]3I:'NJ:NG4NL0/#A\AT/+U7/?$R/(AE0M27@[+D)I\ MJ5\:TS.:.7_CUH1#,)3'DE_9Z!NK?M;]@2OZ.VH]6>5_/3'B(C@\YMZC&+0&4FV?)/44F;,7([&A]V#-BJ.FU3M\"WQB96BISJ38B\:0R8Z[:7#Z%=?:LXTIBP!-CA<:G>!BR-H3LDJVQN3XO9_M>>_LZ.7S(KP+QSC_J]K6G'5/6[K213;S[6Y]'Y**JSS_^V'#U@G=IRD.G7]P M..V/*]8%VY<^(,7+K#:$+J#O,.7/TXP"XMP=^_R/"NA/ZB+M?>G.VQIF@\) MQB+TXR?Q

*MP.%]A=GTT#/G(7+6,Q301R@97Y+D)??OJ(‘&+3;CF)(WHA-FEMWZA=Z1,73M-M[#=+!DC!Z-'JBUC]VD':E52)2$"8CBAA5]((J3G=@Z*?=@NVB&_6|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

{0)HYQ7,9NB^/X#4SI^_^$'5?2<8|6$QD.1`M2SST??H2F8@2*C7=?*-E-,+-YB=Z@X7#AEOPB3?:GLA`B933JF.L,;6(5"PL`M9S=.
[*TY6V:/\;/U.\|/$ZXWBS?:VO9_022\':FS=\RHV[Q=Z6+3,)"(3D1O`M#6B@YD>@ZLO3706&ST%!GMXDPXB O/VR^SI\_UR_K1<+6[_Y\OB|>[^`M97G_OZ_SU;^&%7YY`AGO#5&UD^-
:80R\MFQIA>EL(T3-" .-:N?#DR*=.<>>`M6|6ZF[MP[W@!$ZG*`LA0? K(E*/"S95&V>?6+YQCNP4UR8YQ@C1.;.$L/-`O<7)XH<+.?FP0O.;>C$Q`M?;AW7H36F)"QAD\|\{"GOF#2>?
6>-|C*PBTVQXFT8)S&K)<7\MYY(::8`M!)3G#XL<.LZT0`_9V<-IE"=@\)ED17#D6A//:$OM-/"J4REQHH&7D`MTA*V^I`1HP%'\G4|\[DI05E#&&V0EZ1-
"6UL66@(R4[0/$HUH6&$GJ8]+,%`MM2K%]Q\H6GLQ-VA7?QUH(&>G90!FT4+7!-:,A)K#.W'^G<59@>15R'F?TY-`^P`MX'<)Z!AN:FY\0?B9'WL)6J+HW5NC#*(7M`ZW
5V%J35J[6NOJ1>=&CI__?37`M`9I*?OWT-R#>%+YA7+$HKE%GTR$3\(D3)9!<3DHV[8[']DVTYGD2PLM![JS]F% M4CS4)X$@+|4-
WE0NK9N1I8;MB.V>BA25265.=;=6_0)!|GGTP+/|0DPN;5Z93GDIH$EC2>FW)7-MV+0JF[:I6,/#-JV2IfV)3."WFU9VT_9$)W+_32)OX'(5/.832*fP`!:.F%S`MW"D(EY,FQXTW<0P$
\0HP=~4`1#=>U0++!mJ_P',F%3#<_>.UP+?UZ<-+S7U`MT`4-PW/NGE!D|,V2F:CO W>`.&(YDT]8,OHNX6-I&-EKL^67A\;?%+P-K%8#E`M0T2ZM-^A[+_SX%2|
{O?'\NKN[@O8K&M:V^-LO0Y3? GA^P-Y[X)$&:6I-L-N`M;IUX]QR%[QZFHIOC*[XU2R>Z:C2*[*ZR]DL7=CN/$20:!1:8#|+*S% MAB#VP0^_R\Y_.`4:B_QRA@W.DRNLL
M<&|=WX\7F]F[X_E$"N"7_=+QT?E9P*=._VO#")TDZG>P]GQ4T317H1FAU,E7`M64/<'<*JP-JCB@#^V4=4V0OD#*&)5]GGN7OQ:*2FA!YEHGQ7T;Z+IP,7L72R[C5^%LC5^=
M$>*+^#OTE2,4W57LQBS?U$TYHL#EYT`02=^3&QA>/8\0+Q'N8)4QA4LC6FY+`MC|6G8LZ'=1`QUX,)G$"`1@G>+]Y<YY$]#D,.`4<+&MP;08\0B`@>O$ZJZ,.W',9Y2G$
MC^X6H(D>A@WB8B,&I/LY>QOG//#H.6^=+X)1??Z58?K9P]\6$Y.,'U.|]UE10`M\2`,6G>5SB^7TZ/OD?S.9PKMZ3#\`_.J.WUI]>`6/IM%LR)\SMWR`MB3K!E(H`M17LO:!FE9,?FM-)
{!2[26C23-IHG@4X"XUTZ07>7Z:@"`,A22#2D(*BZSN?`MB)SH2QGA.?.G3,**ZH=&2,$DL&E,;^!$,1@MO0%7`>A1%'2")R;1SM0|2\4`M$9,H#M/1]2^(>YD(XW=|\QL(VIG(2?1AG9
%$$U"EG3EMC<@9)DVK,1+BU=9W`MJ%,GAP!-OS!5++>B$B[Z*WT2DT"K;U"5!,__K7`M,@<X!9#4@TVOMB0"=1%U3H|\[=(:|PUOP$G=LQ$1[UPSB-T:.)34.+S4T:>P$Z
M%X$91KVE1;1U@MR(BIDD#GW/=?*HKN?2UA>;_(YU_).0E-5/,+.VO:YVEVS_M3!\K?.8W/C\|V_C7P)`V1@FK4AK3^+'T%QH'0F`MT`W>B8Z+S=+:,!M[&6Q-W
M569V)O5",3[7I:R"88BQYOYEM7SX$^Q5!Q"=ATR,*$Z&(1SDQU4)|%'$R|CY`M^,S"+XBV>GEVHG/^TC`8M;SS5>0$,3YS\KJ1L*MTFC6FY>U,70'060$&^ZH>
M8K7SBP;>5D/L8>B6B|Z*WY,X=^+`|!9.3$,5"OM#@G+R$-DD17`M2O*0#`&FM86$[U(V=U\M^/D9?NDYH`M&%&]\4Y:22ED2&XT\0-T;2|8 # F@
MF3"I@Z"Q.\4Y.9)#9% XF9(9B=6#9&YK^E5;,MKT3,&1>`>&K'[^,U\N@UJP"'OA6W@_8[!H<5]"8P:`MMEG#WP< A8W,J-EW)W++K0O(\R #+({J??8W347*R)? $-;F\|,`)
MHSW|VCN4.)X_L*=7*5;O1+C*"D=$`fM?$3X%|S8:8#YXD"JP3XY>53[\,KY!-QAO6[T!1WR`MJ#8G?-4W=1?N'2]@[%Y]+I2LLA7^*L91R$9#VC[S-.3CK8%]K#8E 2-`/`L
ML5"P+Y2D[+&&Y>5GST>.NUQ[*%@CTE\IC`Y$VB&7+R.EZKU.!WTIKS`M/N9V/@<++&BA^88(OZ`,OH5AH7#4TK8&8O/PR$*`MWQ$^L=!-
UTD=%/%@8>TE[^8Y.A0B6:%LI,U//+A:,ZF?G[.%M%3C4;^4`M9?HTP9FF*ML%OGP_]%4>P6U\!HJYMBQ0\1-*\!04H=8G]DSL$%#89F:7|`MM#X)?[F>/VKD=?] D C 3
Z,G8D[ZV#8Q;F-`3"Z>+R)Y00U7^/'L-89KIEC{58!V<$3*.?B[\(,,3L;(7D`01-OE-UZM-#"'<4RH%NQKYD]$R`M3L.Q9)9+'B^.XK2-H-F>\$(*3+6SQG1PKN"/JYX!\Y3K_-E^O9Q
MM$Y6X7,>)/2*=82HLI/BD^(1]^H=55>DE7%9A(&HAXTI$HLI_18IH%U2Z6)NXOF@H=BPQJ,G(]U`M+_]G$,W:K?!TQ"+L$F<49O+4]#E3<3 "IZR'QNQ2^/\V)NB0L;D'P33:1;60
M$)*$Q?B-Y;IV\O`4IR+$%Y$YBPV-@)C2PVI9!*<0B\>A3+I#`5!4V<>0L>Q9=Q9 MX*Z^8ZP>9\E]&D)&%8L>)CB5/GO?Z!T5C#SU8[3^XS9_Y,+0.P\\|__G8\"_M_]/22LY1.I"=^-
ATX2X/TW,8?'-\'QUOG. W/NYX0.NMPD("?YE[K`:,Z[-^M.A_>/F4:GI]?VRXQXH9R2Q!S* "OQI+$!CB1&[\>7"=#/_[YT[\^_20NW:0T`MMW\|IYE0Z.GI[#!ONO\.|)<5#&
E;_8F<:UIK6*U<@[4E?.&7KC-)X2/\>,,." M6:!|\'PV.C/M51_9$0J?!V6"\(*U=__1EU6I'.(&B%ZR(@"19L]1VX;V6"Y5 MU5G]WLE>(+Z3*Y\/CQV(FHU`-LT3Q;(IZ;Z/:.OXF8;+$+NL$8,ZJ?
F>-/F, M/ P!?EMP>=O{TO8N47(]D>!?15&<-.]J]*F?:<*,P&!]10FI9W=A@'9*V:8 M% *X_Z0,HV09>P#3[M>1M^.;&S)P'6"Q>=C8$*J;T"=>8OCNIC?V\ AUMY9+5
M&,Z^O$'A;"VNS3IV664>QRER6P#<=A48]E9U)K)F*UKR!JU9XMG_3L7\^;9 MJ$:-%HZUJRBD4,XC1H5*N;KBB|.S5HT:IPQS4RG`H\ENAI[P.!6UBQ&W8\;
MV0I=;5++6"7L2>$,"O*6ICK*H5/+C&'C16G>L%WRD:K44M\3=-=Y<+4$Y%C`MI3]9RE4U^QZ3L>64#L9-<=:;$]X%ES+-I&/%C\ F7."B^E@L8KK^.#IQ9($'`MF^,JL5.W:\&'M2?
5=#$Q)=8W?$B4+NCN%)98YCZY>2AJ"Q)8FN?T/-|>@[^]Z63+)8U M.)-;"7L-SFV4-I:,LQ<,47*&5*KD9:)^I'2VRXN$T%D"\'!^04H=N9[^E$4D[#0!*1+YYCKS1-
=3=">F*/!5^^BB.DXIMC`MY1.E*E4Z;T$3YK5-"JA18P${(8A"Z=_<=\V5&UJNW!#;<7-X2"A"Q7,,]["9`MO#YIH(*$7<|(:[8>^[25C[B;25#/I-&@ Z2L47>1L%D_K
MQ28O3SR_=K\):AP&*FOE^C[:83I!_?"9FVU5(0HSP M)$MF"Ql,'&H4"_(7Y#OX2G'Q>8I3/"':6#V/B6V@FEO;]{8#PUB>6^L1)
M85K$URU*#6'<^%OHIWM$FAQI+HI0^Q!&K(VOPEO'7Z?D9LT!9.'!Z/H0!`Q`M;WISO*`UPF?E+O3LN0IK6+1]AFN$W)B4IR.69@>KY(LHVWSV$N/;0:4300!U`MOOK#B*'
+\NOU1MJL8'C_KX=-%`;)K1/OGITCT5L+[+'V`M*AAM\07WCH(49=P5T.?D+UZNRTWC)-RC:!Z0BIFDCU0<(_P_=^5\<%|V^BL9`M/H[<5EFFB=4.!0VZN'4.7H)9D9 %ZZ!:K=.1-
G#G16A-Y-T+N9>)2A){VX $`M!PUZ]H-P[/@DTZE40D#F]IX$R`M%4=W108VVYT\UE0V(Z[H:H5@=5:U\.L'%)L`Z6E=DT4E3S]`MD]P $\66():2A[R)8XQIC]"
{V!AU!8^^7HKC+ENA_31D-[<>Q\N/9U>+_!G`MVBA4M;G68HLFT1'+F&B36!W'6A%$6;C)(\8F06_Z:HBY4+915U8QSM`X&|<;L/+M+252+Q"S1>34<5-(H2`@J4C=L8U:,6
M:)6$4*#3Z$MIX#K,:]5D!3K`9IN_1*4IV$4".5AF6>G'.4+,7*+`MOCE^BKXBA_Q>A$K.@W>4=R^9]UD'/?+4.R=IG%^*TJ%#+&OY@F"'VAPE.WC-`M$$DJB3OB

M>DO.^HBD^]!H#I3,3PP"\+*V#01D""<0;?>4VM:^P+YZ[%^_]>5K&'GX W_=X MGYF;0^E*9<^T!M;KK77-M#1>S?
1@EY!QNPSBY3:.H6<#O@H4,TV+].VL[6J_3/76VNPR6OD&;_$(KYX,-.MI/GU@$14[KN*AV(7+X=!XL;R5F5.9$GEHVM#PMV M#3W \+> QH/H@C;\+;#PVT7"O@$X;.M5'FZH*
[O<=>Z*@;.I-3VI>D) XT!U"RZSJ:Cf.P>.lNZ54*9K%3+6^F !UHL,.$'GFA_&1>;]?4//.O>#BK9H0.#3\^_F).U0PP&
MGKA_^65]+I9AZ%G_5G'9VYNASQ(!D##:G5+89W4!JQAEQ6M./2CO#3P4L2-MIQ/IZ/KQBX&M.!U7X&#[".RVO"-M?#NIOL./A16*]|6+E2-
.E:9<(}BO2=MCS9]TF5;X.7Q'44#=]UN$MU)T8.0\]GRRTV;FP2%-8JJ??1(>FVC&-5&[W?8?PV"K=]V)9H"_[9["8&WD MPBLM9)^#;HXE%?DA0O|)L4P[JKV4N#/M@\7:FO:+H3YSG ?
_XP7VLOA%\B MK&&HR7715'NBA9C(;ISU;\A55"!$,_^R??^GR_%'[NOW1-A@0"DIT-(T=4 M#+2R*P T%M0R'[3< Y5T$#V#]$!0):.9-R++5@T;.=>$T@[H2L%XWN8f!+!NI M(6-
{O9L@.U2*R6 B4S9D7&B_7V06>YE"WC =#P0[BD\6P^@9S2M%PXL@>?=(U-MK/.04=>)H/EI",@Q*&CZKO/19ID!>}=B\+X.'ZN1(NJ;0@R^DQ>U7U6
M2.NQ',4@BA!"23,\BPW]ATC7241>A.=VX/-@$T9[6I?+=H@98HAD#W2@@IDQ[$PSU!C!8L|CC AHO/M1KZ$B-U1 M(T?^#&A@"$,XQ7/& XK].%0[_1<-I)_#F]W^-[W]EY NU
C+++7=O .WB@QI MN;)-M"#RJL#{OB//A?! #N_^XX!U""'1+0I3.A";:MSLGVB*U*R ?:FWCGU& MGWD^*63@8DKQB%4@\=Z1RHFHS36=:YX5|\%?HX!SE1GV;EM,O5A%7"-Z)W|B
MW:BU48;164')(D KK,T34Q$1&EB \%KNJ$SK1T*-V_UF)=0E45YO/,^TI_OL&LMO'D1R%?8; 1MSI:=\7/HJ/4 M0O;*J3^Y]=7X:@%-@7H,&4&J[4FDVK\"-D;D[3:)D-'XM]M*&R-
J_\!QI.Z: MJR%-_BB [+CLBZ!.6N!-D.%-(8K/%,@^IPYH1.E!!-F+T""?>%Y7 _[M,(T=-'(W-5WC+WC+%GM4);INMAL$+FKV.339@7[!7TS8%!44S[&&
M2FTW0DBC[58^N*D$TC*7=3'F=UR"'6E[=>+?SEO%O_SZ0H0?^[&]I_;JWN)UUYL2I>*@,788RTZH*E&_NQ$R5%5:HOG&!;8&3^^KC]!-M8.:_)^/&*=?_0S$;2L?<3?
G^MGSD>,NUQX*UB@FAKT*M'EG[!T#@C$EEA" M(=$,Z"'$=\.T?CL.VO^ MP8P^YW&<(G<>E/A.X=DE7<)T'!;+2,87^:+A$(X \]@:/:.(XD^.[NIPBV(D
M7"//@Q@]1N"=G3OP=BRC;9Z9&<46*=*)A>BG,J/?ZRSKZ1G+=A;;::ML4P,82_>=I?$BS2)$R=P26:]0VSW6 J%DA8-M8LNG&T9W'O7@;#'IE;
[R6YC0=)F2X/B"?.:5K[D"*&YE]BL:3,N>/]@@/S5_ M1L7/;]1I #GR1CW^KP,_"AOE#?<#9/PI.$=:>B5.?E(%A\# ,:3N(C@A1==4 M#QI#2B&F2B;
I,D=Q#..@,2&G%;&YOYK)VC"N#Q1TC@V> ,NP@X,&4HG2A1;S M2I4 7)#)X)3@H6<0.%'0I94?NRT\(Y S\"R_ M9&NW$V1<&7^3R5Q0 T>&\]'.CYK(8*-BR!T?
5%$90("^P#FHYV2"G#UF7F9(G M'V30<\[,)*,/@P9H9W0EHIG&W)&'W0]&T6%1)ZHOLA6CS_1 C5_AXB.5@=$N76#G'Q"O
MTR(N9K")Q00);_6<\G*AIG6X#8CECCTRSSZWG6Y\OS_XX1'?`]2<,;)W9B-3 M?N;[>3V/,ES9+4M3[1O4_],OPM .KIF@%)K?*NR>^"5A'V6j/77L9V1C'(
M91,4N]BBYN1K65]S8%FI[C],2-..KC)VY4FCXA^RU[-%C A*_XC&K\#Y.O#U& MWJE75)Q;!Q;9], 4?&3[C6'HO5XO7=!TB2?9=LXM[L_D7C@8N)F#!E:]EI6QF^D)[(BK641FS /:(U5
MHF\AJ4/KXYOLA9]FVL?GIWGP'A\,F+_0X9 M>K\T=WCOZ+$R]#'B^(3.?M@.RW'P@O_Y]>P]N U]_"0C>?`$+.?2!R#;,+"]-M6Z6SO.5O1A69)ZOP&45DVP]AM$AV*)(&WQP+E0+
(XE!O*7_8%U[+B$VW3 M<8,\XHE5Z,W!&=FK/?DV3(DV,<]>9> M_5R#]6A\X_@D='^Y0T@E8)<[!!0 PE!=P80Q "JYGMUG9[Q2U4*?(71MG?X M?L,*+Z>;A9\,<. M;\L7L]Q$VG2T?
PO@;4E:HA8V_#QO; M;?(;1D>\|+9(O2#PWCO\5GU"4P%,.S'[=2$# SO2H1^^V\<+E1?Z5Q=\;3.(9RXOZ94,*(=ROPQQMOS(M/-=G]"PM;4F"A1,*BOKR2 M.
<8;*)6^@CC26)M#C*$B{WLK;HT/H8:);;/ Q;2.'N1_1<-=?O&G\2[T M"]_88H-ETSQX0,R(>L%HT_UJP@2O7[;@\3Z]DRGO!Z,!ZZ-R&[^2,V(H&]V;2 MFM_9WJE+E-
+4QJ/.@L4!$>)H/MH]A'&-~"'_BIFL9".K+=,1/#\CWP^_T2O&P M?H3V28EWKCY[S1],1.!>5>$XW M'2^?PN"6V&$)!GW$NQ#X@V$B^#:S>;;!VX;V$JSC5N*O/U;&L6$ M+G)[")-
_F>,&&(]N.D"#';1^>7S#R.)R305\6*HM/*"N8KSX!=!HD<;RB^(<-M3K';ZB$&H)%QS5Y0BH4;,\,H)=S(XB?*Z!%Y^0>"B=R"W2$!3E;RH.!DM&D_M"K>D/&ZE?.C"*
S0F)">MC!*HSAY0;#!0*!GL?_EX ^$Y24*@6YDY5A:S:FT MVS/HF3VA33Ff8KK8$SZ3)2$< \6:4E!77Z+5PT! PZl8M\]@G(B<;K1Y>2 8 M%JF[L%'<[9W:?U/!3DU8AHX2,J9[,'E)XY
&BA_[">0]$H%];8,39 4Y$=ZR M4.JAWD6/!0DN%2IZL7*$1U9WJGZ+T+0(%1F Z_U\BR=DY/7 M;SPR(&CI2O^ M%,1D0B[30 >"BY!@>(6.1M!_;3&A(.'$&=:*F,X%
[(31$\^'!=)SM!F"B2?.'M*#O!ERC"?>#-*;O!:EU;D?1<8_'DT&-2(_^_$.C9@9YQ[M_D$G>!NZ65$[(Z(3+([/B1)M^@$;0-^MLLR0#K!UX!?5WD))YU@;\#O!^W.
MEDX0./3W!#O%9EC%6$M=W-*W&/TG)?$ZQ-(#LOYJ;8^-HZD7#>4-MU# RGQFI.QX&E.?XE9K$RP862^NE,4;#6G[0NSSQUM,W-[OPX"VEA5>2\UQUVK#@ZDV#*V]^K"K
MVM:X6,@VI+'7@J5#+BAX+5AZ+9QYK5#7086ZX96Q7.VR-MA)G4J2>987A_KX=-.MA)G@UHEWN5_Z\:V1]WXVBI7WAAM>%\WD:SY*\DACUEP*%\XE>C,5-[+DH
MVU>!N450LMGPE 2M-<9<_]'D<13N7>HFC^=QG")WKG<:\B4@ $!ITN(;CNY2 M#E1U^'+5&YK5&YK5&YK5&YE1]9/+4IKQI9*4/WB!$ZSOZ1)#]8^I6K1VD61H M\4H3^\!W;0?
2[/ZXP7L9C?H6"1)G'B!"3OZ5M(..C6.7B)X].I;9F^_1N1 M!QO]CXTREN$/Q.O(.#&VD[2H= MGMYSA/9>NE^%OR!ON\,T(\-R'7]"=S?>[Y'K85KWC_$N[*">'C23D(LM.[M;'% 4",?
]^S1<;%YP@2QO@O<^F&,*9$GO+K[KHYNCOG&'\+_72/BK<*G#B,D:_"7'4ADB"#]46E5PR M'"*-NJ@<'$C0B+@8)^+A$V\)1-5:+WNB$[1_UJGEB1D "]0VDM(I.K!.L_]3
MKNV2DJX!YH5,!7[TR//15CK\/'C'S_M']B)TBW&YQ0C\G5_'0&.BO=IL3KPC MRB-6@!"OE(QXK/U0*#G[J!=);J;C1N#C+/.Y;+I[OI_MI^7]'?YAN7B&<_G8XK
M3O=9%>,_>'A+'!\6!BUAVMJS3TX5Q<^D)\U>D/AR_^.?_ZP@XGL'J?3BB+/7 M&@L\?{IO$(;-I<,_.3Y)6QL.D$71<@1!$Y<;R*4Y P55 M4 B;7&96S12&*(MJQ)REMPZ470D3^\!4ZX
[-EZ3<+8XF?G2+0@@SU9)FSOC&[7>#7!O%H+M+$Z MC2A"[M!;4H2*$ I+\YET4K,NR M>%B@LZ%4;*\Q'(BE E]5F^LB; "PBT4U?05C.1VER&4[(8L>(0,$G2^'GZ/P
M@*+D^.P[08+A)3Q/H7U"9PA_A ^AFMPZ6ZJ?'<^=![F-OR2^AP1S&\G-&C5(MB%G G7WCR(F12%0/ %:YJ,Z5RBR$E\ALS+-UX30 0-54:+5.80RH(8+,E\=5 M$J9&V,7F-
49T1CF4&OJI*@KD]3K=4T^$2P.JB7<^0CMBPGU')#]WCTB<"R;L MQ6;E? P) 5+ ^?8[0 =]"N5!0GL(!MB&]@']\,&&8R9FB6P=0P 7@$/G)\^1 M S2:,O5&&BQB0+#1\#
<-6NDM6VKOG]I,$BG M00!(OG<0VQ3$)&.@5;?G@C^!"?'OBD>-#8,M)F'!IFV_A)& #IK0A/YU M0KJK#[,Z8:Y9G[MWW@R+8"G:I3@J!99?'UJKV'P_R^VUO/>T=*8](I189-
D4*9YD&9B&Z54 M0WVLQ7:DH$3'6F;">$KM!9935<#H<8CCQ;?'F9GL* M!;_T04(K9@ &4IHP_@$]D#U+?H'H'$Z I:),Q,C*@;M! =;-F$&D?QB#0.,]
MY5Z#"#F^]SMROX0^*:,P&>NN!&F+X&QSG$4>S>3&OP;,9Q1YH=N(!H 42C) MQL^8$'"*9! /W+T7>"%"YKP/D0D4I>,+*129HD*XU$TU>+*?$LH@3S/\/Y=W
MZF"B*GH0F(W,X.Z^T?Y;L4D^O =B::2U;4M5_]KF^>,M$C#C0<(AO.9(>YAG M7;IU;%?&V/2LRF[/IF>5.\, ^B]9O-!Z#GL99-*L)WQX;>+Kl.&0*FJR,2#;)9%SFRA!W+X57^E,5B1;V?
++P^/BU! M&(R)UYCTX24$DS],HZO,2ET?KH"9FM,==S4K.S Z="L7QR83_44V3!GI<I*.M51A)47@\@=0P.\=%8(;IA5;@3^)Y\(*VF"%)3.'^1O--BLT%$-.%!SY'W3BIQ
M^OPMGZ/RE&DSC$:5 V.8*66F J M5E*2R",53O/ U>H?2B.S^.PM+P8CXT^Y0]M^35+S_6.](&?873$7WF*]6;#,= M!GI/GH$5A=8=PLK%YJ-?@G _.RLJ2BW8?1DE>)FI(!AS#*_,
<-91N0U1,JWS'/ M9/"4ILAWM,SL#<8E:49*M-@JIPT@Y[E+Q>$5:Z+1_?[@AT>$LNXB1=U>S(B# MR9&^4!B5L/352?)fGP9B'4_AZH[OQXL-7TT8$D6!E51,FAX.7MM)JE.,>]82
ME/0!K)%QBZ3]AY4YO=TZT%=^O@P6Z M-IBD]XID \(+&/#-1E]MEN#6"G-@6&8X(BG]=9!UH^BS"L3/)9MJF'2_PB M$N)-4K[-\D_)/V1.C+(__]_X2'W!MW.X>,,$F)'_*_Q
$84)7H'\C?I(^?2O^ ME^>,*H<6.'N,Z8N7R0Z.G(GWWW@.O@:S-@LK_/<0:UB)Y_A?/1\S M-3[A(/N1$**6"H8XU/0DP>-\@C)<-GVPC13[XBL5(.K.*I\MR9P- MML;!,ATMG\!?
>CH8(I>*P XLNSGMF%_8,%;I(&X<&4UU?NGD"S M=$\DIC2TPE?T;I,O@)(ZL$S?_HW6R2HLM "!?A"%V\C95^6HD:5 "EU6]F6N M)# ^&8[,R+)6'!"DN7C5;X)SFV1-P?
D<2[QFVE=!E@8^>AXXP2_52'D?@P2-MF,I2N3L2-4"!7PR8*@ZR.3*;(9NFWQ,J8H4(T @R@4L9?>)#UA4"VY MC/SS%",_0@F1U BOY+Z0Q\MB\XHYF?
@F"B2TGCZ8BYU=86-&KO M'7K25C!D MZ;Z:W4\?>2=I86"ENF#!.*#+VE8.R$LABK/[>GGPO>0YQ*+QN$(?R8U/4_@S
M;C'U2%,BHI[@_@5,_O./V*%Q2<$;3@[RA5J,.LBX'P]'%BP]_K;>&M2"B?+ MX"9J*3D@+++T?O8!267R^_-1&@WLA=A&S9>0!Q%QY.(+RJ_/A[=,]?L9@A2!Q
MMFBQ6>10$L@3\HW$,/8M9"1RZQR\Q/'SRAXY\[2:RQ"&9+IM07&,Q5!B38!E M+_1BF04E'.7JTKG4Z-7T6*3U9@D$4UGQ8!TZPTC_(F+(3U;#=M,A7KL'80P
M=R%6LI6'0UZ59^,*1?L?6*,*[.(MO-YX!&[.'[_WQ*0LW7*< =&0(0&G=1M4 MCYU%4++F%*:.LV-)92P8#4E.C+GM[OYCS5#P.1]"U=0+G+MVU^4*N0Y:6:XT>< MZSD)\H_X]S!:A7?
{Q^<9'1<;_.[S]+/0#VG/6#RJ*=Q-KP_T!GA=8EF.13 & MD1(ZH0+'?W;P%U7M1@H#05]0.BXY7#63]_1E\ SM2^)U2W;_0DY$8"]=,":86 FLN6&UPZ2X"WTW-RXN-
HM#,@\>TF^BD8,ZHUF_*6 MFZF-KCD<7;F(1"$R(5YLEN3QC#?GDP;HCYBHTP,MBDXBF$YR5F\.2(WT D4# M_X(GU=56M.8,1WR4Z;YA>ZOH85 ^0 M[[*X1656&1^']*)WD#
(NA,_9'EMZ*,9;FOS*X;!B(347FQSX>3"K0WA"H=)8 M>,K\,N=%KE2UEXT"]=B?0D#+Y$WLELGQU]FG$2XJ`M*%VI M!0^#0G:75>0H/* *0X?#L^>$*$'0_RJS:'XD;^7G6ZNI8-
]KI.@F87@M8Q0X M9^D+\O9O:123V?586?9GPZ%=815O?)^X6%TIQY34QX/!@5SG6WT7/5[LPC;'2 MAA6*U?7\X7&6K'8H,YP4RD9O92>Q
MX_Q8"5D0/1*D@.-8DJ5/GY/KX8G_0:0=4U(DI[I.1]%:*OP^G MCY\T.S!Y,U<#MA9.*(OB)4"5N0.[PBH,4KB5US%7[CW&A*W=,)@>]R,8VQS(M/\!Z#/"
3*LUTV^,G;Y!JD&]F#V/,D86:-E*ORV.I$(EO$X[*,%AGRMD!>+ M(Z\K9DVO6>2=T.(D;55@5<^_[[@+1]\XHZCD*.C61F*X0&,;?55%[EKMZ\(:IG>1%Z%GF:-Y\ M&X< .(=[:YA#!\7.C
TR/^]>N &9UR3=Y@2D+C^Y^@MEY-[&\VIC M-^PAC/UX]@D*9$UL!UH@X@X>X&0))?!]$-[9^.$5+87!3!&BA].$_]>UB*3 M^W@KD)8GN#6 TK:$/FVP[$]'IPTVI:LA
2KA8'*55H#)YW)KEECMMRHV1&>, M5Z5^%1(]^A'($]E#Y5'@*_Z+$EG\APP6MD1M/!*ODA70K6-,-N0Q?" ,B$@X MI@-U0KN2UU]=9<%.8=/F8#G;A),9+Q\K)\Z(M Z:-
]4C$3*.H"'\^ M?TPX>2]/(&TIW>G+'I_095WH-"9Z7K=9NO2]SU]Y5K+]KOV'IERS"=P)64"N M@.W;!B.M1)B+!*MQW50POYV[4EDNB!AKYP"U6=Z'KG2O\I'N;C%8WX];M$!,
M_<5X11)!&N)/=<"[G@?KC/7FHI[.@3@-(4C2[F)9(&I*N(U/5,Y2I3+SF.;% MGNSK(!E25X3D=([V_K^$V0:,Y(R$T5Y_?+V ?2NWME#Y7@/U!2-;YZ_0ODVU MH9,-
Q,N3309ZC_59G"$7T]R;L-9)^D0[5,>C39.@0@%9A?X-]"T=3^;>Y] MZ+X;?:#-UBB_.],[=(H .^XHUG-,C8IYGP)^"*3 _] VB!,T"!O&.E'XQ)< MO%GL!=^6VN)F@*.O@ZL9$22816\(??
F1%<+*669*> /QP/K%2$XI(1KBBL]M:'%RY1X,8W4Q3Z4J0W<3%4:5E+[*7LF730 MXP"SOV]M?>4.B(5%,Y;TQDWZ U^.[U+@9(.E9Z.CQ\O1RHVS7QGW?,P^_0-0 M2P,$% @ 8-
G60O,T"^L" S4 \!AUI2A5L2RR@6XTSD$WFJ[!U>H][^PW@"XP$_6<](I>'_^=W34 MW>OV]L-7%-AO)'JI%A-FW43![5L%-WU9QHS73O]+%I4VCI
MS(@NI)O&E+,"RSS!B7W7!RU8PU<[I F4=C%W$E>R7L8+H ^OJ4-=("G>(<^FB#"6A)"6_ONJ^/4AZ^]3V?6^_PO_H
M/_.$IQRB(9\OCC'32I$0$!_EZP>]2C,6*]52!9LNX\+SO_^A@:-+2%N^\C^]?+BT\)'1\N++Y_O[H>W]W?#?VOK9#ZYKQ\>_M-
NR-+#OL/M[ID9WOLRQ7_Q]]DAV5@R"+F!MS%K2_^_[:QA6F@92U3W-K?=U!A M$2EI700*"B XH-(*S$YKHI"V4GP2YPK&BQ/5>+Q5Y64BZ[AQB9^2B+]W<- P"C)NPK4)1DB.=/
MVA2L>_#K]_'A0:>;_,5TSLZLA2)%L0!2VTQ"F8'ML(LRVTMF6*/U?Q8%MIA[M6LP=K@'F/N"<"\)4.6,%7I1XI$'WH!.B9 #BAL:=2.T:MN"P9+R>L+!VI 6WE MSN.%(.A9@=^,Y(KE/,-
+ANE".N9TD+LA4 *"U'(S(9&"7P'JG>O3XC6!QJ!* M1?&0=)!`)DU6%RA&&$=+,'=CZ)!LP&Q-/V:M1V"@Z80&4$BK,!?%E(^-!!O@~M &T%F3>0^D6X2RUPF$-L)E@ZF??
#ED7/Q**C=681L%R6B%."_ R7':00BN-M M,W=?ECFNZYQV*?A[!IF]!?2+VYT#80=Y(B@5HO"76$1N5FM&J0;1=4(V6"K_] MZ9!$K5 N:01F52=]?9DW Y8KO3(MD0ST$.+[8UYH:U
M6\H\$V6.UX RE]?P%5*9WQ+;L*+)TFFEUGDN\;N'W@7C!CS($;0R54!@9(#C M3A%# Q(GL0*C%$4[^HYCS92V-;8CY4:K@/;*Z P$7K9L%\$M -D2$'P^S@;\ M[,
/P]#PM58HT3WB;,+5/=F%-[Z'[HFX=C%OAN!J&-9^7IR6'Wl-W;X]\.CTZ/ M3P]/'HFB? TH^@=8=#FBTZ=5/R92AS*^C-?VIDTH]4H!:=!H"LFJHMV8%^4;(^.?0A3EM
@QR&5&I4X93*K%;<(C,.RQLORR>Q M-I -K /)2;"""LF+!=Z"B58%$<(L,"U04 PXZ^V9;P7FAX7$=*CAG"G=$Z'2),**R(4; ,-AV>2-TTK* M")U!B6#8(2E4T_ M_$.\JCG!G4C5%#U"P79) .
{"&UJ8QI_5!&RVA-@&2813 MUPGIJ,58+YM(ZU%C.,*/,#2[^'40V^("%W/"/ ME1L2=4(V)LNA5D.@E*SD_>;IN&EB'!25TA/ NZ.!#H&-7Z,H4NIQ4M:]56!_ MRL-_*P#Y5'-RXXBC/X?
JBTR-YN9H)ZFFDYYH+-V-$$RX#\;>QB'2*=#V$&I-.M \24X16%V(9"$X3CH]BI;,NF(E=8FN)6NA%"*7$=Q2?=U_,'3IL1M"=.]YU8 MU>Y^S8Z;[,..?5&+@VJ/S-*,+)VU:,
![GQ%=6#+N(25SN)5I=(&H>HZSM;=8 M&E9N+7'28_89Z56DR+#3#CL\,#R^=IQVB?]?QK#O-_ EYX0W?6#+D+\|:-[. M^T?LZ)@)=]8"#P@1'V8O/<8X_1M%V?]
MT)+Z&DX:TU8+Q_LV_T;I_RW%-DL MBFSLP!Z ^RWF-QL:&SNP!V#^XT!"SL[']D-7TX)I]F7M**>O$YXG_>@'[5(.%?QKW@?:MHE(+:-OL7"M#$S[U3[FO6X5$>O4J.$U@7Y?7B?
_M.>CMH_UKZPKOH2TOA4(KM M2^K3E]1GU>K!=.%N+&X>*OA'!S']^8#D^@UT9+CLYS6LW#QW8&*N1GQB_0K> MVZ<_1O#^E!Z^_S,&_P-02P,$% @ 8-G62<>L+^@!0 >2, |
!A MD4#ME)QLIR:0DDZ MT_LHVNB0[9\DD*2_OLR78(;096H["A_$"WM6^/]N7M=ICG?#C5Z0!AKA M)VEKICD<[!XZS4.5;=?R?%6A5G"T Q'-
B=)S#A]V$BHO6>H1.M'B#Y9D0FJ: M:C^C4<322X\<93.?LQ2<.,#+L?:(Z^]8+1&]+F44S(X6F5>OMECJ?W-8&L', MB"6@R!E,R85(:%HR!D)KD2"OAIEV*&>7]-T89)28 M\;6>4'
AO==U^^5/QTR#HS(.@I=)<*;29KFZ:>Y.('CDK]CV77/0EBF+]-B+ MF79"Y{34V-#[^JG_L3\B>;],A$,IEJ0!NMFU0&- ?E#&8Y_FF-71.ZBV&D>[-M?L14QNGLOD*
{T@]6T1.4:E\@*]P&SO[I3;C1.HK7FX^Z,E-M^K&*[Z!ZV&]XAT?O#MXWFH<'AXW6KC_%,:(32*!7WA5-AE;Q13!8:G>K-B;? MB<'.\9Z[7^9C:2N;*W7K]=T5B4\SV8P6I4CB"
<=9(3I@9O*7E2[A\G3%K0 M*%, -^6T1_=-E;NMO6A_4J0W<\-B7B@JQWW?//!-"2[@:K9]-YN^+5R%*Z- M9P)7EN+*E5"+04.A:V3XE>PC)E9J5$>R5WP813A
M%A2_&A3K7C$_]LL/?Q5RG[&KWR)FXSM\S':.O&;Z"OPTW8&7WR)9ZH!F M]!*<5$10CMFYU9=;NOJ@NW@1DWE;UO0\)DEZNQE.WH\HG;97*%,N3:QM#D(. M_2X7*I[TM?
UJHVZ\F,T*BXLVJVVF>N;JBW^;;@(',]N\YM,:C35(C_(IG2L[-MO;5KYN+,\;MVS5ZY^0]02P$'"% ,4 "-!@V=9,*,801+G 0 8IAH $0 M @ $ 87-M8BTR,#(T,#DS, "YH=&U02P$'"% ,4 "-!
M@V=9"]<@X2;W "760X $0 @ %)YP$ 87-M8BTR,#(T,#DS M,"YX#,Q7S$\N;'1M4$L! A0#% @ 8-G62<>L+^@!0 M>2, (!;^<" &%S;6(M97@$,S,E\Q+FAT;5!+!08 .: $ /@ \|0(! end
XML 56 asmb-20240930_htm.xml IDEA: XBRL DOCUMENT 0001426800 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-
gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001426800 us-gaap:FairValueMeasurementsRecurringMemberasmb:USAndForeignCommercialPaperMember
2023-12-31 0001426800 us-gaap:RetainedEarningsMember 2022-12-31 0001426800 asmb:TwoThousandAndTwentyAtTheMarketOfferingsMember 2020-08-31 0001426800
2023-01-012023-09-30 0001426800 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-
30 0001426800 us-gaap:RetainedEarningsMember 2024-09-30 0001426800 srt:MaximumMember 2023-09-30 0001426800 2024-07-012024-09-30 0001426800 us-
gaap:AdditionalPaidInCapitalMember 2024-09-30 0001426800 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001426800 us-
gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001426800 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-
gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-09-30 0001426800 asmb:TwoThousandAndTwentyAtTheMarketOfferingsMember 2024-07-012024-09-30
0001426800 srt:MaximumMember 2023-07-012023-09-30 0001426800 us-gaap:FairValueMeasurementsRecurringMemberasmb:USAndForeignCommercialPaperMember
2024-09-30 0001426800 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001426800 us-gaap:CommonStockMember 2023-06-30 0001426800 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001426800 us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember
2024-09-30 0001426800 2024-09-30 0001426800 us-gaap:CorporateDebtSecuritiesMember 2024-09-30 0001426800
asmb:GileadSciencesIncorporatedMembersrt:MaximumMemberasmb:OptionLicenseAndCollaborationAgreementMember 2023-10-012023-10-31 0001426800 2022-12-31
0001426800 asmb:SecuritiesPurchaseAgreementMember 2024-06-012024-06-30 0001426800 us-gaap:MoneyMarketFundsMemberus-
gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001426800 us-gaap:FairValueInputsLevel3Memberus-
gaap:FairValueMeasurementsRecurringMemberasmb:USAndForeignCommercialPaperMember 2023-12-31 0001426800 srt:MinimumMember 2024-01-012024-01-31
0001426800 srt:MaximumMemberus-gaap:WarrantMemberasmb:SecuritiesPurchaseAgreementMember 2024-06-012024-06-30 0001426800 us-

gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001426800 us-gaap:CommonStockMember 2023-09-30 0001426800 us-gaap:RetainedEarningsMember 2023-01-012023-09-30 0001426800 2024-11-01 0001426800 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberasmb:USAndForeignCommercialPaperMember 2024-09-30 0001426800 asmb:ArbutusBiopharmaAgreementMember 2023-07-012023-09-30 0001426800 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001426800 us-gaap:CommonStockMember 2023-12-31 0001426800 us-gaap:CommonStockMember 2022-12-31 0001426800 asmb:GileadSciencesIncorporatedMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberasmb:SecuritiesPurchaseAgreementMember 2024-06-012024-06-30 0001426800 asmb:GileadSciencesIncorporatedMembersrt:MinimumMemberasmb:OptionLicenseAndCollaborationAgreementMember 2023-10-012023-10-31 0001426800 us-gaap:AdditionalPaidInCapitalMember 2023-01-012023-09-30 0001426800 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-012023-09-30 0001426800 us-gaap:GeneralAndAdministrativeExpenseMember 2024-07-012024-09-30 0001426800 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberasmb:USAndForeignCommercialPaperMember 2024-09-30 0001426800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001426800 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001426800 us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-09-30 0001426800 us-gaap:AdditionalPaidInCapitalMember 2023-07-012023-09-30 0001426800 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember 2024-09-30 0001426800 us-gaap:RetainedEarningsMember 2023-07-012023-09-30 0001426800 us-gaap:RetainedEarningsMember 2024-06-30 0001426800 us-gaap:CommonStockMember 2023-07-012023-09-30 0001426800 us-gaap:EmployeeStockOptionMember 2024-01-012024-09-30 0001426800 srt:MinimumMember 2024-01-012024-09-30 0001426800 us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberasmb:USAndForeignCommercialPaperMember 2024-09-30 0001426800 us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001426800 srt:MaximumMember 2024-01-012024-09-30 0001426800 asmb:EquityAgreementsMemberasmb:GileadSciencesIncorporatedMemberus-gaap:CommonStockMember 2023-10-012023-10-31 0001426800 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberasmb:USAndForeignCommercialPaperMember 2023-12-31 0001426800 2023-07-012023-09-30 0001426800 asmb:EquityAgreementsMemberasmb:GileadSciencesIncorporatedMemberus-gaap:CommonStockMember 2024-09-30 0001426800 asmb:SecuritiesPurchaseAgreementMember 2024-06-30 0001426800 asmb:CommonStockAndWarrantMemberasmb:SecuritiesPurchaseAgreementMember 2024-06-012024-06-30 0001426800 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-012024-09-30 0001426800 us-gaap:RetainedEarningsMember 2023-06-30 0001426800 asmb:GileadSciencesIncorporatedMemberasmb:CommonStockAndWarrantMemberus-gaap:PrivatePlacementMemberasmb:SecuritiesPurchaseAgreementMember 2024-06-30 0001426800 us-gaap:RetainedEarningsMember 2024-01-012024-09-30 0001426800 us-gaap:USTreasurySecuritiesMember 2023-12-31 0001426800 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001426800 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember 2023-12-31 0001426800 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001426800 asmb:GileadSciencesIncorporatedMemberasmb:SeventhYearOfCollaborationMember 2023-10-31 0001426800 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember 2023-12-31 0001426800 us-gaap:RetainedEarningsMember 2024-07-012024-09-30 0001426800 us-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-09-30 0001426800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-012023-09-30 0001426800 us-gaap:USTreasurySecuritiesMember 2024-09-30 0001426800 2023-09-30 0001426800 us-gaap:CommercialPaperMember 2024-09-30 0001426800 asmb:OptionLicenseAndCollaborationAgreementMemberasmb:GileadSciencesIncorporatedMember 2024-07-012024-09-30 0001426800 asmb:EquityAgreementsMemberasmb:GileadSciencesIncorporatedMemberus-gaap:CommonStockMember 2024-06-30 0001426800 srt:MinimumMember 2023-01-012023-09-30 0001426800 us-gaap:AdditionalPaidInCapitalMember 2024-01-012024-09-30 0001426800 us-gaap:CommonStockMember 2024-07-012024-09-30 0001426800 2024-02-082024-02-08 0001426800 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001426800 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001426800 srt:MaximumMemberasmb:GileadSciencesIncorporatedMemberus-gaap:WarrantMemberus-gaap:PrivatePlacementMemberasmb:SecuritiesPurchaseAgreementMember 2024-06-012024-06-30 0001426800 2024-01-012024-09-30 0001426800 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-012024-09-30 0001426800 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember 2024-09-30 0001426800 asmb:TwoThousandAndTwentyAtTheMarketOfferingsMember 2023-07-012023-09-30 0001426800 asmb:OptionLicenseAndCollaborationAgreementMemberasmb:GileadSciencesIncorporatedMember 2023-10-012023-10-31 0001426800 us-gaap:RetainedEarningsMember 2023-09-30 0001426800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-012023-09-30 0001426800 us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001426800 asmb:CommonStockSubjectToPurchaseUnderEmployeeStockPurchaseProgramMember 2024-01-012024-09-30 0001426800 us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001426800 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001426800 us-gaap:CommonStockMember 2024-06-30 0001426800 us-gaap:RestrictedStockUnitsRSUMember 2023-01-012023-09-30 0001426800 asmb:ArbutusBiopharmaAgreementMember 2024-01-012024-09-30 0001426800 2023-06-30 0001426800 asmb:GileadSciencesIncorporatedMembersrt:MaximumMemberasmb:RegulatoryAndCommercialMilestonesMemberasmb:OptionLicenseAndCollaborationAgreementMember 2023-10-012023-10-31 0001426800 2024-01-012024-01-31 0001426800 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001426800 us-gaap:WarrantMember 2024-01-012024-09-30 0001426800 us-gaap:EmployeeStockOptionMember 2023-01-012023-09-30 0001426800 srt:MinimumMember 2023-07-012023-09-30 0001426800 srt:MaximumMember 2023-01-012023-09-30 0001426800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-012024-09-30 0001426800 srt:MaximumMember 2024-07-012024-09-30 0001426800 us-gaap:MoneyMarketFundsMember 2024-09-30 0001426800 asmb:GileadSciencesIncorporatedMemberasmb:OptionLicenseAndCollaborationAgreementMember 2024-09-30 0001426800 2023-12-31 0001426800 us-gaap:WarrantMember 2023-01-012023-09-30 0001426800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001426800 asmb:GileadSciencesIncorporatedMemberasmb:OptionLicenseAndCollaborationAgreementMember 2024-07-012024-09-30 0001426800 asmb:TwoThousandAndTwentyAtTheMarketOfferingsMember 2024-01-012024-09-30 0001426800 us-gaap:RetainedEarningsMember 2023-12-31 0001426800 us-gaap:AdditionalPaidInCapitalMember 2024-07-012024-09-30 0001426800 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001426800 us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember 2024-09-30 0001426800 us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember 2023-12-31 0001426800 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-012023-09-30 0001426800 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-012024-09-30 0001426800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001426800 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001426800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001426800 asmb:CommonStockAndWarrantMemberasmb:SecuritiesPurchaseAgreementMember 2024-06-30 0001426800 2024-02-092024-02-09 0001426800 asmb:GileadSciencesIncorporatedMemberasmb:CommonStockAndWarrantMemberus-gaap:PrivatePlacementMemberasmb:SecuritiesPurchaseAgreementMember 2024-06-012024-06-30 0001426800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001426800 us-gaap:CommonStockMemberasmb:SecuritiesPurchaseAgreementMember 2024-06-012024-06-30 0001426800 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-012023-09-30 0001426800 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-09-30 0001426800 us-gaap:MoneyMarketFundsMember 2023-12-31 0001426800 asmb:TwoThousandAndTwentyAtTheMarketOfferingsMember 2023-01-012023-09-30 0001426800 us-gaap:CommercialPaperMember 2023-12-31 0001426800 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001426800 srt:MinimumMember 2023-09-30 0001426800 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-09-30 0001426800 asmb:CommonStockSubjectToPurchaseUnderEmployeeStockPurchaseProgramMember 2023-01-012023-09-30 0001426800 2024-06-30 0001426800 srt:MaximumMemberasmb:EquityAgreementsMemberasmb:GileadSciencesIncorporatedMemberus-gaap:CommonStockMember 2023-10-012023-10-31 0001426800 srt:MinimumMember 2024-07-012024-09-30 0001426800 asmb:ArbutusBiopharmaAgreementMember 2024-07-012024-09-30 0001426800 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001426800 asmb:GileadSciencesIncorporatedMemberasmb:OptionLicenseAndCollaborationAgreementMember 2024-01-012024-09-30 0001426800 us-gaap:CommonStockMember 2024-09-30 0001426800 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember 2024-09-30 0001426800 asmb:ArbutusBiopharmaAgreementMember 2023-01-012023-09-30 0001426800 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001426800 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-012023-09-30 0001426800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-012024-09-30 0001426800 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001426800 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember 2023-12-31 0001426800 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001426800 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberasmb:USAndForeignCommercialPaperMember 2023-12-31 0001426800 us-gaap:CommonStockMember 2023-01-012023-09-30 0001426800 us-gaap:CommonStockMember 2024-01-012024-09-30 0001426800 asmb:OptionLicenseAndCollaborationAgreementMemberasmb:GileadSciencesIncorporatedMember 2024-01-012024-09-30 0001426800 asmb:GileadSciencesIncorporatedMemberasmb:OptionLicenseAndCollaborationAgreementMember 2023-10-012023-10-31 0001426800 srt:MaximumMember 2024-01-012024-01-31 asmb:Timepoint pure shares asmb:Program asmb:Segment asmb:Product iso4217:USD iso4217:USD shares--12-310001426800falseQ3 0.14290.05880.08330.08330.0833http://fasb.org/us-gaap/2024#CashEquivalentsMemberhttp://fasb.org/us-gaap/2024#CashEquivalentsMemberhttp://fasb.org/us-gaap/2024#CashEquivalentsMemberhttp://fasb.org/us-gaap/2024#CashEquivalentsMemberhttp://fasb.org/us-gaap/2024#CashEquivalentsMemberhttp://fasb.org/us-gaap/2024#CashEquivalentsMemberhttp://fasb.org/us-gaap/2024#CashEquivalentsMember10-Qtrue2024-09-302024false001-35005ASSEMBLY BIOSCIENCES, INC.DE20-8729264Two Tower Place7th FloorSouth San FranciscoCA94080833509-4583Common Stock, par value $0.001ASMBNASDAQYesYesNon-accelerated Filertruefalsefalse63562862845200019841000665020001104060000430003259000349700098213000133787000316000385000142100023390003120003120001002620001368156000-81000-815590000-78574800026003000410970001002620001368230006845000021163000013515000108240004165300037894000428600042240001339800014201000178010001504800055051109560001504800033888000-52095000134300062800044520001829000134300062800044520001829000-9613000-14420000-29436000-50266000004060000-9613000-14420000-29842000-50266000137000500000-75000528000-9476000-14370000-29917000-49738000-1.51-1.51-3.29-3.29-5.12-5.12-11.61-11.61635143163514314380444380444582775058277504329260432926063455616000840946000-293000-805977000346820008853137000137000797000797000-9613000-96130006354414600084174300-156000-815590000026003000437086340008156360000-325000-760366000549490001362250000500001135000113500014420000-144200004384485400081677100-275000-774786000417140005482752500008269210000-81000-78574800041097000814000100012394000123950007252550005500049996414400040000-75000-750002369000236900029842000-29842000063544146000841743000-156000-815590000260030004074552400080798300080300072452000082664000261170454600045460007533800008000041230528000528000416200041620005026600-50266000438448540008167710002750007747860004171400054827525000082692100081000078574800041097000814000100012394000123950007252550005500049996414400040000-75000-750002369000236900029842000-29842000063544146000841743000-156000-815590000260030004074552400080798300080300072452000082664000261170454600045460007533800008000041230528000528000416200041620005026600-50266000438448540008167710002750007747860004171400054827525000082692100081000094400023800-9510000-337000874000-1735000701000-1503000-979000-3429000-211630000-1047000-2720000-50710000-509040009650000046315000496050000256150000280001840004686700020516000123950000045460005500080000400001245400046260008611000-257620001984100052418000284520002665600026560000 Note 1 - Nature of Business Overview Assembly Biosciences, Inc. (together with its subsidiaries, Assembly or the Company), incorporated in Delaware in October 2005, is a biotechnology company developing innovative therapeutics. The Company's pipeline includes two clinical-stage helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes, an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, a clinical-stage capsid assembly modulator candidate designed to disrupt the replication cycle of hepatitis B virus (HBV) and research programs focused on a non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses and a small molecule interferon-α (IFN-α) receptor (IFNAR) agonist targeting HBV and HDV. The Company operates in one segment

and is headquartered in South San Francisco, California. Liquidity The Company has not derived any revenue from product sales to date and currently has no approved products. Once a product has been developed, it will need to be approved for sale by the U.S. Food and Drug Administration (FDA) or an applicable foreign regulatory agency. Since inception, the Company's operations have been financed through the sale of equity securities, the proceeds from the exercise of warrants and stock options, the issuance of debt, and upfront payments related to collaboration agreements. The Company has incurred losses from operations since inception and expects to continue to incur substantial losses for the next several years as it continues its product development efforts. Management believes the Company currently has sufficient funds to meet its operating requirements for at least the next twelve months following the date these unaudited condensed consolidated financial statements are issued. The Company intends to obtain any additional funding it requires through strategic relationships, public or private equity or debt financings, grants or other arrangements. The Company cannot assure such funding will be available on reasonable terms, if at all. Market volatility, inflation or other factors could also adversely impact the Company's ability to access capital when and as needed. If the Company is unable to secure additional sources of funding or generate enough revenue from its collaborations, it may be necessary to significantly reduce the current rate of spending through reductions in staff and delaying, scaling back, or stopping certain research and development programs, including more costly clinical trials. 10 Note 2 - Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial information and pursuant to the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the SEC. In management's opinion, the unaudited condensed consolidated financial statements have been prepared on the same basis as the annual audited consolidated financial statements and include normal recurring adjustments necessary for the fair presentation of the Company's financial position and its results of operations and comprehensive loss and its cash flows for the periods presented. These statements do not include all disclosures required by U.S. GAAP and should be read in conjunction with the Company's audited consolidated financial statements and accompanying notes for the fiscal year ended December 31, 2023, which are contained in the 2023 Annual Report. The results for the three and nine months ended September 30, 2024 are not necessarily indicative of results to be expected for the entire year ending December 31, 2024 or future operating periods. Use of Estimates The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates inherent in the preparation of the accompanying unaudited condensed consolidated financial statements include estimates for revenue recognition and costs incurred but not yet invoiced for research and development accruals. The Company's estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible these external factors could have an effect on the Company's estimates and could cause actual results to differ materially from those estimates and assumptions. Other Risks and Uncertainties U.S. and global financial markets have experienced volatility and disruption due to macroeconomic and geopolitical events such as rising inflation, changes in interest rates to combat inflation, the war between Russia and Ukraine, the Israel-Hamas war and the Israel-Hezbollah war in Lebanon. The Company cannot predict at this time to what extent, if at all, it and its employees, contract research organizations, vendors and/or collaborators could potentially be negatively impacted by these events. Reverse Stock Split In September 2023, the Company received a letter from the Listing Qualifications Department of the Nasdaq Stock Market notifying the Company, as the bid price for its common stock had closed below $1.00 per share for the last 30 consecutive business days, it was not in compliance with Nasdaq Listing Rule 5450(a)(1), which is the minimum bid price requirement for continued listing on the Nasdaq Global Select Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided a 180-calendar day period, or until March 25, 2024, to regain compliance with the minimum bid price requirement. The continued listing standard would be met once the closing bid price of the Company's common stock was at least $1.00 per share for a minimum of ten consecutive business days during the 180-calendar day period. In January 2024, the Company's stockholders approved a reverse stock split of its common stock at a range of ratios between 1-for-7 to 1-for-17, and the Company's board of directors approved the implementation of the reverse stock split at a ratio of 1-for-12 (the Reverse Stock Split). The Reverse Stock Split was effective as of February 9, 2024 and the Company regained compliance with the minimum bid price requirement in February 2024. As of the effective time of the Reverse Stock Split, every 12 issued and outstanding shares of the Company's common stock was automatically reclassified into one issued and outstanding share of the Company's common stock. This reduced the number of shares outstanding from 65.8 million shares to 5.5 million shares. The Reverse Stock Split did not affect the number of authorized shares of common stock or the par value of the common stock. No fractional shares of common stock were issued in connection with the Reverse Stock Split and all fractional shares were rounded down to the nearest whole share with respect to outstanding shares of common stock. Any holders of common stock who would have otherwise received a fractional share of common stock pursuant to the Reverse Stock Split, received cash in lieu of the fractional share. All prior period share and per share amounts of the Company's common stock presented have been retroactively adjusted to reflect the 1-for-12 Reverse Stock Split, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital. Net Loss per Share Basic net loss per share of common stock excludes dilution and is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share of common stock reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity unless inclusion of such shares would be anti-dilutive. Diluted net loss per share is the same as basic net loss per share, since the effects of potentially dilutive securities are antidilutive given the net loss for each period presented. A reconciliation of the numerators and the denominators of the basic and diluted net loss per common share computations is as follows (in thousands, except for share and per share amounts): <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"><tr style="visibility:collapse;"><td style="width:46.26%;box-sizing:content-box;"></td><td style="width:1.02%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.18%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.96%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.18%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.02%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.18%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> <span

style="white-space:pre-wrap;min-width:fit-content;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Numerator: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Net loss </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(9,613</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (14,420 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(29,842</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (50,266 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Denominator: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Weighted average common shares outstanding - basic and diluted </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 6,351,431 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 4,380,444 </td> <td style="white-

space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,827,750 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 4,329,260 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Net loss per share - basic and diluted </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(1.51</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (3.29 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(5.12</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (11.61 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr></table> Securities excluded from the computation of diluted net loss per share because including them would have been antidilutive are as follows: <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"><tr style="visibility:collapse;"><td style="width:62.793%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:15.003%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:2.2%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:15.003%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> Warrants to purchase common stock </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 814,000 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> Options to purchase common stock </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 937,268 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 828,789 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> Common stock subject to purchase under ESPP </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,513 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,711 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> Unvested RSUs </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td

style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 69,217 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 90,740 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#cfl0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,827,998 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 926,240 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> </tr> </table> Basis of Presentation The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial information and pursuant to the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the SEC. In management's opinion, the unaudited condensed consolidated financial statements have been prepared on the same basis as the annual audited consolidated financial statements and include normal recurring adjustments necessary for the fair presentation of the Company's financial position and its results of operations and comprehensive loss and its cash flows for the periods presented. These statements do not include all disclosures required by U.S. GAAP and should be read in conjunction with the Company's audited consolidated financial statements and accompanying notes for the fiscal year ended December 31, 2023, which are contained in the 2023 Annual Report. The results for the three and nine months ended September 30, 2024 are not necessarily indicative of results to be expected for the entire year ending December 31, 2024or future operating periods. Use of Estimates The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates inherent in the preparation of the accompanying unaudited condensed consolidated financial statements include estimates for revenue recognition and costs incurred but not yet invoiced for research and development accruals. The Company's estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible these external factors could have an effect on the Company's estimates and could cause actual results to differ materially from those estimates and assumptions. Other Risks and Uncertainties U.S. and global financial markets have experienced volatility and disruption due to macroeconomic and geopolitical events such as rising inflation, changes in interest rates to combat inflation, the war between Russia and Ukraine, the Israel-Hamas war and the Israel-Hezbollah war in Lebanon. The Company cannot predict at this time to what extent, if at all, it and its employees, contract research organizations, vendors and/or collaborators could potentially be negatively impacted by these events. Reverse Stock Split In September 2023, the Company received a letter from the Listing Qualifications Department of the Nasdaq Stock Market notifying the Company, as the bid price for its common stock had closed below $1.00 per share for the last 30 consecutive business days, it was not in compliance with Nasdaq Listing Rule 5450(a)(1), which is the minimum bid price requirement for continued listing on the Nasdaq Global Select Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided a 180-calendar day period, or until March 25, 2024, to regain compliance with the minimum bid price requirement. The continued listing standard would be met once the closing bid price of the Company's common stock was at least $1.00 per share for a minimum of ten consecutive business days during the 180-calendar day period. In January 2024, the Company's stockholders approved a reverse stock split of its common stock at a range of ratios between 1-for-7 to 1-for-17, and the Company's board of directors approved the implementation of the reverse stock split at a ratio of 1-for-12 (the Reverse Stock Split). The Reverse Stock Split was effective as of February 9, 2024 and the Company regained compliance with the minimum bid price requirement in February 2024. As of the effective time of the Reverse Stock Split, every 12 issued and outstanding shares of the Company's common stock was automatically reclassified into one issued and outstanding share of the Company's common stock. This reduced the number of shares outstanding from 65.8 million shares to 5.5 million shares. The Reverse Stock Split did not affect the number of authorized shares of common stock or the par value of the common stock. No fractional shares of common stock were issued in connection with the Reverse Stock Split and all fractional shares were rounded down to the nearest whole share with respect to outstanding shares of common stock. Any holders of common stock who would have otherwise received a fractional share of common stock pursuant to the Reverse Stock Split, received cash in lieu of the fractional share. All prior period share and per share amounts of the Company's common stock presented have been retroactively adjusted to reflect the 1-for-12 Reverse Stock Split, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital. 11In January 2024, the Company's stockholders approved a reverse stock split of its common stock at a range of ratios between 1-for-7 to 1-for-17, and the Company's board of directors approved the implementation of the reverse stock split at a ratio of 1-for-12 (the Reverse Stock Split). The Reverse Stock Split was effective as of February 9, 2024 and the Company regained compliance with the minimum bid price requirement in February 2024. 6580000055000000 Net Loss per Share Basic net loss per share of common stock excludes dilution and is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share of common stock reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity unless inclusion of such shares would be anti-dilutive. Diluted net loss per share is the same as basic net loss per share, since the effects of potentially dilutive securities are antidilutive given the net loss for each period presented. A reconciliation of the numerators and the denominators of the basic and diluted net loss per common share computations is as follows (in thousands, except for share and per share amounts): <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:46.26%;box-sizing:content-box;"></td> <td style="width:1.02%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td

style="width:10.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.96%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.02%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.02%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Numerator: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Net loss </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(9,613</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (14,420 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (50,266 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Denominator: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Weighted average common shares outstanding - basic and diluted </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> <span style="color:#000000;white-

space:pre-wrap;min-width:fit-content;">6,351,431 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 4,380,444 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,827,750 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 4,329,260 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Net loss per share - basic and diluted </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(1.51</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (3.29 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(5.12</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (11.61 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr></table> Securities excluded from the computation of diluted net loss per share because including them would have been antidilutive are as follows: <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"><tr style="visibility:collapse;"><td style="width:62.793%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:15.003%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:2.2%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:15.003%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> Warrants to purchase common stock </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 814,000 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> Options to purchase common stock </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 937,268 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 828,789 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> Common stock subject to purchase under ESPP </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,513 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:right;">6,711 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Unvested RSUs </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 69,217 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 90,740 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,827,998 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 926,240 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> </tr> </table> A reconciliation of the numerators and the denominators of the basic and diluted net loss per common share computations is as follows (in thousands, except for share and per share amounts): <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:46.26%;box-sizing:content-box;"></td> <td style="width:1.02%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.96%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.02%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.02%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Numerator: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Net loss </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(9,613</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (14,420 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double

#000000;text-align:center;"> (29,842 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(50,266</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Denominator:</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Weighted average common shares outstanding - basic and diluted</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,351,431</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,380,444</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,827,750</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,329,260</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Net loss per share - basic and diluted</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (1.51 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(3.29</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (5.12 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (11.61 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr></table>-9613000-14420000-29842000-50266000635143163514314380444438044458277505827750432926043292604329260-1.51-1.51-3.29-3.29-5.12-5.12-11.61-11.61 Securities excluded from the computation of diluted net loss per share because including them would have been antidilutive are as follows: <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:62.793%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.003%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.003%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> <span style="color:#000000;white-space:pre-wrap;min-

width:fit-content;">Warrants to purchase common stock </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 814,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Options to purchase common stock </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 937,268 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 828,789 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Common stock subject to purchase under ESPP </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,513 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,711 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Unvested RSUs </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 69,217 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 90,740 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,827,998 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 926,240 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> </tr> </table>814000093726882878975136711692179074018279989262402p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Note 3 – Related Party In October 2023, the Company entered into an Option, License and Collaboration Agreement (the Gilead Collaboration Agreement), and a Common Stock Purchase Agreement and an Investor Rights Agreement (collectively, the Gilead Equity Agreements) under which it received aggregate gross proceeds of $100.0 million from Gilead Sciences, Inc. (Gilead). During the three and nine months ended September 30, 2024, the Company recognized <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$6.8 million and $21.2 million of collaboration revenue under the Gilead Collaboration Agreement, respectively (see Note 8). Pursuant to the Investor Rights Agreement, Gilead designated two directors to the Company's board of directors, who were appointed in December 2023 and February 2024. In June 2024, the Company entered into a Securities Purchase Agreement with Gilead for the issuance and sale of 179,500 shares of the Company's common stock and a warrant to purchase up to 179,500 shares of the Company's common stock in a private placement (see Note 6). The common stock and warrant were sold at a combined offering price of $15.46, for aggregate gross proceeds to the Company of approximately $2.8 million. Also in June 2024, the Gilead Equity Agreements were amended to extend deadlines relating to the Company's efforts to complete an equity financing and its ability to require Gilead to purchase additional shares of the Company's common stock by three months. The extended deadlines lapsed in October 2024. The amendments also explicitly include the shares of the Company's common stock and warrant sold to Gilead in June 2024 in the definition of registrable securities. The amendments to the Gilead Equity Agreements did not have an impact to the Company's condensed consolidated financial statements. As of September 30, 2024, Gilead held approximately 19.9% of the Company's outstanding voting common stock. Under the Gilead Equity Agreements, Gilead may elect to purchase additional shares to increase its holdings up to a maximum of 29.9% of the Company's then-outstanding voting common stock. The purchase price per share for additional shares purchased by Gilead under the Gilead Common Stock Purchase Agreement will be equal to the lesser of (1) a <span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-

content;">35% premium to the 30 trading day volume weighted average price immediately prior to the date of purchase or (2) a 35% premium to the 30 trading day volume weighted average price immediately prior to delivery by Gilead of notice of the anticipated closing date. 1000000006800000212000001795001795001 5.462800000019.90.299The purchase price per share for additional shares purchased by Gilead under the Gilead Common Stock Purchase Agreement will be equal to the lesser of (1) a 35% premium to the 30 trading day volume weighted average price immediately prior to the date of purchase or (2) a 35% premium to the 30 trading day volume weighted average price immediately prior to delivery by Gilead of notice of the anticipated closing date. 0.35P30D0.35P30D Note 4 – Fair Value Measurements and Investments in Marketable Securities The carrying amounts of cash equivalents and marketable securities approximate their fair value based upon quoted market prices. Certain of the Company's financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as cash, accounts receivable, accounts payable and accrued expenses. The Company uses the following three-level hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs to value its financial instruments: Level 1: Observable inputs such as unadjusted quoted prices in active markets for identical instruments. Level 2: Quoted prices for similar instruments that are directly or indirectly observable in the marketplace. Level 3: Significant unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. Investments in marketable securities consisted of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:46.709%;box-sizing:content-box;"></td><td style="width:1.04%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.282%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.04%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.282%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.04%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.282%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.04%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.282%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized
Cost </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Gross
Unrealized
Gain </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Gross
Unrealized
Loss </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:top;"> Cash equivalents </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Money market fund </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">27,840</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $ </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 27,840 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;">Total cash equivalents </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 27,840 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 27,840 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Short-term marketable securities </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. and foreign corporate debt securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 16,468 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 42 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 16,510 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. treasury securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 47,298 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 64 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 47,362 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. and foreign commercial paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 2,619 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 11 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> 2,630 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total short-term marketable securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 66,385 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 117 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 66,502 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total cash equivalents and marketable securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">94,225</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 117 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 94,342 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> </tr> </table> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:46.709%;box-sizing:content-box;"></td> <td style="width:1.04%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.04%;box-sizing:content-box;"></td> <td style="width:10.282%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.04%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.282%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.04%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.282%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.04%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.282%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized
Cost </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Gross
Unrealized
Gain </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Gross
Unrealized
Loss </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Cash equivalents </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;">

 </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Money market fund </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">18,982</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total cash equivalents </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 18,982 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 18,982 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Short-term marketable securities </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> U.S. and foreign corporate debt securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 17,595 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 41 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (3 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 17,633 </td> <td style="white-

space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. treasury securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 76,891 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 127 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 77,018 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. and foreign commercial paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 15,728 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 27 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 15,755 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total short-term marketable securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 110,214 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 195 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (3 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 110,406 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total cash equivalents and marketable securities </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">129,196</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 195 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(3</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 129,388 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> </tr> </table> <p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> There were no realized gains and losses for the three and nine months ended September 30, 2024 and 2023. As of September 30, 2024, there were no investments in an unrealized loss position. The Company did not recognize any credit losses related to its investments and all unrealized gains and losses on available-for-sale securities are recorded in accumulated other comprehensive loss on the condensed consolidated balance sheets as of September 30, 2024 and December 31, 2023.   Accrued interest receivable was $0.4 million and <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$0.3 million as of September 30, 2024 and December 31, 2023, respectively, and was recorded in prepaid expenses and other current assets on the condensed consolidated balance sheets. The Company did not write off any accrued interest receivable during the three and nine months ended September 30, 2024 and 2023. The following tables present the fair value of the Company's financial assets measured at fair value on a recurring basis (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:46.709%;box-sizing:content-box;"></td><td style="width:1.04%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.282%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.04%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.282%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.04%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.282%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.04%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.282%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;">Level 1 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 2 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 3 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:top;"> Cash equivalents </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Money market fund </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">27,840</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 27,840 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Total cash equivalents </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 27,840 </td>

<td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 27,840 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Short-term marketable securities </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. and foreign corporate debt securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 16,510 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 16,510 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. treasury securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 47,362 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 47,362 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. and foreign commercial paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 2,630 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-

space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 2,630 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total short-term marketable securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 66,502 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 66,502 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total assets measured at fair value </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">27,840</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 66,502 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 94,342 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> </tr></table> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:46.709%;box-sizing:content-box;"></td> <td style="width:1.04%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.282%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.04%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.282%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.04%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.282%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 1 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 2 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 3 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Cash equivalents </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;">

content;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Money market fund </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">18,982</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 18,982 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total cash equivalents </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 18,982 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> 18,982 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Short-term marketable securities </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> U.S. and foreign corporate debt securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 17,633 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 17,633 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. treasury securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"><p

style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 77,018 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 77,018 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. and foreign commercial paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 15,755 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 110,406 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 15,755 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total short-term marketable securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 110,406 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">18,982</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 110,406 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 129,388 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> </tr> </table> The Company estimates the fair value of its investments in marketable securities by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data, and other observable inputs. There were no transfers between Level 1, Level 2 or Level 3 investments during the periods presented. Investments in marketable securities consisted of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-

collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:46.709%;box-sizing:content-box;"></td> <td style="width:1.04%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.282%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.04%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.282%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.04%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.282%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.04%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.282%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized cost </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Gross
Unrealized
Gain </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Gross
Unrealized
Loss </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Cash equivalents </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Money market fund </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">27,840</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 27,840 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total cash equivalents </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 27,840 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 27,840 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> <span style="color:#000000;white-

space:pre-wrap;min-width:fit-content;">Short-term marketable securities </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. and foreign corporate debt securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 16,468 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 42 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 16,510 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. treasury securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 47,298 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 64 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 47,362 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. and foreign commercial paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 2,619 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 11 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total short-term marketable securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 66,385 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 117 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">   </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 66,502 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">   </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total cash equivalents and marketable securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;">   </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">94,225</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 117 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">   </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 94,342 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;">   </td> </tr> </table>   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:46.709%;box-sizing:content-box;"></td> <td style="width:1.04%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.282%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.04%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.282%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.04%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.282%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.04%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.282%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;">   </td> <td style="vertical-align:bottom;">   </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">   </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;">   </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized
Cost </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">   </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">   </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Gross
Unrealized
Gain </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">   </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">   </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Gross
Unrealized
Loss </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">   </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">   </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">   </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Cash equivalents </td> <td style="vertical-align:bottom;">   </td> <td colspan="2" style="vertical-align:bottom;">   </td> <td style="vertical-align:bottom;">   </td> <td style="vertical-align:bottom;">   </td> <td colspan="2" style="vertical-align:bottom;">   </td> <td style="vertical-align:bottom;">   </td> <td style="vertical-align:bottom;">   </td> <td colspan="2" style="vertical-align:bottom;">   </td> <td style="vertical-align:bottom;">   </td> <td style="vertical-align:bottom;">   </td> <td colspan="2" style="vertical-align:bottom;">   </td> <td style="vertical-align:bottom;">   </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Money market fund </td> <td style="white-space:pre-wrap;vertical-align:bottom;">   </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">18,982</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">   </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 18,982 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total cash equivalents </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 18,982 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 18,982 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Short-term marketable securities </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> U.S. and foreign corporate debt securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 17,595 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 41 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (3 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 17,633 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. treasury securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 76,891 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 127 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 77,018 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. and foreign commercial paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 15,728 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 27 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 15,755 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total short-term marketable securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 110,214 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 195 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (3 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 110,406 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total cash equivalents and marketable securities </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">129,196</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 195 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(3</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 129,388 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> </tr>
</table>27840000002784000027840000002784000016468000420000165100004729800064000047362000261900011000026300006638500011700006650200094225000117006
style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The following tables present the fair value of the Company's financial assets measured at fair value on a recurring basis (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:46.709%;box-sizing:content-box;"></td><td style="width:1.04%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.282%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.04%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.282%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.04%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.282%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.04%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.282%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 1 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 2 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> <span style="white-space:pre-wrap;min-

width:fit-content;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 3 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Cash equivalents </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Money market fund </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">27,840</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 27,840 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total cash equivalents </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 27,840 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:right;">16,510 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 16,510 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. treasury securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 47,362 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 47,362 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. and foreign commercial paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 2,630 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 2,630 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total short-term marketable securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 66,502 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 66,502 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total assets measured at fair value </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">27,840</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 66,502 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> <span style="color:#000000;min-width:fit-

content;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 94,342 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> </tr> </table> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:46.709%;box-sizing:content-box;"></td> <td style="width:1.04%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.282%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.04%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.282%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.04%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.282%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.04%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.282%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 1 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 2 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 3 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Cash equivalents </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Money market fund </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">18,982</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="vertical-align:top;"> Total cash equivalents </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 18,982 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-

space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 18,982 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Short-term marketable securities </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 17,633 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. treasury securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 77,018 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. and foreign commercial paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 15,755 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 77,018 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total short-term marketable securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 110,406 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 110,406 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total assets measured at fair value </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">18,982</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 110,406 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 129,388 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> </tr> </table>
2784000000278400002784000002784000001651000001651000004736200004736200002630000026300000665020000665020000943420001898200(
style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Note 5 – Other Accrued Expenses Other accrued expenses consist of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:63.647%;box-sizing:content-box;"></td> <td style="width:1.42%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.757%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.42%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.757%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30,
2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31,
2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Accrued expenses: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Accrued compensation </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,124</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,484 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Accrued professional fees and other </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 641 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 260 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:left;">Total accrued expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,765</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,744 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> </tr> </table> Other accrued expenses consist of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:63.647%;box-sizing:content-box;"></td> <td style="width:1.42%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.757%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.42%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.757%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30,
2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31,
2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Accrued expenses: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Accrued compensation </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,124</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,484 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Accrued professional fees and other </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 641 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 260 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total accrued expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,765</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,744 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> </tr> </table>41240005484000641000260000476500005744000 Note 6 - Sale of Common Stock and Warrants In June 2024, the Company entered into a Securities Purchase Agreement with an investor for the issuance and sale of 634,500 shares of the Company's common stock and a warrant to purchase up to 634,500 shares of the Company's common stock in a registered direct offering, pursuant to its shelf registration statement on Form S-3 on file with the SEC. The common stock and warrant were sold at a combined offering price of $15.46 for aggregate gross proceeds to the Company of approximately $9.8 million. The Company also entered into a Securities Purchase Agreement with Gilead for the issuance and sale of 179,500 shares of the Company's common stock and a warrant to purchase up to 179,500 shares of the Company's common stock in a private placement. The common stock and warrant were sold at a combined offering price of $15.46 for aggregate gross proceeds to the Company of approximately $2.8 million. The sale of common stock to Gilead maintains Gilead's ownership of approximately 19.9% of the Company's outstanding

voting common stock as of the date of closing pursuant to the terms of Gilead's existing Investor Rights Agreement with the Company entered into in October 2023 and amended in June 2024 (see Note 3). The warrants sold to both parties have an exercise price equal to $17.00 per share, became immediately exercisable on the date of issuance and expire on June 18, 2029. Neither party may exercise any portion of the warrants to the extent it would beneficially own more than the limits defined in the warrant agreements. The exercise price and number of shares of common stock issuable upon the exercise of the warrants are subject to adjustment in the event of any stock dividends and distributions, stock splits, stock combinations or stock reclassifications, as described in the respective warrant agreements. Under certain circumstances, the warrants may be exercised on a “cashless” basis. The warrants were classified as a component of permanent stockholders’ equity within additional paid-in-capital and were recorded at the issuance date. The warrants are equity classified because they are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, permit the holders to receive a fixed number of common shares upon exercise, are indexed to the Company’s common stock and meet the equity classification criteria. In addition, such warrants do not provide any guarantee of value or return. There were no warrants exercised during the three and nine months ended September 30, 2024. In August 2020, the Company entered into a sales agreement under which the Company may offer and sell shares of its common stock having an aggregate offering price of up to $100.0 million through “at-the-market” offerings (2020 ATM), pursuant to its shelf registration statement on Form S-3 on file with the SEC. During the three months ended September 30, 2024 and 2023 and during the nine months ended September 30, 2024, the Company did not sell any shares of common stock under the 2020 ATM. During the nine months ended September 30, 2023, the Company sold 261,170 shares of common stock under the 2020 ATM, for which the Company received net proceeds of <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$4.5 million, after deducting commissions, fees and expenses. 634500634500154690000017950017950015462800000199172029-06-18001000000000000261170450000 Note 7 – Stock-Based Compensation The following table summarizes the components of total stock-based compensation expense included in the condensed consolidated statements of operations and comprehensive loss (in thousands): <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:35.787%;box-sizing:content-box;"></td> <td style="width:1.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.902000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.5%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.902000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.94%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.002%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.94%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.002%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.84%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;word-break:break-word;"> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"> Research and development </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">395</p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 512 </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,152</p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,747 </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times

New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">General and administrative</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">402</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">623</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,217</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,413</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;word-break:break-word;"> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total stock-based compensation expense</p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">797</p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,135</p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,369</p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,160</p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">As of September 30, 2024, there was $2.9 million of total unrecognized stock-based compensation related to outstanding equity awards, which is expected to be recognized over a weighted average remaining amortization period of 1.6 years.</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;">The fair value of stock options granted during the periods indicated was estimated using the Black-Scholes option pricing model, based on the following assumptions:</p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:36.433%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:14.157%;box-sizing:content-box;"></td> <td style="width:1.54%;box-sizing:content-box;"></td> <td style="width:14.157%;box-sizing:content-box;"></td> <td style="width:1.98%;box-sizing:content-box;"></td> <td style="width:14.277%;box-sizing:content-box;"></td> <td style="width:1.98%;box-sizing:content-box;"></td> <td style="width:14.277%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Three Months Ended September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Nine Months Ended September 30,</p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Exercise price</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">$13.24</p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">$11.76</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td

style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">$12.90 - $15.06</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">$10.68 - $18.36</p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Expected volatility</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">80.8% - 86.2%</p></td> <td style="vertical-align:bottom,"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">77.5% - 83.1%</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">79.1% - 86.9%</p></td> <td style="vertical-align:bottom;text-align:left,"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">77.5% - 83.1%</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word,"> <td style="vertical-align:bottom,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Risk-free rate</p></td> <td style="vertical-align:bottom,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">4.39% - 4.40%</p></td> <td style="vertical-align:bottom,"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">4.23% - 4.24%</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">4.16% - 4.57%</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">3.59% - 4.24%</p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Expected term (years)</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">5.5 - 7.0</p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">5.5 - 7.0</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Expected dividend yield</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">0%</p></td> <td style="vertical-align:bottom,"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">0%</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">0%</p></td> </tr> </table></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify">The following table summarizes the components of total stock-based compensation expense included in the condensed consolidated statements of operations and comprehensive loss (in thousands):</p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:35.787%;box-sizing:content-box;"></td> <td style="width:1.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.902000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.5%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.902000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.94%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.002%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.94%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.002%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.84%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Three Months Ended September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Nine Months Ended September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom,"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p>

</td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;word-break:break-word;"> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"> Research and development </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">395</p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 512 </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,152</p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,747 </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> General and administrative </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 402 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 623 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,217 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 2,413 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;word-break:break-word;"> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"> Total stock-based compensation expense </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">797</p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,135 </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,369</p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 4,160 </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>39500051200011520001747000402000623000121700024130007970001135000236900041600002900000P1Y7M6D The fair value of stock options granted during the periods indicated was estimated using the Black-Scholes option pricing model, based on the following assumptions: <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr

style="visibility:collapse;"> <td style="width:36.433%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:14.157%;box-sizing:content-box;"></td> <td style="width:1.54%;box-sizing:content-box;"></td> <td style="width:14.157%;box-sizing:content-box;"></td> <td style="width:1.98%;box-sizing:content-box;"></td> <td style="width:14.277%;box-sizing:content-box;"></td> <td style="width:1.98%;box-sizing:content-box;"></td> <td style="width:14.277%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Three Months Ended September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Nine Months Ended September 30,</p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Exercise price</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">$13.24</p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">$11.76</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">$12.90- $15.06</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">$10.68- $18.36</p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Expected volatility</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">80.8% - 86.2%</p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">77.5% - 83.1%</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">79.1% - 86.9%</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">77.5% - 83.1%</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Risk-free rate</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">4.39% - 4.40%</p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">4.23% - 4.24%</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">4.16% - 4.57%</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">3.59% - 4.24%</p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Expected term (years)</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">5.5- 7.0</p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">5.5- 7.0</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">5.5- 7.5</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Expected dividend yield</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">0%</p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">

</td> <td style="vertical-align:bottom;text-align:left;"> 0% </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 0% </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 0% </td> </tr>
</table>13.2411.7612.915.0610.6818.360.8080.8620.7750.8310.7910.8690.7750.8310.04390.0440.04230.04240.04160.04570.03590.0424P5Y6MP7YP5Y6MP7YP5Y6MP7Y6MP4
style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Note 8 – Collaboration Agreements Gilead Agreement In October 2023, the Company entered into the Gilead Collaboration Agreement and the Gilead Equity Agreements under which it received total proceeds of $100.0 million. Under the Gilead Collaboration Agreement, Gilead exclusively licensed to the Company its HPI program and NNPI program, while retaining opt-in rights to these programs and has an option to take an exclusive license, on a program-by-program basis, to all of the Company's other current and future pipeline programs. During the 12-year collaboration term (subject to payment of certain extension fees) and for a specified period thereafter, Gilead may exercise its opt-in rights, on a program-by-program basis, at one of two timepoints—completion of a certain Phase 1 study or completion of a certain Phase 2 study for the first product within the program—upon payment of an opt-in fee ranging from $45.0 million to $125.0 million per program depending on the type of program and when the option is exercised.   If Gilead exercises its opt-in right to any current or future program under the collaboration, the Company is eligible to receive up to $330.0 million in potential regulatory and commercial milestones on that program, in addition to royalties ranging from the high single-digits to high teens, depending on the clinical stage of the program at the time of the opt-in. Following Gilead's exercise of its option for each of the Company's programs, the Company may opt in to cover 40% of the research and development costs in the United States and share 40% of the profits and operating loss in the United States for products within the program in lieu of receiving milestones and royalties for that program in the United States, unless the Company later opts out of the cost/profit share for the program. Prior to Gilead's potential exercise of its opt-in, the Company will be primarily responsible for all discovery, research and development on its programs and the two Gilead-contributed programs. Following Gilead's opt-in, Gilead will control the further discovery, research, development, and commercialization on any optioned programs. During the term, Gilead will continue to support the collaboration through extension fees of $75.0 million in each of the third, fifth and seventh years of the collaboration. The Gilead Collaboration Agreement is subject to termination by either party for the other party's uncured, material breach or insolvency. Subject to certain limitations, the Company and Gilead both have certain termination for convenience rights, upon sufficient prior written notice, with respect to programs that one party in-licenses from the other (subject to Gilead's option rights), and with respect to Gilead, for programs it has option rights to (subject to certain time limitations with respect to existing Company programs). Gilead also has a right to terminate the collaborative activities under the Gilead Collaboration Agreement at certain specified points during the collaboration term. Other customary termination rights are further provided in the Gilead Collaboration Agreement. The Company concluded Gilead is a customer and accordingly, the Gilead Collaboration Agreement is within the scope of the revenue from contracts with customers guidance. The Company identified a single combined performance obligation for the discovery, research and development services during the collaboration term (the R&D Services). As of September 30, 2024, the total transaction price of the Gilead Collaboration Agreement was determined to be $90.7 million. The Company will reevaluate the transaction price in each reporting period as uncertain events are resolved or other changes in circumstances occur.</p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The transaction price is reflected as collaboration revenue when realized in the Company's condensed consolidated statements of operations. The Company will recognize revenue over time using a cost-based input method over the initial non-cancellable term of three years since this method best reflects the transfer of services to Gilead. In applying a cost-based input method of revenue recognition, the Company uses actual costs incurred relative to estimated total costs to fulfill each performance obligation. </p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The Company recognized collaboration revenue of $6.8 million and $21.2 million during the three and nine months ended September 30, 2024. The transaction price for future collaborative activities was recorded as deferred revenue on the condensed consolidated balance sheet as of September 30, 2024, of which $32.6 million was short-term and $32.5 million was long-term. The reimbursable expenses incurred by the Company during the three months ended September 30, 2024 were insignificant. During the nine months ended September 30, 2024, the Company incurred <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$0.3 million in reimbursable expenses due to Gilead. The following table presents changes in the Company's contract liabilities (in thousands): <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:46.098%;box-sizing:content-box;"></td> <td style="width:1.02%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.124%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.02%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.124%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.02%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.124%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.341%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.124%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Balance at
Beginning
of Period </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Additions

</td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Deductions </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Balance at
End of
Period </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Nine Months Ended September 30, 2024 </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Contract liabilities: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Deferred revenue </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">86,294</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(21,163</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 65,131 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> </table>   <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"><tr style="visibility:collapse;"><td style="width:46.098%;box-sizing:content-box;"></td><td style="width:1.02%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.124%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.02%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.124%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.02%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.124%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:2.341%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.124%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> <span style="color:#000000;white-space:pre-wrap;font-

weight:bold;min-width:fit-content;">Nine Months Ended September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Collaboration revenue recognized in the period from</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Amounts included in deferred revenue at the beginning of the period</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,845</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">21,163</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Performance obligations satisfied in previous period</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr></table></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Arbutus Biopharma Agreement</p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">In August 2020, the Company and Arbutus Biopharma Corporation (Arbutus Biopharma) entered into a Clinical Trial Collaboration Agreement (the Arbutus Biopharma Agreement) to conduct a randomized, multi-center, open-label Phase 2 clinical trial to explore the safety, pharmacokinetics and antiviral activity of the triple combination of vebicorvir (VBR), AB-729 and a nucleos(t)ide analog reverse transcriptase inhibitor (NrtI) compared to the double combinations of VBR with a NrtI and AB-729 with a NrtI. Under the Arbutus Biopharma Agreement, Assembly and Arbutus Biopharma shared responsibility for the costs of the trial equally, excluding manufacturing supply which were the burden of each company to supply their respective drugs, VBR and AB-729. Assembly was responsible for conducting this clinical trial with Arbutus Biopharma reimbursing Assembly its share of expenses. In February 2023, Assembly and Arbutus Biopharma terminated the Phase 2 clinical trial early, at the end of the 48-week on-treatment period.</p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Reimbursements and cost-sharing portions from Arbutus Biopharma are reflected as a reduction of research and development expense when realized in the Company's condensed consolidated statements of operations. During the three and nine months ended September 30, 2024, the Company recognized research and development expenses of $0.3 million for net amounts refundable to Arbutus Biopharma after the final reconciliation of clinical trial costs. Amounts refundable to Arbutus Biopharma are recorded as accrued research and development expenses on the condensed consolidated balance sheet as of September 30, 2024. During the three and nine months ended September 30, 2023, the Company recognized a reduction of research and development expenses of <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-

content;">$0.1 million and $1.2 million, respectively, under the Arbutus Biopharma Agreement.
100000000P12¥2450000001250000003300000000.400.40275000000907000003P3¥6800000021200000326000003250000030000 The following table presents changes in the Company's contract liabilities (in thousands): <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:46.098%;box-sizing:content-box;"></td> <td style="width:1.02%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.124%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.02%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.124%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.02%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.124%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.341%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.124%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Balance at
Beginning
of Period </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Additions </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Deductions </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Balance at
End of
Period </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Nine Months Ended September 30, 2024 </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Contract liabilities: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Deferred revenue </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">86,294</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(21,163</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 65,131 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:left;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> </table> 8629400002116300065131000 <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:46.098%;box-sizing:content-box;"></td> <td style="width:1.02%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.124%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.02%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.124%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.02%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.124%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.341%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.124%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Collaboration revenue recognized in the period from </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Amounts included in deferred revenue at the beginning of the period </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,845</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">21,163</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Performance obligations satisfied in previous period </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td

style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table>6845000021163000000003000003000001000001200000 Note 9 - Milestones and Research Agreements HBV Research Agreement with Indiana University Since September 2013, the Company was party to an exclusive License Agreement dated September 3, 2013 with Indiana University Research and Technology Corporation (IURTC) from whom it licensed aspects of the Company's HBV program held by IURTC. The license agreement required the Company to make milestone payments based upon the successful accomplishment of clinical and regulatory milestones. The aggregate amount of all performance milestone payments under the IURTC license agreement, if all milestones through development were met, was $0.8 million, with a portion having been paid. The Company was obligated to pay IURTC royalty payments based on net sales of the licensed technology as well as a portion of any sublicensing revenue Assembly received. The Company was also required to pay diligence maintenance fees each year to the extent that the royalty, sublicensing, and milestone payments to IURTC were less than such fees for that year. Following its decision to discontinue further development or partnering for ABI-H3733, the Company terminated the IURTC license agreement effective April 2024. There were no fees paid to IURTC during the three months ended September 30, 2024 or 2023. The Company paid IURTC $0.1 million in diligence maintenance fees during both the nine months ended September 30, 2024 and 2023. 8000000010000010000falsefalsefalsefalse'

"